datetime,headline,summary,related,lang,source
2020-12-10 02:32:32-05:00,"Covid-19 Product Market With Top Players like 3M, Cardinal Health, Kimberly- Clark, Johnson and Johnson, Sanofi, Ansell, Abbott Laboratories, BD, Henry Schein, Heat Biologics","Covid-19 Product include range of products which are used for protection against covid-19. The range of products mainly include, face mask, sanitizers, disinfectant, personal protection equipment, hand gloves, oximeters and such other products. The covid-19 outbreak has drastically enhanced the",SAN,en,OpenPR
2020-12-09 17:33:38-05:00,Luxembourg’s B Medical systems in talks with all top Covid vaccine makers for refrigeration unit in India,"New Delhi: Vaccine refrigeration systems provider B Medical Systems plans to set up a facility in India by March 2021 and is in talks with top global vaccine manufacturers to provide technology to store their products here, senior management of the Luxembourg-based company told ET.A delegation of B Medical executives, which is currently in India, held meetings with India's principal scientific adviser and officials at the Ministry External Affairs on the proposed unit and the company’s technology, and claimed to have received strong support from them.The manufacturing unit proposed in Gujarat will be the company’s first outside Luxembourg. Besides the Indian market, the unit will cater to export markets as well. The project is an outcome of an India-Luxembourg virtual summit held on November 19 and the process has moved at an extremely fast pace. The project involves setting up an assembly plant within three months and shifting to full-scale production over a 12-15-month period. “Our products belong to a niche category and are used around the world for storing vaccines and other temperature-sensitive products and our clients include GSK, Pfizer, Novartis, Bayer, Sandoz, Sanofi, etc.,” Luc Provost, the chief executive at the Navis Capital Partners-owned company, told ET.The product is 100% European designed and manufactured.",SAN,en,Economic Times India
2020-12-09 14:25:57-05:00,Santander niega delito en los 380 millones en operaciones con Suiza que investiga el juez,"La sombra del blanqueo de capitales planea sobre Banco Santander, en referencia a la operativa que prestó a HSBC Suiza de custodia de valores y corresponsalía en España. La defensa de los seis directivos y exdirectivos del Santander que están investigados en la Audiencia Nacional en el contexto de la llamada «Lista Falciani» ha presentado un escrito para defenderse de las acusaciones del dictamen de los peritos del Banco de España sobre el caso, adelantado por «El Confidencial», y sostiene que no se cometió ninguna irregularidad en los 380 millones de las operaciones con HSBC Suiza entre 2005 y 2012 que están bajo la lupa. En el caso del Santander, en el último informe del Banco de España, al que… Ver Más",SAN,es,ABC Spain
2020-12-09 12:10:19-05:00,Santander vai isentar transferências MBWay sem limite de montante e operações,"O Santander vai isentar as transferências MBWay a partir de janeiro de 2021, sem limite de montante e de número de operações realizadas.",SAN,pt,Jornal de Negócios
2020-12-09 10:40:00-05:00,These are the most innovative university ventures,"Santander awarded the five best university ventures in the Business Innovation Award with 1.6 million pesos. Since 2005 this contest has brought together more than 37,000 entrepreneurs.",SAN,en,Entrepreneur
2020-12-09 10:33:19-05:00,Santander isenta todas as transferências MB Way a partir do próximo ano,"Isenção será aplicada ""sem limite de montante e de número de operações realizadas"".",SAN,pt,Notícias ao Minuto
2020-12-09 08:07:17-05:00,"Consultorio de análisis técnico: Telefónica, Santander, Viscofan, Grenergy, Nasdaq, AMD, Zoom Video y Tesla","A continuación, damos respuesta a los valores por los que más nos han preguntado a lo largo de la mañana. José María Rodríguez, analista técnico de Bolsamanía, analiza Telefónica, Santander, AMD, Tesla, Zoom Video, Viscofan, Grenergy y el Nasdaq 100.",SAN,es,Bolsamanía
2020-12-09 03:07:02-05:00,El Santander blanqueó dinero de españoles en Suiza,"Un informe del Banco de España ha constatado que el Banco Santander colaboró en el blanqueo y la evasión de capital de decenas de clientes españoles en Suiza. Según informa este miércoles 'El Confidencial', la entidad presidida por Ana Botín habría hecho transferencias sin identificar los emisores y los receptores a HSBC Suiza , uno de los bancos más investigados en Estados Unidos y la Unión Europea para la ocultación generalizada de patrimonios. Solo entre el 2005 y el 2008, se produjeron 1.070 operaciones entre las dos entidades por un importe de 73,9 millones de euros. Entre ellas aparecen nombres como el del expiloto de motos Jorge Lorenzo, que movió 850.000 euros. La Audiencia Nacional investiga siete directivos y exdirectivos de la entidad española por esta causa. Seguir leyendo… .",SAN,es,El Periodico
2020-12-09 02:40:24-05:00,"Topical Pain Killers Market With Leading Players like Johnson and Johnson, Novartis AG, GlaxoSmithKline Plc, Pfizer Inc, Reckitt Benckiser Group Plc, Sanofi S.A, Topical BioMedics, AdvaCare Pharma, Sun Pharmaceutical Industries Ltd, Nestle S.A","Topical Pain Killers are mainly used to relive pain, strain, injuries due to sports, minor accidents. Topical Pain Killers include most of non-prescription preparations such as creams, sprays, lotion, ointments. These topical preparations are available in single as well as",SAN,en,OpenPR
2020-12-09 02:11:00-05:00,Fundación Banco Santander buscará otros 80 proyectos en 2021 para 'Santander Ayuda',"Ayudas contra veinte proyectos contra la pobreza y la exclusión social en cada una de las cuatro nuevas convocatorias de Santander Ayuda en 2021. La Fundación Banco Santander ha abierto plazo para presentar candidaturas a la primera, hasta el 18 de enero.",SAN,es,Publico
2020-12-08 23:43:32-05:00,"Leukemia Therapeutics Market Worth Observing Growth | Pfizer, Sanofi, AbbVie","Latest publication on 'Global Leukemia Therapeutics Market – By Disease Type (Chronic Myeloid Leukemia, Chronic Lymphocytic Leukemia, Acute Lymphocytic Leukemia, and Acute Myeloid Leukemia), By Drug Class (Small Molecules and Biologics), and By Regions (North America, Europe, Asia Pacific, and",SAN,en,OpenPR
2020-12-08 12:44:55-05:00,"Global Toxoid Vaccines Market 2020: Report Explored In Latest Research To 2027 | Major Giants –GlaxoSmithKline plc, Grifols, S.A, Zoetis Services LLC., Virbac. Sanofi, Merck & Co., Inc., Emergent BioSolutions Inc","Toxoid Vaccines market research report acts as a great source of information with which businesses can get a telescopic view of the existing market trends, consumer’s demands and preferences, market situations, opportunities and market status. It describes thorough study of",SAN,en,OpenPR
2020-12-08 09:08:00-05:00,Icertis Brings Contract Intelligence to Mid-Market Companies in Response to Major Customer Demand,"BELLEVUE, Wash. , Dec. 8, 2020 /PRNewswire/ -- Icertis , the contract intelligence company that pushes the boundaries of what's possible with contract lifecycle management (CLM), announced that it is bringing contract intelligence to mid-market companies. This launch includes tailored product enhancements for mid-market companies, extended partnerships, and expanded sales, product development and customer delivery teams. In addition, the company introduced major brand updates designed to bring the award-winning Icertis Contract Intelligence (ICI) platform to fast growing disrupters across all industry sectors. These changes bring new capabilities that enhance ease of use and simplify deployment, allowing customers to achieve faster time to value and help them scale rapidly now and into the future. Prioritizing the Mid-Market Already a recognized leader in delivering contract intelligence for large enterprise customers like Airbus, Apple, Daimler, J&J, Microsoft and Sanofi, Icertis is expanding its focus to companies with over $100 million in annual revenue.",SAN,en,Benzinga
2020-12-08 07:12:14-05:00,Denunciadas seis personas por beber en la calle en Santander,"La Policía de Santander ha denunciado a seis personas consumo de alcohol en la vía pública, en varios controles en diferentes puntos de la ciudad durante la tarde noche del lunes. Además, ha detenido al conductor de un turismo por un…",SAN,es,Publico
2020-12-08 05:52:33-05:00,Heridos dos motoristas en dos accidentes de tráfico en Santander,"Dos motoristas han resultado heridos en sendos accidentes en Santander, uno tras caerse en una rotonda y el otro después de colisionar con un turismo. El primer accidente tuvo lugar a las 10:40 horas en la Rotonda de la calle Libertad…",SAN,es,Publico
2020-12-07 22:45:00-05:00,"Santander, sancionado en EEUU por no revisar seis millones de emails de su plantilla",La autoridad regulatoria de Estados Unidos ha sancionado a la filial de la entidad española por un fallo informático que ha dejado fuera de supervisión millones de correos electrónicos de sus empleados,SAN,es,Vozpopuli
2020-12-07 21:00:00-05:00,"THE MILLENNIAL FINANCIAL HEALTH REPORT: How the largest generation is saving and managing their money, and how banks can target products and messaging to reach them","Summary List Placement This is a preview of the Business Insider Intelligence Millennial Financial Health premium research report. Purchase this report here. Business Insider Intelligence offers even more banking coverage with our Banking Briefing. Subscribe today to receive industry-changing financial news and analysis to your inbox. As the largest living generation by population, and soon income, millennials are a prime target for banks — butovergeneralizations of their financial health make it hard to attract the group. Millennials have been the subject of misinformation with regard to financial literacy, spending habits, and brand loyalty. In reality, they're encountering diverse financial milestones, and tailoring products directly to their varied needs can help banks take full advantage of the opportunity presented by serving millennials. Business Insider Intelligence conducted an exclusive survey to better understand US millennials' financial health. The Master Your Money: Learn & Plan Survey was designed by Business Insider Intelligence and fielded online from November 23 to 27, 2019, to a third-party sample of 2,007 US millennials aged 19-37.",SAN,en,Business Insider
2020-12-07 19:50:58-05:00,Jugar a videojuegos para crecer en el Ibex 35,"BBVA, Indra, Mapfre, Santander, Cellnex, Bankinter… Todas estas empresas forman parte del índice bursátil de referencia de la bolsa española, y todas ellas, en su compromiso de formar mejores profesionales y directivos, han recurrido al mismo recurso para explotar el talento. Ofrecer a sus plantillas experiencias virtuales capaces de incrementar sus habilidades y competencias. Dentro de las grandes empresas, sin importar el sector, es cada día más común presentar a sus empleados con retos y situaciones que los saquen de sus zonas de confort. La empresa española de recursos humanos que ofrece este servicio, Psicosoft utiliza solamente tecnologías inmersivas y trabaja en tres ámbitos, el «elearning» o, el presencial y el remoto. Para sus soluciones de «elearning» o aprendizaje online, Psicosoft es capaz de crear escenarios con formato de historia cuya finalidad es concienciar con respecto a algún tema específico, como el diseñado para BBVA, sobre cibersegurirdad. «El videojuego se ambientó en un mundo vikingo y resultó ser un éxito absoluto para la empresa, que mejoró sus prestaciones en el ámbito de seguridad informática» comentan desde la empresa de recursos humanos.",SAN,es,ABC Spain
2020-12-07 13:50:00-05:00,Play Digital Selecciona Featurespace para Defenderse contra el Fraude de Pagos en la Plataforma Lanzada Recientemente,"ATLANTA y BUENOS AIRES, Argentina--(BUSINESS WIRE)--Featurespace™, proveedor líder de software para la prevención de delitos financieros empresariales, anunció que Play Digital, la nueva tecnología financiera (fintech) creada por Santander, Galicia y BBVA, ha elegido su ARIC™ Risk Hub para proteger su nueva plataforma de pagos MODO del fraude. Se trata de una nueva solución de pago digital avalada por más de 30 bancos públicos, privados y cooperativos que marca un hito sin precedentes en Argent",SAN,es,Business Wire
2020-12-07 11:00:00-05:00,Play Digital Selects Featurespace to Defend Against Payments Fraud on Newly Launched Platform,"ATLANTA & BUENOS AIRES, Argentina--(BUSINESS WIRE)--Featurespace™, the leading provider of Enterprise Financial Crime prevention software, announced that Play Digital, the new fintech created by Santander, Galicia and BBVA, has chosen its ARIC™ Risk Hub to protect its new payments platform MODO from fraud. This is a new digital payment solution endorsed by more than 30 public, private and cooperative banks that marks an unprecedented milestone in Argentina. The platform is free to use and facil",SAN,en,Business Wire
2020-12-07 07:28:45-05:00,Banqueiros portugueses dão cartas lá fora,"Portugal é conhecido por ter dos melhores treinadores de futebol do mundo. Mas não é apenas no desporto que dá cartas. Também na banca são vários os casos de sucesso ao longo dos últimos anos, lá fora. O país tem banqueiros a ocupar cargos de topo em instituições financeiras de peso, seja no Santander, HSBC, Goldman Sachs ou, mais recentemente, no Credit Suisse. António Horta Osório será o primeiro estrangeiro a ocupar a cadeira de ""chairman"" num dos maiores bancos do mundo.",SAN,pt,Jornal de Negócios
2020-12-07 07:02:00-05:00,"THE DIGITAL BANKING ECOSYSTEM: These are the key players, biggest shifts, and trends driving short- and long-term growth in one of the world's largest industries","Summary List Placement This is a preview of Digital Banking Ecosystem research report from Business Insider Intelligence. Purchase this report. Business Insider Intelligence offers even more fintech coverage with Banking Pro. Subscribe today to receive industry-changing finance news and analysis to your inbox. The banking industry is in the grips of an identity crisis. Leaders of the world's largest banks — such as Citi, BBVA, and Goldman Sachs — have begun describing themselves as technology companies with banking licenses. However, this description is still aspirational. Executing the vision will require billions of dollars in investments, the restructuring of teams, a reimagining of the entire banking technology stack, and the adoption of a far more customer-centric business view. The stakes of failing to transform are high: Accenture projects that 35% of all bank revenues could be at risk from more tech-savvy competitors like fintechs as soon as 2020 for incumbents that fail to up their game.",SAN,en,Business Insider
2020-12-06 19:00:00-05:00,"Dónde invertir en bolsa este lunes: Corp. Alba, Acerinox, ArcelorMittal y Santander",Hoy se presentan buenas oportunidades de trading en estos valores si se cumplen las condiciones esperadas y ya están en el punto de mira de muchos inversores para esta sesión de lunes 7 de diciembre.,SAN,es,EL ESPAÑOL
2020-12-06 07:45:00-05:00,"Sanofi – Uncommon Neurodegenerative Illness Therapy Market Development, Future Development, COVID-19 Impression, Forecast","Sanofi - Uncommon Neurodegenerative Illness Therapy Market Development, Future Development, COVID-19 Impression, Forecast 2026 -",SAN,en,Fintech Zoom
2020-12-06 04:33:45-05:00,"Sanofi – Artificial Adhesion Obstacles Market 2020: Potential development, enticing valuation make it’s a long-term","Sanofi - Artificial Adhesion Obstacles Market 2020: Potential development, enticing valuation make it's a long-term funding | Know the COVID19 Influence | Prime Gamers: Johnson & Johnson (J&J) (US), Sanofi (France), Baxter Worldwide (US), C.R. Bard (US), and many others. -",SAN,en,Fintech Zoom
2020-12-05 22:30:00-05:00,El Leganés sigue con su castigo en bolsa y 'pierde' 12 millones en solo tres años,"El club de fútbol invirtió una gran bolsa de liquidez en acciones de Banco Santander, que acumula minusvalías sin realizar pero que le ha permitido ingresar dos millones de euros vía dividendos.",SAN,es,La Información
2020-12-05 04:43:49-05:00,"Recombinant Vaccines Market to see Huge Growth by 2025 | Pfizer, Bayer, Sanofi",Recombinant Vaccines Market Comprehensive Study is an expert and top to bottom investigation on the momentum condition of the worldwide Recombinant Vaccines industry with an attention on the Global market. The report gives key insights available status of the Recombinant,SAN,en,OpenPR
2020-12-05 03:31:39-05:00,Dónde y quiénes fabricarán 9.600 millones de dosis de vacuna anti-Covid,"Las españolas Rovi, Mabxience y Biofabri participan en la producción Pfizer, Jannsen, Novavax, Sanofi y AstraZeneca, claves en el reto",SAN,es,El Pais Cinco Dias
2020-12-04 15:29:03-05:00,Banco Santander acepta prejubilaciones desde los 50 años y con indemnizaciones de hasta 250.000 euros,No summary available.,SAN,es,20minutos Spain
2020-12-04 13:00:00-05:00,Big pharma is using AI and machine learning in drug discovery and development to save lives,"Summary List Placement The pharmaceutical industry has been slow-moving when it comes to adopting digital health technology, and pharma companies overall have taken a long time to implement AI and machine learning strategies — making broad-scale digital transformation difficult. There is ample opportunity for drug discovery and development, but it relies on the ability of companies to implement advanced health tech into everyday strategies. While the healthcare industry is rapidly adopting digital tech, the pharma industry is lagging on digital maturity, and any measures even early movers are taking to catch up are patchworked due to a lack of strategy and digital-focused leadership. AI & Machine Learning in the Drug Development Process An incredible amount of time and money goes into drug development — bringing a drug to market costs about $2.8 billion dollars over 12+ years, according to Taconic Biosciences' tally. Utilizing AI and machine learning can help at every stage of the drug discovery process.",SAN,en,Business Insider
2020-12-04 12:26:02-05:00,"El Ibex 35 mantiene su optimismo y repunta un 1,61% durante la semana","Los valores que más han subido este último día hábil de la semana han sido Banco Santander (+5,71%), BBVA (+5,54%), Repsol (+5,29%)",SAN,es,Vozpopuli
2020-12-04 11:04:10-05:00,"Pseudoephedrine Market Size |Incredible Possibilities and Growth Analysis and Forecast To 2025| Pfizer, Sanofi, Hanmi, Merck","The Pseudoephedrine market 2020 research report is a detailed view of market opportunity by end-user segments, product Type segments, sales channels, key countries. It also provides market credentials such as history, various development and trends, market overview, regional markets",SAN,en,OpenPR
2020-12-04 08:03:34-05:00,'Forbes' sitúa a la reina Leticia como la persona más influyente de España en 2020,"La revista Forbes ha publicado su lista de los españoles más influyentes del año y ha colocado a la reina Letícia como la persona española más influyente este 2020. El ranking , en el que la publicación selecciona tradicionalmente a las personalidades con más peso en diferentes sectores, este año solo ha incluido a mujeres, la mayor parte de las cuales del mundo de la política y de la empresa. En este 2020, marcado por la crisis sanitaria y económica provocada por la pandemia, no aparece ni Fernando Simón ni ningún otro epidemiólogo, que tanto rato han ocupado en las pantallas. En total forman la lista ocho políticas, una reina consorte, seis altos cargos de empresas privadas, cinco periodistas, tres figuras del mundo de la cultura –dos galeristas y una cantante–, una científica y una activista. Después de Letícia encontramos en el podio a Ana Patricia Botín, presidenta de Banco Santander. La heredera del linaje Botín se considera ""una de las mujeres más poderosas y reconocidas del planeta"".",SAN,es,Diara ARA
2020-12-04 04:50:14-05:00,"Las personas más influyentes del año en España son mujeres, según la revista Forbes","La revista Forbes ha publicado su tradicional lista con las personas más influyentes del año en España y por primera vez, todas son mujeres. 25 mujeres que han destacado por su labor este 2020, encabezadas por la reina Letizia. Le sigue la presidenta del banco Santander, Ana Patricia Botín. En la lista también aparecen rostros conocidos de la televisión como Ana Rosa Quintana y artistas con reconocimiento mundial como Rosalía. -Redacción-",SAN,es,Publico
2020-12-03 20:46:22-05:00,Basagoiti: «Considero que se cuenta poco la implicación social que tienen las empresas españolas en México»,"Si algo tiene Antonio Basagoiti ha sido saberse bregar en situaciones harto difíciles. El excandidato a Lendakari por el PP vasco a pesar de encontrarse en México, a más de 9018 kilómetros de su querido Bilbao, fue protagonista en la sombra (y totalmente involuntario) de la moción de censura planteada por Vox el 22 de octubre en el Congreso de los Diputados. Santiago Abascal se dirigía a la bancada de sus señorías repitiendo exactamente palabra por palabra el discurso que el exparlamentario dio en el Parlamento Vasco en 2013. Eran ni más ni menos que los 875 nombres que ETA ha asesinado en sus 51 años de terrorífico padecer. Tal y como ha podido comprobar el que suscribe por círculos comunes a Antonio lógicamente sí le recordó su discurso que gracias a oportunas investigaciones hemos podido asegurar que fue escrito durante un vuelo de Iberia precisamente camino a México cuando se encontraba barajando la posibilidad de dejar la escena política. El caprichoso destino ha querido que se encuentre ahora asentado en el país azteca presidiendo la Cámara de Comercio de España en México (Camescom), una entidad con más de 130 años de historia (en la que sólo ha habido hombres) que compagina con su apetecible puesto como director ejecutivo de banca de empresas en el Banco Santander.",SAN,es,ABC Spain
2020-12-03 20:20:12-05:00,Banco Santander prejubilará a sus trabajadores desde los 50 años,"Banco Santander aceptó ayer la demanda de los sindicatos de incluir al colectivo de trabajadores entre los 50 y los 54 años en el expediente de regulación de empleo (ERE) que tiene planteado, según informaron fuentes sindicales. La entidad…",SAN,es,La Vanguardia
2020-12-03 13:25:45-05:00,La empresa de jamones y embutidos ibéricos Bernardo Hernández gana el Pyme de Oro 2020,"La empresa Bernardo Hernández S.L, dedicada a la fabricación y comercialización de jamones y embutidos ibéricos, ha recibido el Premio Pyme del Año 2020 de Salamanca, reconocimiento que conceden el Banco Santander y la Cámara de Comercio de Salamanca, en colaboración con la Cámara de España y LA GACETA DE SALAMANCA. Un galardón que, según el consejero delegado de la compañía, Bernardo Hernández, nieto del fundador, premia el espíritu familiar de la empresa, así como su larga trayectoria, ya que fue fundada en los años 30, y apuesta por la calidad. “Los resultados acaban llegando cuando se hacen bien las cosas”, apuntó, además de hacer referencia a la actual situación económica. El acto sirvió para reconocer a otras cinco sociedades. El accésit de internacionalización fue a parar a la cooperativa de apicultores Reina Kilama, el de Innovación y Digitalización a What Jamón, Lamarc Agropecuaria se llevó el de Formación y Empleo, Manuel Guillén el de Empresa Responsable y Fely Campo la mención especial a la Mejor Iniciativa contra el COVID 19, creada con carácter extraordinario para reconocer la labor de las pymes en un año tan difícil.",SAN,es,Gaceta de Salamanca
2020-12-03 10:21:50-05:00,"Laura Shawver is about to join a lineup of biotech CEOs enjoying overnight fortunes, courtesy of the biotech IPO boom","Laura Shawver capped 2019 with an $88 million windfall from the sale of Synthorx to Sanofi. And she pivoted right back into the sweet spot in 2020. Just months after the sale, the serial entrepreneur returned to the helm of a startup — taking the lead post at Silverback Therapeutics,",SAN,en,Endpoints News
2020-12-03 06:57:29-05:00,Sanofi To Publish COVID-19 Vaccine Price In Development With GSK After Phase I/II Trial Results,"French drug maker Sanofi will announce the price of the potential COVID19 vaccine it is developing with Britain's GlaxoSmithKline after it has released Phase I/II results of the trials, vaccines chief Thomas Triomphe said on Thursday.",SAN,en,CNN-News18
2020-12-03 06:01:15-05:00,"Global Multiple Sclerosis Market 2020-2026 will change the Future | Major Giants –Teva Pharmaceutical Industries Ltd, Sanofi, Novartis AG, Merck & Co., Inc., F. Hoffmann-La Roche Ltd",Databridgemarketresearch.com Present “Global Multiple Sclerosis Market – Industry Trends and Forecast to 2027” new report to its research database. The report spread No of pages: 350 No of Figures: 60 No of Tables: 220 in it. Global Multiple Sclerosis Market,SAN,en,OpenPR
2020-12-02 10:04:41-05:00,"Global Biologics Market Incredible Possibilities, Growth Analysis And Forecast To 2027||Key Players-Novartis International AG, Pfizer, Inc., Amgen, Inc., AbbVie, Inc., Sanofi S.A., Eli Lilly & Company, Novo Nordisk A/S, Johnson & Johnson Services Inc","Data Bridge Market research released a new market study on Biologics with 100+ market data Tables, Pie Chart, Graphs & Figures spread through Pages and easy to understand detailed analysis In Biologics research report also directs the manufacturer about",SAN,en,OpenPR
2020-12-02 04:00:00-05:00,"NatWest Markets Plc, Banco Santander S.A. to Sell 5.6 Percent of SABB Shares",Citigroup Saudi Arabia and Goldman Sachs Saudi Arabia announced receiving a notification from NatWest Markets Plc and Banco Santander S…,SAN,en,Al Bawaba News
2020-11-28 13:08:21-05:00,Attention Biotech Investors: Mark Your Calendar For December PDUFA Dates,"The U.S. Food and Drug Administration's approval machinery churned out a lot of disappointments in November. Most of the negative verdicts were tied to difficulties the agency has had in inspecting facilities where investigational drugs are being manufactured, amid COVID-19-related restrictions. Supernus Pharmaceuticals Inc (NASDAQ: SUPN ), Alkermes Plc (NASDAQ: ALKS ), Adamis Pharmaceuticals Corp (NASDAQ: ADMP ), Bristol-Myers Squibb Co (NYSE: BMY ), Liquidia Technologies Inc (NASDAQ: LQDA ) and Revance Therapeutics Inc (NASDAQ: RVNC ) were among the companies that either received complete response letters (which indicate that the application is not ready for approval) or saw the review periods extended. Notable among the approvals issued during the month were Eiger Biopharmaceuticals Inc 's (NASDAQ: EIGR ) progeria treatment Zokinvy and Sanofi SA's (NASDAQ: SNY ) sutimlimab for treating hemolysis in adult patients with cold agglutinin disease. Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY ) was fortunate to get the FDA nod for its Oxlumo drug to treat primary hyperoxaluria type 1, ahead of the Dec. 3 PDUFA date.",SAN,en,Benzinga
2020-11-28 02:18:45-05:00,"Sanofi – World LAMEA Oncology/Anti-cancer medicine Market Developments, Progress Demand, Alternatives & Forecast To 2","Sanofi - World LAMEA Oncology/Anti-cancer medicine Market Developments, Progress Demand, Alternatives & Forecast To 2026 – The Courier -",SAN,en,Fintech Zoom
2020-11-27 14:18:08-05:00,Intelbras protocola prospecto para IPO,"Oferta de ações da fabricante de câmeras e equipamentos de segurança eletrônica e comunicação será primária e secundária A Intelbras protocolou na Comissão de Valores Mobiliários (CVM) o prospecto preliminar para a realização de uma oferta pública inicial de ações (IPO, na sigla em inglês). A oferta será primária - quando os recursos vão para o caixa da empresa - e secundária, quando os acionistas atuais vendem parte das suas fatias. Fundada em 1976 em Santa Catarina, a Intelbras se define como a maior fabricante nacional de câmeras e equipamentos de segurança eletrônica e comunicação. Diz estar presente em 98% dos municípios com potencial de consumo eletrônico no Brasil e exportar para diversos países. A rede de distribuição tem 370 distribuidores e quase 80 mil revendedores. Nos nove primeiros meses deste ano, a receita operacional líquida totalizou R$ 1,463 bilhão, representando um aumento de 20,2% quando comparado ao mesmo intervalo de 2019. O lucro foi de R$ 121,210 milhões, com expansão de 2,6%.",SAN,pt,Valor Econômico
2020-11-27 10:00:03-05:00,"Prostate Cancer Therapeutics Market 2020: Industry Analysis and Forecast : Top Key Players Johnson & Johnson Services, Inc., Astellas Pharma US, Inc., Sanofi, Ipsen Pharma, AbbVie Inc., Myovant Sciences Ltd.",DBMR has added a new report titled Global Prostate Cancer Therapeutics Market with data Tables for historical and forecast years represented with Chats & Graphs spread through Pages with easy to understand detailed analysis. Global Prostate Cancer Therapeutics Market analysis,SAN,en,OpenPR
2020-11-27 09:11:00-05:00,La ruptura BBVA-Sabadell aleja el mayor riesgo de oligopolio en el sector financiero,"No habrá fusión entre BBVA y Banco Sabadell y, más allá de las implicaciones que tenga para la rentabilidad, eficiencia y sostenibilidad de estas entidades y del sector, supone un alivio para la dinámica de mayor concentración bancaria . Aunque los supervisores financieros, preocupados por las variables mencionadas más que por la competencia, invitan a más fusiones e insisten en que hay margen, las alarmas saltaban en regiones como Cataluña , así como la amenaza de ajustes masivos a medio plazo en oficinas y plantilla. Los dos bancos han roto las negociaciones tras no llegar a un acuerdo de precio. Es decir, Sabadell pedía más de lo que BBVA estaba dispuesto a poner encima de la mesa . El mercado ha reaccionado con ventas de acciones del Sabadell, aunque la caída es menor a la subida que experimentó cuando se confirmaron las conversaciones, adelantadas por este medio. Con Banco Santander auto excluyéndose de las ecuaciones posibles de fusión mientras ultima otro expediente de regulación de empleo (ERE) y termina de digerir Popular , la fusión entre BBVA y Sabadell era la que añadía más presión contra la competencia después del acuerdo de unión entre CaixaBank y Bankia, que tendrán que ratificar las juntas de accionistas la semana que viene.",SAN,es,El Confidencial
2020-11-27 08:27:03-05:00,"Global Pancreatic Enzyme Replacement Therapy Market To Reflect Impressive Growth Rate by 2027 ||Shire Plc; Sanofi S.A., Biomarin Pharmaceutical Inc., AbbVie Inc, Alexion Pharmaceuticals Inc., Allergan plc, Horizon Pharma Public Limited Company","Data Bridge Market Research has provides the Qualitative and informative knowledge by adding titled “Global Pancreatic Enzyme Replacement Therapy Market, By Type (Enteric Coated and Non-Enteric Coated), Treatment (Medication, Therapy), Route of Administration (Oral, Parenteral, Others), End-Users (Hospitals, Specialty Clinics,",SAN,en,OpenPR
2020-11-26 19:41:08-05:00,El Santander propone prejubilaciones con 55 años,"El Banco Santander presentó ayer su propuesta para el expediente de regulación de empleo (ERE), que recoge cuatro tramos económicos en función de la edad del empleado y los años que lleve trabajando en el banco. La entidad prevé eliminar 5.072…",SAN,es,La Vanguardia
2020-11-26 14:24:57-05:00,Banco Santander propone prejubilaciones de hasta el 70% del salario pensionable para mayores de 55 años,"Banco Santander ha propuesto a los sindicatos indemnizaciones de 30 días por año trabajado para los empleados menores de 55 años que abandonen la entidad, con un máximo de 20 mensualidades , mientras que para aquellos que superen esa edad y…",SAN,es,Publico
2020-11-26 10:30:00-05:00,"Worldwide Male Infertility Industry to 2027 - Players Include Sanofi, Bayer & Endo Pharmaceuticals Among Others","DUBLIN, Nov. 26, 2020 /PRNewswire/ -- The ""Male Infertility Market Forecast to 2027 - COVID-19 Impact and Global Analysis by Test; Treatment Type; Distribution Channel; End User, and Geography"" report has been added to ResearchAndMarkets.com's offering. According to this report the market…",SAN,en,PR Newswire
2020-11-26 10:12:32-05:00,Santander propone prejubilaciones desde los 55 años con hasta el 70% del salario pensionable,"Banco Santander ha propuesto a los sindicatos indemnizaciones de 30 días por año trabajado para los empleados menores de 55 años que abandonen la entidad, con un máximo de 20 mensualidades, mientras que para aquellos que superen esa edad y lleven en el banco más de 15 años ofrece prejubilaciones que van desde el 55% hasta el 70% del salario pensionable, en función de la edad. Así lo han trasladado fuentes sindicales a Europa Press, tras la mesa de negociación celebrada este jueves, en la que el banco ha planteado las condiciones económicas por tramos de edad para el ERE, que inicialmente supondrá la salida de un máximo de 4.000 empleados. Para los empleados menores de 55 años o mayores de esa edad pero con menos de 15 años de antigüedad en la entidad, el Santander ha propuesto el pago de 30 días por año trabajado, con tope de 20 mensualidades. A los trabajadores de entre 55 y 57 años con al menos 15 años de antigüedad, les ofrece el 65% del salario pensionable, con descuento del importe de desempleo durante dos años, o el 55% del salario pensionable, con el 50% del complemento voluntario personal y descuento del importe de desempleo durante dos años, así como un convenio especial hasta los 63 años, con revalorización máxima del convenio especial 1%.",SAN,es,ABC Spain
2020-11-26 06:18:11-05:00,Finanzas para no dejar a nadie fuera,"Solucionar problemas cotidianos de la España vacía, ayudar a la población más vulnerable a acceder a servicios financieros o dar una base formativa en esta materia a niños, jóvenes o mayores, son algunos de los retos que afronta Banco Santander para lograr el empoderamiento financiero de millones de personas",SAN,es,El Pais
2020-11-26 03:10:00-05:00,El Ibex 35 pone en peligro los 8.100 puntos sin Wall Street,"Crónica de la sesión del Ibex 35 hoy. Apertura con caídas del Ibex 35 hoy, sin Wall Street. Caídas de Repsol y Banco Santander en el Ibex 35 hoy.",SAN,es,Estrategias de inversión
2020-11-25 19:25:48-05:00,Claves para encontrar viviendas con precios rebajados,"Tanto si estamos buscando una propiedad para mudarnos, como si queremos invertir en una segunda casa o un inmueble en la playa, hay algunos trucos que podemos tener en cuenta para poder encontrar viviendas con precios rebajados. Se puede tratar de unos pocos miles de euros o de rebajas mucho más abultadas. A veces, ese descuento nos servirá para tener acceso a pisos a los que, por presupuesto, antes no podíamos aspirar. En otras ocasiones, el ahorro que consigamos lo podremos utilizar para afrontar otros gastos que siempre vienen asociados a la compra de una casa (notario, impuestos, muebles, etc.). Tiempo y análisis La adquisición de una vivienda debe ser algo meditado y estudiado con tiempo. La decisión de dar un paso tan fundamental en la vida de cualquier persona debe venir acompañada de un proceso y una evolución, el tiempo y la paciencia juegan un papel clave. Una vez definidas las posibles zonas en las que realizar la operación de compra, es conveniente hacer un primer análisis del mercado inmobiliario en esos lugares.",SAN,es,ABC Spain
2020-11-24 21:12:41-05:00,El Banco Santander plantea el cierre de 44 oficinas en Euskadi dentro de su ajuste de plantilla,No summary available.,SAN,es,El Correo
2020-11-24 19:04:23-05:00,"Dengue Vaccine Market is Booming Worldwide with Sanofi, GlaxoSmithKline, Vabiotec","Global Dengue Vaccine Market Report 2020 by Key Players, Types, Applications, Countries, Market Size, Forecast to 2026 (Based on 2020 COVID-19 Worldwide Spread) is latest research study released by HTF MI evaluating the market, highlighting opportunities, risk side analysis, and",SAN,en,OpenPR
2020-11-24 13:08:07-05:00,Brussels secures 160 million doses of Moderna vaccines,"This Tuesday, the president of the Community executive, Ursula Von der Leyen, announced that on Wednesday Brussels will close the advance purchase of 160 million doses of the Moderna vaccine, a week after the American company announced that its treatment is 94.5% effective . ""According to the results of the first trials, it could be highly effective,"" explained Von der Leyen. This will be the sixth contract that the European Commission signs with pharmacists working on covid-19 vaccine Brussels is extending the catalogue of vaccines of which millions of doses have been pre-purchased to reach all the member states of the European Union in an ""equal"" way, as the president of the Commission reminds each time she announces a new contract. The last announcement was last week, when she announced the advance purchase of 405 million doses of vaccine from the German pharmaceutical company CureVac . Advance purchases of doses have already been signed with Pfizer-BioNTech, Johnson&Johnson, AstraZeneca, Sanofi, CureVac and Moderna.",SAN,en,Diara ARA
2020-11-24 11:05:15-05:00,Banco Santander compra negocio de pagos para comercios de Wirecard,https://es.investing.com/news/cryptocurrency-news/banco-santander-compra-negocio-de-pagos-para-comercios-de-wirecard-2060364,SAN,es,Investing.com Spain
2020-11-24 09:42:56-05:00,"Illa calcula que España podría llegar a vacunar a 80 millones de personas, el doble de su población","El Consejo de Ministros ha aprobado este martes la estrategia de vacunación contra Covid-19. El Gobierno prevé que en el primer semestre de 2021 se inmunice «a una parte muy sustancial» de la población . El proceso se iniciará en enero y consistirá en «una única estrategia de vacunación para todo el territorio». El ministro de Sanidad, Salvador Ill a , ha explicado las líneas generales de la estrategia durante la rueda de prensa del Consejo de Ministros. «Uno de los retos más importantes del país» , lo ha calificado. Illa ha explicado que se ha realizado «una evaluación de 18 grupos de población en función del criterio de mortalidad, exposición, impacto socio económico y riesgo de transmisión» para fijar quienes serán los primeros segmentos en recibir la vacuna. « Los residentes y personal socio sanitario en residencias de personas mayores, los sanitarios y las personas con discapacidad serán los primeros en vacunarse», ha dicho el ministro de Sanidad, como avanzó ABC hace unos días. Este grupo que se inmunizará en la primera etapa, empezando en enero, suponen un 2,5 millones de personas .",SAN,es,ABC Spain
2020-11-24 07:28:55-05:00,"Hydroxychloroquine Market - Sanofi S.A., Amneal Pharmaceuticals, Inc., Laurus Labs Limited, Zydus Pharmaceuticals, Inc., Prasco Laboratories, Dr. Reddy's Laboratories, Cadila Pharmaceuticals Novartis International AG",An informative study on the Hydroxychloroquine Market from 2020-2027 has lately released for the database of Coherent Market Insights that helps by making business conclusions and shape the future of the organizations. Individual analysis of top regions and countries like,SAN,en,OpenPR
2020-11-24 06:01:58-05:00,El futuro pasa por una economía verde,"En pleno debate sobre cómo atajar el calentamiento global, Banco Santander impulsa numerosas iniciativas en materia de sostenibilidad y de transición hacia energías limpias y renovables",SAN,es,El Pais
2020-11-23 09:00:00-05:00,"Sanofi's pediatric vaccine ""Hexaxim"" remains the most administered hexavalent vaccine in the world with 62% of volume share","NEW YORK, Nov. 23, 2020 /PRNewswire/ -- A new study on the usage patterns of pediatric hexavalent vaccines reveals that Sanofi's vaccine ""Hexaxim"" remains the most administered hexavalent vaccine in the world in 2019 with 62% of volume share, followed by Infanrix Hexa (32%,) and Vaxelis…",SAN,en,PR Newswire
2020-11-23 07:38:15-05:00,"Predictive Analytics in Vitamin D Therapy Market Dynamics, Comprehensive Analysis, Prospects and Opportunities 2020-2026 Abbott, Sanofi, GlaxoSmithKline plc, Pfizer Inc., Merck & Co., Inc. , Torrent Pharmaceuticals Ltd.","Global Vitamin D Therapy Market Research Report study provides extensive information which advances the understanding, scope and application of this report. Global Vitamin D Therapy Market research report provides a real industry outlook, future trends and dynamics for market growth",SAN,en,OpenPR
2020-11-23 07:12:32-05:00,"Influenza Vaccine Market Report 2020 – Industry Capacity, Manufacturer, Value, Consumption, Status, and Growth Prediction 2027 | Seqirus Vaccines Limited, GlaxoSmithKline plc, ID Biomedical Corporation, Sanofi, Protein Sciences Corp., MedImmmune LLC","Stratagem Market Insights has recently added an Influenza Vaccine Market Research Report that reveals diverse information allowing keen market participants to understand the measures of the market. The report provides an overview of competitive landscape analysis, major trends, and key",SAN,en,OpenPR
2020-11-23 06:25:44-05:00,"Global Cancer Care Market 2020:The Next Booming Segment In The World||Sanofi, Ipsen Pharma, AbbVie Inc., Myovant Sciences Ltd., Bayer AG, AstraZeneca, Tolmar Pharmaceuticals, Inc","Global Cancer Care market research report utilizes a SWOT analysis as well as Porter’s Five Forces analysis to reveal the strengths, weaknesses, opportunities, and threats. This report is a valuable source of guidance for companies and individuals offering Industry Chain",SAN,en,OpenPR
2020-11-23 04:09:39-05:00,La financiación alternativa y de impacto también puede ser para las pymes,"El segundo panel digital de Radar Pyme, iniciativa de Retina y Banco Santander, se centrará en la financiación alternativa y de impacto, una vía para pequeñas y medianas empresas con gran potencial de crecimiento. Síguelo aquí mismo en “streaming” a patir de las 18:00h.",SAN,es,El Pais
2020-11-23 01:12:00-05:00,"Se vende cantera en Teruel: razón, Banco Santander","La autorización para explotar una enorme pedrera de la que en 28 años saldría un volumen de roca mayor que el tamaño de estadios como el Santiago Bernabéu o el Camp Nou, en un proyecto que la entidad financiera mantiene vivo para venderlo mientras renuncia a gestionarlo, causa inquietud en el Bajo Aragón y el Maestrazgo turolenses",SAN,es,Publico
2020-11-22 12:04:36-05:00,Cinco sentencias condenan al Banco Santander a devolver más de 400.000 euros en 'Valores Santander',"Cinco sentencias dictadas por juzgados de la capital cántabra condenan al Banco Santander a devolver más de 400.000 euros por el producto 'Valores Santander', una especie de bonos comercializados en 2007 y que mediante un canje ofrecido en 2012…",SAN,es,Publico
2020-11-22 07:22:41-05:00,"The Week Ahead In Biotech: Moderna Vaccine And Roche, Revance, Rhythm, Liquidia FDA Updates","Biotech stocks came under pressure in the week ended Nov. 20, reversing course from the previous week. The sector started the week on a strong note, thanks to positive vaccine data reported by Moderna Inc (NASDAQ: MRNA ). The momentum faltered through the week after the broader market came under pressure amid fresh COVID-19 restrictions. Earnings news flow slowed considerably. On the regulatory front, Sanofi SA (NASDAQ: SNY ) was handed a complete response letter for its sutimlimab biologics license application. ""The CRL refers to certain deficiencies identified by the agency during a pre-license inspection of a third-party facility responsible for manufacturing,"" the company said in a release. Sutimlimab is an investigational monoclonal antibody for the treatment of hemolysis in adults with cold agglutinin disease. Alkermes Plc (NASDAQ: ALKS ) also faced a rejection, with the FDA turning down the regulatory application for its schizophrenia drug. Meanwhile, Eli Lilly And Co (NYSE: LLY ) received …",SAN,en,Benzinga
2020-11-22 02:21:07-05:00,"Astra-Oxford shot is key to escaping pandemic for many nations, including India","Trial successes from Pfizer Inc. and Moderna Inc. have buoyed hopes that a Covid-19 vaccine is coming soon. But much of the world, outside of rich nations like the U.S., is counting on another company’s shot to escape the crisis.Findings from the final stage of AstraZeneca Plc’s vaccine studies are due to be released shortly, and the stakes for lower- and middle-income nations are immense. The shot developed with the University of Oxford accounts for more than 40% of the supplies going to those countries, based on deals tracked by London-based research firm Airfinity Ltd.The Astra vaccine costs a fraction of the price set by Pfizer and will be manufactured in multiple countries, from India to Brazil. It should be easier to deploy far and wide than other shots that need to be stored at ultra-cold temperatures. But if the U.K. partners can’t match the lofty efficacy levels Pfizer and Moderna delivered or roll out their inoculation quickly, the pandemic might continue spreading death and disease in countries relying on it.“There’s a lot riding on the Astra vaccine,” said Suerie Moon, co-director of the Global Health Centre at the Graduate Institute of International and Development Studies in Geneva.",SAN,en,Economic Times India
2020-11-21 20:07:16-05:00,¿Hasta dónde podrá llegar el Ibex 35?,"El Ibex-35 se encuentra en su mejor momento desde el comienzo de la pandemia. Los avances en las vacunas y las operaciones corporativas bancarias están impulsando al selectivo, que vive su particular remontada desde comienzos de noviembre. Entonces, el índice arrancó el mes en algo más de 6.850 puntos. Ahora se mueve en el entorno de las 8.000 unidades y mira hacia cotas más altas, que podrían superar incluso los niveles previos a la crisis sanitaria. «Ha rebotado desde un soporte vital y presenta buen aspecto», comenta Carlos Galán, CEO de Scalping.es. Tras el anuncio de la eficacia de la vacuna de Pfizer, el Ibex registró la mayor subida en más de una década, que le sirvió para recuperar gran parte del terreno perdido. Hasta principios de noviembre, el desplome del índice superaba el 32% frente al 17% actual. «El primer objetivo de rebote, si supera los 8.300 puntos, es que lo veamos en los 10.000. El ángulo que presenta en vertical es positivo, y se suele dar al inicio de los grandes movimientos», apunta Galán, sobre las perspectivas del índice.",SAN,es,ABC Spain
2020-11-21 05:40:29-05:00,El Santander inaugura unas jornadas para promover la igualdad de oportunidades,"El Banco Santander ha inaugurado esta semana la tercera edición de su curso "" Mujeres con S "", unas jornadas de formación para promover la igualdad de oportunidades y reforzar las posibilidades de promoción de las trabajadoras. Así lo ha hecho público la entidad bancaria en un comunicado, en el que destaca la participación en las jornadas celebradas en Barcelona del consejero delegado de la entidad, Rami Aboukhair . Seguir leyendo… .",SAN,es,El Periodico
2020-11-20 10:02:05-05:00,"Facial Injections Market to Reflect Significant Growth During 2020–2025 | Allergan, Galdermal (Q-Med), Sanofi Aventis, Bohus BioTech","The Facial Injections market 2020 research report is a detailed view of market opportunity by end-user segments, product Type segments, sales channels, key countries. It also provides market credentials such as history, various development and trends, market overview, regional markets",SAN,en,OpenPR
2020-11-20 08:03:50-05:00,"Global Biologics Market Outlook On Key Growth Trends and Forecast Until 2027||Top Leaders-Novartis International AG, Pfizer, Inc., Amgen, Inc., AbbVie, Inc., Sanofi S.A., Eli Lilly & Company, Novo Nordisk A/S, Johnson & Johnson Services Inc","Data Bridge Market research presents the top quality and comprehensive Biologics research report which provides clear insights into market dynamics and prospects the whole market including global production, revenue forecast, value and volume. This Biologics report deeply study competitive",SAN,en,OpenPR
2020-11-20 05:47:10-05:00,"Multiple Sclerosis Drugs Market Size & Share Expanding Across the Globe by 2020-2027 | Top Key Players Biogen, Teva Pharmaceutical, Merck KGaA,Novartis, Bayer, Sanofi",Multiple sclerosis (MS) is a sensory system ailment which influences spinal rope and the mind. MS harms the myelin sheath. Myelin sheath is a term which epitomizes that material which encompasses and secures human nerve cells. This harm squares messages,SAN,en,OpenPR
2020-11-19 23:57:12-05:00,"Vaccines and Vaccination Market Will Be Massively Influenced By Macroeconomic Factors 2020-2025 | International Players – J&J, Pfizer, GSK, Abbott, Novartis, Bio-Med, Merck, Sanofi","BusinessIndustryReports has recently broadcasted a new study to its broad research portfolio, which is titled as “Global Vaccines and Vaccination Market” Research Report 2020 provides an in-depth analysis of the Vaccines and Vaccination with the forecast of market size and",SAN,en,OpenPR
2020-11-19 23:55:45-05:00,"Pharma & Cosmetic Market Excessive Growth Opportunities Estimated to Be Experienced 2020-2025 | International Company’s – J&J, GSK, Roche, Novartis, Pfizer, Sanofi, Eli Lilly, Bayer, Merck, L'OREAL, Unilever",Global Pharma & Cosmetic Market Synopsis: The exclusive research report on the Global Pharma & Cosmetic Market 2020-2025 examines the market in detail along with focusing on significant market dynamics for the key players operating in the market. Global Pharma &,SAN,en,OpenPR
2020-11-19 19:34:20-05:00,Justiça rejeita pedido de liminar do Itaú contra aditamento ao plano de recuperação da Oi,"Em recurso apresentado no fim de outubro, o banco pedia a suspensão do cumprimento das disposições contidas no aditamento A desembargadora Mônica Maria da Costa, da 8ª Câmara Cível do Tribunal de Justiça do Estado do Rio de Janeiro, negou nesta quinta-feira (19) pedido de liminar apresentado por advogados que representam o Itaú Unibanco contra a decisão que homologou o aditamento (acréscimo) ao plano de recuperação judicial da Oi. Em recurso apresentado no fim do mês passado, o banco pedia a suspensão do cumprimento das disposições contidas no aditamento, além do bloqueio de recursos provenientes de futuros leilões de ativos da operadora. No texto da sua decisão, datada de hoje, a desembargadora ressalta que “não há como ser acolhido o pedido de efeito suspensivo formulado, nesse momento processual, sob pena de que a pretensão do recorrente [Itaú Unibanco], dissociada da vontade maioria dos credores, amplie o prejuízo social e econômico, culminando em um cenário pior para todos os sujeitos envolvidos neste processo.” Além do pedido do Itaú Unibanco, foram rejeitados nesta semana pela Justiça pedidos de liminares apresentados por Banco do Brasil e Santander, credores da Oi que também tentavam suspender os leilões judiciais de ativos ou bloquear os valores oriundos dessas operações.",SAN,pt,Valor Econômico
2020-11-19 08:47:00-05:00,Allianz lanza sus propios planes de pensiones tras perder los acuerdos del Popular,"Allianz Seguros ha entrado en el mercado de planes de pensiones de España con el lanzamiento de tres nuevos productos para distintos perfiles de ahorradores en función del nivel de riesgo, expectativas de rentabilidad y horizonte temporal, de cara a complementar su pensión para la jubilación. La entrada en el mercado de pensiones se enmarca en su plan estratégico de vida y gestión de activos. ""Allianz ya es uno de los principales gestores del patrimonio de los ciudadanos a nivel global y también queremos serlo en España"", ha afirmado la subdirectora general y responsable de vida, salud y gestión de activos, Susana Mendia . La compañía alemana tenía un acuerdo de seguros y planes de pensiones con el Banco Popular , que se rompió tras su absorción por el Banco Santander, que pagó a Allianz 936 millones de euros por la finalización de ese acuerdo. Ahora, ha optado por crear un equipo específico, para administrar y gestionar sus planes de pensiones. Santander recompra los seguros del Popular a Allianz con un coste de 485 millones J.",SAN,es,El Confidencial
2020-11-19 05:26:43-05:00,"Bladder Cancer Therapeutics Market Is Projected To Witness Vigorous Expansion By 2026 || Pfizer, Inc., Sanofi S.A., Novartis AG, GlaxoSmithKline plc, F Hoffmaan La Roche Ltd",DBMR has added a new report titled Bladder Cancer Therapeutics Market with data Tables for historical and forecast years represented with Chats & Graphs spread through Pages with easy to understand detailed analysis. This Bladder Cancer Therapeutics Market report is,SAN,en,OpenPR
2020-11-18 15:27:10-05:00,Santander avoids merger wave in favor of digital growth,"Banco Santander SA is planning to sit out the wave of banking mergers sweeping its home market of Spain, opting instead to expand its digital platform. “We’re not about to participate in any, let’s say, traditional bank consolidation,” Chairman Ana Botin said in a panel discussion at the Bloomberg New Economy Forum on Tuesday. “We […]",SAN,en,Bank Innovation
2020-11-18 07:40:01-05:00,Oi (OIBR3): Bancos pedem à Justiça suspensão da venda de ativos,"Os bancos Itaú (ITUB4), Santander (SANB11), BB (BBSA3) e Caixa diram a Justiça que os valores da venda da Oi fossem suspensos. Clique aqui",SAN,pt,Suno Research
2020-11-18 07:07:27-05:00,"Recent Updates on Oral Electrolyte Solutions Market 2020-2027, Global Players are Johnson & Johnson Services, Inc., Sanofi, Abbott",Global Oral Electrolyte Solutions Market report brings into light key market dynamics of the sector. It provides guidelines about planning of advertising and sales promotion efforts. The market report is a professional yet exhaustive study on the current state for,SAN,en,OpenPR
2020-11-18 06:48:00-05:00,"Recent Updates on Chronic Kidney Disease (CKD) Market 2020-2026, Global Players are Bristol-Myers Squibb Company, GlaxoSmithKline Plc , Novartis AG, Sanofi S.A",Global Chronic Kidney Disease (CKD) Market report brings into light key market dynamics of the sector. It provides guidelines about planning of advertising and sales promotion efforts. The market report is a professional yet exhaustive study on the current state,SAN,en,OpenPR
2020-11-18 04:02:00-05:00,Banco Santander redobla sus esfuerzos en favor de colectivos vulnerables en Latinoamérica,"La iniciativa global 'Santander Todos. Juntos. Ahora.' ha alcanzado los 105 millones de euros destinados a iniciativas solidarias para luchar contra la COVID-19. En Chile, por ejemplo, ha puesto en marcha el programa Becas de Alfabetización Digital que beneficiará a 200 personas que se capacitarán en conceptos y habilidades básicas de informática, contribuyendo así en su búsqueda de nuevas oportunidades sociales y económicas.",SAN,es,Publico
2020-11-18 01:36:47-05:00,Sanofi's rilzabrutinib Fast Track'd in U.S. for low platelet count (NASDAQ:SNY),"The FDA has granted Fast Track Designation to Sanofi's (NASDAQ:SNY) oral investigational Bruton’s tyrosine kinase inhibitor, rilzabrutinib, for the treatme",SAN,en,Seeking Alpha
2020-11-18 00:42:46-05:00,"Atrial Fibrillation Market: Product Development Strategies by Industry Giants: Medtronic, Abbott, Sanofi, CardioFocus, Biosense Webster, AtriCure, Boston Scientific Corporation","""Atrial Fibrillation Market"" New Report Published by Insight Partners market: Global Analysis and Forecast by 2020-2027. Major industry players operating in the field of Atrial Fibrillation across the globe include Boston Scientific Corporation, Medtronic, AtriCure, Inc, Biosense Webster, Inc., BOEHRINGER INGELHEIM",SAN,en,OpenPR
2020-11-17 16:15:00-05:00,"Ziopharm Oncology Appoints Raffaele Baffa, M.D., Ph.D., as Chief Medical Officer - Stocks News Feed","– Pharmaceutical Executive with 20+ Years of Experience Across All Phases of Clinical Research Including IND Submissions, Trial Design and Regulatory Filings – – Former Chief Medical Officer for Servier Pharmaceuticals; Oncology R&D Leadership Roles at Shire, Pfizer and Sanofi – BOSTON, Nov. 17, 2020 (GLOBE NEWSWIRE) — Ziopharm Oncology, Inc. (“Ziopharm” or “the Company”)… Read More »Ziopharm Oncology Appoints Raffaele Baffa, M.D., Ph.D., as Chief Medical Officer",SAN,en,Stocks News Feed
2020-11-17 12:50:02-05:00,"Immuno-Oncology Drugs Market to Observe Exponential Growth by 2020-2027 | Pfizer, Abbvie, Novartis, Sanofi, Eli lilly, Celgene, Amgen",Oncology medications are flourishing business for the pharmaceutical industry. Almost the major market players in this field are either manufacturing oncology drugs or have oncology medications in their pipeline as potential medications to sell in the coming years. Cancer affects,SAN,en,OpenPR
2020-11-17 12:20:46-05:00,El Banco Santander descarta protagonizar una operación de consolidación en el corto plazo,El consejero delegado de la entidad reconoce que tendrán que mejorar su eficiencia para competir en el sistema bancario actual,SAN,es,El Pais
2020-11-17 12:05:45-05:00,La Cámara de Comercio y Banco Santander entregan el Premio Pyme del Año de Madrid a una empresa dedicada a la investigación en farmacia,"La ganadora, Juste, ha tenido un papel activo durante la pandemia al repartir 12.000 litros de gel hidroalcohólico y 14.000 mascarillas",SAN,es,El Pais
2020-11-17 11:58:00-05:00,When can I get a coronavirus vaccine?,"Summary List Placement People in the US will likely have a few different, highly effective, safe coronavirus vaccines to use in 2021. Last week, Pfizer announced its super cold vaccine was 90% effective at preventing COVID-19 infections. Then on Monday, Moderna chimed in with its latest trial results , showing that shot (which can be kept in the fridge for a month ) is 94.5% effective. But, don't roll up your sleeves and ready your arm for a needle just yet, or start trashing your face masks. It will still take many more months for healthcare providers to insert these new shots into enough members of the general public to make a dent in the pandemic. Here are the key milestones to watch out for. First, the FDA needs to grant Emergency Use Authorization Pfizer and Moderna don't get to decide when their shots go on the market. First, they both need to pass muster with the US Food and Drug Administration (FDA). Dr. Peter Marks, who runs the FDA's Center for Biologics Evaluation and Research, where coronavirus vaccines are reviewed, recently told Business Insider that the process of reviewing Pfizer and Moderna's applications for Emergency Use Authorization, fast-tracking the shots into clinics, will still take ""weeks."" ""We have to take the amount of time that we need to take,"" Marks said.",SAN,en,Business Insider
2020-11-17 11:06:59-05:00,"Las exigencias de la banca al Gobierno: fondos europeos, ayudas directas y confianza","Primera jornada del XXVII Encuentro del Sector Financiero de ABC-Deloitte, con el patrocinio de Sociedad de Tasación. Y primera jornada plagada de reinvindicaciones y peticiones al Gobierno. Una batería de mensajes desde Banco Santander, Bankia y Banco Sabadell de cara a la salida de la crisis y posterior recuperación. Tres ejes muy concretos: fondos europeos, ayudas directas a empresas y confianza. José Antonio Álvarez ha sido el primer ejecutivo bancario en lanzar su discurso, con el Ejecutivo claramente en la diana. «La acción de los bancos centrales y gobiernos necesariamente tiene que prolongarse más allá del puro hecho de la disponibilidad de la vacuna», ha señalado el consejero delegado de Banco Santander, precisamente en un foro que lleva este año por título «Construyendo el futuro». Nada de reitrar los estímulos antes de tiempo. Sobre ese futuro ha hecho mucho hincapié el directivo de la entidad de origen cántabro al señar que «el sector público», esto es, el Gobierno, «tiene que fabricar confianza y un marco para desarrollar la actividad» empresarial.",SAN,es,ABC Spain
2020-11-17 07:04:22-05:00,"Clinical Trials Market : COVID-19 Impact Analysis with Size, Share, Industry Outlook and Future Scope, Leading Players are Eli Lilly and Company, ICON Plc., Novo Nordisk, Pfizer, IQVIA, Sanofi, F. Hoffmann-La Roche","Analysis and discussion of important industry trends, market size, and market share estimates are revealed in the Clinical Trials Market research report. Further, manufacturer can adjust production according to the conditions of demand which are analyzed here. The report aids",SAN,en,OpenPR
2020-11-17 06:32:53-05:00,Spanische Banco Santander übernimmt Kerngeschäft von Wirecard - Aktie zweistellig im Plus,Kurz vor der ersten Gläubigerversammlung beim Skandalkonzern Wirecard kauft die spanische Großbank Santander das Kerngeschäft des insolventen Zahlungsabwicklers.,SAN,de,FOCUS Online
2020-11-17 06:26:28-05:00,La creación de empleo y riqueza tiene premio en Teruel,"La Cámara de Comercio y el Banco Santander distinguen a Transverich, Honze Teruel, Manjares de la Tierra y Contratas Ancar, por su labor",SAN,es,Heraldo
2020-11-17 06:13:41-05:00,"Active Pharmaceutical Ingredients (API) Market : COVID-19 Impact Analysis with Size, Share, Industry Outlook and Future Scope, Leading Players are Pfizer, Novartis AG, Sanofi, Eli Lilly and Company., Mylan N.V., Piramal Pharma Solutions","Analysis and discussion of important industry trends, market size, and market share estimates are revealed in the Active Pharmaceutical Ingredients (API) Market research report. Further, manufacturer can adjust production according to the conditions of demand which are analyzed here. The",SAN,en,OpenPR
2020-11-17 05:21:00-05:00,Álvarez (Santander): “La consolidación del sector bancario responde a la baja rentabilidad”,"El consejero delegado del banco Santander, José Antonio Álvarez, ha defendido, en unas jornadas bancarias organizadas por Deloitte y ABC, que la consolidación del sector bancario responde a la baja rentabilidad del sistema”. En su opinión, hay…",SAN,es,La Vanguardia
2020-11-17 04:56:28-05:00,Álvarez (Santander): «La acción del Gobierno debe prolongarse más allá de la vacuna»,"José Antonio Álvarez, consejero delegado de Banco Santander, ha sido muy claro sobre la crisis: no va a haber una recuperación total temprana. En este sentido, no ha dudado en reclamar el mantenimiento de los estímulos. «La acción de los bancos centrales y gobiernos necesariamente tiene que prolongarse más allá del puro hecho de la disponibilidad de la vacuna», ha asegurado, en el XXVII Encuentro del Sector Financiero organizado por ABC y Deloitte, bajo el patrocinio de Sociedad de Tasación, con el título «Construyendo el futuro». En este sentido, ha hecho hincapié en la necesidad de «recuperar la confianza, las ganas de hacer e invertir, las ganas de tener proyectos». Una labor de la sociedad en su conjunto, pero centrando el tiro en las administraciones: «El sector público tiene que fabricar esa confianza y marco para desarrollar la actividad». «Tenemos un tiempo difícil por delante, con mayor desempleo, en el que habrá que tomar decisiones empresariales. Las compañías viables no podemos dejar de financiarlas, para evitar que tengan problemas y generen riqueza.",SAN,es,ABC Spain
2020-11-17 03:42:05-05:00,Santander compra activos de Wirecard para impulsar su plataforma de pagos Getnet,"Banco Santander anunció a última hora del lunes la compra de activos tecnológicos de la malograda empresa alemana Wirecard, una operación que permitirá al banco español agilizar la expansión en Europa de Getnet, su plataforma de pagos en comercios cuya segregación ya está…",SAN,es,Reuters Latin America
2020-11-17 02:00:32-05:00,Wirecard Aktie wird langsam zur leeren Hülle: Ausverkauf der Kernsparte an Santander | www.4investors.de,"Immer mehr Geschäftsbereiche des insolventen Skandal-Konzerns Wirecard werden verkauft - nun auch die Kernsparte, die an die Banco Santander geht. Der",SAN,de,4investors
2020-11-16 14:34:00-05:00,El Santander compra el negocio de pagos para comercios de Wirecard tras la quiebra,"El Banco Santander ha cerrado este lunes un acuerdo con el administrador de varias entidades de Wirecard , Dr. Michael Jaffé, y Wirecard Bank AG para adquirir varios activos tecnológicos especializados del negocio de servicios de pago para comercios de la 'fintech' alemana quebrada este año, según ha explicado la entidad en un comunicado. El importe de la operación no ha trascendido. Según explica el Santander en la nota, el banco tiene como objetivo reforzar e acelerar sus planes de crecimiento de este negocio en la región, con los cerca de 500 empleados que gestionan en la actualidad los activos adquiridos pasando a formar parte de la entidad. Estos trabajadores continuarán trabajando donde se encuentran actualmente pero formarán parte del equipo global de servicios para comercios de Santander bajo la franquicia global Getnet . La 'fintech' alemana apadrinada por el BBVA descarta pujar por activos de Wirecard Cotizalia ""Al final, decidimos no hacer ofertas - ni siquiera por partes de Wirecard"", dijo el CEO de la 'fintech' Roland Folz en una entrevista.",SAN,es,El Confidencial
2020-11-16 13:35:00-05:00,"Spain's Santander In Talks To Buy Wirecard Bank, Other Assets Out Of Bankruptcy","Spain's Santander In Talks To Buy Wirecard Bank, Other Assets Out Of Bankruptcy Tyler Durden Mon, 11/16/2020 - 13:35 Even though auditors eventually determined that roughly 2/3rds of Wirecard's revenue (including practically all of its Asian business) was fraudulent, there are still a few businesses and assets, including Wirecard's former European banking unit, and its payments software, that have been deemed valuable. And the company's German bankruptcy trustee has been working to sell these businesses off piecemeal, with buyers lined up to buy WC businesses in Brazil and elsewhere. Now, Bloomberg reported Monday that Spanish bank Santander is in late-stage talks to buy Wirecard Bank, a small European lender run by Wirecard, along with some smaller subsidiaries, in what is shaping up to be the biggest deal involving former Wirecard assets, marking ""the final step"" of the bankrupt former tech darling's dissolution. Banco Santander SA is closing in on a purchase of Wirecard AG’s core business, according to people familiar with the matter, a move that would mark the final step of the failed German payment processor’s wind down.",SAN,en,Zero Hedge
2020-11-16 13:11:13-05:00,"La Nocturna de Toledo, virtual del 26 al 29 de noviembre a beneficio de la Fundación Niemann-Pick","El concejal de Deportes del Ayuntamiento de Toledo, Pablo García, ha presentado este lunes una nueva edición de La Nocturna de Toledo. Se desarrollará este fin de semana, durante cuatro jornadas y de manera individual, dadas las restricciones socio-sanitarias motivadas por la pandemia de la Covid-19. Con un total de 13 ediciones, se trata de una de las pruebas deportivas más conocidas y multitudinarias de cuantas se desarrollan en la capital regional. En 2020 contó con alrededor de 4.000 dorsales. La presentación se ha desarrollado ante los medios de manera telemática. «Estamos ante una de las carreras más emblemáticas; por eso, y a pesar de las dificultades para realizar eventos dada la situación sanitaria, desde el Ayuntamiento tuvimos claro que La Nocturna no podía faltar en el calendario de pruebas deportivas del 2020», ha indicado el concejal. Un año más, la recaudación de La Nocturna se destinará a proyectos de la Fundación Niemann-Pick de España. Al tratarse de una prueba virtual, los inscritos tienen para realizar el itinerario oficial desde el jueves 26 hasta el domingo 29; es decir, todo el fin de semana. «Por cuestiones obvias la carrera no puede contar con una salida o meta fija, ni con un recorrido u horario establecido, pero no por ello vamos a dejar de animaros a que cada corredor lo haga desde su punto más cercano para evitar aglomeraciones y en el trayecto que decidan», ha explicado Pablo García.",SAN,es,ABC Spain
2020-11-16 11:22:25-05:00,CureVac deal takes EU's COVID vaccine supplies close to 2 billion | Health,"The deal with CureVac follows EU supply agreements with AstraZeneca, Johnson & Johnson, Sanofi , and Pfizer for a combined 1.4 billion doses of their potential vaccines. ""I am glad to announce a new agreement to buy up to 405 million doses of a vaccine produced by the European company CureVac,"" European Commission President Ursula von der Leyen said, adding the contract was negotiated after EU funding to the company to develop its vaccine.",SAN,en,Devdiscourse
2020-11-16 11:00:34-05:00,"Biologics Market Research Outlook to 2020-2027 |Top leading companies Sanofi, Eli Lilly & Company, GSK Biologicals, Becton","Rise in incidences of chronic diseases, loss of patent extensions of branded drugs, and the increased availability of advanced diagnostics is expected to boost the growth of biologics market. In addition, growth in technology for the production of biologics is",SAN,en,OpenPR
2020-11-16 04:59:11-05:00,France's Pharma Giant Sanofi to Put Its COVID-19 Vaccine on Market by June - Official,No summary available.,SAN,en,UrduPoint
2020-11-16 04:23:03-05:00,Ana Botín reclama la llegada de los fondos de la UE para apoyar a las pymes,La presidenta del Banco Santander ha indicado que los recursos deben impulsar la digitalización de las empresas y acelerar la transición hacia una economía sostenible.,SAN,es,La Información
2020-11-16 03:19:20-05:00,French firm's Covid vaccine 'won't need special fridges for storage',"The coronavirus vaccine being developed by Sanofi won't need to be super-cooled and a normal refrigerator will suffice, the Paris-based drugmaker's France chief Olivier Bogillot said on Sunday.",SAN,en,The Local France
2020-11-16 00:46:05-05:00,"Sanofi says its covid vaccine won't need supercooling, can be kept in fridge","The Sanofi vaccine, one of many in development, will be available for distribution next June",SAN,en,Livemint
2020-11-14 11:33:40-05:00,BBVA lidera la representación española en el Dow Jones Sustainability Index,"En concreto, 19 empresas españolas aparecen en la edición de este año. Además de BBVA, se incluye a ACS, Banco Santander, Bankia, Bankinter, CaixaBank, Enagás, Endesa, Ferrovial, I",SAN,es,Expansion
2020-11-13 22:30:00-05:00,Santander y el Estado salen del consejo de Lleidanet tras el final de su pacto,"Enisa, SEPI y Banco Santander, que agrupaban el 21% del capital de forma sindicada, piden a su consejero en la tecnológica que renuncie al puesto y este presenta su dimisión.",SAN,es,La Información
2020-11-13 22:30:00-05:00,"Operación limpieza en Santander: ajuste de empleo, provisiones... ¿y dividendo?",Banco Santander se ha puesto manos a la obra y ha aprovechado el peor año económico desde la Guerra Civil para llevar a cabo varios movimientos clave que definen la estrategia de futuro tras la pandemia.,SAN,es,La Información
2020-11-13 20:10:58-05:00,El Santander planea un ERE para 4.000 trabajadores y reubicar a otros 1.090,"La dirección del banco Santander comunicó ayer a los sindicatos que sobran 5.090 personas en la plantilla de España, pero que el expediente de regulación de empleo (ERE) puede reducirse a 4.000 personas si 1.090 trabajadores aceptan reubicaciones…",SAN,es,La Vanguardia
2020-11-13 11:45:09-05:00,El Ibex 35 sube menos del 1% y cierra su mejor semana en dos décadas,"El Ibex 35 se ha despedido de su mejor semana en 20 años con una subida de 0,76% hasta los 7.785 puntos. Además en muchos momentos de la sesión, ha rozado la cota de los 7.800 puntos marca que no registraba desde el pasado 8 de junio, cuando tocó los 7.8196,10 punto. De esta forma, el selectivo español ha logrado prolongar la euforia desatada por el anuncio de que la vacuna que elaboran Pfizer y BioNTech tiene una efectividad del 90% tras 28 días de tratamiento, a lo que se ha confirmado el cambio en la Casa Blanca con la victoria del demócrata Joe Biden. La subidas han sido lideradas por el sector bancario, con mucho peso dentro del índice - más de un tercio- y por Naturgy, cuyas acciones se han revalorizado un 7,51% tras conocerse la venta de sus redes electricas en Chile a la compañía estatal China State Grid International Development Limited (SGID) por 2.570 millones de euros. La española mantiene en el país latinoamericano sus negocios de distribución de gas y generación eléctrica a partir de renovables.",SAN,es,ABC Spain
2020-11-13 09:45:24-05:00,El Banco Santander plantea a los sindicatos la salida de 4.000 trabajadores y la reubicación de 1.000 más,"El Banco Santander ha propuesto este viernes a la representación sindica la salida de la entidad de 4.000 empleados en España, cerca del 13% de la plantilla, y la intención de reubicar a 1.090 trabajadores más en otras sociedades del grupo bancario. En total, las necesidades de amortización son 5.040 puestos de trabajo. La idea es que las salidas de los trabajadores se produzcan principalmente mediante prejubilaciones, ya que el banco cuenta con unos 4.000 empleados con más de 55 años, y bajas incentivadas; para las reubicaciones jugará un papel clave Santander Personal, la división de la entidad que atiende a los clientes de forma remota a través de gestores personales. Además, desde el banco han justificado que este nuevo plan de ajuste en que también llevará aparejado el cierre de entre 900 y 1.000 sucursales en España, de un total de unas 3.100 oficinas, por causas económicas y organizativas, tras constatar que la pandemia ha acelerado la relación con los clientes por vías digitales.",SAN,es,ABC Spain
2020-11-13 09:00:26-05:00,Banco Santander plantea un ERE para 4.000 empleados,"La dirección de Banco Santander ha trasladado a los sindicatos su intención de acometer un Expediente de Regulación de Empleo (ERE) para un máximo de 4.000 personas, es decir, el 14,78% de su plantilla en España, y de reubicar a otros 1.100 empleados. (Fuente: Europa Press/CEOE)",SAN,es,Publico
2020-11-13 08:52:06-05:00,Banco Santander planea un ERE para 4.000 empleados y el cierre de hasta 1.000 oficinas,El Banco Santander se suma a la lista de entidades financieras que preparan ajustes de plantilla para hacer frente a los cambios en el sector provocados por la pandemia. La entidad ha planteado a los sindicatos un expediente de regulación de empleo…,SAN,es,La Vanguardia
2020-11-13 08:15:00-05:00,El Banco Santander plantea un ERE de 4.000 empleados y reubicar a otros 1.090,https://es.investing.com/news/economic-indicators/el-banco-santander-plantea-un-ere-de-4000-empleados-y-reubicar-a-otros-1090-2056871,SAN,es,Investing.com Spain
2020-11-13 07:42:00-05:00,El Banco Santander plantea un ERE de 4.000 empleados y reubicar más de 1.000,https://es.investing.com/news/economic-indicators/el-banco-santander-plantea-un-ere-de-4000-empleados-y-reubicar-mas-de-1000-2056846,SAN,es,Investing.com Spain
2020-11-13 07:40:10-05:00,"The Daily Biotech Pulse: Urovant In M&A Deal, Sanofi's Binary Event, Conference Presentations","Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Nov. 12) ALX Oncology Holdings Inc (NASDAQ: ALXO ) Biohaven Pharmaceutical Holding Co Ltd (NYSE: BHVN ) Celldex Therapeutics, Inc. (NASDAQ: CLDX ) Denali Therapeutics Inc (NASDAQ: DNLI ) Eidos Therapeutics Inc (NASDAQ: EIDX ) Fate Therapeutics Inc (NASDAQ: FATE ) Five Prime Therapeutics Inc (NASDAQ: FPRX ) (announced preclinical data supporting evaluation of FPA157 as a novel immunomodulator with the potential to remove Treg-mediated immune suppression in solid tumors) Generation Bio Co (NASDAQ: GBIO ) Guardant Health Inc (NASDAQ: GH ) Halozyme Therapeutics, Inc. (NASDAQ: HALO ) Inspire Medical Systems Inc (NYSE: INSP ) Insulet Corporation (NASDAQ: PODD ) Kodiak Sciences Inc (NASDAQ: KOD ) (announced presentation of clinical study data on its investigational therapy KSI-301 in retinal disorders) Kura Oncology Inc (NASDAQ: KURA ) MannKind Corporation (NASDAQ: MNKD ) Myokardia Inc (NASDAQ: MYOK ) Ocular Therapeutix Inc (NASDAQ: OCUL ) Oncorus Inc (NASDAQ: ONCR ) OncoSec Medical Inc (NASDAQ: ONCS ) Pacific Biosciences of California Inc (NASDAQ: PACB ) Repligen Corporation (NASDAQ: RGEN ) Shockwave Medical Inc (NASDAQ: SWAV ) Spero Therapeutics Inc (NASDAQ: SPRO ) Tcr2 Therapeutics Inc (NASDAQ: TCRR ) (announced its third-quarter results) Twist Bioscience Corp (NASDAQ: TWST ) Ultragenyx Pharmaceutical Inc (NASDAQ: RARE ) Veracyte Inc (NASDAQ: VCYT ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows Nov.",SAN,en,Benzinga
2020-11-13 07:35:32-05:00,"Salvador Illa: «Compraremos más vacunas de las que necesitamos, y si sobran, haremos solidaridad»","El ministro de Sanidad, Salvador Illa, ha avanzado hoy varios detalles relacionados con la llegada de la vacuna para el coronavirus. Tras una semana marcada por el anuncio de BioNTech y Pfizer, Illa ha asegurado que a principio de año habrá «una o varias vacunas» disponibles y se empezará un proceso para aplicarlas al conjunto de la población. Según ha revelado, el Ministerio de Sanidad y las Comunidades Autónomas ya están preparando un plan de vacunación que se dará a conocer en los próximos días. «Compraremos más vacunas de las que necesitamos, queremos ir sobre seguro. Si nos sobran, en un ejercicio de solidaridad, las proporcionaremos a los países que las necesiten», ha apuntado el ministro, que ha participado este viernes en las XXV jornadas de economía de S'Agaró celebradas en Barcelona. Asimismo, ha resaltado que hasta que la pandemia no acabe en todo el mundo, nadie estará seguro del todo. Paralelamente, Illa ha aseverado que el sistema sanitario español está preparado y capacitado para distribuir y aplicar la vacuna de forma eficiente. «Estos días escucho comentarios como si en España no se hubiera vacunado nunca.",SAN,es,ABC Spain
2020-11-13 07:20:19-05:00,Naturgy sube más de un 6% en Bolsa tras vender su negocio en Chile por 2.570 millones,"Naturgy ha llegado a un acuerdo con la compañía estatal China State Grid International Development Limited (SGID) para vender su participación (96,04%) en la Compañía General de Electricidad (CGE) de Chile por 2.570 millones de euros, según ha informado hoy el grupo español. Las acciones de Naturgy subían en la Bolsa un 6,3% a primera hora de la tarde. En términos financieros, la transacción supone valorar el 100% de CGE en 4.312 millones de euros. Adicionalmente se espera que la operación genere unas plusvalías de alrededor de 400 millones de euros, antes de impuestos. Esta operación, en la que la parte compradora ha contado con el asesoramiento de Banco Santander y de BBVA, supondrá una reducción de la deuda neta consolidada de Naturgy de aproximadamente 4.000 millones de euros, proporcionando a la compañía una importante capacidad financiera para abordar oportunidades de crecimiento vinculadas a la transición energética, asegurando siempre la creación de valor. Para Naturgy, «tras una primera etapa centrada en la optimización de sus operaciones, esta transacción supone iniciar una segunda fase focalizada en la transformación del grupo a través de la rotación de sus activos».",SAN,es,ABC Spain
2020-11-13 06:43:10-05:00,"Venous Thromboembolism Drug Market - Current Impact to Make Big Changes Boehringer Ingelheim, Janssen Pharmaceuticals, sanofi, Bristol-Myers Squibb Pharmaceuticals","The venous thromboembolism drug market is driving due to increasing burden of cardiovascular disorders as a result of old age or obesity. However, lack of awareness in low-income countries is expected to hamper the growth of the global venous thromboembolism",SAN,en,OpenPR
2020-11-13 03:45:34-05:00,"La UE pagará menos de 16,50 euros por cada dosis de la vacuna de Pfizer","La Unión Europea ha hecho valer el preacuerdo de compra firmado en septiembre con Pfizer-Biontech para la adquisición de 200 millones de dosis de vacunas, con opción a una ampliación de 100 millones de dosis más. Además ha logrado imponer una rebaja, alegando el apoyo financiero público europeo que el laboratorio ha recibido, por lo que la Comisión Europea pagará las vacunas a un precio ligeramente inferior que los 19,50 dólares (al cambio de hoy 16,50 euros) que Biontech cobrará a su otro cliente preferente, Estados Unidos, que tienen apalabrados 600 millones de dosis. El precio final, con la rebaja ya descontada, no ha sido hecho público. Los términos finales del acuerdo son confidenciales. Fuentes del Ministerio de Sanidad alemán comentan solamente que para Europa será un precio más cercano a los 20 dólares que a los 10 dólares . El precio de cada partida será reembolsado a la Comisión Europea por los Estados miembros. En junio, el Banco Europeo de Inversiones, el brazo financiero de la UE, concedió un préstamo de 100 millones de euros (118 millones de dólares) a BioNTech para el desarrollo y la fabricación de su vacuna, a la que siguió en septiembre una financiación de 375 millones de euros del Ministerio de Investigación de Alemania.",SAN,es,ABC Spain
2020-11-13 01:11:33-05:00,Healthcare group Sanofi invests 50 million euros in Jeito Capital,"French healthcare giant Sanofi <SASY.PA> has invested 50 million euros ($59 million) into Jeito Capital, an investment firm dedicated to biotech and biopharma, in a deal which Sanofi said would support French and European healthcare innovation.",SAN,en,Reuters
2020-11-13 01:00:00-05:00,Banco Santander reconoce a ClearPeaks como Pyme del Año 2020 en la provincia de Tarragona,"ClearPeaks ha sido designada como Pyme del Año 2020 de Tarragona. El galardón, convocado por Banco Santander con la colaboración de La Vanguardia, reconoce la labor de las pequeñas y medianas empresas en la creación de empleo y generación de riqueza….",SAN,es,La Vanguardia
2020-11-12 23:00:00-05:00,"Mapfre, Santander y Santalucía, a la espera: la DGS frena el mercado de hipoteca inversa","Las entidades esperan que los supervisores clarifiquen el consumo de capital. Mapfre, Banco Santander o Santalucía preparan una oferta del producto",SAN,es,El Confidencial
2020-11-12 13:11:53-05:00,"Comercial Salgar, Pyme del Año en Zaragoza","El presidente de la empresa, Óscar Martínez-Cubells, ha recogido este jueves el premio de manos del presidente de Cámara Zaragoza, Manuel Teruel, y del delegado territorial del Banco Santander, Javier Gallardo.",SAN,es,Heraldo
2020-11-12 09:11:47-05:00,"Global Combination Antibody Therapy Market Thriving Worldwide, Investigated In Latest Research||Novartis AG, Genetech Inc., Bristol-Myers Squibb Company, F. Hoffmann-La Roche Ltd, Sanofi","The research report published by Data Bridge Market research report provides the all-inclusive data regarding the market with growth, share, size and recent market trends. Upcoming advancement in the market In this report, Researchers have analyzed Strength, Weakness, opportunities and",SAN,en,OpenPR
2020-11-12 09:05:26-05:00,"Global Toxoid Vaccines Market Growing By Increasing Market Share And Forecast 2027 With Top Key Players-GlaxoSmithKline plc, Grifols, S.A, Zoetis Services LLC., Virbac. Sanofi, Merck & Co., Inc., Emergent BioSolutions Inc, Integrated BioTherapeutics",The Toxoid Vaccines report published by Data Bridge Market research is the representation of data and analysis of the market. It gives detailed analysis of the current market scenario and a market forecast till 2027. The data included,SAN,en,OpenPR
2020-11-12 07:48:36-05:00,"Cytokine Market To Observ Explosive Growth By 2020-2027 | Abbvie, Bayer, Novartis, Roche Holding, Sanofi, Biocon, Pfizer","Cytokine Market Report covering detailed analysis, Competitive landscape, forecast, and strategies has been added to the Insight Partners. The study covers geographic analysis that includes regions like North America, Europe and Asia-Pacific, South America, Middle East, and Africa. The report",SAN,en,OpenPR
2020-11-12 06:13:14-05:00,"Proton Pump Inhibitors Market - AstraZeneca PLC/AB, Bayer AG, Pfizer Inc., Cadila Pharmaceuticals Limited, Eisai Pharmaceuticals India Pvt. Ltd, Santarus, Inc., Wyeth, LLC, Janssen Pharmaceutica, Takeda Pharmaceutical Company Limited, Sanofi S.A.","The Proton Pump Inhibitors research report covers the current scenario and the growth prospects of the global Proton Pump Inhibitors industry forecast 2020 - 2027. The report enlists several important factors, starting from the basics principal to advanced market intelligence",SAN,en,OpenPR
2020-11-12 06:11:18-05:00,"Travel Vaccine Market with Covid 19 Analysis and Challenges On Upcoming Trends 2020 || GlaxoSmithKline plc, Sanofi, Merck & Co., Inc., Novartis AG, Pfizer Inc",Global Travel Vaccine Market research report has been produced with the systematic gathering of market information for industry. All this information is supplied in such a way that it properly gives explanation of various facts and figures to the business.,SAN,en,OpenPR
2020-11-12 05:28:00-05:00,"""Vosotros sois los médicos de nuestros bolsillos""","Durante toda la pandemia, Banco Santander ha estado prestando diariamente cientos de millones de euros a pequeñas empresas en todos los países donde opera. Ya ha superado los 45.000 millones y, pensando en la situación crítica que muchas de ellas van a seguir pasando, desde el verano tenía habilitados otros 60.000 millones para futuras peticiones. Decenas de clientes han dejado testimonio de sus buenas experiencias con el banco en estos momentos tan duros. Como dice Marcos Rodríguez, propietario del bar Santa Olalla (Coslada) y cliente de Santander, ""vosotros sois los médicos de nuestros bolsillos"".",SAN,es,Publico
2020-11-12 04:49:16-05:00,"Amid cold-storage hurdle, Sanofi and J&J may beat logistical challenges (NASDAQ:SNY)","Pfizer this week reported stellar early results from its Phase 3 COVID-19 vaccine trial, but the stringent storage needs poses challenges to a global vacci",SAN,en,Seeking Alpha
2020-11-12 00:24:41-05:00,"Meningococcal Vaccines Market SWOT Analysis by Key Players: Pfizer, Sanofi, CanSino Biologics, GlaxoSmithKline",A new independent 120 page research with title 'Meningococcal Vaccines - Global Drug Forecast and Market Analysis to 2029' guarantees you will remain better informed than your competition. The study covers geographic analysis that includes regions and important players/vendors,SAN,en,OpenPR
2020-11-11 13:29:20-05:00,"Otitis Drug Market Analysis by Sanofi, Bristol-Myers Squibb Company, Otonomy Inc., Torrent Pharmaceuticals Ltd","Otitis Drug Market By Type (Acute Otitis Media, Otitis Media with Effusion and Chronic Otitis Media with Effusion), Treatment Type (Medication and Surgery), Mechanism of Action Types (Corticosteroid, Topoisomerase Enzymes Type II Inhibitor, Cephalosporin Antibiotic and Anti-Infective), Route of Administration (Oral,",SAN,en,OpenPR
2020-11-11 13:25:00-05:00,Europe To Pay Lower Price For Pfizer COVID Vaccine Than US,"Europe To Pay Lower Price For Pfizer COVID Vaccine Than US Tyler Durden Wed, 11/11/2020 - 13:25 Even after the Trump Administration shelled out $2 billion in Operation Warp Speed money to secure 100 million doses of the Pfizer-BioNTech vaccine (don't listen to the MSM when it claims Pfizer hasn't benefited from government money), Europe has still somehow managed to secure a better price as part of a deal reported earlier on Wednesday. Earlier today, Pfizer CEO Dr. Albert Bourla - who was also exposed for dumping a huge quantity of his stock, top-ticking the market - EU agreed to buy up to 300 million doses of the Pfizer-BioNTech vaccine, sealing its newfound status as the most advanced, and most promising, vaccine effort in the West. Exploratory talks involving the deal were initially disclosed back in September, but the news of the deal on Wednesday propelled shares higher, even as insiders revealed they were headed for the exits. Meanwhile, Reuters is reporting that under the terms of the EU deal, the per-dose price of the vaccine will be lower than in the US.",SAN,en,Zero Hedge
2020-11-11 10:20:00-05:00,Deutsche Bank Returns With Updated Primer On Global Race For COVID-19 Vaccine,"Deutsche Bank Returns With Updated Primer On Global Race For COVID-19 Vaccine Tyler Durden Wed, 11/11/2020 - 10:20 With all the vaccine-and therapeutic-related developments already this week (the Pfizer-BioNTech announcement, Novovax's new deal with the federal government, with the Eli Lilly antibody treatment earning FDA emergency-use approval, news of Brazilian authorities halting a trial involving a leading Chinese vaccine candidate etc.) it's not surprising that a team of analysts at Deutsche Bank have just released a follow-up to a comprehensive summary about the global race for a COVID-19 vaccine that was apparently popular with both clients and readers of financial blogs. In the preamble to the research, the analysts note that there are now 12 vaccine projects that have reached 'Phase 3', the most expansive and final stage of testing. Of those, 6 - 4 Chinese and 2 Russian - have already received some limited form of emergency approval (also: Vladimir Putin claimed that his adult daughter tried the Russian vaccine during the trial, and was fine).",SAN,en,Zero Hedge
2020-11-11 09:40:44-05:00,"Global Hormone Replacement Therapy (HRT) Tablets Market Growth Factors, Industry Scenario, Trends, Demand, Statistics and Forecast 2026||Leading Players- Novo Nordisk A/S, Sanofi, Abbott, TherapeuticsMD, Inc., Mithra Pharmaceuticals",Databridgemarketresearch.com added a new study on Global Hormone Replacement Therapy (HRT) Tablets Market Research Review 2019 that has been just made available providing an extensive knowledge and perceptions of the industry. In order to build a through future prospect for,SAN,en,OpenPR
2020-11-11 07:23:19-05:00,EU to sign a deal for 300 million doses of BioNtech/Pfizer vaccine,"The EU has already signed supply deals with AstraZeneca, Sanofi and Johnson & Johnson for their potential COVID-19 shots.",SAN,en,euronews
2020-11-11 00:13:32-05:00,España se garantiza un cartera mínima de 94 millones de vacunas frente al Covid-19,"El contrato con Pfizer se suma a los previos de Sanofi, AstraZeneca y Jannsen Las dosis son suficientes para 56 millones de personas",SAN,es,El Pais Cinco Dias
2020-11-10 08:39:08-05:00,"Feminine Intimate Care Market 2020 SWOT Analysis By Key Players: Procter & Gamble, Johnson & Johnson, Sanofi, Himalaya Drug, Elif Cosmetics","Feminine Intimate Care Market Research Report is a comprehensive and professional report that provides market research data relevant to new market entrants or qualified players. The research study covers important data that makes the document a useful resource for managers,",SAN,en,OpenPR
2020-11-10 08:09:46-05:00,"Vaccines Market: Study Navigating the Future Growth Outlook, Top Major Companies: Johnson & Johnson Services, Bavarian Nordic, VBI Vaccines Inc., Astellas Pharma, Panacea Biotec Limited, Sanofi","The Insight Partners market research study titled ‘Vaccines Market - Global Analysis and Forecasts by Technology, Disease Indication, Route of Administration, and Patient Type. A vaccine is a biological preparation that provides active acquired immunity against a particular disease. A vaccine",SAN,en,OpenPR
2020-11-10 07:10:20-05:00,"Bacterial Pneumonia Market Swot Analysis by key players Sanofi, Lupin Pharmaceuticals, Allergan",The COVID-19 Outbreak-Global Bacterial Pneumonia Market to witnessed good recovery in growth post first half of 2020 and is projected coverup market sizing during the forecast period (2021-2026). The assessment provides a 360° view and insights - outlining the key,SAN,en,OpenPR
2020-11-10 06:49:00-05:00,El fondo 'fintech' del Banco Santander invierte por primera vez en España,La compañía española nació con el objetivo de digitalizar el sector inmobiliario mediante ofertas por propiedades en tan solo 24 horas.,SAN,es,La Información
2020-11-10 06:21:56-05:00,El reto de una España vaciada,Resolver la crisis demográfica es prioritario para garantizar una economía robusta y acabar con las desigualdades territoriales. Banco Santander afronta este reto con la puesta en marcha de distintas iniciativas,SAN,es,El Pais
2020-11-10 00:02:57-05:00,"2020-2025 Human Recombinant Insulin Market Impressive Gains including Top Key Players – Eli Lilly, Novo Nordisk, Sanofi, Bioton, Zhuhai United Lab, Biocon, PeproTech","The Global Human Recombinant Insulin Market research report is the study prepared by analysts, which contain a detailed analysis of drivers, restraints, and opportunities along with their impact on the Human Recombinant Insulin Market growth. Overview of Global Human Recombinant Insulin",SAN,en,OpenPR
2020-11-09 16:53:33-05:00,British drug giants Astrazeneca and GSK still in race for a Covid jab,"Glaxosmithkline, led by chief exec Emma Walmsley (pictured), is involved with three potential vaccines being developed by Sanofi, Medicago and Clover Pharmaceuticals.",SAN,en,This is Money
2020-11-09 14:49:33-05:00,El Ibex registra su mayor subida en diez años tras los avances de la vacuna de Pfizer,"El Ibex 35 ha finalizado la sesión de este lunes con un alza del 8,68%, lo que ha llevado al selectivo a situarse en los 7.467 puntos enteros, en una jornada marcada por el anuncio de Pfizer sobre los avances de su vacuna contra el coronavirus . En concreto, Pfizer y Biontech han anunciado este lunes al mediodía que su vacuna contra el Covid-19 es eficaz en más del 90% , tras el “éxito” del primer análisis intermedio de su ensayo de fase 3, lo que ha disparado las bolsas, entre ellas el Ibex 35, con el sector de viajes y el turismo liderando las subidas. Así, su candidata a vacuna basada en ARNm, BNT162b2 contra el SARS-COV-2 ha demostrado su eficacia contra el coronavirus en participantes sin evidencia previa de infección, según el primera análisis de eficacia provisional realizado el 8 de noviembre. Las pruebas han sido realizadas a un total de 43.538 participantes y el análisis ha evaluado 94 casos confirmados de Covid-19 en participantes del ensayo. No obstante, los inversores siguen atentos al impacto de la segunda ola del Covid-19, con aumento de contagios y nuevas restricciones en distintos países de Europa, entre ellos España.",SAN,es,Gaceta de Salamanca
2020-11-09 12:36:40-05:00,El Gobierno vasco lanzará un bono sostenible de 600 millones para proyectos sociales por la crisis sanitaria,"El Gobierno vasco prevé lanzar la cuarta emisión de su «Bono Sostenible Euskadi» por valor de 600 millones de euros para financiar proyectos relacionados principalmente con la salud, la educación y las políticas sociales, con el objetivo de «hacer frente a la excepcional situación generada por la Covid-19». La cuarta emisión de este tipo de bonos, destinada a captar fondos para financiar proyectos ligados a la economía sostenible, se hará efectiva «en cuanto la situación de los mercados sea favorable», ha informado el departamento vasco de Economía y Hacienda. La mayor parte de esos 600 millones (49%) se reservarán para políticas sociales: proyectos relacionados con la vivienda social, la generación de empleo y el desarrollo socioeconómico. La emisión de este cuarto bono sostenible es posible gracias al aumento de la capacidad de endeudamiento del Gobierno vasco en 1.374,5 millones para este año que fue acordado en septiembre en la Comisión Mixta del Concierto Económico y ratificado después en el Parlamento de Vitoria.",SAN,es,ABC Spain
2020-11-09 12:00:00-05:00,"China Hydroxychloroquine (HCQ) Market Investigation Report 2020-2024 Featuring Sanofi, Shanghai Zhongxi Pharmaceutical, Shanghai Henlius Biotech","DUBLIN, Nov. 9, 2020 /PRNewswire/ -- The ""Investigation Report on China's Hydroxychloroquine(HCQ) Market, 2020-2024"" report has been added to ResearchAndMarkets.com's offering. According to the analyst, in 2019, the global production volume of hydroxychloroquine was approximately 300 tons….",SAN,en,PR Newswire
2020-11-09 10:51:44-05:00,"Anti-Hypertensive Drugs Market Poised to Expand at a Robust Pace Over 2020-2025 | Novartis, Pfizer, Johnson & Johnson, Sanofi, Lupin, Ranbaxy Laboratories, Merck, AstraZeneca, Takeda",This report provides in-depth study on the current state of the Global Anti-Hypertensive Drugs Market 2020-2025. Key players in the Global Anti-Hypertensive Drugs Market have been identified through the secondary research and their market share has been determined through primary,SAN,en,OpenPR
2020-11-09 07:40:46-05:00,El Ibex 35 se dispara más de un 7% en plena euforia por la efectividad de la vacuna de Pfizer y BioNTech,"El anuncio de la farmacéutica estadounidense Pfizer y la firma alemana BioNTech de que la vacuna contra el Covid-19 en la que están trabajando ha desatado la euforia en el selectivo español que sube más del 8% a mediodía superando con creces la cuota de los 7.400 puntos, algo que no conseguía desde el 22 de julio de este año. En concreto, este nivel de eficacia se ha logrado siete días después de la segunda dosis, es decir, 28 días despue´ del inicio de la vacunación que tiene una doble dosis, aunque la citada eficacia podría variar según avance el estudio. En concreto, los valores relacionados con el turismo y la banca están registrando revalorizaciones récord: Lidera la subidas Amadeus cuyos valores se disparan alrededor de un 40%, le sigue IAG que sube la friolera de un 34,48%, Meliá Hotels que se revaloriza un 23,79% y Aena un 17,79%. Por su parte, el sector bancario que es habitualmente uno de los más castigados en este contexto hoy es presa de la euforia con fuertes revalorizaciones: Bankia (+10,30%); BAnco Santander (+13,93%), BBVA (+12,51%), Banco SAbadell (+11,41%), Bankinter (+7,70%) y Caixabank (+9,57%).",SAN,es,ABC Spain
2020-11-08 12:47:42-05:00,"The Week Ahead In Biotech: Supernus, Sanofi Await FDA Decisions","Biotech stocks turned around with the broader market in the week ended Nov. 6, as investors warmed to the idea of a split Congress and a change of guard at the White House. The week witnessed a flurry of earnings from several smid-cap companies. Bluebird bio Inc. (NASDAQ: BLUE ) shares came under pressure after it announced a push back in the timeline for the regulatory filing for its gene therapy to treat sickle cell disease. Biogen Inc. (NASDAQ: BIIB ) was also in the news over an FDA roadblock regarding its Alzheimer's drug aducanumab. On the M&A front, Merck & Co. Inc. (NYSE: MRK ) announced a $2.75 billion deal to buy oncology-focused biopharma VelosBio Inc. Here are the key biotech events to watch out for in the unfolding week: Conferences American College of Rheumatology, or ACR, Convergence 2020: Nov. 5-9 Credit Suisse 29th Annual Virtual Healthcare Conference: Nov. 9-10 35th Annual Meeting of The Society for Immunotherapy of Cancer, or SITC: Nov. 9-14 American Academy of Ophthalmology, or AAO, 2020 Virtual meeting: Nov.",SAN,en,Benzinga
2020-11-06 15:05:35-05:00,De la exclusión a la inclusión financiera: la banca toma posiciones para ganarse a la España vaciada,"España se vacía por sus cuatro puntos cardinales hacia las grandes ciudades. El proceso es imparable. Los habitantes del mundo rural van falleciendo o se mueven a municipios mayores. Y los pocos que permanecen se quedan olvidados, aparcados como un coche viejo que ya dejó atrás sus mejores tiempos. Cierran sus escuelas, el médico deja de ser fijo, las farmacias echan la persiana, los ultramarinos pasan a mejor vida… y las sucursales bancarias tampoco son la excepción. Las entidades financieras iniciaron en la anterior crisis un lento y agónico proceso de cerrar oficinas en los pueblos. «En un momento de ajustes y reducción de costes en la red bancaria, parece justificada la decisión de cerrar oficinas con escaso número de clientes, probablemente, las menos rentables», decía el Banco de España en 2018. Por aquel entonces, y son los últimos datos disponibles, ya había 4.109 municipios españoles sin sucursal -540 más que en 2008-; esto equivalía a 1,25 millones de personas desplazadas del negocio bancario.",SAN,es,ABC Spain
2020-11-06 10:17:51-05:00,"Childhood Vaccines Market to accrue lucrative gains over the forecast timeframe 2020-2025| Sanofi, Merck, Pfizer, Jintan","The Childhood Vaccines market 2020 report analyses global acceptance of trends, future growth potential, key drivers, limitations, opportunities, and best practices that are taken place in market. The report also examines growth potential, market sizes and revenue forecasts (2020-2025)across different",SAN,en,OpenPR
2020-11-06 10:07:54-05:00,Banco Santander dará a conocer las cifras del ERE el 13 de noviembre,"La entidad ha mantenido este viernes su segundo encuentro con los sindicatos, en el que les ha informado de que hasta la semana que viene no cuantificará el ajuste de empleo, según CC. OO. y UGT.",SAN,es,Heraldo
2020-11-06 09:41:44-05:00,"Global Hydroxychloroquine Market Analysis, Revenue, Price, Market Share, Growth Rate, Forecast To 2027 || Sanofi, Novartis AG, Mylan N.V., Zydus Cadila, Amneal Pharmaceuticals Inc, Lupin","The persuasive Global Hydroxychloroquine Market research report provides a comprehensive analysis on the study of industry with respect to a number of aspects. The report includes analysis and discussion of important industry trends, market size, and market share estimates. 2019",SAN,en,OpenPR
2020-11-06 09:09:16-05:00,"Nasal Delivery Devices Market Is Expected To Reach US$ 95,676.62 Million By 2027 With Top Players GlaxoSmithKline plc.;AstraZeneca; Pfizer Inc.; BD; Sanofi; Merck & Co., Inc.; Cadila Pharmaceuticals Ltd.; Novartis AG; Dr. Reddy's Laboratories;and Neurelis","A new research document with title Global Nasal delivery devices Market Report covering detailed analysis, Competitive landscape, forecast and strategies has been added to the Insight Partners. The study covers geographic analysis that includes regions like North America, Europe and",SAN,en,OpenPR
2020-11-06 07:19:48-05:00,"Hydroxychloroquine Market Analysis, Applications, Sale, Growth Insight, Trends By 2026 | Sanofi, Novartis, Shanghai Zhongxisanwei","The global Hydroxychloroquine market is broadly analyzed in this report that sheds light on critical aspects such as the vendor landscape, competitive strategies, market dynamics, and regional analysis. The report helps readers to clearly understand the current and future status",SAN,en,OpenPR
2020-11-06 07:07:12-05:00,"Brand Drugs Market To Witness Astonishing Growth With Pfizer, Roche, Sanofi","The global Brand Drugs market is broadly analyzed in this report that sheds light on critical aspects such as the vendor landscape, competitive strategies, market dynamics, and regional analysis. The report helps readers to clearly understand the current and future",SAN,en,OpenPR
2020-11-06 04:08:39-05:00,"Hydroxychloroquine Market | 2020 Global Industry Analysis By Size, Growth Rate, Share, Trends, Key Players, COVID-19 Impact, Opportunity By Advanz Pharma,Teva Pharmaceutical, Sanofi, Novartis AG","An exhaustive investigation of this Global Hydroxychloroquine Market Size, Share, Growth, Industry Trends and Forecast to 2027 brings you the most recent and the most updated data on the market and the ruthless structure of the general sector worldwide. The",SAN,en,OpenPR
2020-11-05 23:38:54-05:00,"Health Monitoring Device Market To 2026 With Top Key Players Like Medtronic, Apple, Sanofi, Mobisante, AirStrip Technologies, AliveCor, LifeWatch AG, Nike etc","Health Monitoring Device Market report has recently added by The Research Insights which helps to make informed business decisions. This research report further identifies the market segmentation along with their sub-types. Various factors are responsible for the market’s growth, which",SAN,en,OpenPR
2020-11-05 12:23:00-05:00,"TGaS® Advisors, a Division of Trinity Life Sciences, Announces the Third Annual Best of Benchmark Award Winners","WALTHAM, Mass.--(BUSINESS WIRE)-- #bestofbenchmarkawards--Trinity Life Sciences, a leader in global life sciences solutions, announced the winners of the TGaS Best of Benchmark (BoB) Awards. The Awards, which are given for commercial operations excellence within the pharmaceutical industry, were presented to teams at Merck (known as MSD outside the United States and Canada), Gilead, Sanofi, Janssen Oncology, Genentech and Horizon Therapeutics. The BoBs are based on TGaS benchmarking of large, midsize and emerging life",SAN,en,Business Wire
2020-11-05 11:44:23-05:00,Botín pide un mercado único en Europa y reglas iguales para nuevos entrantes,La presidenta de Banco Santander ha apostado por la inversión en mercados emergentes y ha pedido una política fiscal para potenciar a los ahorradores.,SAN,es,La Información
2020-11-05 05:00:00-05:00,"""Remember, Remember, The 5th Of November...""","""Remember, Remember, The 5th Of November…"" Tyler Durden Thu, 11/05/2020 - 05:00 Authored by Gloria Moss via Off-Guardian.org, At midnight tonight, November 4-5 a second lockdown begins in the UK, with scant justification and amid a storm of propaganda. On the same day at the same time 415 years earlier another momentous event was announced, amid a similar storm of propaganda. While not obviously connected in any way the juxtaposition reminds us that official narratives always require interrogation and always will. THE GUNPOWDER PLOT: 5 NOVEMBER 1605 According to historians of the gunpowder plot, the official story of this event concealed the extent to which the British establishment of the day may have enhanced their popularity and personal profits by pushing a version of events that drew Britain into decades of profitable war against Catholic Spain and Portugal. Most recently, this view has been expressed by John Hamer (in his Falsification of History ) and by Webster Tarpley (in his videos about the Gunpowder Plot ).",SAN,en,Zero Hedge
2020-11-04 12:48:32-05:00,"Healthcare Advertising Market New Study Reveals to Boost Growth | Leading Players - Johnson & Johnson, Pfizer, Eli Lilly and Company, Novartis AG, Sanofi, Bayer AG","A market research analysis and estimations carried out in this Healthcare Advertising Market report aids businesses in gaining knowledge about what is already there in the market, what market looks forward to, the competitive background & steps to be followed",SAN,en,OpenPR
2020-11-04 12:12:28-05:00,"Bolsas da Europa avançam, de olho nas eleições americanas","As bolsas da Europa vêm apresentando uma recuperação expressiva nos últimos três dias, após a forte queda registrada na semana anterior Os principais índices acionários europeus fecharam a terceira sessão seguida de ganhos significativos nesta quarta-feira (4), com os investidores de olho na apuração dos votos das eleições presidenciais nos Estados Unidos. O índice Stoxx 600 Europe encerrou o dia em alta de 2,05%, aos 363,31 pontos. O DAX, de Frankfurt, avançou 1,95%, a 12.324,22 pontos, e o FTSE 100, de Londres, teve ganhos de 1,67%, a 5.883,26. Em Paris, o CAC 40 subiu 2,44%, a 4.922,85 pontos. Em Milão e Madri, as referências avançaram 1,96% e 0,45%, respectivamente. As bolsas da Europa vêm apresentando uma recuperação expressiva nos últimos três dias, após a forte queda registrada na semana anterior. Após o fechamento do pregão de hoje, o Stoxx 600 avança 6,12% no período, o DAX sobe 6,64%, o FTSE 100 têm alta de 5,48% e o CAC 40 registra valorização de 7,15%. Na semana anterior, as perdas foram de 5,56% para o índice pan-europeu e de 8,61%, 4,83%, 7,15% para as bolsas de Frankfurt, Londres e Paris, respectivamente.",SAN,pt,Valor Econômico
2020-11-04 10:47:52-05:00,"RNA Therapeutics Market Is Growing At A Healthy CAGR In The Forecast Period Of 2020 To 2027 | Leading Players - Quark, Sanofi, Silence Therapeutics, Sirnaomics, CureVac AG, Marina Biotech","A market research analysis and estimations carried out in this RNA Therapeutics Market report aids businesses in gaining knowledge about what is already there in the market, what market looks forward to, the competitive background & steps to be followed",SAN,en,OpenPR
2020-11-04 08:47:00-05:00,"Lucro do Santander em Portugal cai 35% para 254,5 ME até setembro","O lucro do Santander em Portugal caiu 35% para 254,5 milhões de euros, entre janeiro e setembro, face ao ano anterior, penalizado pela pandemia, divulgou o banco nesta quarta-feira em comunicado.",SAN,pt,Dinheiro Vivo
2020-11-04 07:59:39-05:00,"Antibiotics Market – A comprehensive study by Key Players: Sanofi, Novartis A, Eli Lilly",A latest survey on Global Antibiotics Market is conducted to provide hidden gems performance analysis. The study is a perfect mix of qualitative and quantitative information covering market size breakdown of revenue and volume (if applicable) by important segments. The,SAN,en,OpenPR
2020-11-04 07:15:04-05:00,"Lucro do Santander em Portugal cai 35% para 254,5 milhões",Banco liderado por Pedro Castro e Almeida diz que os resultados revelam o impacto que a pandemia Covid-19 está a ter na sua atividade.,SAN,pt,SAPO
2020-11-04 06:29:09-05:00,"Global Vaccines Market Outlook 2020 Trends, Market Demands, Industry Analysis & Forecast by 2027 || Merck & Co., Inc., Bharat Biotech, GlaxoSmithKline plc, Sanofi","Data Bridge Market Research has recently added a concise research on the Global Vaccines Market to depict valuable insights related to significant market trends driving the industry. The Global Vaccines Market report makes available the basic information about industry, definition,",SAN,en,OpenPR
2020-11-04 06:23:11-05:00,"Travel Vaccine Market Growth Factors and Global Leading Players are Sanofi, Merck & Co., Inc., Novartis AG, Pfizer Inc., ALK, Bavarian Nordic","Data Bridge Market Research has recently added a concise research on the Travel Vaccine Market to depict valuable insights related to significant market trends driving the industry. The Travel Vaccine Market report makes available the basic information about industry, definition,",SAN,en,OpenPR
2020-11-04 05:46:00-05:00,Los tres ejes estratégicos de Banco Santander para ser la mejor plataforma abierta de servicios financieros,El grupo está inmerso en un innovador proceso de transformación digital que busca mejorar la experiencia de cliente y crecer de forma sostenible.,SAN,es,Publico
2020-11-04 05:03:29-05:00,Safra indica melhores ações para investir na Bolsa em novembro,"Veja ajustes na carteira recomendada dos especialistas e confira quais as melhores ações para investir neste mês Veja os ajustes realizados pelos especialistas do Safra na carteira recomendada de ações de novembro Getty Images Novembro se inicia com um cenário bastante diferente de outubro, apesar da pontuação do Ibovespa começar o mês em patamar bastante próximo do último período. A aversão a risco aumentou devido à pandemia. Neste cenário, os especialistas do Safra fizeram ajustes no portfólio de ações para investir neste mês. No radar de quem busca as melhores ações para investir, o último mês foi marcado pela nova onda de coronavírus na Europa e também a aceleração dos novos casos nos Estados Unidos, além das eleições presidenciais americanas. No Brasil, seguem no foco as discussões em torno da situação fiscal e em relação ao cumprimento do teto de gastos em 2021. Recomendação de ações para investir em novembro Em meio ao cenário volátil, a carteira recomendada de ações de outubro, elaborada pela equipe de análise da Safra Corretora, encerrou o mês em queda de 1,12%, contra uma retração de 0,69% do Ibovespa, o principal índice de ações da Bolsa, no mesmo período.",SAN,pt,Valor Econômico
2020-11-03 16:00:07-05:00,Attention Biotech Investors: Mark Your Calendar For These November PDUFA Dates,"The month of October could at best be termed as mixed from the perspective of drug approvals. Avenue Therapeutics Inc's (NASDAQ: ATXI ) pain drug and Zosano Pharma Corp's (NASDAQ: ZSAN ) migraine patch stumbled at the FDA altar. The FDA announced a delay in deciding on Spectrum Pharmaceuticals, Inc.'s (NASDAQ: SPPI ) treatment candidate for chemotherapy-induced neutropenia, citing COVID-19 that impaired its ability to conduct inspections. Regeneron Pharmaceuticals Inc (NASDAQ: REGN ) succeeded in getting its antibody cocktail for Ebola past the finish line. Two new molecular entities, including Gilead Sciences, Inc.'s (NASDAQ: GILD ) Veklury were approved during the month, taking the total NME approvals for the year to 42. PDUFA dates are binary events that invariably serve as make-or-break catalysts for stocks. These dates are deadlines by which the FDA reviews a new drug application before announcing its decision concerning the approvability/non-approvability of the drug. Here are the key PDUFA dates for November.",SAN,en,Benzinga
2020-11-03 13:39:42-05:00,Santander y Norges Bank poseen más de un 3% de la fotovoltaica Soltec tras salir a Bolsa,"El Banco Santander y Norges Bank, el fondo soberano de Noruega, han entrado en el capital de la compañía de energías renovables Soltec Power Holdings con una participación del 3,443% y del 3,178%, respectivamente. Esta compañía protagonizó hace unos días la primera salida al mercado español en casi dos años. En concreto, Santander, a través de su gestora de fondos Santander Asset Management, y Norges Bank, que gestiona el Fondo Global de Pensiones del Gobierno de Noruega -el mayor fondo soberano del mundo-, se erigen en el tercer y cuarto máximo accionista de Soltec. Grupo Corporativo Sefrán, controlado por el empresario José Moreno Riquelme, es el principal accionista de Soltec Power Holdings -con una participación del 45,68% desde el 69,3% que poseía antes de la colocación en Bolsa- junto a Valueteam, sociedad del consejero delegado de la compañía, Raúl Morales Torres, -que del 29,7% ha pasado a ostentar un 19,578%-, según consta en los registros de la Comisión Nacional del Mercado de Valores (CNMV).",SAN,es,ABC Spain
2020-11-03 12:51:33-05:00,La Reina Letizia demuestra que el lila es uno de los colores del otoño,"La Reina Letizia ha retomado su agenda tras el cumpleaños de la Princesa Leonor asistiendo a la clasura del acto 'Euros en tu nómina', un proyecto solidario del Banco Santander para ayudar a los más necesitados. (Fuente: Casa Real)",SAN,es,Publico
2020-11-03 11:51:43-05:00,La Reina y Ana Botín premian una docena de proyectos sociales,"La Reina Letizia ha entregado, este martes, junto a la presidenta de Banco Santander, Ana Botín, los premios de la XII Convocatoria de Proyectos Sociales 'Euros de tu Nómina' de la entidad a doce iniciativas elegidas por los empleados del banco en España, para recibir más de 42.000 euros cada una. (Fuente: Casa Real)",SAN,es,Publico
2020-11-03 11:24:07-05:00,El juez de la operación Voloh investiga si el Ministerio de Industria hizo trato de favor a una empresa japonesa,"La operación Voloh que se desarrolla bajo la tutela del Juzgado de Instrucción número 1 de Barcelona y que investiga, entre otros asuntos, la posible financiación irregular del «procés» independentista catalán podría salpicar también al Ministerio de Industria, Comercio y Turismo que dirige Reyes Maroto. De momento, el juez instructor ha pedido documentación al Ministerio para saber si este departamento favoreció una operación empresarial con un caso de trato de favor. En una providencia firmada el pasado 27 de octubre, que se incluye en el sumario del caso Voloh al que ha tenido acceso ABC, el juez instructor Joaquín Aguirre requiere al Ministerio de Industria, Comercio y Turismo que entregue «de forma inmediata» la documentación relativa a la venta del 24,9 por ciento del capital de la empresa de automoción Bergé a la japonesa Mitsubishi. La investigación en este asunto concreto se centra en un posible trato de favor desde el departamento ministerial de Maroto y consistiría en haber hecho «malabarismos» en el Ministerio para conseguir el permiso de la operación entre Misubishi y Bergé.",SAN,es,ABC Spain
2020-11-03 08:14:00-05:00,El Banco Santander inicia la negociación para un ERE por razones económicas,https://es.investing.com/news/economic-indicators/el-banco-santander-inicia-la-negociacion-para-un-ere-por-razones-economicas-2053088,SAN,es,Investing.com Spain
2020-11-03 06:04:47-05:00,"La CEIM, ganadora del premio ICAM por su compromiso con la igualdad","El colegio también ha galardonado a Deloitte Legal y a las asesorías legales de Banco Santander, Cruz Roja, Iberdrola y Beam Suntory",SAN,es,El Pais Cinco Dias
2020-11-03 05:02:00-05:00,China Hydroxychloroquine (HCQ) Market Report 2020-2024: Impact of the COVD-19 Epidemic on the HCQ Market - ResearchAndMarkets.com,"DUBLIN--(BUSINESS WIRE)--The ""Investigation Report on China's Hydroxychloroquine(HCQ) Market, 2020-2024"" report has been added to ResearchAndMarkets.com's offering. According to the analyst, in 2019, the global production volume of hydroxychloroquine was approximately 300 tons. Among them, India produced about 110 tons, ranking first. The total production volume in Europe is about 80 tons, of which Sanofi's production is about 60 tons, and Novartis's Sandoz production is about 20 tons. Hydroxyc",SAN,en,Business Wire
2020-11-03 00:31:00-05:00,"Fabry Disease Drug Market 2020 Industry Segmentation, CAGR Status, Leading Trends and Forecast To 2026 | Sanofi, Moderna, AVROBIO, Resverlogix, Novartis AG, Pfizer","This Fabry Disease Drug Market research report is a great store to acquire current as well as upcoming technical and financial details of the industry for the precise forecast period. This market report also provides information about the brand awareness,",SAN,en,OpenPR
2020-11-02 14:23:22-05:00,"Atopic Dermatitis Market 2020 Key Country Analysis: LEO Pharma A/S, Sanofi, Novartis AG, Bristol-Myers Squibb Company, Bayer AG","The Global Atopic Dermatitis Market report studies market risk, market overview, and market opportunities. It also evaluates the leading manufacturers of the global market which consists of its revenue, sales, and price of the products. Furthermore, it presents global market by regions,",SAN,en,OpenPR
2020-11-02 08:07:00-05:00,Regulus Therapeutics Announces Achievement of Interim Enrollment Milestone Under Collaboration with Sanofi,"LA JOLLA, Calif., Nov. 2, 2020 /PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs, today announced that it has achieved the remaining $5 million milestone associated…",SAN,en,PR Newswire
2020-11-02 06:09:46-05:00,Sanofi Inks Deal To Snap Up Kiadis For $359M; Street Bullish,French drugmaker Sanofi has made an offer to snap up biotech company Kiadis for an aggregate adjusted equity value of €308 million ($358.5 … The post Sanofi Inks Deal To Snap Up Kiadis For $359M; Street Bullish appeared first on Smarter Analyst .,SAN,en,Smarter Analyst
2020-11-02 06:00:53-05:00,"Global Von Willebrand Disease (Factor VIII Deficiency) Market Emerging Trends 2020||Key Players-Grifols, S.A., Octapharma, CSL Limited, Ferring B.V., Pfizer Inc, Kyowa Kirin Co., Ltd, Baxter, Novo Nordisk A/S, Bayer AG, Sanofi","Global Von Willebrand Disease (Factor VIII Deficiency) Market, By Type (Type 1 von Willebrand Disease, Type 2 von Willebrand Disease, Type 3 von Willebrand Disease), Drugs (Antihemophilic Factor/Von Willebrand Factor Complex, Von Willebrand Factor/Coagulation Factor VIII Complex, Von Willebrand factor",SAN,en,OpenPR
2020-11-02 04:00:24-05:00,"Sanofi offers to acquire Kiadis, a clinical-stage company developing cell-based immunotherapy products (Sanofi) | CompanyNewsHQ",(Sanofi),SAN,en,CompanyNewsHQ
2020-11-02 03:45:16-05:00,Healthcare Group Sanofi Offers To Buy Smaller Peer Kiadis For 308 Mln Euros,Sanofi is offering to buy Dutch biotechnology company Kiadis for 308 million euros ($358.4 million) to boost its range of immunotherapy products.,SAN,en,CNN-News18
2020-11-02 01:19:43-05:00,Healthcare group Sanofi offers to buy smaller peer Kiadis for 308 million euros,"French healthcare group Sanofi <SASY.PA> said on Monday it has made a takeover offer worth 308 million euros ($358.4 million) for smaller peer Kiadis <KDS.AS>, in an attempt to strengthen its product portfolio.",SAN,en,Reuters
2020-11-02 01:02:34-05:00,SANOFI PROPOSE D'ACQUÉRIR KIADIS POUR 308 MILLIONS,SANOFI PROPOSE D'ACQUÉRIR KIADIS POUR 308 MILLIONS …,SAN,en,Zonebourse
2020-11-02 00:46:30-05:00,España comprará al menos 21 millones de vacunas del Covid-19 a Janssen,"La adquisición, a través del acuerdo de la Comisión Europea con el laboratorio, se suma a las de AstraZeneca y el consorcio de Sanofi y GSK El contrato permite sumar otras 21 millones de dosis",SAN,es,El Pais Cinco Dias
2020-11-01 01:00:00-05:00,"Maquinaria Industrial Dara, Pyme del Año Barcelona por su capacidad transformadora","La cuarta edición del premio Pyme del Año 2020 que otorga Banco Santander sigue su recorrido por las provincias de España. La última en proclamar ganador ha sido Barcelona. María José Macià, directora territorial de Banco Santander en Catalunya…",SAN,es,La Vanguardia
2020-10-31 06:32:06-05:00,"Steroid Market Swot Analysis by key players Sanofi, Pfizer, Merck, GSK","Latest 2020 version of COVID-19 Outbreak-Global Steroid Market study of 110+ data Tables, Pie Chat, Graphs & Figures spread through Pages and easy to understand in depth analysis. ""COVID-19 Outbreak- Steroid Market by Type (, Powder, Granule & Liquid), by",SAN,en,OpenPR
2020-10-29 20:18:21-05:00,«Banco Popular es un avión que voy a estampar contra el BCE»,"La caída de Banco Popular dejó por el camino a cientos de miles de accionistas y bonistas. El 7 de junio de 2017 la entidad fue adjudicada por Europa a Banco Santander por un euro. Un precio simbólico, que llevó consigo la necesidad de acometer una ampliación de capital de más de 7.000 millones para digerir el banco. Pero su quiebra no ocurrió de la noche a la mañana; y eso precisamente es lo que se investiga en la Audiencia Nacional. El caso Popular está, teóricamente, en uno de sus últimos tramos de la instrucción. Los expresidentes Ángel Ron y Emilio Saracho están en el punto de mira, y las últimas declaraciones de testigos devuelven a este último al foco… Ver Más",SAN,es,ABC Spain
2020-10-29 15:55:32-05:00,Saracho planteó al BCE intervenir el Popular al mes de asumir la presidencia,"Banco Santander adquirió Banco Popular por un euro el 7 de junio de 2017. La operación se fraguó de madrugada, tras intervenir Europa la entidad ante el riesgo de que no tuviera liquidez ya al día siguiente. Rápido, aunque también doloroso. Más de 300.000 accionistas perdieron su dinero, así como los titulares de bonos. Pronto su quiebra pasó a ser el «caso Popular» en la Audiencia Nacional, con los expresidentes Ángel Ron y Emilio Saracho en el punto de mira. Este último fue quien gestionó el banco desde febrero hasta la resolución… aunque de la documentación y testimonios recabados por ABC se desprende que desde el inicio de su mandato tuvo la intención de deshacerse de la entidad. Saracho tomó posesión... Ver Más",SAN,es,ABC Spain
2020-10-29 13:13:00-05:00,News24.com | WATCH | Strong earnings help stocks regain poise,"After a big slide the day before, European stocks opened with gains on Thursday, helped by stronger than expected results from firms including VW, Shell and Sanofi.",SAN,en,News24
2020-10-29 11:12:36-05:00,"El Estado, condenado a devolver 1.300 millones a Santander, CaixaBank y Bankia por el Castor","El Tribunal Supremo ha estimado el recurso presentado por Banco Santander, CaixaBank y Bankia contra el Estado, al que condenan a pagarles 1.350,7 millones de euros por daños y perjuicios. Estas entidades adelantaron en su día el dinero de la indemnización a ESCAL-UGS (mayoría de ACS) por la cancelación de las operaciones del almacén subterráneo de gas Castor, situado frente a la costa de Vinaroz (Castellón). El proyecto tuvo que ser cancelado después de la serie sísmica que produjo durante la operaciones de llenado durante septiembre de 2013. El Alto Tribunal ha acordado así a acceder a la indemnización «del total de la deuda» reconocida en favor de las entidades Banco Santander, que percibirá el 50,94%; CaixaBank, el 34,05% y Bankia el 15%. Además, de estas cantidades las entidades percibirán el interés legal desde que interpusieron en 2018 para reclamar daños y perjuicios. El mismo, explica que se impugna la desestimación por silencio por parte del Consejo de Ministros de la reclamación de daños y perjuicios que se habían ocasionado a tres entidades financieras (Santander, Caixabank y Bankia) porque había pagado a Enagas la cantidad de 1.",SAN,es,ABC Spain
2020-10-29 09:41:08-05:00,"Consumer Healthcare Market Worth Observing Growth | Procter & Gamble, Boehringer Ingelheim, Sanofi","HTF MI recently Announced Global Consumer Healthcare study with 100+ market data Tables and Figures spread through Pages and easy to understand detailed TOC on ""Consumer Healthcare. Global Consumer Healthcare research allows you to get different methods for maximizing your",SAN,en,OpenPR
2020-10-29 07:56:04-05:00,¿Por qué hay que devolver dinero a los bancos por el Castor?,"Todo el mundo, incluso muchos de los antibanca, concluyen que en la demanda de Banco Santander, CaixaBank y Bankia contra el Estado para recuperar al menos los 1.350 millones de euros que aportaron para indemnizar a la sociedad concesionaria del almacén de gas Castor tenía razón. El Tribunal Supremo les ha aceptado su planteamiento . Previamente, el Consejo de Estado había urgido al Ejecutivo a que se devolviera a los bancos el dinero que habían aportado. En lo que se se suele discrepar es en que lo tenga que pagar el Estado, es decir, todos los contribuyentes, en vez de correr a cargo de la sociedad concesionaria, Escal, de la que la ACS de Florentino Pérez , era el accionista mayoritario. Seguir leyendo… .",SAN,es,El Periodico
2020-10-29 05:28:18-05:00,"Sanofi, Merck Join Forces On Ketruda, THOR-707 Combo In Cancer","Sanofi (SNYNF) has entered into an agreement with Merck to conduct a Phase 2 clinical trial to evaluate the safety, pharmacokinetics, and preliminary … The post Sanofi, Merck Join Forces On Ketruda, THOR-707 Combo In Cancer appeared first on Smarter Analyst .",SAN,en,Smarter Analyst
2020-10-29 03:30:55-05:00,Sanofi Raises Outlook As Speciality Care And Vaccines Lift Sales,"Sanofi raised its 2020 earnings guidance for the second time this year after posting slightly strongerthanexpected thirdquarter results on Thursday, helped by growth at its speciality care and vaccines units.",SAN,en,CNN-News18
2020-10-29 03:08:21-05:00,"Earnings Scheduled For October 29, 2020",Companies Reporting Before The Bell • PG&E (NYSE: PCG ) is likely to report quarterly earnings at $0.27 per share on revenue of $4.72 billion. • Silicom (NASDAQ: SILC ) is estimated to report quarterly earnings at $0.35 per share on revenue of $26.68 million. • Ambev (NYSE: ABEV ) is expected to report quarterly earnings at $0.02 per share on revenue of $2.28 billion. • Ares Commercial Real (NYSE: ACRE ) is estimated to report quarterly earnings at $0.24 per share on revenue of $17.15 million. • Alliance Data Systems (NYSE: ADS ) is expected to report quarterly earnings at $2.20 per share on revenue of $1.01 billion. • Agenus (NASDAQ: AGEN ) is expected to report quarterly loss at $0.26 per share on revenue of $14.00 million. • Alexion Pharmaceuticals (NASDAQ: ALXN ) is projected to report quarterly earnings at $2.58 per share on revenue of $1.42 billion. • AMETEK (NYSE: AME ) is estimated to report quarterly earnings at $0.93 per share on revenue of $1.11 billion. • Amerant Bancorp (NASDAQ: AMTB ) is projected to report quarterly earnings at $0.,"SBBP,SAN",en,Benzinga
2020-10-29 02:57:00-05:00,Sanofi gana 11.233 millones de euros en los nueve primeros meses del año,https://es.investing.com/news/stock-market-news/sanofi-gana-11233-millones-de-euros-en-los-nueve-primeros-meses-del-ano-2051403,SAN,es,Investing.com Spain
2020-10-29 02:56:17-05:00,Sanofi posts strong Q3 driven by solid sales from Dupixent +61% and Vaccines +8%; guidance raised (NASDAQ:SNY),"Sanofi (SNY) Q3 results (€): Revenues: 9,479M (-0.2%); Pharmaceuticals: 6,361M (-1.1%); Consumer Healthcare: 1,041M (-8.3%); Vaccines: 2,077M (+7.7%), driv",SAN,en,Seeking Alpha
2020-10-29 02:40:10-05:00,Sanofi Raises Outlook As Specialty Care And Vaccines Lift Sales,"Sanofi raised its 2020 outlook for the second time this year after posting slightly strongerthanexpected third quarter results on Thursday, helped by growth at its specialty care and vaccines units.",SAN,en,CNN-News18
2020-10-29 01:45:42-05:00,Sanofi Raises Outlook As Specialty Care And Vaccines Lift Third Quarter,"Sanofi raised its 2020 outlook for the second time this year after posting slightly strongerthanexpected thirdquarter results on Thursday, helped by growth at its specialty care and vaccines units.",SAN,en,CNN-News18
2020-10-28 20:33:00-05:00,"Sanofi, GSK to supply Covax with 200 million doses of coronavirus vaccine","Sanofi and GSK have signed a Statement of Intent with Gavi, a global risk-sharing mechanism for pooled procurement and equitable distribution of eventual Covid-19 vaccines.",SAN,en,Business Standard
2020-10-28 15:09:25-05:00,BB Investimentos elogia direcionamento do Santander e propõe novo preço-alvo para ação,"O BB Investimentos aproveitou a divulgação dos novos resultados do Santander (SANB11) para revisar o modelo de investimento do banco. Confiantes com a solidez dos números e a estratégia adotada pela empresa, os analistas reiteraram a compra do papel com um novo preço-alvo de R$ 44 para dezembro de 2021. ""Apesar de acreditarmos que os […]",SAN,pt,Money Times
2020-10-28 11:15:37-05:00,"Sanofi, GSK to supply 200 mln vaccine doses to WHO-backed COVAX alliance",French drugmaker Sanofi and Britain’s GlaxoSmithKline will supply 200 million doses of their COVID-19 candidate vaccine to a global inoculation scheme backed by the World Health Organization.For more,SAN,en,Al Arabiya (English)
2020-10-28 11:01:31-05:00,"Healthcare Advertising Market 2020 Size and Growth Factors Research and Projection || Leading Players – Merck & Co., Inc., GlaxoSmithKline plc., Eli Lilly and Company., Novartis AG, Sanofi",Data Bridge Market Research has recently added a concise research on the Xyz to depict valuable insights related to significant market trends driving the industry. The report features analysis based on key opportunities and challenges confronted by market leaders while,SAN,en,OpenPR
2020-10-28 10:41:23-05:00,"Sanofi, GlaxoSmithKline pledge 200M COVID-19 vaccines for global use","Sanofi and GlaxoSmithKline have committed 200 million doses of their experimental coronavirus vaccine to a global effort to distribute shots around the world, the drugmakers said Wednesday. The doses will go to the COVAX Facility, a World Health Organization-backed initiative meant to give rich and poor countries alike equal access to crucial COVID-19 vaccines once…",SAN,en,New York Post
2020-10-28 09:11:37-05:00,Banco Sabadell plantea un ajuste de empleo de al menos 1.500 empleados en España,"Empieza una nueva ronda de ajustes de plantilla en la banca española. A Banco Santander se une ahora también Banco Sabadell. La entidad de origen catalán planea acometer unas salidas pactadas de empleados de entre 1.500 y 2.000 personas, según confirman fuentes conocedoras de los planes. No se hará bajo la fórmula de un Expediente de Regulación de Empleo (ERE) sino que abarcará prejubilaciones y salidas incentivadas. Una manera de aligerar trabajadores muy utilizada estos años en el sector financiero. En todo caso, no habrá despidos traumáticos, sino que se hará todo de manera pactada y voluntaria. Así las cosas, las fuentes consultadas apuntan a que la semana que viene tendrá lugar un primer encuentro con los sindicatos. Sin embargo, al menos desde Comisiones Obreras afirman no haber recibido todavía ninguna noticia al respecto. Entre las razones para acometer ahora este ajuste de empleo está la necesidad de adaptarse a la digitalización, así como controlar los costes, todo derivado de la nueva realidad competitiva, según las fuentes consultadas.",SAN,es,ABC Spain
2020-10-28 08:41:05-05:00,GSK and Sanofi make global Covid vaccine supply deal,The companies are to supply 200 million doses of Covid vaccine to a global scheme.,SAN,en,BBC
2020-10-28 08:26:53-05:00,Santander Brasil (SANB11) mostra força e mercado deve ter reação positiva também a outras ações de bancos,"Banco mostrou recuperação em “V” em seus principais números, aponta análise de especialistas do Safra sobre balanço do Santander Brasil (SANB11) Safra mantém recomendação de compra para as ações do Santander Brasil (SANB11), com preço-alvo de R$ 46 iStock O Santander Brasil (SANB11) divulgou nesta terça-feira, 27, dados bastante fortes no terceiro trimestre de 2020, acima até mesmo das estimativas de especialistas da Safra Corretora, que já eram positivas. O desempenho foi beneficiado principalmente pelo recuo na provisão de crédito, mas também pelo bom comportamento nas receitas de serviços e despesas operacionais. Entre julho e setembro, o lucro líquido ajustado atingiu R$ 3,902 bilhões, 28% acima da estimativa do Safra, aumento de 82,7% em relação ao segundo trimestre e 5,4% na comparação anual. “Acreditamos que os resultados do Santander Brasil no terceiro trimestre foram surpreendentemente bons, superando as expectativas mais otimistas do mercado. Esperamos que o mercado continue reagindo positivamente às ações do Santander Brasil (SANB11) e também às de outros bancos”, afirma a análise do Safra, divulgada em relatório.",SAN,pt,Valor Econômico
2020-10-28 07:44:00-05:00,Sanofi und GSK liefern 200 Millionen COVID-19-Impfstoffdosen an Covax - Aktien leichter,"Sanofi und GlaxoSmithKline wollen demnach 200 Millionen Dosen ihres adjuvantierten, rekombinanten, proteinbasierten COVID-19-Impfstoffs an die Covax-Plattform liefern, wie die Sanofi SA mitteilte.",SAN,de,Finanzen CH
2020-10-28 07:29:25-05:00,"Sanofi, GSK to provide 200 million Covid vaccine doses to WHO global immunization program","Sanofi and GSK's vaccine is further behind in clinical development than some of the front-runners like Pfizer, Moderna and AstraZeneca, which are all in late-stage trials.",SAN,en,CNBC
2020-10-28 06:48:27-05:00,COVID vaccine: GSK and Sanofi agree deal for 200m doses of vaccine candidate,"Gavi, the vaccine alliance set up by Bill and Melinda Gates, has agreed to buy 200m doses to help distribute them around the world.",SAN,en,Yahoo Finance UK
2020-10-28 06:11:45-05:00,"Sanofi, GSK proveerán vacunas a alianza apoyada por la OMS",La farmacéutica francesa Sanofi y la británica GlaxoSmithKline proveerán 200 millones de dosis de su vacuna candidata contra el COVID-19 a un programa de inoculación global apoyado por la Organización Mundial de la Salud (OMS).,SAN,es,Reuters Latin America
2020-10-28 05:55:42-05:00,GSK and Sanofi to join global Covid crusade with 200m vaccine shots,"GSK Vaccines president: ""This has the potential to be a significant contribution to the global fight against COVID-19.""",SAN,en,Evening Standard
2020-10-28 03:59:00-05:00,"Sanofi, GSK to provide 200 mn doses of Covid-19 vaccine to global alliance","The facility is part of COVAX, a coalition of governments, health organisations, businesses and charities working to accelerate the development of Covid-19 vaccines",SAN,en,Business Standard
2020-10-28 03:40:12-05:00,Sanofi y GSK donarán 200 millones de vacunas contra el coronavirus,No summary available.,SAN,es,20minutos Spain
2020-10-28 03:01:23-05:00,Banco planeja criar operação digital,"Santander divulgou lucro líquido de € 1,75 bilhão no terceiro trimestre, recuperando-se do primeiro prejuízo de sua história, registrado no trimestre anterior Matéria exclusiva para assinantes. Para ter acesso completo, acesse o link da matéria e faça o seu cadastro.",SAN,pt,Valor Econômico
2020-10-28 02:50:02-05:00,"Sanofi, GSK to provide COVID-19 vaccine to global alliance","Drugmakers Sanofi and GlaxoSmithKline have agreed to provide 200 million doses of their potential COVID-19 vaccine to the COVAX Facility, a collaboration designed to give countries around the world equal access to vaccines targeting the global pandemic",SAN,en,ABC News
2020-10-28 02:38:49-05:00,"Sanofi, Glaxo to supply 200M doses to COVID-19 vaccine alliance (NASDAQ:SNY)","While Sanofi (NASDAQ:SNY) and GlaxoSmithKline (NYSE:GSK) aren't the front-runners in the race to develop a COVID-19 vaccine, the companies expect to play a",SAN,en,Seeking Alpha
2020-10-28 02:00:00-05:00,GlaxoSmithKline PLC Sanofi and GSK support COVAX - 200m vaccine doses,"GlaxoSmithKline PLC 28 October 2020 Issued: GlaxoSmithKline plc, 28 October 2020, London, UK and Paris, France Sanofi and GSK to…",SAN,en,ADVFN UK
2020-10-28 01:53:00-05:00,Sanofi und GSK liefern 200 Millionen COVID-19-Impfstoffdosen an Covax,"Sanofi und GlaxoSmithKline wollen demnach 200 Millionen Dosen ihres adjuvantierten, rekombinanten, proteinbasierten COVID-19-Impfstoffs an die Covax-Plattform liefern, wie die Sanofi SA mitteilte.",SAN,de,Finanzen CH
2020-10-28 01:50:00-05:00,"Sanofi, GSK to Supply 200 Million Doses of Covid-19 Vaccine to COVAX Facility","By Mauro Orru Sanofi SA and GlaxoSmithKline PLC signed a supply agreement with Gavi, the administrator of COVAX Facility, a mechanism…",SAN,en,ADVFN UK
2020-10-28 01:44:00-05:00,"COVID-19 vaccine: GSK, Sanofi to make 200 million doses available for WHO's COVAX alliance","The companies said on Wednesday they have signed a statement of intent with vaccine alliance GAVI, which is coordinating the global plan known as COVAX",SAN,en,Business Today
2020-10-28 01:27:38-05:00,"GSK, Sanofi To Make 200 Million Doses Available For COVID-19 Vaccine Alliance",French drugmaker Sanofi SA and Britain's GlaxoSmithKline plan to make 200 million doses of their COVID19 vaccine candidate available to the vaccine allocation plan coled by GAVI and the World Health Organization.,SAN,en,CNN-News18
2020-10-28 01:18:32-05:00,"GSK, Sanofi to make 200 mn doses available for COVID-19 vaccine alliance","French drugmaker Sanofi SA and Britain's GlaxoSmithKline plan to make 200 million doses of their COVID-19 vaccine candidate available to the vaccine allocation plan co-led by GAVI and the World Health Organization. The companies said on Wednesday they have signed a statement of intent with vaccine alliance GAVI, which is coordinating the global plan known as COVAX. COVAX aims to deliver 2 billion vaccine doses around the world by the end of 2021, and more than 180 nations have joined the plan. The United States and UK are leading a rush to strike deals with drugmakers to reserve supplies of experimental coronavirus vaccines. GSK-Sanofi has currently signed a $2.1 billion deal with the U.S. to supply it with more than 100 million doses of its coronavirus vaccine candidate. The companies also have deals with the European Union and UK. The first results from an early mid-stage study of the Sanofi-GSK vaccine are expected in early December 2020, and the companies plan to file for regulatory approval in 2021.",SAN,en,Economic Times India
2020-10-27 15:34:32-05:00,Investidor embolsa lucro e Ibovespa perde os 100 mil pontos,"Durante a tarde, o movimento de queda na bolsa foi intensificado ainda por sinais de atrito entre o presidente da Câmara, Rodrigo Maia, e a base aliada do governo Depois de iniciar o dia em alta, o Ibovespa reverteu a direção e fechou em firme queda, abaixo da marca de 100 mil pontos, em uma realização de lucros puxada pelo setor bancário. Santander Brasil deu largada à temporada de balanços de grandes bancos, com resultados positivos no terceiro trimestre, mas a ação foi alvo de uma correção após subir mais de 20% nas últimas semanas. Durante a tarde, o movimento de queda na bolsa foi intensificado ainda por sinais de atrito entre o presidente da Câmara, Rodrigo Maia, e a base aliada do governo. Após ajustes, o Ibovespa fechou em queda de 1,40%, aos 99.606 pontos, depois de tocar 99.414 pontos na mínima do dia. O giro financeiro ficou em R$ 18,9 bilhões, abaixo da média diária no ano, de R$ 20,5 bilhões. No setor bancário, Santander Units perdeu 4,73% e Itaú Unibanco PN caiu 3,85%. Já Bradesco ON cedeu 2,57% e Bradesco PN perdeu 2,97% - amanhã é a vez de o Bradesco divulgar seus resultados do terceiro trimestre.",SAN,pt,Valor Econômico
2020-10-27 13:51:33-05:00,"Global Healthcare Advertising Market to Witness a Pronounce Growth During 2027 || Merck & Co., Inc., GlaxoSmithKline plc., Eli Lilly and Company., Novartis AG, Sanofi, AstraZeneca",Data Bridge Market Research has added an exhaustive research study of the Global Healthcare Advertising Market detailing every single market driver and intricately analyzing the business vertical. Global Healthcare Advertising Market report brings together a meticulous study of the present,SAN,en,OpenPR
2020-10-27 12:15:00-05:00,"El Banco Santander cae un 1,46 % en bolsa tras presentar los resultados",https://es.investing.com/news/stock-market-news/el-banco-santander-cae-un-146--en-bolsa-tras-presentar-los-resultados-2050514,SAN,es,Investing.com Spain
2020-10-27 10:09:51-05:00,"Ações do Santander Brasil saltam mais de 3%, repercutindo lucro do 3° trimestre","As ações do Santander Brasil (SANB11) performavam bem acima do Ibovespa (IBOV), principal índice da bolsa brasileira, após o banco revelar o registro de lucro bilionário durante o terceiro trimestre de 2020. Por volta das 12h08 (horário de Brasília), as units do Santander Brasil saltavam cerca de 3,74%, negociadas a R$34,92. Enquanto isso, o Ibovespa cedia […]",SAN,pt,Money Times
2020-10-27 09:22:43-05:00,"Ibovespa ensaia alta, mas fica perto da estabilidade com desaceleração de bancos","Safra de resultados do terceiro trimestre segue no radar O Ibovespa chegou a iniciar o pregão desta terça-feira no positivo, mas perdeu força e oscila perto da estabilidade, à medida que as ações do setor bancário também perderam ritmo e viraram para o negativo. A safra de resultados do terceiro trimestre segue no radar, com destaque para os números já divulgados do Santander e expectativa com os balanços que serão informados após o fechamento. No exterior, o dia aparenta ser mais ameno, mas as atenções continuam no avanço do coronavírus no Hemisfério Norte e em torno do novo pacote de estímulos americano, que segue sem um desfecho. Às 10h52, o Ibovespa operava com leve baixa de 0,16%, aos 100.858 pontos, próximo da mínima do dia, de 100.810 pontos (-0,20%). Reprodução/Facebook Logo após a abertura, contudo, o Ibovespa chegou a subir 0,64%, na máxima dos 101.660 pontos, impulsionado pelas ações do setor bancário. Santander units, por exemplo, avançou 3,87%, na máxima do dia, de R$ 36,27, mas há pouco recuava 1,15%, a R$ 34,51.",SAN,pt,Valor Econômico
2020-10-27 08:22:46-05:00,"Drug Transport Technology Market Growing Vigorously with Prominent vendors like Johnson & Johnson Services, Novartis AG, F. Hoffmann-La Roche, Pfizer, Antares Pharma, BD, Glaxosmithkline, 3M, Merck, Sanofi",The movement of drug molecules after their absorption is essential to get their pharmacological action. Transportation is a process by which drug molecule moves from the site of administration to the bloodstream via a different mechanism to show effect. Drugs,SAN,en,OpenPR
2020-10-27 08:12:25-05:00,Calviño defiende que los Presupuestos «están centrados en el crecimiento y la creación de empleo»,"Mientras la plana mayor del Gobierno presenta el acuerdo presupuestario alcanzado entre PSOE y Unidas Podemos, la vicepresidenta económica, Nadia Calviño, ha acudido en representación del Ejecutivo a la clausura del XXIII Congreso de la Empresa Familiar, patrocinado por Banco Santander y KPMG. Calviño ha destacado durante su intervención los «instrumentos de ayudas a familias» aprobadas por el Gobierno durante la pandemia. Unos incentivos que, según la vicepresidenta, empiezan a dar sus frutos. «Una prueba clara de que hicimos lo correcto es la EPA que se ha conocido este martes, que muestra que hemos recuperado más de la mitad del empleo perdido durante el primer trimestre». Sobre los Presupuestos, Calviño ha destacado que están enfocados «en el crecimiento y la creación de emepleo», y ha reconocido que la «incertidumbre» que rodea en la actualidad al panorama económico complica la visibilidad del cuadro macroeconómico trazado por el Ejecutivo.",SAN,es,ABC Spain
2020-10-27 07:49:07-05:00,"Active Pharmaceutical Ingredient (API) Market Top Key Players- Novartis International AG (Switzerland), Sanofi (France), Boehringer Ingelheim (Germany) Growth Trends, quantitative analysis Industry Analysis and Market Dynamics of the Global Market, 2020 t","Summary of the Active Pharmaceutical Ingredient (API) Market Report Due to the various economic, technological, research & development and geographical aspects, the Active Pharmaceutical Ingredient (API) Market would gain a healthy CAGR and market size from 2020 to 2027. The growth",SAN,en,OpenPR
2020-10-27 07:20:53-05:00,"Nasal Delivery Devices Market to highest CAGR to reach US$ 95,676.62 million by 2027 | GlaxoSmithKline, AstraZeneca, Pfizer, BD, Sanofi, Merck","The Global Nasal Delivery Devices Market is expected to reach US$ 95,676.62 million by 2027 from US$ 58,502.18 million in 2019. The market is estimated to grow at a CAGR of 6.4% from 2020 to 2027. The research report on",SAN,en,OpenPR
2020-10-27 07:16:36-05:00,"Volume de pagamentos da Getnet sobe 30,9%, a R$ 68,7 bi, diz Santander","Banco diz que iniciativa conjunta entre as equipes comerciais incrementou o volume de credenciamentos em todos os canais no terceiro trimestre O Santander informou que o volume de pagamentos processados por sua credenciadora Getnet ficou em R$ 68,7 bilhões no terceiro trimestre de 2020, com alta de 30,9% no trimestre e de 32,4% em 12 meses. Do volume faturado no período, R$ 26,7 bilhões foram de cartão de débito e R$ 42,0 bilhões de cartão de crédito. Em número de transações, foram 692,9 milhões. Santander tem lucro gerencial de R$ 3,902 bi no 3º tri, com alta anual de 5,3% “No terceiro trimestre de 2020 realizamos uma iniciativa conjunta entre as equipes comerciais do Santander e Getnet, o que incrementou o volume de credenciamentos em todos os canais. Como resultado, nossa base ativa alcançou 851 mil clientes, crescimento de 17% no ano”, diz o banco. O Santander afirma que, a partir do fortalecimento da plataforma multisserviços, acredita que pode atingir uma participação de mercado de 15% no fim deste ano.",SAN,pt,Valor Econômico
2020-10-27 07:12:40-05:00,"RNA Therapeutics Market (COVID-19 Impact Analysis) 2020 Outlook Industry Analysis, Size, Share, Growth, Trends And Forecast, Leading Players are Quark, Tekmira Pharmaceuticals, Sanofi, Silence Therapeutics, Arbutus Biopharma","This RNA Therapeutics Market research report makes available state-of-the-art information about the entire market along with the holistic view of the market. This global market research report displays a complete overview of the market, including myriad of aspects such as",SAN,en,OpenPR
2020-10-27 07:09:25-05:00,Santander demite 2.045 funcionários e fecha 91 agências de abril a setembro,"Apenas no terceiro trimestre, foram 1.201 desligamentos e 41 agências fechadas O Santander demitiu 2.045 funcionários entre o início de abril e o fim de setembro, meses mais agudos da pandemia de covid-19. No mesmo período, foram fechadas 91 agências. Apenas no terceiro trimestre, foram 1.201 desligamentos e 41 agências fechadas. Santander tem lucro gerencial de R$ 3,902 bi no 3º tri, com alta anual de 5,3% O banco encerrou setembro com 45.147 funcionários e uma rede de 2.168 agências, além de 1.416 postos de atendimento. Com a digitalização ganhando força durante o período de isolamento social, o aumento da competição e dúvidas sobre a evolução da economia, os bancos vêm revendo seus custos e o tamanho de suas redes de agências. O Bradesco também fez mais de 500 demissões nas últimas semanas, segundo informações do Sindicato dos Bancários e Financiários de São Paulo, Osasco e Região. Os cortes no Santander atingiram diversas áreas. Conforme noticiou o Valor em junho, o banco informou que estava reavaliando a produtividade “para fazer frente a um entorno muito mais desafiador”.",SAN,pt,Valor Econômico
2020-10-27 06:43:09-05:00,Santander (SANB11) anuncia pagamento de R$ 1 bilhão em JCP,O Santander (SANB11) aprovou o pagamento de Juros sobre o Capital Próprio (JCP) no montante bruto de R$ 1 bilhão. Clique aqui e saiba mais,SAN,pt,Suno Research
2020-10-27 06:39:11-05:00,Espanhol Santander volta a registrar lucro no 3º trimestre ao economizar € 1 bilhão,"O espanhol Santander espera que seu lucro principal em 2020 supere as atuais expectativas do mercado, ajudado em parte pela economia de custos adicional de 1 bilhão de euros na Europa até 2022, que pode incluir milhares de cortes de empregos. Mais ganhos de eficiência e melhor comportamento de clientes no pagamento de empréstimos permitiram […]",SAN,pt,Money Times
2020-10-27 06:31:24-05:00,"Lucro lquido gerencial do Santander Brasil sobe 82,7% no 3 trimestre ante 2 tri","Carteira de crdito teve expanso de 3,8% na mesma base de comparao, para R$ 397,38 bilhes",SAN,pt,Jornal do Comercio
2020-10-27 06:10:41-05:00,Ana Botín defiende el pago de dividendos por la fortaleza del balance,"La presidenta del Banco Santander, Ana Botín, defiende el pago de dividendos, pese a que el Banco de España y el Banco Central Europeo mantienen la recomendación de que la banca se abstenga de repartir dividendos con cargo a los ejercicios 2019 y…",SAN,es,La Vanguardia
2020-10-27 06:07:37-05:00,"Santander (SANB) 3T20: Lucro líquido de R$ 3,902 bilhões, alta de 5,3%","O Santander Brasil registrou lucro líquido gerencial de R$ 3,902 bilhões no terceiro trimestre, superando a expectativa do mercado. O resultado…",SAN,pt,ADVFN Brazil
2020-10-27 05:51:43-05:00,"Meningococcal Vaccine Market Top Key Players- Hualan Biological Engineering Inc., Incepta Pharmaceuticals Ltd., Pfizer Inc., Sanofi S.A. Growth Trends, quantitative analysis Industry Analysis and Market Dynamics of the Global Market, 2020 to 2027","Summary of the Meningococcal Vaccine Market Report Due to the various economic, technological, research & development and geographical aspects, the Meningococcal Vaccine Market would gain a healthy CAGR and market size from 2020 to 2027. The growth trend would continue to",SAN,en,OpenPR
2020-10-27 05:41:44-05:00,"Santander tem lucro gerencial de R$ 3,902 bi no 3º tri, com alta anual de 5,3%","Resultado veio bem acima das projeções de analistas, que apontavam ganho de R$ 2,958 bi O Santander Brasil obteve lucro líquido gerencial de R$ 3,902 bilhões no terceiro trimestre, o que representa alta de 5,3% na comparação com o mesmo período do ano passado e alta de 82,7% ante o trimestre imediatamente anterior. O resultado veio bem acima das projeções dos analistas consultados pelo Valor, que apontavam um ganho de R$ 2,958 bilhões. O lucro societário do Santander ficou em R$ 3,811 bilhões entre julho e setembro, com elevação de 5,6% ante igual intervalo de 2019. O terceiro maior banco privado do país em ativos contabilizou margem financeira bruta de R$ 12,432 bilhões no terceiro trimestre, o que representa queda de 8,7% em três meses e avanço de 6,5% na comparação anual. As despesas líquidas com provisões para devedores duvidosos (PDD) ficaram em R$ 2,916 bilhões, com queda de 12,5% ante o trimestre anterior e alta de 3,4% em relação ao terceiro trimestre de 2019. As receitas de prestação de serviços e tarifas bancárias atingiram R$ 4,746 bilhões, com queda anual de 0,1%.",SAN,pt,Valor Econômico
2020-10-27 05:35:09-05:00,Santander Brasil distribuirá R$ 850 milhões em juros sobre capital próprio,"O conselho de administração do Santander Brasil (SANB11) aprovou, por unanimidade, o pagamento bruto de R$ 1 bilhão em juros sobre o capital próprio (JCP), que descontado o Imposto de Renda, corresponde ao valor líquido de R$ 850 milhões a serem distribuídos entre os acionistas do banco. Com base no valor líquido, cada acionista receberá […]",SAN,pt,Money Times
2020-10-27 05:22:33-05:00,"Santander lucra 1,745 bi de euros, impulsionado por operações no Brasil","Resultado do banco espanhol superou as estimativas de lucro de cerca de 1 bilhão de euros O espanhol Banco Santander SA se recuperou do pior trimestre de sua história, com lucros que superaram as estimativas, e melhorou seu capital, enquanto busca convencer os reguladores de que seu balanço é forte o suficiente para retomar o pagamento de dividendos. Após registrar o primeiro prejuízo em sua história de 163 anos no segundo trimestre de 2020, o lucro líquido totalizou 1,75 bilhão de euros (US$ 2,1 bilhões) no terceiro, superando as estimativas de cerca de 1 bilhão de euros, disse o banco nesta terça-feira. O índice CET1 (capital de nível 1), uma medida chave da solidez do capital, melhorou de 11,84% para 11,98% no final de junho. Os resultados reforçam um impulso dos credores para derrubar a proibição de fato do Banco Central Europeu (BCE) de pagar dividendos, que derrubou os preços das ações. A presidente do Santander, Ana Botín, argumentou que a medida é prejudicial não só para as ações dos bancos, mas também para a economia como um todo, porque restringe o fluxo de capitais e aumenta o custo do patrimônio líquido.",SAN,pt,Valor Econômico
2020-10-27 04:36:39-05:00,Banco Santander planea un ERE que afectará a 3.000 empleados,La entidad ya habría comunicado a los sindicatos que habrá un ajuste de empleo por motivos económicos fruto del impacto de la crisis del coronavirus que afectará al 11% de la plantilla,SAN,es,Vozpopuli
2020-10-27 04:15:00-05:00,"El Banco Santander gana un 31,3 % menos en Brasil por el covid-19",https://es.investing.com/news/stock-market-news/el-banco-santander-gana-un-313--menos-en-brasil-por-el-covid19-2050245,SAN,es,Investing.com Spain
2020-10-27 03:56:00-05:00,"El Banco Santander sube el 3,80 % en bolsa tras presentar los resultados",https://es.investing.com/news/stock-market-news/el-banco-santander-sube-el-380--en-bolsa-tras-presentar-los-resultados-2050225,SAN,es,Investing.com Spain
2020-10-27 02:28:00-05:00,Banco Santander pierde 9.048 millones de euros a septiembre por provisiones,https://es.investing.com/news/stock-market-news/banco-santander-pierde-9048-millones-de-euros-a-septiembre-por-provisiones-2050168,SAN,es,Investing.com Spain
2020-10-27 01:23:06-05:00,El Santander registra pérdidas de 9.048 millones en el tercer trimestre,"El Banco Santander registró pérdidas de 9.048 millones de euros en el tercer trimestre del año, frente a un beneficio de 3.732 millones de euros logrado un año antes, debido a que en el trimestre pasado contabilizó una actualización del fondo de comercio de sus inversiones históricas y de los activos fiscales diferidos (DTAs), así como dotaciones por deterioros, lo que generó un cargo extraordinario sin efecto en caja de 12.600 millones de euros. Como ya comunicó en el segundo trimestre, este ajuste no afecta a la posición de liquidez ni de solvencia, según ha informado la entidad a la Comisión Nacional del Mercado de Valores (CNMV). Seguir leyendo… .",SAN,es,El Periodico
2020-10-27 01:14:00-05:00,"Banco Santander gana un 40,8 % menos a septiembre por provisiones por covid",https://es.investing.com/news/stock-market-news/banco-santander-gana-un-408--menos-a-septiembre-por-provisiones-por-covid-2050139,SAN,es,Investing.com Spain
2020-10-26 10:09:02-05:00,"Anti-inflammatory Therapeutics Market Extreme Growth Prospects Expected to Be Experienced 2025| Sanofi , Novartis, Roche, Merck",The Anti-inflammatory Therapeutics market 2020 report includes thorough gathering of the quantitative analysis of the industry in order to assist players to grow in the market. Perceptions on specific revenue figures generated are also given in the report. This study,SAN,en,OpenPR
2020-10-26 09:18:40-05:00,"Nasal delivery devices Market With Top Players like GlaxoSmithKline, AstraZeneca,Pfizer, BD, Sanofi, Merck & Co., Cadila Pharmaceuticals Ltd. Novartis AG, Dr. Reddy's Laboratories, Neurelis, Inc","An off-the-shelf report on Nasal delivery devices Market which has been compiled after an in-depth analysis of the market trends prevailing across five geographies (North America, Europe, Asia-Pacific, Middle-East and Africa, and South America). Various segments of the market such",SAN,en,OpenPR
2020-10-26 08:43:12-05:00,"Dasa renegocia R$ 224 milhões em dívidas com Santander, Banco do Brasil e BV","A Dasa (DASA3) informou que concluiu a renegociação de suas dívidas de curto prazo, com o objetivo de alongar seu perfil. No total, foram renegociados R$ 224 milhões com o Santander (SANB11), Banco do Brasil (BBAS3) e BV. Em 30 de junho, 61% das dívidas da Dasa venceriam no curto prazo, isto é, num intervalo […]",SAN,pt,Money Times
2020-10-26 07:03:00-05:00,"Allergic Rhinitis Market New Business Expert Ideas by Merck, GlaxoSmithKline, Sanofi, Cigna, Himalaya, Olain Farm, Glenmark Pharmaceutical",The worldwide Allergic Rhinitis Market is a specialized and in-depth study of the pharmaceuticals industry with a special focus on the global market trend analysis. The report aims to provide an overview of Allergic Rhinitis market with detailed market segmentation,SAN,en,OpenPR
2020-10-26 06:19:54-05:00,"Male Infertility Market 2020 Covid-19 Analysis | Industry Global Key Vendors MERCK KGaA, Sanofi, Bayer AG, Endo Pharmaceuticals, SCSA Diagnostics","The standardization of regulations in majority of countries has helped the male infertility market players to launch their innovative solutions. For instance, in January 2016, AytuBioScience obtained the CE mark for MiOXSYS System that assesses the levels of oxidative stress",SAN,en,OpenPR
2020-10-26 01:52:20-05:00,"Global Cancer Care Market Latest Innovative Solutions to Boost Global Growth, Overview, Driver, Restraints, Deployments and Key Players 2027||Sanofi, Ipsen Pharma, AbbVie Inc., Myovant Sciences Ltd., Bayer AG, AstraZeneca, Tolmar Pharmaceuticals","According to the latest report published by Data Bridge Market Research, the Cancer Care Market is anticipated to grow at a steady pace over the forecast period 2020 – 2027. The report sheds light on the various trends and restraining",SAN,en,OpenPR
2020-10-24 17:38:44-05:00,FY2020 EPS Estimates for Sanofi SA Reduced by SVB Leerink (NYSE:SNY),"Sanofi SA (NYSE:SNY) – Equities researchers at SVB Leerink dropped their FY2020 earnings per share estimates for Sanofi in a research report issued to clients and investors on Wednesday, October 21st. SVB Leerink analyst G. Porges now forecasts that the company will earn $3.63 per share for the year, down from their prior estimate of […]",SAN,en,Daily Political
2020-10-23 11:59:46-05:00,"Meningococcal Vaccine Market To Reach $4,192.6 million by 2026 | Pfizer, Sanofi, Walvax Biotechnology","global meningococcal vaccine market is projected to reach $4,192.6 million by 2026, registering a CAGR of 9.5% from 2019 to 2026.",SAN,en,EIN News
2020-10-23 05:55:43-05:00,Economía ‘verde’ para salvar el planeta,"Banco Santander impulsa numerosas iniciativas para liderar la transición ecológica hacia nuevos modelos sostenibles, basados en energías limpias",SAN,es,El Pais
2020-10-23 02:21:18-05:00,"Active Pharmaceutical Ingredients (API) Market Size 2020 Industry Price Trend, Industry Outlook, Business Growth, Report Latest Research| Pfizer Inc., Novartis AG, Sanofi, Teva Pharmaceutical Industries Ltd., Eli Lilly and Company",The Active Pharmaceutical Ingredients (API) Market Research Report delivers all-inclusive analysis of the market structure along with forecast of the diverse segments and sub-segments of the market. Active Pharmaceutical Ingredients (API) Market 2020 Industry Research Report is an in-depth and,SAN,en,OpenPR
2020-10-22 18:30:49-05:00,Britons are to get unlicensed flu injections from the US in bid to vaccinate 30million this winter,The Department of Health has reached a deal with drugs giant Sanofi to purchase a substantial quantity of its vaccine Flublok -despite the fact it is not licensed for use anywhere in Europe.,SAN,en,Daily Mail Online
2020-10-22 18:29:45-05:00,Britons to get UNLICENSED flu injections from the US in bid to vaccinate 30million this winter,The Department of Health has reached a deal with drugs giant Sanofi to purchase a substantial quantity of its vaccine Flublok -despite the fact it is not licensed for use anywhere in Europe.,SAN,en,Daily Mail Online
2020-10-22 14:56:11-05:00,Valor de mercado dos bancos sobe R$ 85 bilhões em outubro,"Conforme a média das estimativas de nove casas ouvidas pelo Valor, Itaú, Bradesco, Santander e Banco do Brasil devem apresentar uma alta de 19,1% no lucro consolidado do terceiro trimestre ante o trimestre anterior Os quatro grandes bancos — Banco do Brasil, Bradesco, Itaú Unibanco e Santander - listados no Ibovespa tiveram um aumento de R$ 84,8 bilhões em valor de mercado em outubro, de R$ 570,5 bilhões em 30 de setembro para R$ 655,3 bilhões até o pregão de hoje, por volta das 15h35. A maior expansão é vista no Itaú Unibanco, de R$ 27,3 bilhões, indo para R$ 242,2 bilhões, seguido pelo Bradesco, que subiu R$ 25,6 bilhões (somando R$ 191,6 bilhões). Já o valor dos ativos do Santander subiu R$ 20,8 bilhões (alcançando R$ 125,4 bilhões), e do Banco do Brasil foi de R$ 11,1 bilhões (chegando a R$ 95,9 bilhões). Para efeitos de comparação, esse aumento em percentual é de 14,8%, ante uma alta de 8,6% no valor de mercado no Ibovespa no mesmo período, de R$ 3,3 bilhões para R$ 3,6 bilhões. O aumento no preço das ações das instituições financeiras ocorre por alguns motivos, segundo profissionais do mercado.",SAN,pt,Valor Econômico
2020-10-22 10:04:00-05:00,THE DIGITAL THERAPEUTICS EXPLAINER: How digital treatments could be a $9 billion opportunity by 2025,"Summary List Placement This is a preview of The Digital Therapeutics research report from Business Insider Intelligence. Purchase this report. Business Insider Intelligence offers even more healthcare coverage with Digital Health Pro. Subscribe today to receive industry-changing digital health news and analysis to your inbox. A new class of medicine — digital therapeutics (DTx) — has emerged, offering a novel means of treating the swelling number of patients with chronic diseases and keeping associated costs down. Digital therapeutics deliver evidence-based therapies via software — often in the form of consumer-facing mobile health apps — that replace or complement the existing treatment of a disease. They diverge from the broader digital health market in that they must be approved by regulatory bodies — and displaying proof-of-concept is at the core of their model. DTx vendors leverage their tech to treat chronic conditions, which gobble up the lion's share of the US' healthcare spending: Business Insider Intelligence estimates that the US shelled out up to $3.3 trillion on chronic disease in 2018.",SAN,en,Business Insider
2020-10-22 07:33:35-05:00,"Pain Management Drugs Market Detail Analysis Report by 2020-2027 Focusing on Top Players - Pfizer, GSK, Grunenthal, Bayer, Sanofi, Eli Lilly",Pain Management Drugs Market report is to provide accurate and strategic analysis of the Profile Projectors industry. The report closely examines each segment and its sub-segment futures before looking at the 360-degree view of the market mentioned above. Market forecasts,SAN,en,OpenPR
2020-10-22 06:47:25-05:00,"Global Intravenous Iron Market to Show Tremendous Growth by 2027 | Leading Players- American Regent Inc., AMAG Pharmaceuticals Inc., Allergan, Hikma Pharmaceuticals PLC, Sanofi, PHARMACOSMOS A/S, Fresenius Kabi AG","A most recent review on Intravenous Iron Market is led covering different associations of the business from various topographies to think of 100+ page report. The examination is an ideal blend of subjective and quantitative data featuring key market improvements,",SAN,en,OpenPR
2020-10-22 06:18:19-05:00,"Polymers Drug Delivery Market Reach Values of High Millions by the End of the Forecast 2020-2025 | Sanofi, J & J, Inovio, Alkermes, Janssen Biotech, Heron, Eisai, Perrigo, Quark, Vectura, SurModics",The growing demand for Polymers Drug Delivery has provided a major boost to the Global Polymers Drug Delivery Market as more people are shifting their preferences to this growing sector. The market is expected to keep rising at a high,SAN,en,OpenPR
2020-10-22 04:20:23-05:00,SK Telecom lanza un monedero blockchain para documentos gubernamentales - ESP BlockBoard,"La empresa surcoreana SK Telecom está emitiendo una solución blockchain para el almacenamiento y la gestión de los certificados gubernamentales. El gigante de las telecomunicaciones de Corea del Sur SK Telecom ha anunciado que emitirá su primer monedero digital para el almacenamiento y la gestión de certificados digitales impulsado por blockchain con la aprobación del Ministerio de Administración Pública y Seguridad.Según NewsTomato, el SK’s Wallet es compatible con la iniciativa de certificados digitales del propio Government24, que promueve el uso de sistemas de emisión y distribución de certificados electrónicos en Corea del Sur tras la pandemia del COVID-19.El Banco de España y Banco Santander participarán en el encuentro online “II Jornada Blockchain Economía”Los certificados públicos digitalizados de SK Telecom incluyen copias de tarjetas de registro de residentes, certificados de calificación del seguro médico, certificados de inmigración, entre otros documentos previamente emitidos en papel y firmados a mano.",SAN,es,Blockboard News
2020-10-22 03:42:43-05:00,Sanofi (NYSE:SNY) Raised to “Buy” at Zacks Investment Research,"Zacks Investment Research upgraded shares of Sanofi (NYSE:SNY) from a hold rating to a buy rating in a report published on Monday morning, Zacks.com reports. They currently have $53.00 price target on the stock. According to Zacks, “Sanofi’s Specialty Care segment is on a strong footing, particularly with regular label expansion of Dupixent. The drug […]",SAN,en,Transcript Daily
2020-10-21 23:55:00-05:00,Banco Santander reconoce a Maquinaria Industrial Dara como Pyme del Año 2020 de Barcelona,"La empresa Maquinaria Industrial Dara ha sido designada como Pyme del Año 2020 de Barcelona, un premio convocado por el Banco Santander, con la colaboración del diario La Vanguardia, para reconocer la labor de las pequeñas y medianas empresas en la…",SAN,es,La Vanguardia
2020-10-21 21:35:45-05:00,El Banco de España y Banco Santander participarán en el encuentro online “II Jornada Blockchain Economía” • Bitcoin Feed Noticias,"El próximo 26 de octubre se llevará a cabo la “II Jornada Blockchain Economía” en España, que se celebrará en la Universidad Pontificia Comillas ICA/ICADE. La misma, estará abierta de forma…",SAN,es,Bitcoin Feed News
2020-10-21 17:58:00-05:00,El Banco de España y Banco Santander participarán en el encuentro online “II Jornada Blockchain Economía”,Expertos en la cadena de bloques junto al Banco de España y Banco Santander participarán en la “II Jornada Blockchain Economía” en España.,SAN,es,Cointelegraph
2020-10-21 13:51:04-05:00,"Graft-Versus-Host Disease (GVHD) Market to Worth USD 656.00 million by 2026, Top Leading Players Sanofi (France), Novartis AG (Switzerland), Neovii Biotech GmbH (Germany), Merck & Co., Inc. (US)","Global Graft-Versus-Host Disease (GVHD) Market is expected to rise gradually to an estimated value of USD 656.00 million by 2026, registering a CAGR of 6.05% in the forecast period of 2019-2026 with the annual sales of USD 410.00 million in",SAN,en,OpenPR
2020-10-21 13:40:14-05:00,"Genetic Disorders Market to Grow at a CAGR of 13.68%, Leading Players Amicus Therapeutics, Inc.; Alexion Pharmaceuticals, Inc.; Sanofi; Takeda Pharmaceutical Company Limited; Vertex Pharmaceuticals Incorporated",Genetic Disorders Market is expected to register a healthy CAGR of 13.68% in the forecast period of 2019-2026. The report contains data from the base year of 2018 and the historic year of 2017. This rise in market value can be,SAN,en,OpenPR
2020-10-21 10:24:21-05:00,Controladora da Tok&Stok protocola prospecto para IPO,"Com 59 lojas, grupo tem como investidores o fundo Carlyle A Estok Comércio e Representações, controladora das lojas de móveis e acessórios Tok&Stok, protocolou na Comissão de Valores Mobiliários (CVM), o prospecto preliminar para a realização de uma oferta pública inicial de ações (IPO, na sigla em inglês). A oferta será primária, quando os recursos vão para o caixa da empresa, e secundária, quando os acionistas atuais vendem parte de suas fatias. Fundada há mais de 40 anos pelo casal de empreendedores Régis e Ghislaine Dubrule, a Tok&Stok tem atualmente 59 lojas em quatro formatos diferentes. “Nossos últimos anos têm sido marcados pelo maior foco em eficiência e rentabilidade e pela transformação digital, que acelerou a participação de vendas online de 5% da nossa receita líquida no exercício de 2017 para mais de 24% no período de nove meses findo em 30 de setembro”, diz a companhia no prospecto. Nos nove primeiros meses deste ano, teve receita líquida de R$ 668,1 milhões, com queda de 23,4% sobre igual período do ano passado.",SAN,pt,Valor Econômico
2020-10-21 08:43:35-05:00,"Veterinary Reference Laboratory Market 2020 Global Industry Growth, Share, Size, Trends, COVID-19 Impact Analysis and 2027 Forecasts Report - Sanofi, Idexx Laboratories, Mars, GD, Zoetis, Phoenix Lab, Virbac",A complete discussion about numerous market related topics in this Veterinary Reference Laboratory Market research report is sure to aid the client in studying the market on competitive landscape. With the use of few steps or the combination of several,SAN,en,OpenPR
2020-10-21 07:41:24-05:00,"Diabetes Care Drugs Market 2020 COVID-19 Impact, Share, Trend, Segmentation and Forecast to 2027 |Pfizer, Sanofi, Novartis, Abbott, GSK, Merck, Roche, Eli Lilly, B. Braun Melsungen, AstraZeneca, Bayer, DexCom",Diabetes Care Drugs market is expected to reach USD +94 billion by the end of 2027 with +6% CAGR during forecast period 2020-2027. The latest report devised by the analysts at Market Research Inc accumulates the current working of the market,SAN,en,OpenPR
2020-10-21 07:35:41-05:00,"Obsessive Compulsive Disorder (OCD) Drug Market : Research Report And Predictive Business Strategy 2020 - 2026 | Emerging Players - Abbott, Pfizer Inc., Merck & Co., Inc., Sanofi, Novartis AG","Obsessive Compulsive Disorder (OCD) Drug Market research report comprises of several parameters which are thoroughly studied by the experts. Market research analysis and data lend a hand to businesses for the planning of production, product launches, costing, inventory, purchasing and",SAN,en,OpenPR
2020-10-21 05:06:00-05:00,Banco Santander y el Centro de Cirugía de Mínima Invasión Jesús Usón impulsan un proyecto de I+D frente al covid-19,Esta iniciativa investigadora pretende aportar una predicción fiable del desarrollo de la enfermedad a través del estudio de determinadas moléculas relacionadas con los mecanismos de entrada del virus y cómo se alteran en función de la edad y del estado inmunológico del individuo.,SAN,es,Publico
2020-10-20 12:05:57-05:00,"Globally Growing Hepatitis Vaccine Market Demands and Analysis Forecast 2020-2025 | GSK, NCPC, Merck, Bio Kangtai, Dynavax, Hissen, KM Biologics, LG Life Sciences, Serum Institute, Sanofi, Sinovac","Business Industry Reports Research has recently announced a report on Global Hepatitis Vaccine Market based on the Category Industry. The Hepatitis Vaccine Market report emphasizes various key aspects, which include growth drivers, restraints, opportunities and recent market trends for the",SAN,en,OpenPR
2020-10-20 11:51:49-05:00,"Global Travel Vaccine Market Surprising Growth due to Covid 19 include Major Players GlaxoSmithKline plc, Sanofi, Merck & Co., Inc., Novartis AG, Pfizer Inc., ALK, Bavarian Nordic, Janssen Global Services, LLC","Data Bridge Market Research has recently added a concise research on the Travel Vaccine Market - Industry Trends and Forecast to 2026. Travel Vaccine Market research report has been prepared with a nice combination of industry insight, smart solutions, practical",SAN,en,OpenPR
2020-10-20 10:10:54-05:00,El Banco Santander vuelve a cerrar 134 oficinas por la menor actividad generada por la COVID-19,"Los nuevos rebrotes de coronavirus y la menor actividad asociada por las nuevas medidas de contención han llevado a Banco Santander a volver a cerrar temporalmente algunas oficinas bancarias, como ya hizo al inicio de la pandemia, según fuentes…",SAN,es,Publico
2020-10-20 07:48:31-05:00,De Cos da un toque a BBVA y Santander por su exposición internacional y pide prudencia con los dividendos,"Pocas veces Pablo Hernández de Cos ha lanzado tantos mensajes directos e indirectos. El gobernador del Banco de España ha pronunciado un discurso muy extenso con alertas para el Gobierno y las empresas, siendo la banca uno de sus principales destinatarios. El foro del sector financiero de Expansión, en colaboración con KPMG, Microsoft y American Express, ha reunido ayer y hoy a consejeros delegados y presidentes de entidades financieras y aseguradoras. Cada cual ha lanzado sus mensajes, aunque han quedado eclipsados por las palabras del gobernador. La banca ha centrado buena parte de las advertencias de Hernández de Cos. «En la primera mitad de 2020 el resultado neto consolidado del conjunto del sistema bancario español fue negativo por un importe de alrededor de 9.500 millones de euros, lo que supone un retroceso de casi 20.000 millones respecto a los beneficios registrados en junio de 2019, que se traduce en una ROA del −0,5 % (1,1 pp menos que en junio de 2019) y una rentabilidad sobre patrimonio neto (ROE) del −7,3 % (15 pp menos que un año antes)», ha señalado.",SAN,es,ABC Spain
2020-10-20 07:22:27-05:00,"Bladder Cancer Treatment Market Challenges and Growth Factor By 2027 with COVID 19 Impact Analysis, Leading Players are Genetech, Novartis AG, Sanofi, Pfizer, Genetech, Johnson & Johnson",A comprehensive analysis of the market structure along with the forecast of the various segments & sub-segments of the market have been delivered through this Bladder Cancer Treatment Market document. The market is greatly transforming because of the moves of,SAN,en,OpenPR
2020-10-20 05:50:06-05:00,"Surgical Sealants and Adhesives Market: Global Trends, Segmentation and Opportunities Forecast To 2027 | Baxter International Inc., Cohera Medical, Inc., CryoLife, Inc., Sanofi, Medtronic, Mallinckrodt Pharmaceuticals","The growth of the surgical sealants and adhesives market is driven by rise in geriatric population and increase in awareness towards the potential benefits of surgical sealants in surgical procedures. However, high cost associated with surgical sealants and the availability",SAN,en,OpenPR
2020-10-20 05:02:00-05:00,"THE DIGITAL HEALTH ECOSYSTEM: The most important players, tech, and trends propelling the digital transformation of the $3.7 trillion healthcare industry (AAPL, IBM, ANTM, GOOGL, MSFT, AMZN, PFE, GE, MCK, TMUS, WMT, WBA, MRK, CVS)","Summary List Placement This is a preview of a research report from Business Insider Intelligence , Business Insider's premium research service. Current subscribers can read the report here . Until now, healthcare was the only remaining industry that had yet to feel the rapid impact of digitization endured by retail, banking, and media. But consumer adoption of digital tech, regulatory overhauls, and a shifting reimbursement model are forcing healthcare players' hands. Digital health innovation offers market incumbents new opportunities to combat constricting margins, labor shortages, and rising costs. But it also poses a threat to slow movers, as new entrants lean on their digital prowess and lack of legacy infrastructure to cut costs and remain nimble. As such, incumbents are turning to acquisitions, partnerships, and new investments to strengthen their digital health services. The first Digital Health Ecosystem Report from Business Insider Intelligence explores the current healthcare ecosystem, industry trends that are driving digital transformation, and where the industry is headed.",SAN,en,Business Insider
2020-10-19 20:40:41-05:00,Sanofi (NYSE:SNY) Upgraded by Zacks Investment Research to Buy,"Zacks Investment Research upgraded shares of Sanofi (NYSE:SNY) from a hold rating to a buy rating in a research note published on Monday morning, Zacks.com reports. They currently have $53.00 price objective on the stock. According to Zacks, “Sanofi’s Specialty Care segment is on a strong footing, particularly with regular label expansion of Dupixent. The […]",SAN,en,Daily Political
2020-10-19 20:00:57-05:00,CSN pede registro para oferta de ações de unidade de mineração,"Operação promete ser uma das maiores realizadas por empresas brasileiras este ano. CSN Reprodução/TV Rio Sul A CSN Mineração pediu nesta segunda-feira registro para sua muito aguardada oferta inicial de ações (IPO, na sigla em inglês), com a operação da unidade de minério de ferro da CSN prometendo ser uma das maiores feitas por empresas brasileiras em 2020. O porte da transação pode ser medido pela quantidade de instituições financeiras que vão coordenar a oferta, 11 ao todo, incluindo Morgan Stanley, XP, Bank of America, Bradesco BBI, BTG Pactual, UBS-BB, Caixa, Citi, Banco Fibra, Safra e Santander. Em fato relevante publicado mais cedo, a CSN informou que ainda avalia se participará da operação como vendedora. Mesmo com crise, entrada de empresas na bolsa este ano já é mais do dobro da registrada em 2019 Varejista Grupo Big pede registro para IPO No prospecto preliminar, a CSN Mineração se apresenta como segunda maior exportadora de minério de ferro no Brasil e detentora de uma das maiores reservas de minério de ferro no mundo, certificada em mais de 3 bilhões de toneladas.",SAN,pt,Globo G1
2020-10-19 11:50:37-05:00,Banco Santander inaugura en Málaga su primer Work Café de Andalucía,"Con este novedoso centro, ya son nueve los que la entidad tiene en España, repartidos entre Madrid, donde hay 6, Barcelona, Bilbao y Málaga Próximamente se sumarán Valencia y Valladolid",SAN,es,Malaga Hoy
2020-10-19 11:25:58-05:00,"Aeris define faixa de preço e pode levantar R$ 1,3 bilhão em IPO","Fabricante de pás eólicas prevê usar os recursos para ampliação e modernização do parque produtivo, além do pagamento de dívidas A fabricante de pás eólicas Aeris definiu entre R$ 6,50 e R$ 8,10 a faixa indicativa de preços na sua oferta pública inicial de ações (IPO, na sigla em inglês). Considerando o meio da faixa indicativa, de R$ 7,30, e o número de 176.923.070 ações da oferta base, a operação pode movimentar R$ 1,291 bilhão. Há ainda possibilidade de um lote adicional de até 20%, ou 35.384.614 ações, e lote suplementar de até 15%, ou 26.538.460 ações. Nesse caso, ainda considerando o meio da faixa indicativa, a oferta total subiria para R$ 1,743 bilhão. A oferta base será primária (130.769.230 ações, ou R$ 954,615 milhões) - quando os recursos vão para o caixa da empresa - e secundária (46.153.840 ações, ou R$ 336,923 milhões), quando os acionistas atuais vendem parte de suas fatias. A precificação está marcada para o dia 9 de novembro. As ações da companhia serão negociadas na B3 sob o ticker ‘AERI3’.",SAN,pt,Valor Econômico
2020-10-19 07:57:49-05:00,"Eczema Therapeutics Market 2020-28 advance research lead towards gigantic hike| Bausch Health Companies, Bayer AG, Eli Lilly, Encore Dermatology, LEO Pharma AS, Mylan NV, Pfizer, and Sanofi",Eczema is a term for a group of conditions that make your skin inflamed or irritated. The most common type is atopic dermatitis or atopic eczema. “Atopic” refers to a person's tendency to get allergic conditions such as asthma and,SAN,en,OpenPR
2020-10-19 05:59:06-05:00,La banca insta ante De Guindos a levantar el veto a los dividendos,"No hay ninguna duda de que los bancos quieren repartir dividendos en 2021. Aunque ninguno lo hará sin el beneplácito del Banco Central Europeo (BCE). Un tira y afloja entre entidades y supervisor que va tensando cada vez más la cuerda y que hoy ha tenido un nuevo capítulo en el foro del sector financiero organizado por Expansión, en colaboración con KPMG, Microsofr y American Express. José Antonio Álvarez, Onur Genç y Gonzalo Gortázar han sido muy claros. Los consejeros delegados de Banco Santander, BBVA y Caixaban k han instado ante el vicepresidente del BCE a levantar para el próximo año el veto a remunerar a los accionistas. Quieren y pueden volver a ello, y la presión va en aumento. Todos ellos se han pronunciado en términos muy similares. Quieren que el supervisor comunitaraio levante la recomendación-prohibición. De hecho, en los últimos meses varias entidades han ido anunciando decisiones en ese sentido, siempre que el BCE no prolongue el veto. Álvarez ha explicado que la prohibición eleva «innecesariamente» el coste de capital de los bancos, por lo que ve recomendable que se retire.",SAN,es,ABC Spain
2020-10-17 12:45:31-05:00,"Celebrada una concentración en contra de la ""ocupación del arco"" del Banco Santander: ""Museo sí, calle también""","La Federación Cántabra de Asociaciones de Vecinos (FECAV) y representantes de otras asociaciones vecinales han llevado a cabo este sábado una concentración de protesta contra la ""ocupación del arco"" del Banco Santander prevista en la ejecución…",SAN,es,Publico
2020-10-16 15:58:28-05:00,Focus Energia pede registro para IPO e mira investir em projetos de geração,"A comercializadora de energia elétrica Focus Energia divulgou nesta sexta-feira prospecto preliminar de sua oferta inicial de ações (IPO, na sigla em inglês) que visa levantar recursos principalmente para investimentos em projetos de geração. A oferta, com distribuição primária e secundária, terá como coordenador líder o Morgan Stanley (MS), que atuará junto a Santander (SANB11) […]",SAN,pt,Money Times
2020-10-16 13:40:17-05:00,Cielo opera perto das mínimas históricas; credenciadora divulga balanço no dia 27,"A companhia será uma das primeiras do setor financeiro a divulgar seus resultados do terceiro trimestre A Cielo opera em queda firme nesta sexta-feira e se aproxima das suas mínimas históricas. O papel recua 1,92%, a R$ 3,58. Com isso, se aproxima da sua mínima histórica de fechamento, de R$ 3,33, registrada em 13 de maio deste ano. A companhia será uma das primeiras do setor financeiro a divulgar seus resultados do terceiro trimestre, no dia 27, junto com Santander. No segundo trimestre, a Cielo teve o primeiro prejuízo desde que abriu seu capital, em 2009, ao registrar resultado negativo de R$ 75,2 milhões. Para o terceiro trimestre, em meio à continuação do cenário competitivo no setor de credenciadoras e com o advento de novas tecnologias, como o sistema de pagamentos instantâneos Pix, do Banco Central, as previsões dos analistas não são muito alvissareiras. Os analistas do Safra, por exemplo, esperam que a Cielo apresente lucro de R$ 111 milhões, uma queda de 81,9% na comparação com o mesmo trimestre do ano passado.",SAN,pt,Valor Econômico
2020-10-16 08:40:20-05:00,"Rotavirus Prophylaxis Market Current and Future Trend Scenario Explored In New Latest Research Report| Merck & Co., Inc., Bharat Biotech, GlaxoSmithKline plc, Sanofi, Lanzhou Institute of Biologicals Products Co., Ltd","The company profiles of all the major market players and brands that are dominating the Rotavirus Prophylaxis Market with moves like product launches, joint ventures, merges and accusations which in turn is affecting the sales, import, export, revenue and CAGR",SAN,en,OpenPR
2020-10-16 05:54:22-05:00,"Prostate Cancer Market Size Estimation, Outbreak Impact Analysis, Key Insights and Application By 2027 | Johnson & Johnson, Sanofi S.A, Bristol Myers Squibb (BMS), Bayer","Global prostate cancer market is poised to grow at an exponential pace, primarily due to the mounting prevalence of prostate cancer, rapidly aging population and strong bolstering pipeline. The market would undergo a transformation during the analysis period, attributed by",SAN,en,OpenPR
2020-10-16 05:31:05-05:00,"Atherosclerosis Market Shows Strong Growth 2020-2027| Novartis AG, Merck & Co., Inc., Sanofi, F. Hoffmann-La Roche Ltd., GlaxoSmithKline plc, Ionis Pharmaceuticals, Inc., Anthera Pharmaceuticals",Atherosclerosis Market analysis report is a professional yet exhaustive study on the current state for the market. The market study of Atherosclerosis Market business document helps minimize the risks of uncertainties and helps in taking sound decisions. With this market,SAN,en,OpenPR
2020-10-16 02:13:39-05:00,"Una misionera zamorana de 74 años que trabaja en Angola, imagen de la campaña del Domund","Juana María Domínguez, una misionera de 74 años, natural de Figueruela de Arriba (Zamora) y que desarrolla su trabajo en Angola, protagoniza este año la campaña del Domund, que se celebra el próximo domingo, día 18 de octubre, bajo el lema «Aquí estoy. Envíame». Cuando era pequeña, Juana María, misionera Hija de la Virgen de los Dolores, salía con las huchas del Domund por las calles de Zamora. «Para ella y sus amigas, era un reto ver quién llenaba más la hucha. Ahora, en 2020, su imagen es el cartel del Domund de este año. Participó en el programa Misioneros por el Mundo de 13 Televisión. Actualmente, está en Angola y es un ejemplo de entrega a los demás», según señalaron fuentes de la Delegación de Misiones. De esta forma, teniendo en cuenta que la emergencia sanitaria ha provocado que no se puedan hacer colectas con normalidad en las misas y los colegios, y con la idea de que el coronavirus «no frene» la llegada de donativos, el Domund de este año se adapta a las nuevas tecnologías y la Delegación de Misiones ofrece la posibilidad de colaborar por Bizum, con un donativo a través de la aplicación bancaria al 00500; por transferencia, a las cuentas de las Obras Misionales Pontificias en Caja Rural de Zamora y en el Banco Santander, y a través de la página web www.domund.es, que facilita la participación en la I Carrera Solidaria Virtual por el Domund.",SAN,es,ABC Spain
2020-10-15 17:05:00-05:00,El Banco Santander reconoce a la empresa TEISA como Pyme del año 2020 de Girona,"EISA sido designada como Pyme del Año 2020 de Girona, un premio convocado por el Banco Santander, con la colaboración del diario La Vanguardia, para reconocer la labor de las pequeñas y medianas empresas en la creación de empleo y generación de…",SAN,es,La Vanguardia
2020-10-15 13:29:28-05:00,"Sleeping Medications Market COVID-19 Impact, Global Analysis and Forecast to 2027| Pfizer, Sanofi, Sumitomo Dainippon Pharma Co., Takeda Pharmaceutical Company Ltd., Teva Pharmaceutical Industries Ltd.",Sleeping medications are known as sleeping pills. Sleeping pills mainly refers to a generic term that is used for describing both over-the-counter (OTC) or prescription medications. Sleeping pills are majorly used for helping individuals who face difficulty in falling asleep,SAN,en,OpenPR
2020-10-15 10:31:21-05:00,Big Pharma's Vaccine Race – A Chance For Redemption,"The whole world is coming together in the fight against COVID-19. The quest for a vaccine is revolutionizing the controversial Big Pharma. Nearly 200 vaccine candidates are in development, 39 in human clinical trials and nine in Phase III trials. Cooperation Perhaps the most unexpected aspect of this unprecedented pandemic has been the wholehearted embrace of collaboration in the pharmaceutical industry, which was characterized as everything but a collective spirit. We've seen traditional pharma giant AstraZeneca (NYSE: AZN ) joining forces with a legendary academic institution such as University of Oxford to compensate for the effect it was not a major player in vaccines. We've seen rivals snuggle up in pairs such as Sanofi (NASDAQ: SNY ) and GSK (NYSE: GSK ) and international collaborations galore: Germany's BioNTech (NASDAQ: BNTX ), for instance, is testing one novel messenger RNA vaccine with giant Pfizer (NYSE: PFE ), in New York, and a second with Shanghai Fosun Pharmaceutical (OTC: SFOSF ).",SAN,en,Benzinga
2020-10-15 08:35:53-05:00,Safra: o que esperar das ações de bancos com início da temporada de balanços,"Resultados do setor financeiro no terceiro trimestre podem trazer gatilhos para ações de bancos; veja quais devem se destacar, segundo os especialistas Santander (SANB11) e Bradesco (BBDC4) devem ser os destaque entre os bancos, segundo avaliação do Safra Getty Images As instituições financeiras devem apresentar uma recuperação consistente no terceiro trimestre do ano em relação ao anterior, reforçando que o pior da crise da pandemia e dos impactos no mercado e na economia já ficou para trás. Isso significa que, mesmo com resultados mais fracos do que o esperado na comparação anual, o investidor deve olhar com atenção para as ações de bancos. Essa é a expectativa da equipe de analistas da Safra Corretora para a temporada de balanços que se aproxima, relativa ao terceiro trimestre. Os especialistas esperam que os bancos reduzam os níveis de reserva de valores para Provisão de Devedores Duvidosos (PDD), embora ainda não esteja claro como e quando ocorrerá o pico dos índices de inadimplência - as projeções apontam que isso deve acontecer no primeiro semestre de 2021.",SAN,pt,Valor Econômico
2020-10-14 21:45:00-05:00,Bomba de relojería en la banca: ya tienen más de 100.000 millones bajo moratoria,"Banco Santander es la entidad que más moratorias ha otorgado, un total de 64.000 millones de euros",SAN,es,Vozpopuli
2020-10-14 10:12:51-05:00,"RNA Therapeutics Market 2020 Analysis, Size, Share, Growth, Trends And Forecast, Leading Players are Quark, Sanofi, Ionis Pharmaceuticals, Silence Therapeutics, Cenix BioScience, Marina Biotech","The winning RNA Therapeutics Market report makes available the current and forthcoming technical and financial details of the industry. Few of the chief insights of this business report include; distinct analysis of the market drivers & restraints, major market players",SAN,en,OpenPR
2020-10-14 06:40:46-05:00,"Prostate Cancer Therapeutics Market 2020 Size, Share, Global Trends, Comprehensive Research Study, Opportunities, Leading Players are Johnson & Johnson, Sanofi, Bayer AG, Pfizer, Abbott, Novartis AG","The winning Prostate Cancer Therapeutics Market report makes available the current and forthcoming technical and financial details of the industry. Few of the chief insights of this business report include; distinct analysis of the market drivers & restraints, major market",SAN,en,OpenPR
2020-10-14 05:27:09-05:00,"Astonishing Growth of Digital Health Pharmaceutical Market to See Huge Growth in Future by 2020-2028 | Leading Key Vendors Bayer, Pfizer, Boehringer Ingelheim, Novartis, Sanofi, AstraZeneca, GlaxoSmithKline, AbbVie, Johnson and Johnson",The global analysis of Digital Health Pharmaceutical Market and its upcoming prospects have recently added by healthcareintelligencemarkets to its extensive repository. It has been employed through the primary and secondary research methodologies. This market is expected to become competitive in,SAN,en,OpenPR
2020-10-14 04:16:30-05:00,"Global Hydroxychloroquine Market Shows Strong Growth with Leading Players are Advanz Pharma, Teva Pharmaceutical Industries Ltd, Sanofi, Novartis AG",Data Bridge Market Research has recently added a concise research on the Global Hydroxychloroquine Market to depict valuable insights related to significant market trends driving the industry. Global Hydroxychloroquine Market report comprises of crucial aspects of the market that contains industry,SAN,en,OpenPR
2020-10-14 03:58:00-05:00,Banco Santander lanza 11.100 becas de inmersión en inglés para mejorar el acceso de los jóvenes al mercado laboral,"Hablar ingles continúa siendo una asignatura pendiente para muchos jóvenes españoles. Banco Santander y el British Council han puesto en marcha un programa de becas de inmersión en inglés, el idioma universal por excelencia, para ayudar a los jóvenes universitarios de nuestro país a acceder al mercado laboral.",SAN,es,Publico
2020-10-13 15:58:32-05:00,Rede D’Or protocola prospecto para IPO,"Expectativa é que oferta possa movimentar até R$ 10 bilhões A Rede D’Or São Luiz protocolou na Comissão de Valores Mobiliários (CVM) o prospecto preliminar para a realização de uma oferta pública inicial de ações (IPO, na sigla em inglês), conforme antecipou o Valor. A oferta será primária - quando os recursos vão para o caixa da empresa - e secundária - quando os acionistas atuais vendem parte de suas fatias. Ainda não há informações oficiais sobre o número de ações a serem vendidas, mas o Valor apurou que a oferta pode chegar a R$ 10 bilhões. A Rede D’Or diz que opera a maior rede independente de hospitais privados do Brasil, composta por 51 hospitais próprios, um hospital sob administração e 32 projetos de hospitais em desenvolvimento, licenciamento ou construção, distribuídos nos estados do Rio de Janeiro, São Paulo, Pernambuco, Bahia, Sergipe, Maranhão, Paraná e Ceará e no Distrito Federal. Também opera a maior rede de clínicas oncológicas do país, com 39 unidades, além de 11 laboratórios e 54 unidades de diálise.",SAN,pt,Valor Econômico
2020-10-13 11:22:47-05:00,"Epilepsy Drug Market: Global Trends, Segmentation and Opportunities Forecast To 2027 | Pfizer, Novartis, Sanofi ,Abbott Laboratories, GSK","Rising incidence of neurological disorders, higher incidence of birth related injuries, increasing road traffic injuries, growing disease awareness and rising patient base in developing countries, are the significant factors driving the global Epilepsy drug market. Moreover, increasing R&D investment and",SAN,en,OpenPR
2020-10-13 10:49:23-05:00,"North America Cancer Vaccines Market projected to reach US$ 6,626.6 million and Growing at a CAGR of 17.5% during forecast period 2020–2027, Key Players- AstraZeneca, GlaxoSmithKline plc., Aduro Biotech Inc, Pfizer Inc., Sanofi, Bristol-Myers Squibb, Mo","North America cancer vaccines market was valued at US$ 1,875.7 million in 2019 and is projected to reach US$ 6,626.6 million by 2027; it is expected to grow at a CAGR of 17.5% during 2020–2027. Demand for cancer vaccines is",SAN,en,OpenPR
2020-10-13 09:03:21-05:00,"Cold Pain Therapy Market Insights, Status, Latest Amendments And Outlook | Leading Players are Sanofi, 3M, FrozenPeaz, Medichill UK, Romsons, MeyerDC, Breg","The Cold Pain Therapy Market business report provides market shares at global level mainly for Europe, North America, Asia Pacific and South America. By using an excellent research methodology, this report focuses on market share analysis and key trend analysis.",SAN,en,OpenPR
2020-10-13 08:27:44-05:00,"Glycosylated Hemoglobin C-peptide Market to grow with electrifying over Forecast Period 2020-2028| Prominent Players - Medtronic, Dr.Reddy's Laboratories, Roche, Biocon, Sanofi, Celltrion, Sandoz International","Due to the pandemic, we have included a special section on the Impact of COVID 19 on the Glycosylated Hemoglobin C-peptide Market which would mention How the Covid-19 is affecting the Glycosylated Hemoglobin C-peptide Industry, Market Trends and Potential Opportunities",SAN,en,OpenPR
2020-10-13 07:07:00-05:00,Regulus Therapeutics Announces Receipt of $5 Million Milestone and Material Payments from Sanofi,"LA JOLLA, Calif., Oct. 13, 2020 /PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS) (the ""Company"" or ""Regulus""), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs, today announced receipt of a total of $5 million in…",SAN,en,PR Newswire
2020-10-13 04:46:10-05:00,"Sanofi, Regeneron Report Positive Phase 3 Results For Asthma Drug Dupixent's Use In Children","Sanofi SA (NASDAQ: SNY ) and Regeneron Pharmaceuticals Inc (NASDAQ: REGN ) disclosed that their asthma drug Dupixent (dupilumab) met its primary and all key secondary endpoints in randomized Phase 3 clinical trials demonstrating improved lung functions in children aged between six to 11 years. Data from trial results hint that Dupixent holds a lot of promise for children (aged between six to 11 years) with uncontrolled moderate-to-severe asthma. The drug is the outcome of a collaboration between Sanofi and Regeneron, using the latter's VelocImmune technology , which utilizes a proprietary genetically-engineered mouse platform endowed with a genetically-humanized immune system … Full story available on Benzinga.com",SAN,en,Benzinga
2020-10-13 03:36:22-05:00,"Lung Cancer Diagnosis and Therapeutics Market Growth, Regional Analysis, Segments, Region and Forecasts 2020-2026 | AstraZeneca, Eli Lilly, Sanofi, ArQule, Daiichi Sankyo, Celgene","The market study titled Global Lung Cancer Diagnosis and Therapeutics Market 2020 by Company, Type and Application, Forecast to 2025 delivers a thorough investigation by manufacturers, regions, type, and application, forecast to 2025. The report offers comprehensive research on product",SAN,en,OpenPR
2020-10-13 03:34:07-05:00,"Bronchitis Treatment Market 2020 Industry Will Grow in Near Future by Growth - Pfizer, GlaxoSmithKline Pharmaceuticals Limited, Sanofi Aventis, Boehringer Ingelheim, Dr. Reddy’s Laboratories Ltd","The “Bronchitis Treatment Market” report 2020 provides information for market players, stakeholders, investors, and business strategists to achieve a leading position in the market. It maintains the record of Unusual growth strategies adopted by various companies that are creating new",SAN,en,OpenPR
2020-10-13 00:48:44-05:00,Sanofi/Regeneron Dupixent reduces asthma attacks and improves lung function in children (NASDAQ:SNY),A pivotal Phase 3 trial of Sanofi (NASDAQ:SNY) and Regeneron's (NASDAQ:REGN) Dupixent (dupilumab) met its primary and all key secondary endpoints in childr,SAN,en,Seeking Alpha
2020-10-12 20:40:16-05:00,Johnson & Johnson pauses COVID vaccine trial as participant becomes ill,"WASHINGTON -- Johnson & Johnson said Monday it had temporarily halted its Covid-19 vaccine trial because one of its participants had become sick. ""We have temporarily paused further dosing in all our COVID-19 vaccine candidate clinical trials, including the Phase 3 ENSEMBLEtrial, due to an unexplained illness in a study participant,"" the company said in a statement. The pause means the online enrollment system has been closed for the 60,000-patient clinical trial while the independent patient safety committee is convened. JPV RELATED STORY: Sanofi, GSK launch trial for COVID-19 protein-based vaccine… Keep on reading: Johnson & Johnson pauses COVID vaccine trial as participant becomes ill",SAN,en,Inquirer News Info
2020-10-12 16:51:28-05:00,Thousands of people want to be exposed to coronavirus for science,"Coronavirus vaccine research is advancing at an incredible pace, with some of the first results expected by the end of the year. The UK government is actively exploring the idea of starting a challenge trial where volunteers would receive the experimental drug and then the virus. The World Health Organization (WHO) already cleared the controversial testing method , but governments and vaccine makers are still reluctant to embark on research that would expose volunteers to a deadly pathogen. Tens of thousands of people have signed up for challenge trials nonetheless. There’s hope that vaccines combined with continued precautions (social distancing, hand washing, and face masks) can defeat the COVID-19 pandemic by the end of 2021. While we have no definitive proof that vaccines are effective and safe, there’s plenty of promising evidence to keep the hope alive. First of all, there are hundreds of coronavirus vaccine candidates in the works. The more shots on goal, the higher the chances that at least one will score.",SAN,en,BGR
2020-10-12 13:41:31-05:00,"Atrial Fibrillation Market Growth Insights by Emerging Key Players Biotronik, Sanofi, Abbott, CardioFocus, Biosense Webster, AtriCure, Medtronic","Atrial fibrillation also referred to as AFib or AF is a medical condition that causes irregular heartbeat (arrhythmia) and which can further lead to blood clots, stroke, heart failure and other heart-related complications.The global atrial fibrillation market is driven by",SAN,en,OpenPR
2020-10-12 11:08:58-05:00,"Informative Report on Codeine Market Analysis by Regions, Share, Top Key Players (J&J, Taiji, Mallinckrodt, TEVA, Medreich, Sanofi Aventis, Cipla, Novartis, Mylan) and Forecasts to 2025","The Global Codeine Market is comprehensively and Insightful information in the report, taking into consideration various factors such as competition, regional growth, segmentation, and Codeine Market size by value and volume. This is an excellent research study specially compiled to",SAN,en,OpenPR
2020-10-12 09:15:57-05:00,"Lower Respiratory Tract Infection Treatment Market (COVID-19 Impact Analysis), Emerging Trends, Business Opportunities, Segmentation, Brand Shares and Forecast | Abbott., AZ Network, Novartis AG, Sanofi, Pfizer","The LOWER RESPIRATORY TRACT INFECTION TREATMENT Market report makes available a thoughtful overview of product specification, technology, product type and production analysis taking into account major factors such as revenue, cost, and gross margin. The report is sure to offer",SAN,en,OpenPR
2020-10-12 08:21:31-05:00,"Global Meningococcal Disease Vaccine Market 2020:Valuable Growth Prospects,Covid-19 Impact Analysis, Advancement And Outlook 2027||Pfizer Inc., GlaxoSmithKline Plc., Sanofi, Novartis AG, and Baxter",Global Meningococcal Disease Vaccine Market Research Report has been analyzed in detail to help clients with all the vital data to frame tactical business judgments and propose strategic growth plans. The Global Meningococcal Disease Vaccine Market report offers,SAN,en,OpenPR
2020-10-12 07:11:10-05:00,"Neuroendocrine Tumors Market (COVID-19 Impact Analysis), 2020 Size, Global Industry Growth, Statistics, Trends, Revenue Analysis 2027 | Novartis AG, Pfizer, Amgen, Mylan N.V, Sanofi S.A, F. Hoffmann-La Roche, Eli Lilly and Company","The NEUROENDOCRINE TUMORS Market report makes available a thoughtful overview of product specification, technology, product type and production analysis taking into account major factors such as revenue, cost, and gross margin. The report is sure to offer brilliant solution to",SAN,en,OpenPR
2020-10-12 03:27:03-05:00,De Juan Roig a Antonio Llardén: los cien ejecutivos con mejor reputación de España,"El presidente de Mercadona, Juan Roig, es el directivo con mejor reputación de España. El empresario valenciano lidera el ranking «Merco Líderes 2020» por delante del consejero delegado de Inditex. Pablo Isla, y la presidenta del Banco Santander, Ana Botín. Juan Roig logra la máxima nota con 10.000 puntos en un ranking de cien ejecutivos que cierra el presidente de Enagás, Antonio Llardén, con 3.000. En un ejercicio marcado por el impacto de la pandemia del coronavirus, Juan Roig ha encabezado el movimiento bautizado como «Eactívate» para poner en valor el trabajo de los empresarios que han mantenido el pulso durante la crisis sanitaria y que busca acelerar la economía española. Merco elabora la clasificación de líderes empresariales tras un «exhaustivo y pormenorizado análisis de más de 44.505 encuestas, seis evaluaciones y veinticuatro fuentes de información; verificado a través de una revisión independiente por parte de KPMG». En concreto, Merco ha contado con la participación de 1.",SAN,es,ABC Spain
2020-10-12 01:39:40-05:00,"COVID-19 UPDATE: Global Hydroxychloroquine Market Surprising Growth due to Covid 19 include Major Players Advanz Pharma, Teva Pharmaceutical Industries Ltd, Sanofi, Novartis AG, Mylan N.V., Zydus Cadila",Data Bridge Market Research has recently added a concise research on the Global Hydroxychloroquine Market to depict valuable insights related to significant market trends driving the industry. The report features analysis based on key opportunities and challenges confronted by market,SAN,en,OpenPR
2020-10-11 03:53:04-05:00,Una nueva campaña de phishing suplanta a entidades bancarias para robar datos de los usuarios,"La Oficina de Seguridad del Internauta alerta de una nueva campaña de phishing que suplanta a entidades bancarias, Bankia y Banco Santander entre ellas, para robar credenciales de acceso y hacerse con información bancaria de los usuarios con…",SAN,es,Publico
2020-10-10 11:03:43-05:00,"Global Bispecific Antibody Therapeutics Market Share, Trends, Key Players, COVID-19 Impact, Opportunity, and Regional Insights With Forecast To 2027|| Innovent Biologics, Inc, Affimed GmbH, Amgen Inc, AstraZeneca, , Sanofi, F. Hoffmann-La Roche Ltd, Regen","“Global Bispecific Antibody Therapeutics Market–Industry Trends and Forecast to 2027” Comprehensive Research Report to Added In Data Bridge Market Research's directory. Report carrying 350 pages, 60 Figures And 220 Tables in it. The Bispecific Antibody Therapeutics market study analyzes the",SAN,en,OpenPR
2020-10-09 09:15:55-05:00,"(Covid 19 Impact Analysis) Global Combination Antibody Therapy Market 2020:Growth Insights and Forecast By Novartis AG, Genetech Inc., Bristol-Myers Squibb Company, F. Hoffmann-La Roche Ltd, Sanofi","A new research study from “Data Bridge Market Research” with title combination Antibody Therapy Insights 2020, Global Analysis and Forecast to 2027 provides an in-depth assessment of the Combination Antibody Therapy including key market trends, upcoming technologies, industry",SAN,en,OpenPR
2020-10-09 08:34:47-05:00,"Biologics (Biosimilar) Market to See Huge Growth by 2026 | Sanofi, Mylan, Teva, Amgen, Pfizer","A study published on COVID-19 Outbreak-Global Biologics (Biosimilar) Market, includes exploratory survey, qualitative commentary on changing market dynamics with market sizing and estimates for 18+ Global Countries, business segments and applications. The identification of hot and emerging players is completed",SAN,en,OpenPR
2020-10-09 07:50:12-05:00,"Multiple Sclerosis Therapeutics Market Size, Share, Trends, Regional Analysis & Forecast 2027 | Major Players Novartis AG, Teva Pharmaceuticals Industries Ltd., Sanofi Genzyme, Bayer AG, Pfizer, Inc., Biogen Idec, Merck & Co., Inc., AbbVie, Inc.","Stratagem Market Insights has announced the addition of the ""Multiple Sclerosis Therapeutics Market Report 2020-2027 Production, Sales and Consumption Status and Prospects Professional Research"", the report classifies the global Multiple Sclerosis Therapeutics Market in a precise manner to offer detailed",SAN,en,OpenPR
2020-10-09 05:40:48-05:00,"Global Pulmonary Embolism Market 2020 Indepth Study Including COVID 19 Update with of Top Key Players Profile: Fresenius Kabi USA, Hikma Pharmaceutical PLC., Pfizer Inc., Sanofi, Novartis AG, Teva Pharmaceutical Industries Ltd",Data Bridge Market Research has recently added a concise research on the Global Pulmonary Embolism Market to depict valuable insights related to significant market trends driving the industry. The report features analysis based on key opportunities and challenges confronted by,SAN,en,OpenPR
2020-10-09 03:54:01-05:00,El Santander solo quería comprar el Popular si era intervenido,"El consejo de administración de Banco Santander reunido en mayo del 2017 decidió no autorizar la compra de Banco Popular porque el precio de la operación estaba por debajo de la cotización de la entidad en aquel momento. Pero en ese instante, el…",SAN,es,La Vanguardia
2020-10-08 11:24:48-05:00,"RNA Therapeutics Market (COVID - 19 Updates) Complete Survey 2020 Insights, Demand, Analysis, Type, Size and Share, Leading Players are Quark, Alnylam Pharmaceuticals, Benitec Biopharma, Sanofi, Cenix BioScience, Sirnaomics","This RNA Therapeutics Market research report is a detailed synopsis on the study of industry and its impact on the market environment. By systematically understanding and keeping into thought customer requirement, one step or combination of many steps has been",SAN,en,OpenPR
2020-10-08 10:41:45-05:00,Botín niega presiones de De Guindos para hacerse con el Popular - Republica.com,"La presidenta del Banco Santander, Ana Botín, ha negado este jueves haber recibido presiones del Gobierno o del Banco de España para que se hiciera con el Popular tras su resolución, y ha defendido la compra de la entidad, que, en el momento de su intervención, cumplía las ratios que marcaba la ley. La declaración […]",SAN,es,Republica.com
2020-10-08 10:10:46-05:00,"Rare Neurological Disease Treatment Market Growth, Trends And Forecasts (2020-2027) by Allergan plc, Bayer AG, GlaxoSmithKline plc, Johnson & Johnson Services, Inc, Merck & Co., Inc., Novartis AG, Pfizer Inc., Sanofi, Teva Pharmaceutical Industries Ltd","The rare neurological disease treatment market is expected to reach US$13,830.96 Mn in 2027 from US$ 7,300.12Mn in 2019. The market is estimated to grow with a CAGR of 8.5% from 2020-2027. The key players profiled in the Rare Neurological Disease",SAN,en,OpenPR
2020-10-08 09:29:32-05:00,"Raquel Tapia, nueva directora general de SanofiGenzyme Iberia","La farmacéutica Sanofi ha nombrado a Raquel Tapia directora general de Sanofi Genzyme Iberia , la unidad de Sanofi especializada en la investigación y el desarrollo de tratamientos para pacientes con enfermedades minoritarias, enfermedades hematológicas raras, esclerosis múltiple, oncología e inmunología. También formará parte del European Leadership Team de Sanofi Genzyme y se integrará en el Comité de Dirección de Sanofi. Seguir leyendo… .",SAN,es,El Periodico
2020-10-08 06:51:59-05:00,Salida de Ana Patricia Botín de la Audiencia Nacional,"Imágenes de la salida de la presidenta del banco Santander, Ana Patricia Botín, tras declarar este jueves como testigo ante el juez de la Audiencia Nacional José Luis Calama en relación a la causa en la que se investigan las presuntas irregularidades que llevaron a la resolución y posterior venta del Banco Popular a mediados de 2017.",SAN,es,Publico
2020-10-08 04:40:00-05:00,Botín admite llamadas de Guindos y Linde pero niega presiones para comprar Popular,La presidenta del Banco Santander declara hoy en el caso promovido por inversores de la entidad que quebró en junio de 2017 y fue adquirida por el banco cántabro por 1 euro,SAN,es,El Confidencial
2020-10-08 04:16:41-05:00,La importancia de la excelencia educativa,"La educación es un pilar fundamental para garantizar el progreso de la sociedad. Banco Santander apoya a universitarios y jóvenes profesionales de entre 18 y 32 años a través de un amplio programa de becas e iniciativas académicas enfocadas a impulsar la educación, el emprendimiento, la investigación y la empleabilidad de las nuevas generaciones",SAN,es,El Pais
2020-10-08 04:01:11-05:00,La justicia madrileña concluye que las cuentas de Banco Popular no eran reales desde 2012,"Nuevo golpe a la caída del Banco Popular. La Audiencia Provincial de Madrid concluye en una sentencia que las cuentas de la entidad «no reflejaban la imagen fiel al menos desde el 17 de febrero de 2012». Esto es desde la integración de Banco Pastor, después de llevar a cabo «una ocultación de pérdida sostenida en el tiempo hasta la propia resolución de banco». El caso, defendido por el despacho Rúa Abogados, tiene que ver con un afectado que compró acciones del Popular el 1 de junio de 2017, apenas unos días antes de la resolución del banco. La Audiencia, en segunda instancia, confirma la primera sentencia y obliga a Banco Santander como heredero de la entidad a indemnizar al afectado con 40.000 euros. Asimismo, el fallo es demoledor con respecto a las cuentas: «Se dio al inversor una apariencia errónea de solvencia cuando se estaba en presencia de una entidad con graves dificultades económicas». Es decir, que por aquel entonces, según la sentencia, ya llevaban años con las cuentas sin reflejar la imagen fiel del banco.",SAN,es,ABC Spain
2020-10-08 02:51:11-05:00,"La presidenta del Santander, Ana Patricia Botín, testifica ante el juez del 'caso Popular'","La presidenta del banco Santander, Ana Patricia Botín, acude a declarar como testigo ante el juez de la Audiencia Nacional José Luis Calama en relación a la causa en la que se investigan las presuntas irregularidades que llevaron a la resolución y posterior venta del Banco Popular a mediados de 2017.",SAN,es,Publico
2020-10-08 01:49:10-05:00,Botín testifica hoy en la Audiencia Nacional sobre la compra del Banco Popular,"La presidenta del Banco Santander, Ana Botín, testifica este jueves en persona ante la Audiencia Nacional en el marco de la causa que investiga a los dos últimos equipos gestores del Banco Popular, incluidos sus expresidentes Ángel Ron y Emilio…",SAN,es,La Vanguardia
2020-10-08 01:42:29-05:00,"Global Post-Acute Myocardial Infarction Market to Show Tremendous Growth by 2027 | Leading Players-AstraZeneca, Sanofi, Merck & Co., Inc, Pfizer, Inc, Daiichi Sankyo Company, Limited, Amgen, Inc","A new business intelligence report released by Data Bridge Market Research with title Global Post-Acute Myocardial Infarction Market are taken from trustworthy sources such as websites, annual reports of the companies, journals, and others and were checked and validated by",SAN,en,OpenPR
2020-10-07 09:03:38-05:00,"COVID-19 UPDATE: Travel vaccine market Likely to Experience a Tremendous Growth in Near Future||GlaxoSmithKline plc, Sanofi, Merck & Co., Inc., Novartis AG, Pfizer Inc., ALK, Bavarian Nordic",Data Bridge Market Research has added an exhaustive research study of the Travel vaccine market driver and intricately analyzing the business vertical. The research report has abilities to raise as the most significant market worldwide as it has remained playing,SAN,en,OpenPR
2020-10-07 08:28:56-05:00,"Bladder Cancer Treatment Market Size, Share 2020-Industry & Regional Trend, Future Growth, Leading Players are Novartis AG, Sanofi, F. Hoffmann-LA Roche, Pfizer, Genetech, Johnson & Johnson","To prepare this Bladder Cancer Treatment Market research report, an array of objectives of market research has been considered. While formulating this market report, marketing administration stays extremely aware about certain things that include the minds of target markets, feelings,",SAN,en,OpenPR
2020-10-07 08:09:02-05:00,"RNAi Therapeutics Market CAGR Projected to Grow at 8.8% Through 2027 - Alnylam Pharmaceuticals, Sanofi, Benitec Biopharma, Arbutus Biopharma and Quark","RNAi Therapeutics Market was valued at US$ 618.79 million in 2019 and is projected to reach US$ 1,209.29 million by 2027; it is expected to grow at a CAGR of 8.8% from 2020 to 2027. RNAi refers to the interference",SAN,en,OpenPR
2020-10-07 07:03:29-05:00,"Healthcare Advertising Market 2020 Major Players Hitting the Reset Button, Johnson & Johnson, Pfizer, Eli Lilly and Company., Novartis AG, Sanofi, Bayer AG","To prepare this Healthcare Advertising Market research report, an array of objectives of market research has been considered. While formulating this market report, marketing administration stays extremely aware about certain things that include the minds of target markets, feelings, preferences,",SAN,en,OpenPR
2020-10-07 06:46:23-05:00,"Hydroxychloroquine Market 2020 Major Players Hitting the Reset Button, Advanz Pharma, Sanofi, Novartis AG, Mylan N.V., Lupin, Dr. Reddy’s Laboratories","To prepare this Hydroxychloroquine Market research report, an array of objectives of market research has been considered. While formulating this market report, marketing administration stays extremely aware about certain things that include the minds of target markets, feelings, preferences, attitudes,",SAN,en,OpenPR
2020-10-07 03:51:00-05:00,"La diversidad de sus 145 millones de clientes, eje principal del Santander para diseñar productos y servicios","Banco Santander ha diseñado productos personalizados para sus grupos clave y ofrece propuestas de valor atractivas para favorecer la captación, la vinculación y el dinamismo comercial.",SAN,es,Publico
2020-10-06 18:14:21-05:00,Ábalos dará protagonismo al tren y a la vivienda en el reparto de los fondos europeos,"Si bien estará copado por líneas de actuación generales, el plan que el Gobierno remitirá a Bruselas el próximo 15 de octubre para explicarle en qué gastará los 140.000 millones que recibirá de la UE también contendrá aspectos más concretos. Entre ellos, iniciativas del Ministerio de Transporte, que está decidido a convertir al sector ferroviario y a la vivienda en dos de los grandes receptores de las ayudas comunitarias. Según ha podido saber este periódico, el departamento dirigido por José Luis Ábalos se ha comprometido con los empresarios a impulsar planes que se encuentren en una fase madura. Es decir, que hayan pasado trámites como consultas públicas o informes de impacto medioambiental. La intención es agilizar el reparto de los fondos, y para ello el Ejecutivo también se muestra dispuesto a modificar la ley de contratos del sector público para agilizar los plazos de contratación. Las actuaciones en el sector ferroviario encajan en estos parámetros. Sobre todo, las inversiones en Cercanías.",SAN,es,ABC Spain
2020-10-06 13:46:21-05:00,Feirão do Santander disponibiliza imóveis para leilão com até 65% de desconto,"O Feirão de Imóveis do Santander (SANB11) colocará mais de 100 imóveis em leilão no fim de outubro. Dentre as oportunidades estão casas, apartamentos e salas comerciais com descontos de até 65%. Os lotes abrangem 13 estados do Brasil: São Paulo, Rio de Janeiro, Minas Gerais, Rio Grande do Sul, Santa Catarina, Paraná, Ceará, Pernambuco, […]",SAN,pt,Money Times
2020-10-06 09:12:35-05:00,"RNA Therapeutics Market 2020 with Impact of COVID-19 Pandemic Analysis & Future Growth Analysis Report, Leading Players are Quark, Benitec Biopharma, Sanofi, Silence Therapeutics, Arbutus Biopharma","When globalization is growing day by day, many businesses call for global market research consisting of actionable market insights that helps with decision making. This RNA Therapeutics Market analysis report gives out the data for industry about company profile, product",SAN,en,OpenPR
2020-10-06 08:07:27-05:00,"Adrenocortical Hormones API Market to Exhibit Impressive Growth by 2025: International Company’s – GSK, Pfizer, Sanofi, Tianjin Pharma, Xianju Pharma, Sun Pharma, Teva",Global Adrenocortical Hormones API Market Synopsis: The exclusive research report on the Global Adrenocortical Hormones API Market 2020-2025 examines the market in detail along with focusing on significant market dynamics for the key players operating in the market. Global Adrenocortical Hormones,SAN,en,OpenPR
2020-10-06 07:05:22-05:00,"Live Attenuated Vaccines Market Size and Growth to 2026: Sanofi, Emergent BioSolutions Inc, GlaxoSmithKline plc, Daiichi Sankyo Company, Limited, AstraZeneca",Global live attenuated vaccines market is expected to grow at a growing CAGR in the forecast period of 2019-2026. Increase in strategic alliances between the pharmaceuticals companies and high demand of disease specific novel therapies are the key factors that fueling,SAN,en,OpenPR
2020-10-06 06:24:03-05:00,"Leishmaniasis Treatment Market Research Study Growth - CAGR of 8.8% Top Key Players are | Sanofi S.A., Sequus Pharmaceuticals Inc., Paladin Labs Inc","Reports and Data released the research report of Leishmaniasis Treatment Market, a study that offers a meticulously studied overview of the factors and drivers of the global market. Leishmaniasis Treatment Market research report depicts the latest market scenario with updated",SAN,en,OpenPR
2020-10-05 13:48:43-05:00,"Emilio Moro, Premio Pyme del año 2020 de Valladolid","Bodegas Emilio Moro ha recibido este lunes el IV Premio Pyme del año de Valladolid otorgado por el Banco Santander y la Cámara de Comercio de Valladolid, en colaboración con la Cámara de España y El Norte de Castilla. Este galardón reconoce la labor de la bodega de Ribera del Duero como generadora de riqueza y creadora de empleo en la región. Este premio se falló tras valorar las acciones llevadas a cabo por la bodega de la familia Moro en materia de formación a empleados, actividad internacional, evolución de las exportaciones y apertura de nuevos mercados, además de considerar la apuesta de Emilio Moro por la innovación y responsabilidad social. Con este galardón, podrá acceder además al premio Nacional Pyme del Año 2020 que se concederá a principios del año 2021. «Para nosotros es un verdadero orgullo recoger este galardón precisamente por ser un premio de nuestra tierra, la que llevamos siempre por bandera allá donde vamos. Además, en un año tan complicado como el que estamos viviendo, es realmente ilusionante ver que se reconoce el esfuerzo de muchas empresas por salvar las dificultades y seguir haciendo crecer las oportunidades.",SAN,es,ABC Spain
2020-10-05 09:22:56-05:00,"COVID-19 UPDATE: Hydroxychloroquine Market Likely to Experience a Tremendous Growth in Near Future|| Advanz Pharma, Teva Pharmaceutical Industries Ltd, Sanofi, Novartis AG, Mylan N.V",Data Bridge Market Research has recently added a concise research on the Hydroxychloroquine Market to depict valuable insights related to significant market trends driving the industry. The report features analysis based on key opportunities and challenges confronted by market leaders,SAN,en,OpenPR
2020-10-05 06:18:33-05:00,"Vaccine Market Estimated to Perceive Exponential Growth till 2027 | Industry Size, Demand, Forecast with Depth Assessment by Top Key Players-Merck & Co, Bharat Biotech, GlaxoSmithKline plc, Sanofi","The ""Vaccine Market Size, Share, Growth, Industry Trends, Forecast 2027"" Study has been added to DBMR database. The study envisage qualitative as well as quantitative market data and follows Industry benchmark classification and NAICS standards to built strong players coverage",SAN,en,OpenPR
2020-10-05 05:58:59-05:00,"Oral Vaccines Market 2020 To See Excellent Long-Term Growth Outlook 2025 with: Merck, GSK, Sanofi, Valneva",This report is an extensive analysis of current and potential trends in the Oral Vaccines market. The report provides an in-depth quantitative analysis of the current and future market estimations which helps to recognize the prevailing market opportunities. Key market,SAN,en,OpenPR
2020-10-04 22:00:00-05:00,Santander y BBVA pierden ingresos y cuota de mercado en banca de inversión,"La banca de inversión vive un mal año. Aunque las cifras ya muestran una recuperación en septiembre, hasta el verano, los ingresos de las entidades han caído en picado por el desplome de la actividad, lo que ha golpeado especialmente a Banco Santander y a BBVA . Los dos grandes españoles han sufrido fuertes descensos en los ingresos generados en este negocio, según el 'ranking' de Dealogic. La caída, aun así, es mayor que en el conjunto del sector. De hecho, las dos entidades han perdido cuota de mercado y varios puestos en el 'ranking' en 2020. Mientras que el conjunto de ingresos generados por la actividad de banca de inversión en España alcanza los 421 millones entre enero y septiembre (datos hasta el 30 de septiembre) y va camino de poder alcanzar la cifra del pasado ejercicio, Banco Santander y BBVA se quedan lejos. Aún están un 60% por debajo . Así, BNP Paribas y Citi han superado en el 'ranking' a Banco Santander , que pierde la segunda posición. El banco francés se acerca a JP Morgan, que sigue en el ‘top’.",SAN,es,El Confidencial
2020-10-04 10:59:33-05:00,"La presidenta del Santander, Ana Botín, testifica el jueves por el 'caso Popular'","La presidenta del banco Santander, Ana Patricia Botín, declara este jueves como testigo ante el juez de la Audiencia Nacional José Calama en relación a la causa en la que se investigan las presuntas irregularidades que llevaron a la resolución y…",SAN,es,Publico
2020-10-03 18:25:15-05:00,"Hipotecas fijas, santo y seña de una banca ahogada por la crisis","La presión del Banco Central Europeo (BCE) y el Banco de España sobre los bancos para que incrementen su rentabilidad está dando sus frutos. Las entidades han recogido el guante estos meses, más aún si cabe por la crisis del Covid-19, y se han lanzado a exprimir sus productos para captar clientes. Uno de ellos, las hipotecas. Pero no todos los préstamos para adquisición de vivienda despiertan el interés del sector sino que, a la luz de los últimos datos y anuncios, son las hipotecas a tipo fijo las que son objetivo ahora del gremio bancario. Están echando el resto para captar clientes bajo este producto. La tormenta perfecta se ha formado sobre la banca. El BCE está inyectando 1,35 billones de euros en la economía de la Eurozona; la política de tipos bajos tiene visos de extenderse varios años más; y, por ende, el Euríbor se mueve en mínimos históricos. Con estas condiciones se hace muy difícil sacar rédito económico cuando tu materia prima, el dinero, no vale nada. Aun así, no todo está perdido.",SAN,es,ABC Spain
2020-10-02 16:28:22-05:00,Track & Field define faixa de preço e pode levantar R$ 629 milhões em IPO,"A varejista de artigos esportivos definiu entre R$ 10,65 e R$ 14,95 a faixa indicativa de preços na sua oferta pública inicial de ações (IPO, na sigla em inglês) A varejista Track & Field definiu entre R$ 10,65 e R$ 14,95 a faixa indicativa de preços na sua oferta pública inicial de ações (IPO, na sigla em inglês). Considerando o meio da faixa indicativa, de R$ 12,80, e o número de 49.166.000 ações da oferta base, a operação pode movimentar R$ 629,324 milhões. Há ainda possibilidade de um lote suplementar de até 15%, ou 7.374.900 ações. Nesse caso, ainda considerando o meio da faixa indicativa, a oferta total subiria para R$ 723,723 milhões. A oferta será primária, quando os recursos vão para o caixa da empresa (19.718.000 ações, ou R$ 252,390 milhões considerando o meio da faixa indicativa); e secundária, quando acionistas atuais vendem parte de suas fatias (29.448.000 ações, ou R$ 376,934 milhões). A precificação do IPO deve ocorrer no dia 22 de outubro A companhia será negociada no Novo Mercado da B3 sob o ticker ‘TFCO4’.",SAN,pt,Valor Econômico
2020-10-02 10:26:50-05:00,"Insulin API Market Prescribes Strong Growth, Business Enhancing Strategies, CAGR Status, by Forecast 2025| Sanofi, Novo Nordisk",The research study covers the current scenario and growth prospects of the Insulin API market (2020-2025) according to the analysis . This study includes a extensive analysis of the key segments of the industry and also the regional analysis,SAN,en,OpenPR
2020-10-02 09:30:00-05:00,"Global $6 Billion Diabetes Reusable Insulin Delivery Pen Market to 2026 with Sanofi, Ypsomed, Biocon, Novo Nordisk, Eli Lilly and Co, Owen Mumford & Berlin-Chemie Dominating","DUBLIN , Oct. 2, 2020 /PRNewswire/ -- The ""Worldwide Diabetes Reusable Insulin Delivery Pen Market: Demand, Insights, Trends, Analysis, Opportunities, Growth Potential and Forecast to 2026"" report has been added to ResearchAndMarkets.com's offering. The Worldwide Diabetes Reusable Insulin Delivery Pen Market size is expected to touch US$ 6 billion by 2026. The report offers the most up-to-date industry data on the actual market situation and future outlook for the worldwide diabetes reusable insulin delivery pen market. The report provides historical market data for 2013 - 2019, and forecasts from 2020 until 2026. The report contains a granular analysis of the present industry situations, market demands, reveal facts on the market size, reusable insulin pen volume, revenues for reusable insulin delivery pen, and illustrative forecast to 2026. It also provides 16 countries with an all-round analysis of an overall number of patients with diabetes and insulin users. A comprehensive analysis has been done on the market share of the countries-based market.",SAN,en,Benzinga
2020-10-02 03:18:47-05:00,"Insulin Market is Forecast To Reach USD 35.74 Billion By 2027 | Sanofi, Eli Lily and Company, ADOCIA, Julphar, Pfizer, Inc","The latest updated report on the Global Insulin Market added by Reports and Data presents a comprehensive analysis of the industry size, revenue forecast, regional spectrum of the business vertical, and further elaborates on the major hurdles, challenges, and latest",SAN,en,OpenPR
2020-10-02 00:24:11-05:00,EMA accepts Sanofi's marketing application for avalglucosidase for Pompe disease (NASDAQ:SNY),"The European Medicines Agency (EMA) has accepted for review Sanofi's (NASDAQ:SNY) marketing authorization application for avalglucosidase alfa, for long-te",SAN,en,Seeking Alpha
2020-10-01 14:37:00-05:00,"Banco Santander elimina la cuenta 1,2,3 y unifica todas en la Santander One",La entidad se alía con Iberia para lanzar un plan de fidelización,SAN,es,Publico
2020-10-01 12:07:01-05:00,"Banco Santander elimina la cuenta 1,2,3 y unifica todas en la cuenta única Santander One - Republica.com","Para avanzar en la simplificación de la oferta de productos, Santander One sustituirá al resto de cuentas que hasta la fecha comercializa el banco (Cuenta 1,2,3 Particulares, Cuenta Día a Día, Cuenta Zero 1,2,3, Cuenta 81, o Cuenta Estándar, entre otras), solo continuando disponibles la Cuenta Smart para jóvenes, la Cuenta Mini para niños y […]",SAN,es,Republica.com
2020-10-01 07:00:00-05:00,We could know if a coronavirus vaccine works in October. Here are the 7 most important events to watch for this month.,"Summary List Placement The month of October could be a turning point in the fight against the pandemic. Within the month, we could have results from the final stage of clinical trials for leading coronavirus vaccine candidates. While the timeline is aggressive because late-stage vaccine trials started just a few months ago, Pfizer's CEO has repeatedly said he expects results in October. If successful, a safe and effective vaccine would shift the challenge from science to logistics: ramping up production and distributing the shot across the nation and world. It's far from certain that any vaccine will have results so early. The studies depend on enough volunteers falling sick, so a board of independent experts can see if a group getting the experimental shots is getting less sick than people receiving a placebo. The trials may require more time to run, going into November, December, or even later before any results are unveiled. Here are the seven key events to watch out for in October in the vaccine race.",SAN,en,Business Insider
2020-10-01 04:25:53-05:00,"Blood Glucose Test Strips Market to Garner $ 6.92 Billion, Globally, By 2027 at 6.7% CAGR, Says Reports and Data | Top Players are AgaMatrix, Inc., Trividia Health, Inc., B. Braun Melsungen AG, Sanofi, etc.","Blood Glucose Test Strips Market Industry Forecast To 2027 The Global Blood Glucose Test Strips Market is forecast to reach USD 6.92 Billion by 2027, according to a new report by Reports and Data. Blood glucose strips are one of the",SAN,en,OpenPR
2020-10-01 01:12:27-05:00,"Global Reversible Airway Diseases Treatment Market 2020: Covering Competitive Scenario And Dynamics By Mylan N.V., Boehringer Ingelheim International GmbH, Regeneron, Sanofi, Genentech, Inc. (F. HoffmannLa Roche Ltd), Novartis AG","Data Bridge Market Research has provides the Qualitative and informative knowledge by adding titled “Global Reversible Airway Diseases Treatment Market, By Type (Bronchodilators, Cytotoxic Drugs, Antibiotics, Others), Treatment (Chest X Ray, CT Scan, Lung Therapies, Surgery Transplant and Medications), Diseases",SAN,en,OpenPR
2020-10-01 00:00:00-05:00,Más de un millón de participantes en los programas culturales del Banco Santander,No summary available.,SAN,es,20minutos Spain
2020-09-30 23:55:00-05:00,Más de 1.570 empresas optan al Premio Pyme del Año de Banco Santander y Cámara de España,Un total de 1.573 empresas se han inscrito en toda España en el Premio Pyme del Año 2020 que convocan anualmente Banco Santander y la Cámara de Comercio de España. Este premio nació con el objetivo de reconocer la labor de las pequeñas y medianas…,SAN,es,La Vanguardia
2020-09-30 19:06:42-05:00,Botín pide al BCE que reconsidere el veto a la banca de pagar dividendos,"La presidenta del Banco Santander, A na Botín , pidió ayer al Banco Central Europeo (BCE) que reconsidere su recomendación a la banca de no pagar dividendos hasta enero del 2021. La directiva, que participó en la 12.ª conferencia European…",SAN,es,La Vanguardia
2020-09-30 14:18:02-05:00,"Vaginitis Therapeutics Market Shares and SWOT Analysis by Lupin, Pfizer Inc, Sanofi, Teva Pharmaceutical Industries Ltd, Bausch Health, DARÉ BIOSCIENCE, INC","Vaginitis Therapeutics Market By Types (Bacterial Vaginosis, Trichomoniasis, Vulvovaginal Candidiasis and Others), Drug Class (Anti-fungal, Anti-bacterial, Hormone and Others), Medication Type (Over-The-Counter (OTC), Prescription (Rx)), Route of Administration (Oral, Topical), End- Users (Hospitals, Specialized Gynecology Centers and Others), Distribution Channel",SAN,en,OpenPR
2020-09-30 14:15:01-05:00,"Vaccine Market Professional Survey Report: Merck Co., Inc, Sanofi, CSL Limited, Panacea Biotec Ltd., Novavax, Emergent BioSolutions Inc, Inovio Pharmaceuticals, Inc","Vaccine Market By Technology (Conjugate Vaccines, Inactivated and Subunit Vaccines, Live Attenuated Vaccines, Others), Type (Monovalent Vaccines, Multivalent Vaccines), Indication (Pneumococcal Disease, Influenza, Meningococcal Disease, Polio, Rotavirus, Hepatitis, Dengue, Herpes Zoster, Others), Route of Administration (Oral, Parenteral), By End Users (Hospitals,",SAN,en,OpenPR
2020-09-30 10:02:36-05:00,De Guindos asegura que ninguno de los cinco grandes bancos españoles quería comprar Popular en 2017,"El vicepresidente del Banco Central Europeo (BCE) y exministro de Economía, Luis de Guindos, ha señalado este miércoles en su declaración por videoconferencia como testigo ante el juez de la Audiencia Nacional José Luis Calama que en 2017, a un mes de la resolución del Banco Popular, mantuvo una reunión con cinco de los grandes bancos para sondear su posible interés en adquirirlo, si bien todos ellos descartaron presentar una oferta por dicha entidad. El número dos del BCE también ha criticado que la Junta Única de Resolución (JUR) no publicara íntegramente el informe de Deloitte. El citado documento sirvió de base a la resolución y posterior venta del Banco Popular al Santander por un euro en junio de 2017. De Guindos se ha referido así a las preguntas del magistrado -muy incisivo con la presunta «falta de transparencia» del organismo europeo-, aunque ha defendido que la resolución fue «la mejor opción posible». Según fuentes jurídicas, durante su comparecencia, el exministro ha explicado que siendo él ministro de Economía, cuando se produjo la resolución del banco y su posterior venta al Santander por un euro, se tomó esa decisión para evitar el rescate de los depositantes de la entidad.",SAN,es,ABC Spain
2020-09-30 08:26:00-05:00,"COVID-19 Vaccine & Therapeutics Clinical Trial Analysis 2020 Featuring Major Players - Pfizer, GSK, Inovio Pharma, J&J, Novavax, Heat Biologics, Sanofi, BioNTech, Vaxart, and Vir Biotechnology - ResearchAndMarkets.com","DUBLIN--(BUSINESS WIRE)--The ""COVID-19 Vaccine & Therapeutics Clinical Trial Analysis 2020"" report has been added to ResearchAndMarkets.com's offering. COVID-19 Vaccine & Therapeutics Clinical Trial Analysis 2020 provides the strategists, marketers and senior management with the critical information they need to assess the global COVID-19 vaccine & therapeutics clinical trial analysis 2020 market. Major players in the COVID-19 vaccine and therapeutics clinical trial analysis market",SAN,en,Business Wire
2020-09-30 06:24:38-05:00,"Glycosylated Hemoglobin C-peptide Market Size, Key Trends, Challenges and Standardization, Research, Key Players, Economic Impact and Forecast to 2026(Sandoz International GmbH, Sanofi, Roche Ltd)","Los Angeles, United State, – – QY Research recently added a research report, Global Glycosylated Hemoglobin C-peptide Market Research Report 2020 to its ever-increasing repository. The research report discusses the future of the global Glycosylated Hemoglobin C-peptide market. It highlights",SAN,en,OpenPR
2020-09-30 05:35:42-05:00,La Junta ayudará con 3.000 euros a las empresas que realicen contrataciones nuevas en modalidad de teletrabajo,"El Consejo de Gobierno de Castilla-La Mancha ha aprobado este martes el Decreto de ayudas al fomento del teletrabajo, un nuevo decreto que contará con una dotación económica inicial de 500.000 euros y con dos líneas: una para incentivar la conversión de puestos de trabajo presencial en trabajo a distancia, y otra para apoyar las nuevas contrataciones en modalidad de teletrabajo por parte de las empresas. Según ha informado la consejera de Economía, Empresas y Empleo, Patricia Franco, en rueda de prensa, son ya 13 los decretos aprobados en Consejo de Gobierno desde la puesta en marcha del Plan de Medidas Extraordinarias para la Recuperación Económica de la región con motivo del Covid, de los cuales siete de ellos son «totalmente novedosos». Este Decreto tiene carácter retroactivo, es decir, que aquellas empresas que transformaron puestos de trabajo a la modalidad de teletrabajo en Castilla-La Mancha o que iniciaron contrataciones en materia de teletrabajo desde el 14 de marzo podrán solicitar esta nueva línea de ayudas, una vez que el decreto se publique en el Diario Oficial de la región, que lo hará en los próximos días.",SAN,es,ABC Spain
2020-09-30 05:24:11-05:00,"Multiple Sclerosis Market to 2027 Report on Industry Insights, Market Overview, Top Company Players-Pfizer, Sanofi, Novartis AG, F. Hoffmann-La Roche Ltd, Biogen, Bayer AG, Actelion Pharmaceuticals Ltd","Global Multiple Sclerosis Market Research Report best suits the requirements of the client. The report represents a basic overview of the Multiple Sclerosis market share, competitor segment with a basic introduction of key vendors, top regions, product types, and end",SAN,en,OpenPR
2020-09-30 04:28:00-05:00,Banco Santander impulsa la formación de la próxima generación de mujeres líderes,"Se trata de una apuesta por el desarrollo profesional, la capacidad de liderazgo y las habilidades de negociación de la próxima generación de mujeres de entre 25 y 32 años.",SAN,es,Publico
2020-09-29 18:42:42-05:00,Dividendos 2020: Banco Santander sitúa su dividendo como el segundo más alto del Ibex 35,"El banco distribuirá en octubre acciones equivalentes a un dividendo de 10 céntimos, lo que elevará la rentabilidad de sus títulos hasta el 12,5%",SAN,es,El Correo
2020-09-29 12:34:00-05:00,Logista nombra a Luis Isasi Fernández como independiente tras fallecer Carvajal Hoyos,"Fernández es presidente no ejecutivo de Santander España, consejero independiente de Banco Santander y miembro de su comité ejecutivo y de remuneraciones",SAN,es,El Confidencial
2020-09-29 10:02:15-05:00,Banco Santander ofrece a empresas seguimiento de pagos y cobros internacionales,Es la primera entidad en ofrecer este servicio completo en España,SAN,es,Cinco Dias El Pais
2020-09-29 08:49:05-05:00,"Botanical Plant Derived Drugs Market 2020-28 approved natural history of botanical therapeutics| Bayer Healthcare, GlaxoSmithKline, Pfizer, Sanofi, Actelion, Allergan, AstraZeneca, Boehringer Ingelheim","Botanical drugs are those drugs that are derived from medicinal plants. Plant derived drugs are a combination of botanical as well as other approved drugs that contains plant materials, synthetic and semi synthetic substances. Plant-derived substances serving as pharmaceutical excipients,",SAN,en,OpenPR
2020-09-29 08:32:58-05:00,"Oral Antidiabetic Drugs Market Comprehensive study by Key Players - Merck & Co., Inc.,, AstraZeneca plc, Novartis International AG, Sanofi S.A.","Global Oral Antidiabetic Drugs Market Size study, by Drug (Biguanides, Alpha-glucosidase inhibitors, Dopamine-D2 Receptor Agonist, Sodium - glucose Cotransport -2 (SGLT-2) inhibitor, Dipeptidyl Peptidase - 4 (DPP-4) Inhibitors, Sulfonylureas, Meglitinides) and Regional Forecasts 2020-2027 Covid 19 Outbreak Impact research",SAN,en,OpenPR
2020-09-28 13:14:00-05:00,Santander inaugura centro de pesquisa e desenvolvimento no campus Onovolab,"O Santander Tecnologia e Inovação, braço tecnológico do Santander Brasil (SANB11), acaba de inaugurar um novo centro de pesquisa e desenvolvimento no campus Onovolab, localizado em São Carlos, São Paulo. Com o objetivo de desenvolver soluções digitais para a instituição financeira e seus clientes, o projeto já gerou 300 empregos só na primeira etapa. “São […]",SAN,pt,Money Times
2020-09-28 09:57:19-05:00,Sanofi picks up Principia Biopharma for US$3.7 billion,"PARIS: French pharmaceutical group Sanofi said on Monday (Sep 28) it has finalised acquisition of US biotech firm Principia Biopharma for US$3.7 billion. The operation, first announced in August, was aimed at boosting Sanofi's research and development into auto-immune and allergic diseases …",SAN,en,Channel NewsAsia
2020-09-28 07:27:34-05:00,"Helpful research report of M-Health Application Market Astonishing Growth By 2026 | WellDoc, Inc., Sanofi, Jawbone, FitBit, Inc., Livongo Health, Ginger.io, Inc., Omron healthcare","The ‘M-Health Application Market’ study added by Reports web, exhibits a comprehensive analysis of the growth trends present in the global business scenario. The study further presents conclusive data referring to the commercialization aspects, industry size and profit estimation of",SAN,en,OpenPR
2020-09-28 01:05:29-05:00,"Biosimilar Therapeutic Peptides Market Highlights 2020-2023 | Worldwide Top Key Players -Eli Lilly, Sanofi, Takeda Pharmaceuticals, Teva Pharmaceuticals, Pfizer Inc| Covid 19 Growth And Change","The Business Research Company offers "" Biosimilar Therapeutic Peptides Global Market Report 2020-30: Covid 19 Growth And Change"" in its research report store. It is the most comprehensive report available on this market and will help gain a truly global",SAN,en,OpenPR
2020-09-28 00:00:31-05:00,EU Strikes Low-Cost Deal With AstraZeneca to Pay COVID-19 Vaccine Claims,"European governments will pay claims above an agreed limit against AstraZeneca over side-effects from its potential COVID-19 vaccine, under different terms to a deal struck with Sanofi, an EU official told Reuters. The deals reflect different strategies by two of …",SAN,en,Insurance Journal
2020-09-27 23:14:40-05:00,España se reservará más vacunas contra el Covid con una compra a Sanofi,"Podría recibir más de 30 millones de dosis del laboratorio francés La compra se articula a través de la UE, como la primera a AstraZeneca",SAN,es,Cinco Dias El Pais
2020-09-26 19:02:54-05:00,Puertas giratorias y populismos,"El salto de la empresa a la política y de la política a la empresa ha sido habitual durante la democracia. Independientemente del color político son numerosos los ministros o secretarios de Estado, especialmente de ramas económicas, que luego han pasado a formar parte de los consejos o equipos directivos de grandes empresas: Felipe González, Aznar, Solchaga, Piqué, Ana Palacio, Elena Salgado, Isabel Tocino, Cristina Garmendia, José Borrell, Arias Cañete, Teresa Ribera… Esta misma semana Iberdrola ha anunciado el fichaje de dos ministras del Gobierno de Rajoy, Fátima Báñez, ex ministra de Empleo, e Isabel García Tejerina, exministra de Agricultura, para formar parte de consejos en sus filiales de México y Brasil, respectivamente. Y cómo no podía ser de otra manera, el vicepresidente Iglesias ha puesto el grito en el cielo. Le parece corrupción que la ministra que aprobó una reforma laboral que permitió a España recuperar dos millones de empleos, y que ha dado a nuestro mercado de trabajo la flexibilidad suficiente para poder teletrabajar durante el confinamiento, o para poder aplicar ERTE en vez de despidos sea fichada por una gran empresa eléctrica española.",SAN,es,ABC Spain
2020-09-25 07:15:44-05:00,"Hidrovias do Brasil estreia hoje na B3 com valor inicial de R$ 7,56","Preço da ação no IPO ficou no piso da faixa indicativa, que ia até R$ 8,88 A companhia de logística Hidrovias do Brasil vai estrear nesta sexta-feira na B3. As ações serão negociadas no mercado com o código “HBSA3”, no Novo Mercado, o nível mais alto do chamado segmento de governança da bolsa brasileira. O preço da ação ficou em R$ 7,56 na oferta pública inicial, no piso da faixa indicativa, que ia até R$ 8,88, e rendeu mais de R$ 3,4 bilhões aos acionistas vendedores, como o Fundo Pátria, a canadense Aimco, a BNDESPar e alguns executivos. Empresas reveem ambições em IPOs Coordenaram a oferta os bancos Bank of America, Itaú BBA, Santander, Morgan Stanley, BTG Pactual, Citi e Credit Suisse. A companhia, que atua no transporte hidroviário, fechou 2019 com lucro líquido de R$ 58,61 milhões, recuo de 64% em relação a 2018. Criada em 2010 com o projeto de integrar a América Latina por meio do transporte fluvial, a companhia hoje tem a maior capacidade para o carregamento e transporte de grãos no Norte do Brasil, é a única operadora integrada de fertilizantes na região, detém 40% de participação de mercado no transporte de bauxita por cabotagem e 30% de participação no transporte fluvial na hidrovia Paraguai-Paraná, com minério de ferro, grãos e fertilizantes.",SAN,pt,Valor Econômico
2020-09-23 19:01:50-05:00,La posición de la Fiscalía ante los indultos pondrá a prueba a Dolores Delgado,"La fiscal General del Estado, Dolores Delgado «está inhabilitada» para entender de la causa del procés y su número 2, Luis Navajas, «inutilizado» por las declaraciones incendiarias contra fiscales del procés que estos días convulsionan la Carrera. Este es el panorama con el que los fiscales de la Sala de lo Penal del Tribunal Supremo que llevaron la acusación en el juicio por el procés afrontan la próxima tramitación del expediente de indulto de todos los condenados y que requerirá, preceptivamente, que elaboren un informe de posicionamiento. Teniendo en cuenta que los fiscales Javier Zaragoza, Consuelo Madrigal, Fidel Cadena y Jaime Moreno acusaron por rebelión durante el juicio y han informado en contra de todos los recursos y peticiones de libertad de los condenados, no parece previsible un informe favorable al indulto, si bien habrá que esperar al análisis pormenorizado de las circunstancias individuales de cada uno para conocer el dictamen que propongan. De acuerdo a las fuentes consultadas, la clave es que Delgado, que era ministra de Justicia cuando se celebró el juicio y que impuso a la Abogacía del Estado rebajar la acusación a sedición, se abstenga absolutamente de esta fase del expediente de indulto.",SAN,es,ABC Spain
2020-09-22 17:43:02-05:00,Bancos e empresários reconhecem impacto do desmatamento no fluxo de negócios,"Representantes do mercado financeiro e de grandes empresas participaram de audiência pública convocada pelo STF sobre a gestão do Fundo Clima pelo governo federal O presidente do Itaú Unibanco, Candido Botelho Bracher, afirmou nesta terça-feira (22) que o aumento do desmatamento e das queimadas preocupa o setor financeiro. Segundo ele, foi por conta dessa preocupação que os bancos Santander, Itaú e Unibanco decidiram criar o plano para a Amazônia. “Houve por parte dos três bancos o reconhecimento da gravidade do problema do desmatamento da floresta Amazônica”, disse Bracher, durante audiência pública convocada pelo ministro Luís Roberto Barroso, do Supremo Tribunal Federal (STF), para discutir a gestão do Fundo Clima pelo governo federal. Segundo ele, estando no mercado financeiro, “fica claro o impacto negativo dessa realidade para a imagem do Brasil no exterior e, consequentemente, para o fluxo de investimentos estrangeiros para o país”. “A avaliação que se faz internacionalmente é que as políticas adotadas no Brasil em relação ao problema é de que elas não estão sendo eficazes, certamente não na intensidade e efetividade que o problema requer”, disse o presidente do Itaú Unibanco.",SAN,pt,Valor Econômico
2020-09-22 12:19:00-05:00,"Sanofi, GSK to Supply Adjuvanted Covid-19 Vaccine to Canadian Government",By Stephen Nakrosis Sanofi and GlaxoSmithKline PLC on Tuesday said they signed agreements which will see the companies supply up to 72…,SAN,en,ADVFN UK
2020-09-22 11:08:00-05:00,LETTER: Local legislators vote again on insulin cap bill,"To the Editor: Are you diabetic? Or do you happen to have friend or family member who has been diagnosed with diabetes? If so, you know how critical it is to have access to the wonder drug insulin. Because access to insulin can literally mean the difference between life and death, the Illinois State Legislature recently mandated a cap on the cost of insulin at $100 per 30-day supply. The Governor signed it into law and now Illinois residents are protected from price gouging on this critical medication. You would think that every single state legislator would have voted yes on this bill. And you would almost be right. It passed with strong support from both Democrats and Republicans. Our local Republican State Rep. Tom Demmer, voted no and our local Republican State Sen. Brian Stewart did not vote at all on this issue. Wonder why? Check out who donates to their campaigns. You'll find big pharmaceutical companies generously support them. Only three major pharmaceutical companies (Eli Lilly, Novo Nordisk and Sanofi) make insulin and there is no generic version, so the companies can charge pretty much whatever they want.",SAN,en,Sauk Valley Media
2020-09-22 01:22:45-05:00,"Banco Santander propone un dividendo en efectivo de 0,10 euros por acción",https://es.investing.com/news/stock-market-news/banco-santander-propone-un-dividendo-en-efectivo-de-010-euros-por-accion-2039089,SAN,es,Investing.com Spain
2020-09-21 18:28:21-05:00,El banco Santander convoca su junta de accionistas el 27 de octubre en Boadilla,"El consejo de administración de Banco Santander ha acordado convocar la próxima junta ordinaria de accionistas para el próximo 26 de octubre, en primera convocatoria, y para el 27 de octubre, en segunda convocatoria. Asimismo, ha decidido trasladar de Santander a Boadilla del Monte (Madrid) el lugar de celebración con el fin de minimizar desplazamientos. Tal y como el banco anunció en julio, el consejo someterá a la junta de accionistas la aprobación de una ampliación de capital liberada para la distribución de nuevas acciones equivalentes a 0,10 euros por acción como remuneración complementaria de 2019 y que se pagaría este año. Con ello, la remuneración total correspondiente a 2019 asciende a 0,20 euros por acción. Adicionalmente, el consejo somete también a la aprobación de los accionistas el reparto en 2021 de 0,10 euros por acción con cargo a la reserva por prima de emisión de acciones. Además de estar sujeto a que la distribución sea posible conforme a las recomendaciones del Banco Central Europeo (BCE) y se obtenga su autorización, el abono de esta cantidad fija está condicionado a que tras el pago la ratio de capital CET1 se mantenga dentro de su objetivo del 11-12% o por encima y a que el importe total a abonar no exceda del 50% del beneficio ordinario (underlying) consolidado de 2020.",SAN,es,ABC Spain
2020-09-21 08:05:39-05:00,"Grupo Mateus define faixa de preço e pode levantar R$ 4,1 bi em IPO","Total em oferta da rede de supermercados maranhense pode chegar a R$ 5,534 bi com lotes adicional e suplementar A rede de supermercados maranhense Grupo Mateus definiu entre R$ 8,97 e R$ 11,66 a faixa indicativa de preços na sua oferta pública inicial de ações (IPO, na sigla em inglês). Considerando o meio da faixa, de R$ 10,32, e o número de 397.286.822 ações da oferta base, a operação pode movimentar R$ 4,100 bilhões. Há ainda possibilidade de um lote adicional de até 20%, ou 79.457.364 ações, e suplementar de até 15%, ou 59.593.023 ações. Nesse caso, ainda considerando o meio da faixa indicativa, a oferta total subiria para R$ 5,534 bilhões. A oferta será primária, quando os recursos vão para o caixa da empresa (339.147.287 ações, ou R$ 3,500 bilhões considerando o meio da faixa indicativa); e secundária, quando acionistas atuais vendem parte de suas fatias (58.139.535 ações, ou R$ 600,000 milhões). A precificação do IPO deve ocorrer no dia 8 de outubro. A companhia será negociada no Novo Mercado da B3 sob o ticker ‘GMAT3’.",SAN,pt,Valor Econômico
2020-09-21 05:46:50-05:00,El Ibex pierde más de un 3% y toca niveles de mayo,"La Bolsa perdía un 3,56% en la media sesión de este lunes, lo que llevaba al selectivo a situarse en los 6.683,4 enteros a las 12.01 horas. Unos niveles que no tocaba desde el pasado mes de mayo. La jornada está marcada por los temores a los rebrotes del Covid-19 y a nuevos confinamientos y en la que la fusión entre Caixabank y Bankia sigue siendo protagonista en el sector bancario. De esta forma, el selectivo madrileño se teñía completamente de 'rojo', después de que las agencias de calificación crediticia Moody's y S&P Global hayan decidido mantener sus respectivos ratings soberanos asignados a España, situados en 'Baa1' y 'A', respectivamente. Asimismo, los inversores tienen puesta la vista en PharmaMar, incorporado este lunes al Ibex 35, que estará integrado por 34 valores hasta el próximo 19 de octubre, tras la suspensión de MásMóvil por la opa de Lorca Telecom Bidco. La farmacéutica, que ocupa el hueco que deja Ence, valor que abandona este índice para incorporarse al 'Ibex Medium Cap', cedía un 3,9% a mediodía.",SAN,es,ABC Spain
2020-09-21 02:05:19-05:00,"Sanofi, Regeneron’s Libtayo Delivers Positive Results In Pivotal Lung Cancer Trial","Sanofi (SNYNF) and Regeneron have announced positive pivotal trial data for the investigational use of PD-1 inhibitor Libtayo (cemiplimab) in first-line locally advanced … The post Sanofi, Regeneron’s Libtayo Delivers Positive Results In Pivotal Lung Cancer Trial appeared first on Smarter Analyst .",SAN,en,Smarter Analyst
2020-09-21 01:23:52-05:00,"Sanofi, Regeneron Libtayo extends overall survival in first-line lung cancer (NASDAQ:SNY)",Sanofi (NASDAQ:SNY) and Regeneron (NASDAQ:REGN) presents positive trial data for the investigational use of PD-1 inhibitor Libtayo (cemiplimab) in first-li,SAN,en,Seeking Alpha
2020-09-18 19:00:36-05:00,BBVA y Telefónica abandonan el Euro Stoxx 50 después de 22 años en el índice,"Adyen, Prosus, Vonovia, Kone… quizás sus nombres no les suenen, pero desde el lunes pasarán a formar parte del índice de las 50 grandes cotizadas europeas, el Euro Stoxx 50. Y su irrupción en este selecto grupo no será ajena para España, porque implica la salida del índice de BBVA y Telefónica, que vivieron ayer su última sesión como parte de él. Con este movimiento, el país pierde peso en el parqué del Viejo Continente, ya que se queda con apenas cuatro representantes en el Euro Stoxx 50: Amadeus, Iberdrola, Inditex y Banco Santander, tan solo un 6% del total. Es el fin de una era. Porque BBVA y Telefónica eran dos de las compañías que llevaban en el índice desde su fundación, allá por 1998. Y porque con su despedida evidencian la compleja crisis bursátil que están atravesando dos sectores de la talla de la banca y las telecomunicaciones. Además de las multinacionales españolas, tras este cambio también se caen del índice gigantes europeos como Société Générale y Orange. Por contra, los buenos resultados bursátiles permiten que entren en el exclusivo club de los «blue chips» europeos compañías dedicadas al desarrollo de empresas tecnológicas y plataformas de pago.",SAN,es,ABC Spain
2020-09-18 12:30:00-05:00,"Global Clinical Stage Partnering Terms and Agreements in Pharma and Biotech 2014-2020: Comprehensive Listing of 2,300+ Clinical Stage Partnering Deals","DUBLIN , Sept. 18, 2020 /PRNewswire/ -- The ""Global Clinical Stage Partnering Terms and Agreements in Pharma and Biotech 2014-2020"" report has been added to ResearchAndMarkets.com's offering. The Global Clinical Stage Partnering Terms and Agreements in Pharma and Biotech 2014-2020 report provides a detailed understanding and analysis of how and why companies enter clinical stage partnering deals and provides details of the latest clinical agreements announced in the healthcare sector. Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases and databases do not. This report contains a comprehensive listing of over 2,300 clinical stage partnering deals announced since 2014 including financial terms where available including numerous links to online deal records of actual clinical partnering deals as disclosed by the deal parties.",SAN,en,Benzinga
2020-09-18 08:41:33-05:00,GlaxoSmithKline and Sanofi Stock Rally on EU Vaccine Deal,GlaxoSmithKline and Sanofi stock are rallying in early trading on Friday thanks to news they would supply the EU 300 million vaccine doses.,SAN,en,InvestorPlace
2020-09-18 07:09:49-05:00,"Coronavirus live updates: Israel locks down again ahead of High Holidays; EU strikes vaccine deal with Sanofi, GSK","The coronavirus has infected more than 30.2 million people globally as of Friday, killing at least 946,673 people so far.",SAN,en,CNBC
2020-09-18 06:17:32-05:00,Sanofi and Glaxo finalize deal in Europe to supply 300M doses of COVID-19 vaccine (NASDAQ:SNY),"Following up on their earlier announcement, Sanofi (NASDAQ:SNY) and collaboration partner GlaxoSmithKline (NYSE:GSK) have inked an agreement with the Europ",SAN,en,Seeking Alpha
2020-09-18 02:27:38-05:00,Sanofi/Regeneron Libtayo shows positive effect in skin cancer study (NASDAQ:SNY),"Sanofi (NASDAQ:SNY) presents positive results from the Phase 2 trial for the PD-1 inhibitor Libtayo (cemiplimab), jointly developed by Regeneron (NASDAQ:RE",SAN,en,Seeking Alpha
2020-09-17 23:16:15-05:00,La nueva entidad tendrá la mayor cuota de oficinas en 12 de las 17 autonomías,"Solo sería superada en Extremadura, Aragón, Asturias, Galicia y Cantabria, donde se impone Banco Santander",SAN,es,Cinco Dias El Pais
2020-09-17 12:07:37-05:00,"Destruição da Amazônia é erro estratégico que país terá de resolver, diz Abramovay","Professor de Ciências Ambientais da USP e um dos maiores especialistas brasileiros no tema diz que Brasil poderia ser um líder da chamada biodiplomacia Num mundo em que a pauta ganha ambiental ganha espaço entre a sociedade, governos, empresas e mercado financeiro, o mau uso e a destruição da Amazônia são um dos graves problemas estratégicos que o Brasil terá que resolver nos próximos anos, afirma Ricardo Abramovay, professor de Ciências Ambientais da USP e um dos maiores especialistas brasileiros no tema. “Usamos uma parte importante no nosso território, que é a Amazônia, mas também o Cerrado e a Caatinga, sob a base da destruição ou de uma produção de riqueza muito precária”, afirmou Abramovay durante live promovida pelo Valor nesta quinta-feira. “Este é um dos mais graves problemas estratégicos que o Brasil tem que resolver nos próximos dez anos.” Na Amazônia, o Brasil precisa ir além da ótica extrativista diante do potencial econômico da floresta. “Nosso desafio é fazer com que uma parte importante da Amazônia seja conservada, regenerada e seja fonte de riqueza de inovação, de aplicação de ciência e tecnologia.",SAN,pt,Valor Econômico
2020-09-17 06:46:07-05:00,Albella descarga responsabilidades sobre su socio en Linklaters en el caso Banco Popular,"Sebastián Albella, actual presidente de la Comisión Nacional del Mercado de Valores (CNMV), ha tratado de descargar responsabilidades sobre su socio en Linklaters, Jorge Alegre, respecto a su participación en la ampliación de capital de 2016 de Banco Popular. Así lo aseguran fuentes conocedoras de la declaración como testigo del que fuera socio-director de dicho despacho en la Audiencia Nacional. Así las cosas, las mismas fuentes indican que esta posición no concuerda con el hecho de que fue Albella quien habló en el consejo de administración que decidió la ampliación y quien firmó la «legal opinion» de la operación. Una operación sobre la que, además, el mandatario de la CNMV ha explicado y ratificado que al tratarse de una manera de reforzar el capital nunca supondría responsabilidad alguna para el consejo. Pese a todo, este habría contestado con evasivas a ciertas cuestiones y tratando de minimizar algunas actuaciones, como puede ser en el caso del posible conflicto de intereses entre su papel como asesor del Popular y su actual presencia ahora en la CNMV.",SAN,es,ABC Spain
2020-09-17 06:00:00-05:00,"The CEO of coronavirus vaccine frontrunner Moderna shares why the biotech plans to make a flu vaccine, including a potential combo shot that would also prevent COVID-19 (MRNA)","Summary List Placement Moderna , a frontrunner in the race to create the first coronavirus vaccine , announced Thursday that it will start working on vaccines that can prevent the seasonal flu, expanding its research portfolio into a space dominated by pharmaceutical giants. In an interview with Business Insider, Moderna CEO Stephane Bancel said the decision to enter the influenza market became ""self-evident"" after reviewing early results from elderly volunteers who took the company's experimental coronavirus vaccine. That data showed older individuals who got the experimental shot generated high levels of neutralizing antibodies, or virus-fighting proteins that play a critical role in the body's immune response. The data gave Bancel hope that Moderna can develop a more effective flu vaccine, he said. Read more: There are 176 coronavirus vaccines in the works. Here's how top drugmakers see the race for a cure playing out in 2020 and 2021 and when the first shots might be available. Since its founding in 2010, Moderna has developed a unique approach to vaccines based on messenger RNA, or mRNA.",SAN,en,Business Insider
2020-09-16 18:41:47-05:00,PwC toma la delantera para el contrato millonario de auditar a «Caixabankia»,"Más allá del acuerdo de fusión entre Caixabank y Bankia, hay otro asunto por el que se mantiene -y mantendrá- cierta lucha en los próximos meses. Será para cuando la operación esté ejecutada y los dos bancos se conviertan en uno. Se trata del millonario contrato de auditoría de la entidad resultante. Fuentes financieras señalan que PwC ha tomado ya la delantera para hacerse con esa labor, aunque todavía estemos en una etapa prematura. «Tiene mucho sentido que se lo quede PwC», explican fuentes del mercado. Está bien posicionado para estar en la terna, siendo un viejo conocido de la entidad absorbente. Lo cierto es que se trata de un contrato muy jugoso dentro del Ibex 35, aunque lejos de los dos ceros que supone el de Banco Santander. Hasta la fecha, entre ambas entidades que están por fusionarse, los honorarios por su auditoría rondaban los ocho millones de euros (cinco Caixabank y otros tres Bankia). Todavía es imposible conocer el montante final al que ascenderá el contrato, pero, por lo pronto, PwC ya ha tomado posiciones para hacerse con él.",SAN,es,ABC Spain
2020-09-16 18:41:17-05:00,Pacto total para la fusión de Caixabank y Bankia ante el «sí» de hoy de sus consejos,"Lehman Brothers quebró hace doce años un 15 de septiembre. Casualidad o no, otro 15 de septiembre se cerraron los últimos flecos para crear el mayor banco en España. El anunció llegó con un día de retraso, ayer, pero el pescado, que se dice, estaba vendido desde el lunes. Ahora sí, el acuerdo de fusión -absorción, más bien- entre Caixabank y Bankia es total. Todos los escollos están salvados, con la mano invisible de Isidro Fainé mediante. Hoy se celebran los consejos de administración de cada una de las entidades para dar luz verde a la operación, aunque este solo sea el primer paso para que salga adelante. Aun así, si hace unos días el camino era más bien empedrado, ahora el terreno está alisado para que nada pueda hacer torcer la dirección de la unión que alumbrará un banco con 630.000 millones de activos en España -más de 660.000 a nivel de grupo-. Todo está dispuesto para que los consejos de administración den su visto bueno a la fusión. Los tiempos están controlados. Una vez aprobada la operación en el órgano de gestión de las dos sociedades habrán de convocarse las juntas de accionistas.",SAN,es,ABC Spain
2020-09-16 07:21:05-05:00,"Sequoia Logística define faixa de preço e pode levantar R$ 1,123 bi em IPO","Oferta pode chegar a R$ 1,516 bi com lotes adicional e suplementar A Sequoia Logística e Transportes definiu entre R$ 14,25 e R$ 17,75 a faixa indicativa de preços na sua oferta pública inicial de ações (IPO, na sigla em inglês). Considerando o meio da faixa indicativa, de R$ 16,00, e o número de 70.175.438 ações da oferta base, a operação pode movimentar R$ 1,123 bilhão. Há ainda possibilidade de um lote adicional de até 20%, ou 14.035.088 ações, e suplementar de até 15%, ou 10.526.315 ações. Nesse caso, ainda considerando o meio da faixa indicativa, a oferta total subiria para R$ 1,516 bilhão. A oferta será primária, quando os recursos vão para o caixa da empresa (28.070.175 ações, ou R$ 449,123 milhões considerando o meio da faixa indicativa); e secundária, quando acionistas atuais vendem parte de suas fatias (42.105.263 ações, ou R$ 673,684 milhões). A precificação do IPO deve ocorrer no dia 5 de outubro A companhia será negociada no Novo Mercado da B3 sob o ticker ‘SEQL3’. Os principais acionistas vendedores são a gestora Warburg Pincus, que tem uma fatia de 70,50% e pode reduzir para até 10,67%, se forem exercidos os lotes adicional e suplementar; Fram Capital, que tem 26,20% e pode cair para até 12,16%; e o fundador Armando Marchesan Neto, que tem 0,60% e pode cair para 0,49%.",SAN,pt,Valor Econômico
2020-09-16 03:38:00-05:00,"Santander, el 'mejor banco del mundo' en diversidad e inclusión","La prestigiosa revista británica 'Euromoney' acaba de otorgar al gigante financiero el premio de 'Mejor banco del mundo en diversidad e inclusión 2020', galardón que reconoce el gran esfuerzo realizado por Banco Santander en este ámbito durante los últimos años. Un profundo cambio cultural que continúa siendo un importante desafío social y empresarial.",SAN,es,Publico
2020-09-15 18:10:16-05:00,Los bancos vuelven a abaratar las hipotecas ante la contracción del mercado inmobiliario,"Los efectos colaterales de la pandemia por el coronavirus también han llegado al mercado de la vivienda y por ende, al hipotecario. A día de hoy, la banca española está redoblando los esfuerzos por recuperar la demanda perdida durante los meses de confinamiento y se lanza a captar clientes con una mejora de las condiciones de los créditos. Los anzuelos para conseguir la firma de hipotecas van desde anunciar ofertas más atractivas a rebajar intereses, conseguir subrogaciones o potenciar las campañas publicitarias. Los expertos consultados hablan de un recrudecimiento de la «guerra hipotecaria» con movimientos de rebajas de tipos que benefician claramente a los consumidores por el abaratamiento final de los créditos. El primer campo de batalla esá consistiendo en bajar los tipos fijos, que ya suponen la mitad de las hipotecas, para conseguir aumentar la concesión de estos préstamos. «El crédito hipotecario suele ser la puerta de entrada a la entidad de los clientes, por lo que no podemos obviar el valor que este producto tiene para las entidades bancarias, no por la rentabilidad intrínseca al producto, sino por la fidelización del cliente así como la contratación de productos combinados que conlleva», detalla Sergio Carbajal, responsable de hipotecas de Rastreator. «Estamos sin duda ante una guerra de precios dentro del mercado hipotecario.",SAN,es,ABC Spain
2020-09-15 08:25:00-05:00,Boehringer Ingelheim and Click Therapeutics ink a $500 million deal,"Summary List Placement Pharma giant Boehringer Ingelheim signed a $500 million contract with prescription digital therapeutics (DTx) company Click Therapeutics to codevelop and commercialize digital treatments for patients with schizophrenia. The DTx app—dubbed CT-155—will be designed on Click's tech platform, and will be prescribed as either a standalone treatment or as a supplement to traditional pharmaceuticals. Pharma companies are increasingly commercializing DTx for psychiatric conditions, which should help them pry open massive revenue streams. This isn't the first time a major pharmaceutical company tapped a DTx developer's tools for behavioral health: In 2019, Otsuka pumped $300 million into Click Therapeutics to codevelop a DTx for major depressive disorder; and Sanofi teamed up with Happify Health last September to build a prescription-based digital depression therapy for patients living with multiple sclerosis. Big pharma's interest in DTx solutions makes sense—tie-ups with behavioral health-focused DTx vendors, for example, give pharma incumbents an avenue to reach mental health patients averse to traditional medication.",SAN,en,Business Insider
2020-09-14 19:24:15-05:00,El Santander devolverá 550.000 euros a un registrador de la propiedad por venderle productos complejos,"Banco Santander tendrá que devolver 548.000 euros a un cliente al que la entidad vendió bonos estructurados hace más de una década. Así consta en una sentencia del Tribunal Supremo, que confirma la de la Audiencia Provincial de Granada, a la que ha tenido acceso este periódico. La inversión se llevó a cabo a través de Banif, la banca privada de la entidad cántabra. Pero la sentencia de la Audiencia Provincial -ahora confirmada por el Supremo- entendió que no se informó de manera suficiente sobre los riesgos que asumía el cliente. Y, en este caso, llama la atención que el inversor no se trataba de una persona con estudios básicos sino con formación superior y ocupando puesto de registrador de la propiedad. Aun así, pese a su cargo, no se le puede considerar como experto en materia financiera y con conocimientos suficientes para invertir en bonos estructurados. Asimismo, el fallo que recurrió el Santander y que el Supremo ha confirmado incide en que resulta «absurdo» que la entidad financiera prescinda de las respuestas que dio el propio cliente sobre el riesgo que este estaba dispuesto a soportar.",SAN,es,ABC Spain
2020-09-14 14:21:18-05:00,Día «D» para la fusión entre Caixabank y Bankia,"Llegó el día D. Y la hora H. Más incluso que el día que los consejeros de cada cual den su visto bueno. Por lo crucial de los términos que aún están sobre la mesa para aprobar la operación de la futura fusión entre Caixabank y Bankia. Tras el descanso para la reflexión de un largo fin de semana que incluyó la jornada de ayer, el presidente de la Fundación Bancaria La Caixa, Isidro Fainé -sobre el que cae el peso de las negociaciones por parte de la entidad catalana-, retoma hoy las conversaciones con el representante del Estado -en este caso, el FROB, con su presidente al frente, Jaime Ponce- y de Bankia, que preside José Ignacio Goirigolzarri. Según ha podido saber ABC de fuentes próximas a ambas entidades, este martes se antoja clave para una operación que causó estupor en los mercados tras anunciarse por sorpresa, sin ni siquiera tener cerrada una ecuación de canje para llevarla a buen puerto. Inversores consultados por este periódico coinciden en que todo señala a la aparición en escena de una tercera entidad interesada en la nacionalizada -hablan de Banco Santander, tal y como avanzó este periódico-, lo que precipitó los acontecimientos y se filtró inmediatamente a los medios de comunicación para dejar claro de dónde partía la oferta y que no había rival posible.",SAN,es,ABC Spain
2020-09-14 10:12:04-05:00,El juicio entre Andrea Orcel y Banco Santander comenzará en marzo con Botín como testigo,"El Juzgado de Primera Instancia número 46 de Madrid ha fijado el próximo 10 de marzo de 2021 como fecha clave en la disputa fraguada entre Andrea Orcel y Banco Santander en 2018, después de que este lunes se haya celebrado la vista previa del juicio…",SAN,es,La Vanguardia
2020-09-14 09:56:00-05:00,Orcel reclama 112 millones al Santander por no haberle contratado,"El ejecutivo italiano Andrea Orcel reclama al Banco Santander 112 millones de euros por no haberle contratado. El Juzgado de Primera Instancia número 46 de Madrid ha fijado para el próximo 10 de marzo del 2021 como fecha clave en la disputa abierta entre Orcel y Banco Santander en el 2018, después de que este lunes se haya celebrado la vista previa del juicio y las partes no hayan alcanzado ningún acuerdo. De este modo, el próximo mes de marzo se iniciará el juicio civil por el fichaje frustrado del banquero italiano procedente de UBS , en el que será interrogada como parte la presidenta de Banco Santander, Ana Botín . Seguir leyendo… .",SAN,es,El Periodico
2020-09-14 06:42:13-05:00,Banco Santander y Andrea Orcel irán a juicio en marzo por el fichaje frustrado del banquero,"La vista previa celebrada hoy entre Andrea Orcel y Banco Santander por su fichaje frustrado como consejero delegado no ha servido para acercar posturas. El acuerdo ha sido imposible entre las partes e irán a juicio el próximo 10 de marzo de 2021. Ana Botín, presidenta del Santander, declarará como testigo en el juicio a petición del demandante, el banquero italiano, quien reclama a la entidad cántabra un total de 112 millones de euros por no haberse culminado su llegada a la entidad como número dos. La tensión en la resolución del caso está servida. Pero Orcel y la dirigente del Santander no tendrán que verse las caras ya que el banquero italiano no ha sido llamado a declarar por parte del banco demandado. Por parte de UBS, la entidad de la que era consejero delegado Orcel hasta que decidió dar el salto a España, será Axel Weber, su presidente, el que comparecerá como testigo en el juicio. Las diferencias entre el banquero italiano y el banco español se iniciaron a principios de 2019, aunque estallaron el verano de dicho año.",SAN,es,ABC Spain
2020-09-14 05:06:00-05:00,Orcel y Botín rechazan un acuerdo extrajudicial e irán a juicio el 10 de marzo,"Andrea Orcel, va a por todas. Quiere los 112 millones de indemnización del Banco Santander por su fichaje fallido como consejero delegado de la entidad que",SAN,es,El Confidencial
2020-09-14 01:42:52-05:00,Sanofi's Dupixent Fast Track'd for eosinophilic esophagitis (NASDAQ:SNY),The FDA has granted Breakthrough Therapy designation to Sanofi's (NASDAQ:SNY) Dupixent (dupilumab) for the treatment of patients 12 years and older with eo,SAN,en,Seeking Alpha
2020-09-12 23:23:01-05:00,Hyderabad is the world's vaccine capital,"HYDERABAD: As international vaccine companies and academic institutions race the clock to deliver a safe Covid-19 vaccine, all eyes are on India that makes 60% of the world’s vaccines. And within India, if there is one destination that all of them are making a beeline for it is Hyderabad. The city has the capacity to churn out well over a third of the global vaccine supply.Be it India’s first indigenous Covid-19 vaccine candidate Covaxin or Russia’s Sputnik V, Johnson & Johnson’s Ad26.Cov2.S, FluGen’s CoroFlu or even Sanofi’s under development vaccine candidates, all have a Hyderabad connect.Whether a successful Covid-19 vaccine is developed in Hyderabad or not, a vaccine developed anywhere in the world will be churned out of Hyderabad, says Dr Varaprasad Reddy, founder & chairman, Shantha Biotechnics Ltd.“All Hyderabad vaccine companies are robust in manufacturing technology and have the capacity to manufacture millions of doses with good standards,” says Reddy, who is awaiting Sanofi’s own vaccine candidate in the first half of 2021, a chunk of which is expected to be manufactured in Hyderabad.",SAN,en,Economic Times India
2020-09-10 21:45:00-05:00,"Ana Botín y los ""millonarios"" del Ibex, en la diana del sindicato ligado a Vox",La organización sindical promovida por Abascal y su equipo señala a la presidenta de Banco Santander tras el 'abrazo' de Pedro Sánchez con la clase empresarial en Casa de América,SAN,es,Vozpopuli
2020-09-10 11:48:27-05:00,"Banco Santander, mejor banco del mundo en diversidad e inclusión, y para pymes",Banco Santander ha sido reconocido como el mejor banco del mundo en diversidad e inclusión y como mejor banco del mundo para pymes en la edición 2020 de los premios 'Excellence in Leadership' de la revista ' Euromoney '. Se trata de la primera vez que Santander es nombrado mejor banco del mundo en diversidad e inclusión. Euromoney destaca el alto nivel de exigencia y alcance de los programas de diversidad e inclusión de Santander y su capacidad para desarrollarlos en países con distinto nivel de desarrollo y diversidad cultural. Seguir leyendo… .,SAN,es,El Periodico
2020-09-09 23:00:00-05:00,"SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Is Investigating the Following Mergers; Shareholders are Encouraged to Contact the Firm - PRNB, BLDR, AKCA, YIN","NEW YORK, Sept. 10, 2020 /PRNewswire/ -- Halper Sadeh LLP, a global investor rights law firm, is investigating: Principia Biopharma Inc. (NASDAQ: PRNB) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating to its sale to Sanofi for…",SAN,en,PR Newswire
2020-09-09 11:20:09-05:00,"Compass define faixa de preço em IPO e pode levantar R$ 3,3 bilhões","Subsidiária da Cosan atua na distribuição de gás natural por meio da Comgás A Compass Gás e Energia definiu entre R$ 25,50 e R$ 31,50 a faixa indicativa de preços na sua oferta pública inicial de ações (IPO, na sigla em inglês). Considerando o meio da faixa indicativa, de R$ 28,50, e o número de 117.647.060 ações da oferta base, a operação pode movimentar R$ 3,353 bilhões. Há ainda possibilidade de um lote adicional de até 20%, ou 23.529.412 ações, e suplementar de até 15%, ou 17.647.059 ações. Nesse caso, ainda considerando o meio da faixa indicativa, a oferta total subiria para R$ 4,527 bilhões. A oferta será totalmente primária, quando os recursos vão para o caixa da empresa. Se forem exercidos os lotes suplementar e adicional, a participação da Cosan seria diluída de 99,01% para 79,04%. A precificação do IPO deve ocorrer no dia 28. A companhia será negociada no Novo Mercado da B3 sob o ticker ‘PASS3’. A Compass pretende utilizar os recursos líquidos da oferta para: potenciais aquisições de empresas, assim como investimentos em privatizações considerados estratégicos para consolidação de ativos de distribuição de gás (80%); e reforço da sua estrutura de capital (20%).",SAN,pt,Valor Econômico
2020-09-09 08:39:27-05:00,US stocks rebound after 3-day sell-off driven by tech giants,"Summary List Placement US stocks rebounded on Wednesday after a three-day sell-off driven by tech giants led to a more than 10% decline in the Nasdaq composite index. Tech giant Apple climbed more than 3% after sliding below the $2 trillion market cap threshold on Tuesday. Oil recouped a fraction of the sharp losses experienced on Tuesday, with WTI crude contracts climbing as much as 2.5%, to $37.69 per barrel. Watch major indexes update live here . US stocks rebounded on Wednesday after a three-day sell-off driven by tech shares led to a more than 10% decline in the Nasdaq composite index. Leading the markets higher on Wednesday were the same stocks that led the market lower over the past week. Shares of Apple climbed more than 3%, while Tesla jumped roughly 5%. Apple's three-day decline ultimately amounted to a 14% skid, which pushed its market capitalization below the $2 trillion threshold for the first time since August 20, according to data from YCharts.com. Here's where US indexes stood shortly after the 9:30 a.m.",SAN,en,Business Insider
2020-09-09 07:32:04-05:00,La fusión de Santander con BBVA es posible - Republica.com,"Nervios en BBVA desde donde se dice que han reanudado los contactos para una fusión entre BBVA y Banco Sabadell, aunque algunos analistas consideran que el nuevo gran Banco español puede ser el resultado de una gran fusión del Banco Santander con BBVA, liderada por Ana Botín. Lo que además de constituir el primer Banco […]",SAN,es,Republica.com
2020-09-09 05:37:57-05:00,AstraZeneca shares slide after its coronavirus vaccine trial is put on hold due to suspected adverse reaction,"Summary List Placement AstraZeneca shares fell on Wednesday, extending a 6% fall on Tuesday, after the pharmaceutical company halted its coronavirus vaccine trial following a suspected severe adverse reaction from a participant. Shares in the company, a front-runner in the race for a coronavirus vaccine, were down by around 1% on London's FTSE 100 index in mid-morning trading on Wednesday. AstraZeneca's US-listed shares fell by as much as 6% during after-hours trading on Tuesday. AstraZeneca is developing a vaccine with the University of Oxford. Pausing the phase-three study — the final phase before potential approval — is a ""routine action which has to happen whenever there is a potentially unexplained illness in one of the trials,"" the British company said in a statement to CNBC . Illnesses in large trials are expected, but each one must be reviewed carefully, it added. AstraZeneca also said it was ""working to expedite the review of the single event to minimize any potential impact on the trial timeline."" The suspected serious adverse reaction was first reported by STAT .",SAN,en,Business Insider
2020-09-09 01:32:00-05:00,Más de 50 convocatorias de becas y ayudas económicas del Banco Santander para estudiantes y profesionales STEM,No summary available.,SAN,es,Publico
2020-09-08 16:28:40-05:00,"As Political Pressure Mounts, COVID-19 Vaccine Developers Pledge To Put Safety First","Against the backdrop of pressure to expeditiously bring out a coronavirus vaccine as quickly as possible, biopharma companies working on vaccine candidates said as a group Tuesday that safety comes first. The CEOs of nine biopharma companies that are among the frontrunners in the COVID-19 vaccine race released a signed pledge Tuesday that underlined their commitment to make the safety and well-being of vaccinated individuals their ""top priority"" in the development and testing process. The signatories of the pledge include the CEOs of: AstraZeneca plc (NYSE: AZN ) BioNTech SE – ADR (NASDAQ: BNTX ) Pfizer Inc. (NYSE: PFE ) Moderna Inc (NASDAQ: MRNA ) Merck & Co., Inc. (NYSE: MRK ) Johnson & Johnson (NYSE: JNJ ) Novavax, Inc. (NASDAQ: NVAX ) Sanofi SA (NASDAQ: SNY ) GlaxoSmithKline plc (NYSE: GSK ) The CEOs commited to adhere to high ""scientific and ethical standards"" in conducting clinical trials and manufacturing; to apply for emergency use authorization only after safety and … Full story available on Benzinga.",SAN,en,Benzinga
2020-09-08 15:44:52-05:00,Here’s the safety pledge that 9 coronavirus vaccine makers just signed,"Nine companies involved in coronavirus vaccine research inked a pledge to uphold the scientific principles that would ensure the safe development of COVID-19 vaccines. A report a few days ago said the pledge was in development, in response to recent coronavirus vaccine-related developments. Russia and China have started providing vaccine candidates under emergency programs before completing the final stages of testing. At the same time, rumors of the Trump administration issuing an emergency approval of its own before the presidential election began to spring up. A vaccine might end the coronavirus the pandemic, but it will take a while longer for that to happen. First of all, the world needs at least one safe, effective vaccine to complete the last phase of testing successfully. We then need to wait for governments to devise and execute vaccination campaigns, and we’ll need to continue observing safety measures meant to reduce the spread of the illness. We’ll have to wear face masks, social distance, and wash our hands often.",SAN,en,BGR
2020-09-08 05:00:00-05:00,American Finance Trust Announces Refinancing And Provides August Rent Update,"NEW YORK , Sept. 8, 2020 /PRNewswire/ -- American Finance Trust, Inc. (NASDAQ: AFIN ) (""AFIN"" or the ""Company"") announced today that the Company entered into a financing transaction with Bank of Texas to borrow $125 million in a syndicated balance sheet loan (the ""Loan"") on three buildings located in Bridgewater, New Jersey that serve as the US Headquarters for Sanofi. A multinational, investment-grade pharmaceutical company, Sanofi's campus is a mission critical facility for supporting operations in the United States . ""Thanks to the high quality of the Sanofi properties and our long-standing relationship with Bank of Texas , we were able to complete this financing on what we believe to be very attractive terms,"" said Michael Weil , CEO of AFIN. ""The Loan capitalizes on the historically low interest rate environment and Sanofi's investment-grade credit rating to replace the existing financing, which had four months of term remaining, with new five-year … Full story available on Benzinga.",SAN,en,Benzinga
2020-09-08 03:59:59-05:00,"Regeneron, Sanofi’s Dupixent Shows Sustained Asthma Benefits In 3-Yr Trial","Regeneron Pharmaceuticals (REGN) and Sanofi have announced new results from a Dupixent (dupilumab) Phase 3 open-label extension trial that showed the safety and efficacy … The post Regeneron, Sanofi’s Dupixent Shows Sustained Asthma Benefits In 3-Yr Trial appeared first on Smarter Analyst .",SAN,en,Smarter Analyst
2020-09-08 02:54:31-05:00,Sanofi/Regeneron Dupixent shows sustained benefit in asthma extension study (NASDAQ:SNY),Sanofi (NASDAQ:SNY) and Regeneron Pharmaceuticals (NASDAQ:REGN) announce new results from a Dupixent (dupilumab) Phase 3 open-label extension trial that sh,SAN,en,Seeking Alpha
2020-09-06 07:55:44-05:00,La vacuna contra el COVID-19 de Sanofi y GSK costará menos de 10 euros y los europeos la tendrán al mismo tiempo que los estadounidenses,Los europeos tendrán la vacuna de Sanofi y GlaxoSmithKline (GSK) al mismo tiempo que los estadounidenses y estará a la venta por un precio menor a 10 euros.,SAN,es,Business Insider Spain
2020-09-06 07:45:15-05:00,Sanofi France chief sees coronavirus vaccine priced below 10 euros,"A coronavirus vaccine that Sanofi is developing with Britain's GlaxoSmithKline is likely to be priced at less than 10 euros (US$11.80) per shot if it is approved for use, Sanofi's chief in France said on Saturday.",SAN,en,Channel NewsAsia
2020-09-05 18:53:38-05:00,El BCE redobla su presión y la banca asume que las fusiones son necesarias,"El anuncio público de las negociaciones entre Caixabank y Bankia es más una declaración formal que sustancial. Cuando la noticia llegó a la Prensa y a la Comisión Nacional del Mercado de Valores (CNMV) vía hecho relevante la operación estaba ya tan encarrilada que apenas harán falta unas semanas para que fructifique. Todo está dispuesto para un principio de acuerdo, y que el resto sientan el aliento de los reguladores para hacer lo propio. La presión, si cabe, viene ahora con más fuerza tanto desde dentro como desde fuera del sector financiero. Una pareja ya se ha echado a la pista de baile y la música está sonando a la espera de que otros decidan sumarse a la fiesta. El sector, según las fuentes consultadas, ya ha asumido que tendrá que haber más movimientos. El Banco Central Europeo (BCE), el Banco de España y la Asociación Española de Banca (AEB) dan a entender por activa y por pasiva que el camino de «Caixabankia» –no se llamará así a futuro, a la espera de decidir nombre– es el correcto para enfrentarse a las amenazas, que no son pocas, que se ciernen sobre la banca.",SAN,es,ABC Spain
2020-09-05 04:42:27-05:00,"Sanofi plans ingredient unit IPO within months, Bogillot says","Sanofi, the French pharmaceutical giant, plans to sell shares in its drug-ingredients division in the next few months, a senior executive said.",SAN,en,The Edge Markets
2020-09-05 03:54:26-05:00,Sanofi France chief: future COVID-19 vaccine seen below 10 euros,"Sanofi's <SAY.PA> chief in France, Olivier Bogillot, said on Saturday that its future COVID-19 vaccine was likely to be priced below 10 euros per shot.",SAN,en,Reuters UK
2020-09-04 18:58:04-05:00,El beneplácito de Sánchez a Fainé tumba los planes de Botín,"No lo vio venir. Ni por asomo. Y se encontró rodeada de homólogos del Ibex 35 el pasado lunes en la Casa América con la sorpresa. O eso dicen algunos de los allí presentes, porque en el seno del banco no lo confirman. Se había presentado previamente ante Sanchez con su propia solución bajo el brazo sobre el futuro de Bankia, y la de Isidro Fainé, más experimentado en estas lides, la había adelantado hacía tiempo ya por la derecha y a toda pastilla. Como a Banco Sabadell, a quien daban por descontado desde hace meses como próxima pareja de la nacionalizada. «Estas cosas o se hacen rápido, o se pierden», dice una fuente conocedora de los tiempos que manejan en la sede de la entidad catalana. Y es que la futura operación, apalabrada entre el propio presidente del Gobierno y el de la Fundación Bancaria La Caixa, ha dado al traste en un abrir y cerrar de ojos con los planes sobre Bankia de cualquier otra entidad, entre ellos, el Banco Santander. Según ha podido saber ABC, Ana Botín se enteraba de la fatídica noticia en el mismo lunes por boca de Sánchez, que ya habría dado el «sí» previamente a Fainé, que curiosamente sustituía en el acto institucional al propio presidente de Caixabank.",SAN,es,ABC Spain
2020-09-04 10:50:00-05:00,Wirtschaft: Institute erwägen Fusion zur größten Bank Spaniens,"Madrid (dpa) - In Spanien zeichnet sich eine endgültige Lösung für das nach der Finanzkrise vom Staat gerettete Geldinstitut Bankia ab. Die Bank und die Caixabank bestätigten Gespräche über einen möglichen Zusammenschluss. Die Wirtschaftszeitung «Cinco Días» berichtete am Freitag, das entscheidende Treffen werde am 13. September stattfinden. Mit Blick auf den Heimatmarkt würde bei einer Einigung das größte spanische Kreditinstitut entstehen. Die Zeitung «El País» sprach von «einem Erdbeben» im Bankensektor. Doch noch ist es nicht so weit. Der staatliche Fernsehsender «RTVE» sagte am Freitag «lange und komplizierte Verhandlungen» voraus. Eine Vereinbarung zwischen beiden Unternehmen müsste anschließend von der linken Regierung abgesegnet werden. Der Staat ist mit knapp 62 Prozent der Anteile zur Zeit Mehrheitsaktionär von Bankia. Nach einem Bericht der Zeitung «El Confidencial» würde der Staat an dem fusionierten Institut rund 14 Prozent halten. Der Juniorpartner der linken Regierungskoalition von Ministerpräsident Pedro Sánchez, das Linksbündnis Unidas Podemos (UP), sprach derweil von einer «besorgniserregenden Nachricht für die spanische Wirtschaft». «Eine Fortsetzung der Oligopolisierung des Finanzsektors wäre sowohl für die Wettbewerbsfähigkeit als auch für die Stabilität des Marktes», schrieb auf Twitter der Wirtschaftssprecher von UP, Nacho Álvarez.",SAN,de,Westfalen-Blatt
2020-09-04 10:43:00-05:00,Caixabank y Bankia inician el baile de fusiones,"El grupo fusionado tendría alrededor de un 30% de cuota de mercado en España, adelantando a Banco Santander.",SAN,es,Publico
2020-09-04 09:50:40-05:00,Comienzan a probar en seres humanos posible vacuna contra covid-19,El laboratorio francés Sanofi y el británico GSK comenzaron los ensayos clínicos en seres humanos.,SAN,es,El Tiempo
2020-09-04 05:35:51-05:00,Drugmakers Sanofi and Glaxo launch human trials for Covid-19 vaccine,"Summary List Placement European Drug makers, Glaxosmithkline and Sanofi, have begun testing their new protein-based coronavirus vaccine on humans for the first time. If effective, they aim to produce up to one billion doses in 2021. GSK, the world's largest vaccine manufacturer, and French pharmaceutical company Sanofi, have enrolled 440 people across 11 sites in the United States, both companies confirmed to Business Insider. Previous studies have shown promising results. Both firms expect to have results by early December this year and will then look to progress into phase three by the end of this year. If the results are successful, GSK and Sanofi will request regulatory approval in the first half of next year. Their vaccine combines the same technology Sanofi uses to make its flu vaccine and with help from GSK to create a stronger immune response. Thomas Triomphe, Executive Vice President and Global Head of Sanofi Pasteur said in a statement that the beginning of the clinical study is an important step in helping defeat COVID-19.",SAN,en,Business Insider
2020-09-04 04:30:00-05:00,Here Is Everything We Know About A COVID-19 Vaccine,"Here Is Everything We Know About A COVID-19 Vaccine Tyler Durden Fri, 09/04/2020 - 05:30 Under normal conditions, vaccines require as long as ten years of testing before they're approved by regulators, then it takes some more time for drug companies to produce and distribute the product to millions of patients around the world. Until very recently, the notion that the world could quickly develop and mass produce a vaccine for some new infectious disease within a matter of months seemed impossible. Of course, these aren't normal times. After unveiling the adenovirus-vector vaccine developed by the Gameleya Institute, Russian President Putin claimed that the vaccine was tested first on a small group of willing participants, including one of his own adult daughters. The implication was that traditional standards of medical ethics don't always apply during extreme situations. With vaccine news being the dominant story on Thursday , as investors around the world watched as the administration pushed the states to prepare to start distributing vaccine doses on an emergency basis come Nov. 1.",SAN,en,Zero Hedge
2020-09-03 14:50:11-05:00,"Empresarios y bancos, a favor de la unidad política para salir de la crisis del COVID-19","El Pleno de la Cámara de Comercio ha reunido a los principales empresarios de España para valorar la situación política y económica en nuestro país. Ana Botín, la presidenta del Banco Santander, ha sido una de las personalidades que han apoyado los pactos políticos que promueve el Gobierno para superar la crisis provocada por la pandemia del COVID-19. Nadia Calviño, vicepresidenta tercera del Gobierno y ministra de Asuntos Económicos y Transformación Digital, ha celebrado el apoyo de los empresarios a la unidad política. - Redacción -",SAN,es,Publico
2020-09-03 10:05:16-05:00,"Sanofi, GSK to start clinical tests of virus vaccine",No summary available.,SAN,en,UrduPoint
2020-09-03 06:55:02-05:00,"The Daily Biotech Pulse: Sanofi, GSK Begin Phase 1/2 Coronavirus Vaccine Study, Fulgent Strikes COVID-19 Testing Deal, New Data From Novavax","Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 2) Acutus Medical Inc (NASDAQ: AFIB ) Akouos Inc (NASDAQ: AKUS ) Avid Bioservices Inc (NASDAQ: CDMO ) ( reacted to strong quarterly results) BioLife Solutions Inc (NASDAQ: BLFS ) Corcept Therapeutics Incorporated (NASDAQ: CORT ) Edwards Lifesciences Corp (NYSE: EW ) Evogene Ltd (NASDAQ: EVGN ) Fortress Biotech (NASDAQ: FBIO ) Generation Bio Co (NASDAQ: GBIO ) Immunovant Inc (NASDAQ: IMVT ) (priced its 5.27-million-share common stock offering at $33 per share) Inspire Medical Systems Inc (NYSE: INSP ) Intuitive Surgical, Inc. (NASDAQ: ISRG ) Silk Road Medical Inc (NASDAQ: SILK ) Shockwave Medical Inc (NASDAQ: SWAV ) Tandem Diabetes Care Inc (NASDAQ: TNDM ) TG Therapeutics Inc common stock (NASDAQ: TGTX ) Twist Bioscience Corp (NASDAQ: TWST ) (announced potent SARS-CoV-2 neutralizing data from COVID-19 therapeutic antibody program) West Pharmaceutical Services Inc. (NYSE: WST ) Zoetis Inc (NYSE: ZTS ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows Sept. 2) Acorda Therapeutics Inc (NASDAQ: ACOR ) ADiTx Therapeutics Inc (NASDAQ: ADTX ) (priced a $9.6-million follow-on offering) China SXT Pharmaceuticals Inc (NASDAQ: SXTC ) Cyclacel Pharmaceuticals Inc (NASDAQ: CYCC ) Entera Bio Ltd (NASDAQ: ENTX ) Eyepoint Pharmaceuticals Inc (NASDAQ: EYPT ) Gritstone Oncology Inc (NASDAQ: GRTS ) Happiness Biotech Group Ltd (NASDAQ: HAPP ) Histogen Inc (NASDAQ: HSTO ) Interpace Biosciences Inc (NASDAQ: IDXG ) Iterum Therapeutics PLC (NASDAQ: ITRM ) NanoVibronix Inc (NASDAQ: NAOV ) Neurobo Pharmaceuticals Inc (NASDAQ: NRBO ) Nkarta Inc (NASDAQ: NKTX ) Oncternal Therapeutics Inc (NASDAQ: ONCT ) Psychemedics Corp. (NASDAQ: PMD ) Rockwell Medical Inc (NASDAQ: RMTI ) Sun BioPharma, Inc. (NASDAQ: SNBP ) Sunesis Pharmaceuticals, Inc. (NASDAQ: SNSS ) Stocks In Focus Sutro To Present Positive Phase 1 Ovarian Cancer Data In an abstract submitted to the International Gynecologic Cancer Society …",SAN,en,Benzinga
2020-09-03 06:00:32-05:00,"Botín: ""Cada empresa que salvemos ahora hará más fácil la recuperación""","La presidenta de Banco Santander, Ana Botín, ha instado a invertir los recursos en los proyectos de cada sector que tengan un esfuerzo multiplicador, salvando a las empresas ""que merezcan ser salvadas"" para hacer más fácil la recuperación en el medio plazo. (Fuente: Cámara de Comercio)",SAN,es,Publico
2020-09-03 05:57:25-05:00,El Ibex pide al Gobierno un marco atractivo para la inversión y seguridad jurídica,"Gerardo Cuerva, presidente de Cepyme, ha resumido a la perfección lo vivido esta mañana en el pleno extraordinario de la Cámara de Comercio de España: «Es sencillo vicepresidenta (Calviño), hay que hacerle caso al mundo de la empresa» para lograr la recuperación económica. Lo ha dicho en un tono distendido ante la responsable económica del Gobierno. Pero dentro de esa frase queda claro que se ha tratado de un evento de reivindicaciones. José Luis Bonet, presidente de la Cámara de España, ha sido el primero en tomar la palabra para reclamar «altura de miras» a la clase política para llegar a consensos amplios. Con la coletilla, también, de que sin la participación del tejido productivo no habrá salida de la crisis. El entrante de lo que vendría minutos más tarde con varios primeros espadas del Ibex 35 . De hecho, en el acto ha estado presente alrededor del 50% de la ponderación del selectivo español. Fernando Abril-Martorell, presidente de Indra, y Ana Botín, presidenta de Banco Santander, han tomado la palabra para reclamar acuerdos y apoyo a las compañías , en busca también de la tan ansiada recuperación vía revolución tecnológica y «verde».",SAN,es,ABC Spain
2020-09-03 05:37:00-05:00,"Covid-19 vaccine update: Sanofi, GlaxoSmithKline begin human clinical trials for jointly developed vaccine",The announcement was made by the pharma companies after they got positive results during the preclinical stage trials of the vaccine candidate.,SAN,en,The Financial Express
2020-09-03 05:07:32-05:00,GSK and Sanofi to begin clinical trial for potential Covid-19 vaccine,coronavirus vaccine gsk sanofi clinical trials,SAN,en,The Independent
2020-09-03 05:03:31-05:00,Pharmaceutical firms GlaxoSmithKline and Sanofi launch human trials of promising coronavirus vaccine,"French drugmaker Sanofi and British GSK have enrolled more than 400 people in the US for the phase one and two trial, which will assess the safety of the vaccine candidate.",SAN,en,Daily Mail Online
2020-09-03 04:41:00-05:00,"COVID-19 pandemic: Sanofi, GSK kickstart trial for protein-based vaccine","Drugmakers and governments around the world are battling to develop treatments against the COVID-19 pandemic that has claimed more than 861,000 lives and crippled economies",SAN,en,Business Today
2020-09-03 04:26:04-05:00,"Sanofi, GSK Start Early-Stage Clinical Trials Of Jointly-Developed COVID-19 Vaccine",Sanofi SA (NASDAQ: SNY ) and GlaxoSmithKline PLC (NYSE: GSK ) on Thursday announced they had started the early-stage clincial trials for for their COVID-19 vaccine candidate the same day. What Happened: This untested vaccine is made by blending the technology used in Sanofi’s seasonal influenza vaccine and GSK’s pandemic adjuvant technology. The initial testing combines the early and middle stages (Phase 1/2 Trials) and is being carried out in 11 … Full story available on Benzinga.com,SAN,en,Benzinga
2020-09-03 03:45:42-05:00,Sanofi and GSK initiate clinical trials for Covid-19 vaccine,Sanofi and GSK are beginning clinical trials for a Covid-19 vaccine with 440 healthy adults at 11 investigational sites in the US.,SAN,en,SiliconRepublic
2020-09-03 02:50:06-05:00,"Sanofi, GSK start human trials of jointly-developed covid-19 vaccine","Development of the adjuvanted covid-19 vaccine candidate is being supported through funding and collaboration with the Biomedical Advanced Research and Development Authority, part of the US Department of Health and Human Services",SAN,en,Livemint
2020-09-03 01:41:14-05:00,Sanofi y GSK inician un ensayo de una vacuna COVID-19 basada en proteínas,"La farmacéutica francesa Sanofi y la británica GSK han comenzado un ensayo clínico para una vacuna COVID-19 basada en una proteína, sumándose a la carrera de las farmacéuticas para desarrollar tratamientos contra la pandemia de COVID-19.",SAN,es,Reuters Latin America
2020-09-03 01:01:00-05:00,"Sanofi, GlaxoSmithKline Start Phase 1/2 Trial of Covid-19 Vaccine Candidate",By Pietro Lombardi Sanofi SA and GlaxoSmithKline PLC are enrolling more than 400 people to start the Phase 1/2 clinical trial of their…,SAN,en,ADVFN UK
2020-09-03 01:00:00-05:00,GlaxoSmithKline PLC Sanofi/GSK: Phase 1/2 trial of COVID-19 vaccine,"GlaxoSmithKline PLC 03 September 2020 Issued: 3 September 2020, London, UK and Paris, France Sanofi and GSK initiate Phase 1/2 clinical…",SAN,en,ADVFN UK
2020-09-03 00:48:55-05:00,"Sanofi, GSK Launch Trial For COVID-19 Protein-based Vaccine","French drugmaker Sanofi and its British peer GSK have started a clinical trial for a proteinbased COVID19 vaccine candidate, as pharmaceutical companies race to develop treatments against the COVID19 pandemic.",SAN,en,CNN-News18
2020-09-03 00:46:57-05:00,"Sanofi/GSK initiate Phase 1/2 COVID-19 trial, first results expected early December (NASDAQ:SNY)",Sanofi (NASDAQ:SNY) and GlaxoSmithKline (NYSE:GSK) have started the Phase 1/2 clinical trial for their COVID-19 adjuvanted recombinant protein-based vaccin,SAN,en,Seeking Alpha
2020-09-03 00:00:00-05:00,GlaxoSmithKline and Sanofi Just Launched the First Human Trial of Their Covid-19 Vaccine. Why That Matters.,"As the first generation of Covid-19 vaccines moves into large-scale Phase 3 trials, a slower but much-watched effort from two of the world’s biggest vaccine…",SAN,en,MarketWatch
2020-09-02 18:37:43-05:00,La banca arrastra al Ibex 35 y desata las alarmas en la CNMV europea,"La banca española afronta serios problemas para remontar el vuelo en Bolsa. Hubo dos momentos durante la pandemia que su curva se alineó para mirar hacia arriba pero el verano ha echado por tierra esas esperanzas. La cuesta de septiembre ha llegado para las entidades financieras, que ya despiertan «especial preocupación» en la Autoridad Europea de Valores y Mercados (ESMA, por sus siglas en inglés), la CNMV comunitaria. Ayer todo el sector cayó a plomo, entre el 2,45% de Banco Santander y el 4,6% de Bankinter. La historia de los bancos nacionales durante la crisis del Covid-19 se está escribiendo por capítulos. Uno, para la solidaridad mostrada a nivel sanitario y económico; otro, por su reacción a nivel de resultados financieros; y otro para su experiencia en los mercados. Este último es, quizás, el más negro de todos. Ninguna de las seis entidades se salvan del descalabro en Bolsa; unas con peor desempeño que otras, con amplias diferencias entre Banco Sabadell (en mínimos históricos) y Bankinter (no tan hundido), por ejemplo.",SAN,es,ABC Spain
2020-09-02 14:02:15-05:00,Housi e Açu Petróleo registram pedido de IPO na CVM,"A Açu é o maior terminal privado de petróleo do Brasil e a Housi é uma plataforma de locação de imóveis Duas companhias aumentam a lista de ofertas de ações registradas na CVM. A plataforma de locação de imóveis Housi e a Açu Petróleo disponibilizaram seus prospectos preliminares. A Açu é o maior terminal privado de petróleo do Brasil, e presta serviços de infraestrutura logística de transbordo de petróleo a grandes companhias do setor de óleo e gás, nacionais e internacionais, e produtores de petróleo, com operação no Complexo do Porto do Açu. Com tranches primária e secundária, os acionistas vendedores são a Prumo Logística e a Oiltanking GmbH. É a segunda companhia ligada ao setor de óleo e gás na fila de oferta, dado que a 3R Petroleum registrou ontem os documentos para sua oferta. Bank of America, Bradesco BBI e Santander coordenarão a oferta. No primeiro semestre, a receita líquida de serviços foi de R$ 180,7 milhões, ante R$ 91 milhões no mesmo período do ano passado. A empresa registrou prejuízo de R$ 112,5 milhões no período, ante lucro de R$ 1,3 milhão no primeiro semestre de 2019.",SAN,pt,Valor Econômico
2020-09-02 13:04:02-05:00,Santander inclui Alupar e Vale na carteira de dividendos de setembro,"O Santander (SANB11) realizou duas alterações na carteira recomendada de dividendos para setembro. A BR Distribuidora (BRDT3) e a Taesa (TAEE11) deixaram a seleção, para a entrada da Alupar (ALUP11) e Vale (VALE3). Para justificar a escolha da Alupar, Renato Chanes, o estrategista que assina o relatório de recomendações, observa que o setor de energia […]",SAN,pt,Money Times
2020-09-01 05:50:57-05:00,Sanofi Says Kevzara Drug Fails To Meet Endpoints in Covid-19 Study,French drugmaker Sanofi announced Tuesday that a late-stage study of the rheumatoid arthritis drug Kevzara tested in severely or critically ill patients hospitalized with … The post Sanofi Says Kevzara Drug Fails To Meet Endpoints in Covid-19 Study appeared first on Smarter Analyst .,SAN,en,Smarter Analyst
2020-09-01 04:41:16-05:00,Sanofi's late-stage Kevzara trial in COVID-19 patients fails to meet endpoints (NASDAQ:SNY),Sanofi (NASDAQ:SNY) announces that the global Phase 3 trial investigating Kevzara (sarilumab) at a dose of 200 mg or 400 mg in severely or critically ill C,SAN,en,Seeking Alpha
2020-09-01 04:04:00-05:00,"World Coronavirus Dispatch: US crosses six mn mark, cases in sun belt ease","WHO warns against opening up without control of Covid, Hong Kong begins mass testing, Sanofi's Kevzara drug fails as possible treatment and other pandemic-related news across the globe",SAN,en,Business Standard
2020-09-01 03:03:08-05:00,"Sanofi, Regeneron Rheumatoid Arthritis Drug Proves Ineffective Against COVID-19","Sanofi SA (NASDAQ: SNY ) announced Tuesday that its rheumatoid arthritis drug Kevzara, developed in partnership with Regeneron Pharmaceuticals Inc. (NASDAQ: REGN ), isn't effective against COVID-19. What Happened: The global Phase 3 trial involving the administration of the drug to severely- or critically-ill hospitalized patients didn't meet its “primary endpoint,” the drugmaker said in a statement . No statistically significant shortening of hospitalization was observed in the 420 people trial conducted in multiple countries outside the United States, according to the French drugmaker. “Although this trial did not yield the … Full story available on Benzinga.com",SAN,en,Benzinga
2020-09-01 02:55:00-05:00,Sanofi-Mittel Kevzara verfehlt Endpunkte in COVID-19-Studie - Aktie dennoch fester,"Eine Phase-3-Studie zur Untersuchung des Einsatzes des Arthritis-Medikamentes Kevzara bei schwer oder kritisch kranken Patienten habe ihren primären Endpunkt und den wichtigsten sekundären Endpunkt nicht erreicht, teilte die Sanofi SA mit. Die randomisierte…",SAN,de,Finanzen AT
2020-09-01 01:40:57-05:00,Sanofi halts trial of Covid-19 drug after tests,…,SAN,en,RTL Today
2020-08-31 18:01:11-05:00,Santander vai leiloar 20 imóveis retomados,"O Santander (SANB11) colocará em leilão 20 imóveis retomados por inadimplência em contratos de alienação fiduciária. Sob responsabilidade da Frazão Leilões, o evento será dividido em duas partes. O primeiro leilão, que terá 12 imóveis (casas, apartamentos e salas comerciais), está previsto para acontecer amanhã (1º), às 14h30. Os empreendimentos estão localizados em Espírito Santo, […]",SAN,pt,Money Times
2020-08-31 17:26:21-05:00,"Varejista Le Biscuit, Farmácias Nissei e loteadora Urba protocolam prospecto para IPO","Três novas companhias protocolaram na Comissão de Valores Mobiliários (CVM) prospectos preliminares para a realização de ofertas públicas iniciais de ações (IPO, na sigla em inglês). As mais novas candidatas na lista de abertura de capital são a varejista baiana Le Biscuit, a rede de farmácias paranaense Nissei e a loteadora mineira Urba, que é uma subsidiária da construtora MRV. A oferta da Le Biscuit será primária - quando os recursos vão para o caixa da empresa - e secundária, quando acionistas atuais vendem parte das suas fatias. Além de uma plataforma digital, a varejista tem 136 lojas próprias e 5 franquias, que totalizam aproximadamente 140 mil metros quadrados de área de vendas, localizadas em 14 Estados. Teve receita de R$ 770 milhões em 2019, com lucro de R$ 13 milhões. Varejista baiana Le Biscuit é uma das três novas companhias à caminho da bolsa de valores Divulgação A Le Biscuit pretende utilizar os recursos da oferta primária para pré-pagamento de dívidas; investimentos em retrofits e expansão de suas lojas físicas; investimentos em TI, omnicanalidade e logística; e reforço de capital de giro.",SAN,pt,Valor Econômico
2020-08-31 14:18:59-05:00,Sánchez «se olvida» de la asociación mayoritaria de los autónomos en su acto por la unidad,"La conferencia que el presidente del Gobierno Pedro Sánchez ha pronunciado esta mañana en Casa América, en la que ha apelado numerosas veces a la unidad y asegurado que sus ministros ya trabajan en un plan que impulse el crecimiento de la economía por encima del 2%, ha tenido un importante ausente: ATA (Federación Nacional de Trabajadores Autónomos), la asociación mayoritaria entre los autónomos, que presidente Lorenzo Amor. Todo ello, en un acto en el que Sánchez se ha rodeado de empresarios, sindicatos y las principales organizaciones agrarias. En concreto, en Casa América han estado presentes el presidente de la CEOE, Antonio Garamendi; la presidenta del Banco Santander, Ana Botín; el presidente de Repsol, Antonio Brufau; el presidente de BBVA, Carlos Torres Vila; el presidente y director ejecutivo de Inditex, Pablo Isla; los secretarios generales de UGT y CCOO, Pepe Álvarez y Unai Sordo; el presidente de Asaja Pedro Barato; el presidente de la Unión de Pequeños Agricultores y Ganaderos (UPA), Lorenzo Ramos Silva; el secretario general de la Organización de profesionales y autónomos (UPTA), Eduardo Abad, entre otros En declaraciones a ABC, Amor ha asegurado que no habían sido invitados a este evento y apuntado que «quien estaba convocando este acto estaría más preocupado por convocar a lo que son los grandes portaviones de la economía y se ha olvidado de la infantería empresarial», en referencia a un colectivo cuya principal organización forma parte de la CEOE.",SAN,es,ABC Spain
2020-08-31 11:52:18-05:00,Pharmaceutical Companies Are Doing Much More Than Battling COVID-19,"The merger of Pfizer's Upjohn business with Mylan NV (NASDAQ: MYL ), along with the potential of its COVID-19 vaccine candidate that it's developing with BioNTech, makes Pfizer a potential winner during COVID-19. Yet, Sanofi SA (NASDAQ: SNY ) is considered by many to be the closest to developing the vaccine. Last Friday, Paul Hudson said in an interview that early data further increased its confidence. Back in July, the company announced it is 70% more likely to create an efficient vaccine than its rivals, in part, due to its experience in vaccines. But also last week, the EU announced it will only partially cover vaccine makers against legal risks from potential side-effects. The Good-Side Of Pharmaceuticals Several big pharma companies are collectively investing close to $1 billion to help smaller biotechs. In July, over 20 top drugmakers announced the launch of the AMR Action Fund. Key investors in the AMR Action Fund include Dow Jones members Pfizer Inc. (NYSE: PFE ), Merck & Co., Inc. (NYSE: MRK ) and Johnson & Johnson (NYSE: JNJ ), but also Roche Holdings (OTC: RHHBY ) and Eli Lilly And Co (NYSE: LLY ).",SAN,en,Benzinga
2020-08-31 10:42:08-05:00,El Ibex 35 pierde la cota de los 7.000 puntos y cierra agosto con unas pérdidas similares a las de julio,"El Ibex 35 ha cerrado el mes de agosto con pérdidas muy similares a las de julio, tras caer en la última jornada del mes más de un 2% y dejarse la cota de los 7.000 puntos por el camino. En una sesión en que la banca, con fuerte peso en el selectivo ha registrado fuertes caídas: BBVA (-5,73%), Bankia (-2,85%), Banco Sabadell (-1,75%), CAixabank (-3%), Bankinter (-2,9%) y Banco Santander (-4,79%)",SAN,es,ABC Spain
2020-08-31 09:02:13-05:00,Dr. Fauci says this is when we might know if our first coronavirus vaccine works,"An answer about coronavirus vaccine safety and efficacy might be available as soon as November, Dr. Anthony Fauci said in a new interview. He made it clear that vaccines should not be approved for emergency use until they’re proven to be safe and effective. The comments follow several recent updates in the world of COVID-19 vaccine candidates. Russia approved a drug for public use without revealing any scientific data, and China has started using three vaccines under emergency programs. Separately, rumors said President Trump may pressure the FDA into giving emergency approval to at least one COVID-19 vaccine before the election. Vaccine research for the novel coronavirus has advanced at a tremendous pace this year, with more than 170 experimental drugs already being tested to see whether they can prevent COVID-19. Of those, at least six are in the final stage of development, and another one has been approved for use in Russia even though no one knows if it actually works . Three of the six Phase 3 vaccine candidates were developed in China, and they’re all being used on volunteers outside of Phase 3 trials.",SAN,en,BGR
2020-08-31 08:17:35-05:00,El Ibex arropa a Sánchez en el incio del curso político,"Las grandes personalidades del mundo empresarial y del Ibex 35 han arropado al presidente del Gobierno, Pedro Sánchez , en la apertura del primero curso político de la era 'post covid' . Los máximos dirigentes de los buques insignia de la economía española, como Ana Botín (Banco Santander), José Ignacio Sánchez Galán (Iberdrola) o Pablo Isla (Inditex), han acudido este lunes a escuchar el discurso de Sánchez en la Casa América de Madrid . Del acto también han participado líderes del mundo patronal y sindical, así como representantes de entidades del tercer sector, como ONGs o asociaciones de consumidores. También han sido invitadas personalidades del mundo del cine, el teatro o la música. Seguir leyendo… .",SAN,es,El Periodico
2020-08-31 05:36:00-05:00,Banco Santander y Cámara de Albacete lanzan la cuarta edición del Premio Pyme del Año,"Las empresas interesadas podrán presentar las candidaturas a través de la página web de la Cámara Albacete desde el 1 de septiembre hasta el 16 de octubre Además del ganador, se concederán cuatro accésits: Internacionalización, Innovación y Digitalización, Formación y Empleo, y Empresa Responsable Con carácter extraordinario, se ha incluido en esta edición una mención…",SAN,es,La Cerca
2020-08-30 16:07:56-05:00,El Gobierno rebaja el tono contra las empresas ante un fin de año aciago,"Gobernar, por momentos, de espaldas a los empresarios y a los autónomos ha deparado a Pedro Sánchez unos meses de pandemia sin consensos amplios. Cada paso requería de días de negociación o, en el peor de los casos, de medidas unilaterales. La situación llegó a ser insostenible con la CEOE. Pero el jefe del Ejecutivo, si algo ha demostrado estos años, es que es un político camaleónico. Por ello ha mutado su estrategia con el tejido productivo en esta última semana de agosto: ahora, mano tendida y rebaja en el tono de sus ministros para escenificar unidad y capacidad de entendimiento. Sabedor, también, de que se avecina un fin de año turbulento tras el rebrote de la pandemia y para el que necesitará el apoyo empresarial. Hoy tiene lugar el primer día del nuevo curso económico –aunque aún sea agosto– con un discurso de Sánchez ante los primeros espadas del Ibex en Madrid. No hay lista de invitados anunciada, pero ABC ha podido saber que al menos la banca, con la que ha tenido sus rifirrafes estos meses, estará bien representada: irán los presidentes de Banco Santander (Ana Botín), BBVA (Carlos Torres), Bankia (José Ignacio Goirigolzarri), etc…",SAN,es,ABC Spain
2020-08-28 21:56:00-05:00,"Sanofi more confident about its coronavirus vaccines, trials next month",The company is working on two of the more than 150 potential vaccines being developed across the world to tackle the Covid-19 pandemic,SAN,en,Business Standard
2020-08-28 13:09:06-05:00,Exclusive: Sanofi more confident about its coronavirus vaccines,"Sanofi's confidence in its coronavirus vaccine candidates has increased this summer as the French drugmaker prepares to start clinical trials, its chief executive told Reuters.",SAN,en,Reuters India
2020-08-28 08:21:06-05:00,Dynamo venderá ações da HBR Realty em IPO; Aeris registra oferta,"Plataforma de propriedades urbanas e fabricante de pás eólicas encaminharam pedidos à CVM na quinta-feira A HBR Realty registrou na quinta-feira (27) pedido de oferta pública inicial de ações (IPO) na Comissão de Valores Mobiliários (CVM), em operação primária (quando os recursos vão para o caixa da empresa) e secundária (quando acionistas atuais vendem seus papéis). Os acionistas vendedores na tranche secundária serão os controladores Hélio Borenstein e a gestora Dynamo, por meio de seu fundo Tierra FIP. Parte do Grupo Hélio Borenstein, a HBR atua em renda imobiliária e se define como uma plataforma de propriedades urbanas com forte presença em São Paulo. Ao fim de junho, a companhia detinha 30 propriedades de renda em seu portfólio de ativos. A estratégia da companhia é alocar recursos em centros de conveniência, lajes corporativas de alto padrão, shoppings centers e gestão de ativos de fundos imobiliários. Pela característica de seu negócio, o retorno supera o faturamento. No ano passado, a receita líquida foi de R$ 68 milhões, ante R$ 57 milhões em 2018, e o lucro líquido foi de R$ 278,5 milhões, alta sobre os R$ 191,6 milhões do ano anterior.",SAN,pt,Valor Econômico
2020-08-27 14:32:36-05:00,"“E agora, Brasil?” debate desafios da reforma tributária; veja na integra","Ana Paula Vescovi, Bernardo Appy, Fabio Pina e Vanessa Canado levantaram impactos que nova legislação pode ter para a economia do Brasil Urgente ao desenvolvimento do país, a reforma tributária foi tema da segunda edição deste ano do “E Agora, Brasil?”, realizada neste 26 de agosto. Os especialistas reunidos no debate discutiram por duas horas os reflexos econômicos da legislação fiscal em debate no Congresso Nacional. O evento é uma realização dos jornais O Globo e Valor Econômico, com patrocínio do Sistema de Comércio, através da CNC, do Sesc, do Senac e de suas Federações. Participaram desta edição: Vanessa Canado, assessora especial do Ministério da Economia, Bernard Appy, diretor do Centro de Cidadania Fiscal, Ana Paula Vescovi, economista-chefe do Banco Santander, e Fábio Pina, economista e consultor nas áreas de comércio e serviços. A mediação ficou por conta de Miriam Leitão, colunista do GLOBO, e Ribamar Oliveira, articulista do Valor. Por conta da pandemia de covid-19, o evento foi realizado pela segunda vez no formato webinar, com transmissão ao vivo nos perfis do GLOBO e Valor no Youtube, Facebook e Linkedin.",SAN,pt,Valor Econômico
2020-08-27 08:46:55-05:00,Sanofi plans to start human testing of COVID-19 vaccine next week - Bloomberg (NASDAQ:SNY),"""Sanofi (NASDAQ:SNY) expects to move to a large late-stage trial with an experimental coronavirus vaccine toward the end of the year,"" said CEO Paul Hudson",SAN,en,Seeking Alpha
2020-08-25 14:13:53-05:00,"Translate Bio, Sanofi COVID-19 vaccine candidate produces immune response in animal studies","Translate Bio Inc said on Tuesday that an experimental coronavirus vaccine it developed with French drugmaker Sanofi SA induced immune response in non-human studies, with trials in humans expected to start in November.",SAN,en,Reuters
2020-08-25 07:40:22-05:00,Incorporadora gaúcha CFL protocola prospecto de IPO,"Oferta será primária e secundária; empresa pretende usar recursos para incorporação de empreendimentos, aquisição de terrenos e custos de construção A incorporadora gaúcha CFL Inc Par protocolou na Comissão de Valores Mobiliários (CVM) o prospecto preliminar para uma oferta pública inicial de ações (IPO, na sigla em inglês). A oferta será primária - quando os recursos vão para o caixa da empresa - e secundária, quando acionistas atuais vendem parte de sua fatia. A CFL foi fundada em 1993 por Péricles Pretto Corrêa e seu filho Luciano Bocorny Corrêa. A companhia atua principalmente em Porto Alegre, Florianópolis e Caxias do Sul. No primeiro semestre de 2020, teve receita operacional líquida de R$ 42 milhões, com lucro de R$ 11,3 milhões. A incorporadora diz ter um banco de terrenos com valor geral de vendas (VGV) potencial de R$ 2,65 bilhões. A companhia é controlado por Luciano Bocorny (70,6%), Marcelo Schiavon (12,2%), Richard Gerdau Johannpeter (9,8%) e outros minoritários (7,4%). A empresa pretende utilizar os recursos líquidos provenientes da oferta primária para incorporação de empreendimentos, aquisição de terrenos e custos de construção.",SAN,pt,Valor Econômico
2020-08-24 03:00:51-05:00,"Com mais acionistas pessoas físicas, bancos reveem comunicação","Lives com investidores, relatórios enxutos e mudança nas áreas de RI entram no radar das instituições financeiras, que viram crescer suas bases de investidores O diretor de relações com investidores do Bradesco, Leandro Miranda, encerrou a maratona de divulgação do balanço do segundo trimestre comentando os resultados do banco em uma “live” para 10 mil participantes. Àquela altura do dia, o executivo já havia participado de teleconferências com jornalistas e analistas e de reuniões com fundos. Mas faltava falar com um público que tem peso crescente na base acionária da instituição financeira: a pessoa física. Foi a primeira vez que o Bradesco fez um evento desse tipo, uma resposta ao crescimento de quase 60% no número de acionistas pessoa física do banco na primeira metade deste ano. “Antigamente, não tínhamos com esse público a mesma atenção e sofisticação que tínhamos no relacionamento com investidores institucionais”, reconhece Miranda. “Agora, estamos fazendo um esforço para ter mais contato.” A mudança vem a reboque do salto no número de CPFs registrados na B3, que chegou a 2,8 milhões no fim de julho.",SAN,pt,Valor Econômico
2020-08-22 18:36:52-05:00,"Los fondos soberanos, mucho más que inversión","El informe «Sovereign Wealth Funds 2019» estima que hay 94 fondos soberanos en el mundo. Tras el de Noruega se sitúan el «China Investment Corporation» (940.600 millones de dólares), el «Abu Dhabi Investment Authority» (ADIA, 745.000 millones) y el también chino «State Administration of Foreign Exchange» (690.000 millones de dólares). En opinión de Cano (AFI) «lo que busca un fondo soberano es ahorrar: tiene una visión macroeconómica» y lo considera una buena herramienta si su gestión es profesionalizada. Todo ello, contando una cartera diversificada. Sin embargo, reconoce que su actividad puede crear suspicacias si entran en compañías estratégicas. En su opinión, sobre la labor de los fondos soberanos hay «quienes le suponen un objetivo geoestratégico» y, como ejemplo, cita la negativa de varios gobierno durante la anterior crisis a que este tipo de inversores participaran en el rescate de las entidades financieras y, sobre España, menciona las dudas que generó la participación de Qatar Investment Authority (QIA) en Iberdrola (8,69%) A su juicio, este no es el caso del Fondo Noruego de Pensiones. «Noruega es una democracia parlamentaria, los gestores rinden cuentas y el objetivo es una cartera muy diversificada: el petróleo se va a acabar tarde o temprano, cuando eso pase tendrán para pagar su estado de bienestar», ha apuntado.",SAN,es,ABC Spain
2020-08-22 05:11:44-05:00,Ronaldo Nazario se aisla por haber estado con un positivo aunque su test fue negativo,"El presidente del Real Valladolid, Ronaldo Nazario, está aislado voluntariamente junto a su familia después de que haya estado en contacto con una persona que dio positivo en Covid-19 aunque él ha dado negativo en su test, según ha comunicado el brasileño en una de sus redes sociales. Esta circunstancia ha propiciado que Ronaldo haya tenido que aplazar su presencia, que estaba prevista para esta tarde, en un acto de la Champions League. En una historia de su cuenta de Instagram, el presidente del club vallisoletano ha escrito: «En colaboración con el Banco Santander España y algunos medios de comunicación deportivos, habíamos organizado, con motivo de la final de la Liga de Campeones, un encuentro con los ganadores de una promoción del banco, la acción consistía en recibir a estas personas en mi casa para presenciar juntos el partido entre PSG y Bayern». El comunicado subraya que «a lo largo de esta semana, recibí la noticia de que una persona, con la que tanto yo como mi familia tuvimos contacto, resultó positivo en una prueba de Covid-19 e inmediatamente, también nosotros pasamos los correspondientes test, que han sido negativos, pero preferimos evitar este evento con las personas agraciadas, siguiendo las recomendaciones de las autoridades sanitarias de España y, por esta razón, de acuerdo con Banco Santander, quiero expresar mi sentimiento al anunciar la cancelación de mi concurso en esta acción», recoge Efe.",SAN,es,ABC Spain
2020-08-21 02:28:00-05:00,"Sanofi India gains 5%, hits 52-week high; stock soars 8% so far in August","Read more about Sanofi India gains 5%, hits 52-week high; stock soars 8% so far in August on Business Standard. Early this week, the comany's parent firm Sanofi said it will acquire all of the outstanding shares of US-based Principia Biopharma Inc. for a total approximate aggregate equity value of $3.68 billion",SAN,en,Business Standard
2020-08-20 15:51:58-05:00,Santander libera crédito de R$ 350 milhões a lojistas de shoppings da brMalls,"A brMalls (BRML3) e o Santander Brasil (SANB11) firmaram uma parceria para ajudar os lojistas dos 26 empreendimentos administrados pela operadora de shopping centers durante a pandemia de covid-19. ""Mesmo com a retomada gradual e consciente do varejo, os impactos provocados pela covid-19 ainda serão sentidos no curto e médio prazo. Diante disso, é fundamental […]",SAN,pt,Money Times
2020-08-20 11:05:07-05:00,Banco Santander S A : 18/08/2020 - Cierre de Mercados | MarketScreener,"CIERRE DE MERCADOS 18/08/2020 SAN … | August 20, 2020",SAN,en,MarketScreener
2020-08-20 10:50:00-05:00,"PRINCIPIA BIOPHARMA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Principia Biopharma Inc. - PRNB","NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Principia Biopharma Inc. (NasdaqGS: PRNB) to Sanofi (NasdaqGS: SNY). Under the terms of the proposed transaction, shareholders of Principia will receive only $100.00 in cash for each share of Principia that they own. KSF is seeking to determine whether this consideration and the process that led to it are adeq",SAN,en,Business Wire
2020-08-20 04:00:00-05:00,"Dermatologists Are Extremely Satisfied with Sanofi/Regeneron's Dupixent in Atopic Dermatitis, Though the Brand Leaves Certain Patient Segments Untapped: Will JAK Inhibitors Be the One to Fill the Gap?","EXTON, Pa., Aug. 20, 2020 /PRNewswire/ -- Atopic dermatitis (AD), commonly referred to as eczema, affects millions of patients across the globe. In 2017, Sanofi/Regeneron's Dupixent, an IL-4/13 blocker, became the first commercially available biologic to treat adults with moderate to…",SAN,en,PR Newswire
2020-08-19 04:16:39-05:00,"Once Slow, Stable SNY Stock is Now Pharma's Most-Talked About Name",Sanofi CEO Paul Hudson prefers growth and capital gains to reliable SNY stock dividends. Investors are taking notice.,SAN,en,InvestorPlace
2020-08-18 09:49:00-05:00,"Sanofi acquista Principia Biopharma per 3,68 MLD di dollari",No summary available.,SAN,en,Quotidiano Libero
2020-08-18 09:42:00-05:00,Sanofi Is Buying Principia Biopharma for $3.7 Billion. Why Wall Street Is Cheering the Deal.,"The French drugmaker Sanofi’s $3.7 billion acquisition of the biotech Principia Biopharma is good news for Sanofi stock, Wall Street has determined.",SAN,en,Barron's
2020-08-18 05:32:05-05:00,SANOFI : Gets a Buy rating from UBS | MarketScreener,"Laura Sutcliffe from UBS retains his positive opinion on the stock with a Buy rating. The target price remains unchanged at EUR 100. | August 18, 2020",SAN,en,MarketScreener
2020-08-17 21:56:00-05:00,Sanofi begins M&A spree; to purchase Principia Biopharma at $3.7 billion,"The French group already owns the licensing rights to Principia's key multiple sclerosis drugs, which should give it a clearer view on its prospects",SAN,en,Business Today
2020-08-17 17:35:37-05:00,Banco Santander consolida One Pay FX: servicio de transferencias internacionales basado en blockchain,https://es.investing.com/news/cryptocurrency-news/banco-santander-consolida-one-pay-fx-servicio-de-transferencias-internacionales-basado-en-blockchain-2029099,SAN,es,Investing.com Spain
2020-08-17 12:35:00-05:00,"PRINCIPIA ALERT: Bragar Eagel & Squire, P.C. Investigates Sale of PRNB and Encourages Investors to Contact the Firm","NEW YORK--(BUSINESS WIRE)-- #Acquisition--Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, has launched an investigation into whether the board members of Principia Biopharma Inc. (NASDAQ: PRNB) breached their fiduciary duties or violated the federal securities laws in connection with the company’s acquisition by Sanofi (NASDAQ: SNY). Click here to learn more and participate in the action. On August 17, 2020, Principia announced that it had signed an agreement to be acquir",SAN,en,Business Wire
2020-08-17 11:39:35-05:00,Santander coloca 22 imóveis residenciais de São Paulo para leilão,"O Santander Brasil (SANB11) leiloará no dia 26 de agosto 22 imóveis residenciais localizados em São Paulo. Os empreendimentos disponíveis para lances no site da Frazão Leilões são casas e apartamentos distribuídos em 19 regiões diferentes do estado. Com taxa anual de 6,99%, os imóveis podem ser financiados em até 420 meses. Na capital de […]",SAN,pt,Money Times
2020-08-17 09:26:00-05:00,Sanofi Stock Is Rising Following a $3.7 Billion Deal for a U.S. Biotech Firm,The French pharmaceutical giant is digging into the cash it amassed earlier this year with the sale of its $11.7 billion stake in Regeneron.,SAN,en,Barron's
2020-08-17 09:24:00-05:00,France's Sanofi SA to buy US-based Principia Biopharma for $3.7 billion,"The deal will strengthen Sanofi's research capabilities in areas such as autoimmune and allergic diseases, the companies said",SAN,en,Business Standard
2020-08-17 07:20:34-05:00,Sanofi to Purchase US Based Principia Biopharma for $3.68 Billion,French healthcare giant Sanofi is set to purchase U.S.-based company Principia Biopharma in a deal worth $3.68 billion.,SAN,en,Coinspeaker
2020-08-17 06:00:00-05:00,French healthcare company Sanofi to acquire Principia Biopharma for $3.7bn,"French healthcare company Sanofi SA is to buy US company Principia Biopharma Inc for around $3.7bn, the companies both said, bolstering Sanofi’s presence in research and development areas Read More…",SAN,en,Capital Com
2020-08-17 04:09:00-05:00,Sanofi comprará Principia Biopharma por 3.110 millones,"Sanofi abonará 100 dólares en efectivo por cada acción de Principia Biopharma, lo que representa una prima del 10% respecto al precio de cierre de los títulos de la empresa del viernes",SAN,es,El Confidencial
2020-08-17 03:25:17-05:00,Sanofi to Buy Principia Biopharma in $3.4 Billion Deal,Aug.17 -- Sanofi has agreed to acquire Principia Biopharma Inc. in a $3.4 billion deal. The move comes as the French drug maker pivots toward innovative therapies to spur growth. The all-cash deal will see Sanofi taking full control of the U.S. autoimmune drug maker. Bloomberg’s James Paton reports on “Bloomberg Markets: European Open.”,SAN,en,Yahoo Finance
2020-08-17 03:14:18-05:00,Sanofi To Purchase Immune System-Focused Drugmaker Principia Biopharma For $3.7B,"Sanofi SA (NASDAQ: SNY ) will acquire Principia Biopharma Inc (NASDAQ: PRNB ) for $3.68 billion in cash, the two companies announced Monday. What Happened Under the agreement, the French drugmaker will purchase all of Principia’s outstanding shares at $100 each, in cash. The boards of the two companies have given their approval for the transaction, the drugmakers said. The two companies have been cooperating on autoimmune diseases, specifically, a multiple sclerosis treatment termed ""BTK inhibitor ‘168,"" … Full story available on Benzinga.com",SAN,en,Benzinga
2020-08-17 02:57:42-05:00,Sanofi announce $3.7bn deal to acquire US-based Principa Biopharma,French pharma giant Sanofi has agreed to purchase Principa Biopharma in a deal that will be worth $3.7bn.,SAN,en,SiliconRepublic
2020-08-17 02:11:02-05:00,Sanofi : to Acquire US Company Principia Biopharma for $3.68 Billion -- Update | MarketScreener,"--Sanofi will acquire Principia Biopharma for an enterprise value of about $3.36 billion --The move will strengthen Sanofi's R&D areas of autoimmune and allergic diseases --The deal is… | August 17, 2020",SAN,en,MarketScreener
2020-08-17 01:08:01-05:00,Sanofi : Correction to Sanofi Article | MarketScreener,"Sanofi has agreed to buy Principia Biopharma Inc. for a total enterprise value of roughly $3.36 billion, and an equity value of $3.68 billion. Sanofi to Acquire US Company Principia Biopharma for… | August 17, 2020",SAN,en,MarketScreener
2020-08-17 00:52:01-05:00,Sanofi : to Acquire US Company Principia Biopharma for $3.68 Billion | MarketScreener,"By Cecilia Butini Sanofi SA said Monday that it entered into a definitive agreement for the acquisition of U.S.-based biopharmaceutical company Principia Biopharma Inc. for a total… | August 17, 2020",SAN,en,MarketScreener
2020-08-14 07:43:27-05:00,European Commission: First Agreement on a Potential Vaccine Against COVID-19,"Today, the European Commission has reached a first agreement with the pharmaceutical company AstraZeneca to purchase a potential vaccine against COVID-19 as well as to donate to lower and middle income countries or re-direct to other European countries. This is following the positive steps regarding the conclusion of exploratory talks with Sanofi-GSK announced on 31 July and with Johnson & Johnson on 13 August. Once the vaccine has proven to be safe and effective against COVID-19, the Commission now has agreed the basis for a contractual framework for the purchase of 300 million doses of the AstraZeneca vaccine, with an option to purchase 100 million more, on behalf of EU Member States. The Commission continues discussing similar agreements with other vaccine manufacturers. Ursula von der Leyen, President of the European Commission, said: “ The European Commission's intense negotiations continue to achieve results. Today's agreement is the first cornerstone in implementing the European Commission's Vaccines Strategy.",SAN,en,Novinite
2020-08-13 23:32:20-05:00,Trump impulsa la I+D de la vacuna con 10.000 millones en ayudas y contratos,"EE UU se garantiza millones de dosis de los proyectos experimentales Moderna, Pfizer, AstraZeneca, GSK, Sanofi y Janssen, entre los laboratorios beneficiados",SAN,es,Cinco Dias El Pais
2020-08-13 22:00:00-05:00,La banca marca el camino: ahorra 1.400 M por el confinamiento y los últimos ERE,"Minimizar daños y reducir gastos. Son las dos únicas fórmulas que tienen a mano los banqueros para sobrevivir a la crisis del covid-19 . Respecto a la primera han anticipado provisiones , pero todavía no saben cómo de grande va a ser el agujero. Con el ahorro de costes sí que hay avances y resultados: casi 1.400 millones menos de gastos de empleado y generales, un 5,8% , en apenas seis meses. Así, los gastos generales de los grandes bancos españoles —los 12 supervisados por el BCE— bajaron de 24.017 millones a 22.620 millones en la primera mitad del año. El confinamiento y los grandes ajustes de plantilla de Santander y CaixaBank en 2019 están detrás de esta tendencia, que como han explicado los banqueros en las últimas semanas ha venido para quedarse. Todas las entidades están estudiando cómo trasladar los ahorros del confinamiento a su práctica habitual , ya sea cerrando oficinas o con otro tipo de medidas destinadas a sus servicios centrales. No hay ajustes planteados actualmente para las plantillas, pero se esperan para 2021.",SAN,es,El Confidencial
2020-08-13 17:33:45-05:00,EU to Buy 200 Million Doses of the Potential COVID-19 Vaccine From Johnson & Johnson,"The European Commission has concluded exploratory talks with Johnson & Johnson to buy 200 million doses of a potential COVID-19 vaccine, the EU executive and the U.S. pharmaceutical company said on Thursday. The EU executive arm said this paved the way for contractual talks and the possible purchase of the vaccine on behalf of all 27 EU states once it has proven safe and effective. The commission also said it could purchase an additional 200 million vaccine doses. Johnson & Johnson, through its Belgian subsidiary Janssen, “will now enter into contract negotiations with the European Commission,” J&J said in a statement, confirming the volumes indicated by the Commission. “If regulatory approval for the company’s vaccine is received, the Commission would be expected to facilitate a process for allocation of the vaccine doses among the member states,” Johnson & Johnson said. J&J could produce up to 1 billion doses of its vaccine by the end of 2021, a company executive told Reuters on Tuesday.",SAN,en,Novinite
2020-08-12 07:17:46-05:00,"La vacuna llegará a Italia en diciembre, pero se debate sobre la obligatoriedad","Las primeras vacunas, nacidas gracias a la colaboración de una empresa italiana, Irbm, y la Universidad de Oxford , que serán producidas y distribuidas por AstraZeneca, serán inyectadas, como muy tarde, a primeros de diciembre en Italia , según los planes del gobierno italiano. En mayo, Italia estableció una alianza con Alemania, Francia y Holanda, firmando con AstraZeneca un contrato para tener la garantía de recibir 400 millones de dosis . Después de esta iniciativa se han dado nuevos pasos, según ha explicado el ministro de Sanidad, Roberto Speranza: «La Comisión europea está negociando con otras empresas - Sanofi, Pfizer, Johnson - para aumentar la asignación de 400 millones de dosis garantizadas, que se destinarán a toda la población europea». Según el ministro Speranza, «los primeros 60 millones llegarán a Europa en 2020» . Pero al principio a Italia podrían corresponderle algo más de tres millones. Las dosis no llegarán todas juntas, según aclara el ministro de Sanidad: «Esperamos que las primeras lleguen antes de fin de año.",SAN,es,ABC Spain
2020-08-11 21:41:00-05:00,"Nifty outlook and stock pick by HDFC Sec: Buy UltraTech Cement, Sanofi","Read more about Nifty outlook and stock pick by HDFC Sec: Buy UltraTech Cement, Sanofi on Business Standard. NIfty has been forming higher tops and higher bottoms on the daily charts. Nifty is placed above 20,50,100 and 200 days moving averages, indicating bullish trend on all time frames",SAN,en,Business Standard
2020-08-11 11:25:00-05:00,"Insulin Pens Market and COVID-19 Impact Assessment 2020-2030 Featuring Novo Nordisk, Eli Lilly & Co, Sanofi and Ypsomed - ResearchAndMarkets.com","DUBLIN--(BUSINESS WIRE)--The ""Insulin Pens (Diabetes Care Devices) - Global Market Analysis and Forecast Model (COVID-19 market impact)"" report has been added to ResearchAndMarkets.com's offering. The market model is built to visualize quantitative market trends within Diabetes Care Devices therapeutic area. This model discusses in detail the impact of COVID-19 on Insulin Pens market for the year 2020 and beyond. Each of the covered 39 country's color-coded and fully-sourced market models are e",SAN,en,Business Wire
2020-08-11 03:37:24-05:00,80% return in 95 sessions! Analysts say this Dark Horse has miles to run,"The pharma sector emerged the dark horse in the ruins of the Covid-19 destruction on Dalal Street, and the BSE Healthcare index rallied some 80 per cent in 95 sessions to hit an all-time high of 19,720 on August 10 rising from its 52-week low of 10,948 hit on March 23.Increased demand for pharma goods amid the health emergency, better-than-expected June quarter earnings and the government’s push to reduce the country’s dependency on imports for active pharmaceutical ingredient (API) played their part in driving the rally.Some 117 stocks from the sector delivered an average return of 126 per cent during this period, with Bharat Immunological & Biologicals gaining the most at 490 per cent.It was followed by IOL Chemicals (up 410 per cent), Aarti Drugs (up 402 per cent), Marksans Pharma (up 364 per cent) and Venus Remedies (up 312 per cent). Other stocks on the list all delivered positive returns. “Prior to Covid, pharma was under-owned. It was a sector which did nothing for five years, and everyone was underweight on these stocks.",SAN,en,Economic Times India
2020-08-10 09:00:00-05:00,"Bayer Names Lori Moore as Vice President, Head of U.S. Pharmaceutical Communications","WHIPPANY, N.J.--(BUSINESS WIRE)--Lori Moore, former Managing Director at Deloitte, will be joining Bayer as Vice President, Head of Pharmaceutical Communications in the United States, the company announced today. Moore spent the last six years in senior communications roles at Deloitte, most recently as the Managing Director leading efforts to transform internal communications. Prior to joining Deloitte, Moore served in communications leadership positions at Novo Nordisk and Sanofi. In her new",SAN,en,Business Wire
2020-08-10 00:14:40-05:00,"Las seis noticias que debes conocer hoy, lunes 10 de agosto","1. Ninguna administración del PP entregará «un euro» del «ahorro de los vecinos». La rebelión de los alcaldes empieza a tomar forma contra el polémico acuerdo alcanzado por el Ejecutivo con la Federación Española de Municipios y Provincias (FEMP), en virtud del cual los ayuntamientos que cedan su superávit al Gobierno (15.000 millones) podrán acceder a un fondo de 5.000 millones entre 2020 y 2021, independientemente del dinero cedido, que le será devuelto en quince años. Pero el primer paso para esta insumisión total lo dará hoy el Partido Popular. El vicesecretario de Territorial de esta formación política, Antonio González Terol, que coordina esta ofensiva ha convocado en Madrid a unos 125 alcaldes y portavoces de ayuntamientos de mas de 20.000 habitantes gobernados por los populares, a los que les dará una instrucción muy clara: ninguna administración gobernada por el partido que preside Pablo Casado entregará un solo euro a las arcas de la Hacienda Púbica, según han confirmado a ABC fuentes de esta formación política. 2.",SAN,es,ABC Spain
2020-08-09 18:00:58-05:00,Gobierno y banca trabajan en un plan de compra de vivienda para jóvenes,"Ana Botín propone y el Gobierno recoge el guante. Más tarde que pronto, pero lo hace. La presidenta de Banco Santander planteó hace más de dos meses un nuevo plan de compra de vivienda para jóvenes que ya se está estudiando. Las conversaciones entre el Ejecutivo de Pedro Sánchez y la banca están en marcha para convertir lo que al principio parecía una idea al aire en una propuesta sobre el papel, según confirman fuentes financieras a ABC. «Los jóvenes fueron los grandes perdedores de la última crisis», afirmó la banquera en la macrocumbre empresarial de CEOE a mediados de junio. Fue de las únicas que lanzó de entre los primeros espadas de las entidades financieras un planteamiento al Gobierno. Entonces,… Ver Más",SAN,es,ABC Spain
2020-08-08 22:00:00-05:00,Las alfombras del Ibex y el rey emérito: el fin de una era,"Empresas como Banco Santander, La Caixa, Telefónica, Abengoa, OHL e Iberdrola conocen bien las andanzas de don Juan Carlos, al que obsequiaron para engordar su fortuna personal",SAN,es,El Confidencial
2020-08-07 10:30:03-05:00,"Pharma Stock Roundup: ABBV, MRK Q2 Earnings & Coronavirus Updates in Focus",Sanofi (SNY)/Glaxo (GSK) and J&J (JNJ) sign deals with U.S. government for coronavirus vaccine candidate. Several drugmakers announce second-quarter results.,SAN,en,Yahoo Finance
2020-08-06 13:44:08-05:00,Lucro líquido dos grandes bancos cai 40% no segundo trimestre de 2020,"Acumulado foi de R$ 12,1 bilhões contra R$ 20,4 bilhões no mesmo período de 2019. O lucro líquido conjunto dos grandes bancos brasileiros no segundo trimestre deste ano foi 40% menor do que em mesmo período de 2019, aponta levantamento da consultoria Economatica. Os números foram apresentados nos últimos dias, em divulgação de resultados de Banco do Brasil, Bradesco, Itaú Unibanco e Santander. O acumulado das quatro instituições financeiras somam um lucro de R$ 12,1 bilhões no segundo trimestre de 2020. A redução contra igual período do ano passado foi de 40%, quando a soma foi de R$ 20,4 bilhões. Lucro dos quatro maiores bancos G1 Economia O resultado conjunto é o pior desde o trimestre terminado em dezembro de 2016, quando os bancos tiveram lucro de R$ 11,6 bilhões. Os valores do levantamento, contudo, não estão corrigidos pela inflação. A queda continua sendo expressiva mesmo em janelas mais recentes. O desempenho dos bancos neste ano tem sido especialmente afetado pelas provisões realizadas para cobrir potenciais perdas durante a crise provocada pelo novo coronavírus.",SAN,pt,Globo
2020-08-05 09:34:00-05:00,"Worldwide Oral Antibiotics Industry to 2027 - Featuring Mylan, Pfizer & Sanofi Among Others - ResearchAndMarkets.com","DUBLIN--(BUSINESS WIRE)--The ""Oral Antibiotics Market, by Class, Application, Drug Origin, Spectrum of Activity and Drug Type: Global Opportunity Analysis and Industry Forecast, 2020-2027"" report has been added to ResearchAndMarkets.com's offering. The global oral antibiotics market generated $18,365.80 million in 2018, and is projected to reach $23,306.10 million by 2027, growing at a CAGR of 2.7% from 2019 to 2027. Antibiotic is an antimicrobial substance or a compound that fights against bac",SAN,en,Business Wire
2020-08-05 06:29:45-05:00,Regeneron profit beats on Dupixent strength,"Regeneron Pharmaceuticals Inc beat second-quarter profit estimates on Wednesday, spurred by higher sales of its blockbuster eczema treatment Dupixent, and higher revenues connected to its collaboration with Sanofi SA and Bayer AG .",SAN,en,Reuters
2020-08-04 12:28:00-05:00,El fondo Brookfield estudia una opa por la inmobiliaria Merlin,"Las acciones de la socimi, que tiene como principal accionista al Banco Santander, suben casi un diez por ciento ante el eventual interés del fondo canadiense y la entrada en su capital del empresario Juan Abelló.",SAN,es,Publico
2020-08-04 04:07:51-05:00,Ana Botín da el toque de campana en la Bolsa de Nueva York,El mercado reconoce la gestión de Banco Santander en la gestión del Covid-19,SAN,es,Cinco Dias El Pais
2020-08-04 00:00:00-05:00,Drug giants in talks over vaccine volumes,DRUG giants Sanofi and GlaxoSmithKline are in advanced discussions with the European Commission for the supply of up to 300 million doses of a…,SAN,en,Herald Scotland
2020-08-03 17:23:28-05:00,"Itaú lucra R$ 3,4 bilhões no segundo trimestre","No mesmo período do ano passado, o banco registrou lucro de R$ 6,815 bilhões. Fachada de agência do banco Itaú no Rio de Janeiro Sergio Moraes/Reuters O Itaú informou nesta segunda-feira (3) que registrou lucro líquido contábil de R$ 3,424 bilhões no segundo trimestre de 2020. No mesmo período do ano passado, o banco registrou lucro de R$ 6,815 bilhões. No primeiro trimestre, o banco registrou lucro líquido contábil de R$ 3,401 bilhões no primeiro trimestre de 2020. Já o lucro líquido recorrente do banco, que exclui fatores extraordinários no trimestre fiscal, somou R$ 4,.205 bilhões, abaixo do registrado no primeiro trimestre de 2019 (R$ 7,034 bilhões). Outros bancos O Bradesco anunciou ter registrado lucro líquido contábil de R$ 3,506 bilhões no segundo trimestre de 2020, uma queda de 42% em relação ao mesmo período de 2019 (R$ 6,042 bilhões). Já o Santander reportou lucro líquido societário de R$ 2.025,6 bilhões no segundo trimestre, o que representa uma queda de 40,76% em relação ao mesmo período do ano passado (R$ 3,41 bilhões).",SAN,pt,Globo
2020-08-03 11:04:38-05:00,"DOJ probes Sanofi, GSK over possible carcinogen in Zantac","The theory is the drugs should not have been reimbursed by the government if they were unapproved, misbranded or adulterated, an expert said.",SAN,en,STAT News
2020-08-03 07:19:24-05:00,French firm Sanofi indicted over epilepsy drug,"The pharmaceutical giant is accused of manslaughter after babies died, but it denies wrongdoing.",SAN,en,BBC
2020-08-03 06:22:00-05:00,GSK and Sanofi in 'advanced discussions' with EU over Covid-19 vaccine,"Drugs giants GlaxoSmithKline and Sanofi today neared the completed a trio of key agreements to supply their Covid-19 vaccine, amid discussions with the EU. The pair said they are in “advanced discussions” with the European bloc to supply 300 million doses of their candidate, which uses Sanofi's recombinant protein-based technology combined with GSK's pandemic adjuvant system.",SAN,en,Evening Standard
2020-08-03 05:57:00-05:00,Sanofi under investigation on charges including manslaughter over Depakine,Sanofi Aventis France added it had respected all its obligations regarding information provided on Depakine,SAN,en,Business Standard
2020-08-03 05:56:08-05:00,Imputan a Sanofi por un antiepiléptico que provoca malformaciones en fetos,"El grupo farmacéutico Sanofi indicó este lunes que sido imputado por la justicia francesa por homicidios involuntarios en relación con uno de sus medicamentos utilizados contra la epilepsia, la Dépakina, al que se responsabiliza de haber causado malformaciones en fetos. Seguir leyendo… .",SAN,es,El Periodico
2020-08-03 05:27:11-05:00,Pharma giant Sanofi charged with manslaughter in birth defects case,"Children were born with congenital malformations, autism, or learning difficulties after mothers took its anti-epilepsy medication.",SAN,en,Free Malaysia Today
2020-08-03 04:54:25-05:00,"Santander, BBVA y Telefónica marcan mínimos en Bolsa de más de 20 años","En el caso de Banco Santander, los títulos cotizan a su nivel más bajo en casi 30 años, desde 1992",SAN,es,Cinco Dias El Pais
2020-08-03 02:38:16-05:00,"Sanofi, GSK to supply 300M COVID-19 vaccine doses to EU (NASDAQ:SNY)",Sanofi (NASDAQ:SNY) and development partner GlaxoSmithKline (NYSE:GSK) are in advanced discussions with the European Union (EU) to supply up to 300M doses,SAN,en,Seeking Alpha
2020-08-02 10:08:50-05:00,"The Week Ahead In Biotech: Novavax Coronavirus Vaccine Readout, FDA Decisions And More Earnings","Biotech stocks came under pressure in the week ended July 31 amid mixed earnings from the sector and some adverse clinical readouts. COVID-19 news flow continued to pour in, with big pharma tie-ups flaunting positive tidings. In the biggest ever coronavirus funding deal, the Sanofi SA (NASDAQ: SNY ) GlaxoSmithKline plc (NYSE: GSK ) won a joint $2.1 billion U.S. federal funding award. Here're the key catalysts for the unfolding week: Conferences 72nd National Hemophilia Foundation's Annual Bleeding Disorders Meeting 2020 (virtual meeting): Aug. 1-8 PDUFA Dates FDA is scheduled to rule on DBV TECHNOLOGIE/S' ADR (NASDAQ: DBVT ) Viaskin peanut allergy patch Wednesday. However, cancellation of the Adcom meeting scheduled May 15 has poured cold water on the prospects of an approval coming through. Trevena Inc (NASDAQ: TRVN ) has a tryst with the FDA Friday, with respect to the NDA for its pain drug oleceridine, which was once rejected by the agency on the premise of inadequacy of clinical data.","SBBP,SAN",en,Benzinga
2020-08-02 02:39:41-05:00,The rich will be the first to get vaccines,"By James PatonWealthy countries have already locked up more than a billion doses of coronavirus vaccines, raising worries that the rest of the world will be at the back of the queue in the global effort to defeat the pathogen.Moves by the U.S. and U.K. to secure supplies from Sanofi and partner GlaxoSmithKline Plc, and another pact between Japan and Pfizer Inc., are the latest in a string of agreements. The European Union has also been aggressive in obtaining shots, well before anyone knows whether they will work.Although international groups and a number of nations are promising to make vaccines affordable and accessible to all, doses will likely struggle to keep up with demand in a world of roughly 7.8 billion people. The possibility wealthier countries will monopolize supply, a scenario that played out in the 2009 swine flu pandemic, has fueled concerns among poor nations and health advocates.The U.S., Britain, European Union and Japan have so far secured about 1.3 billion doses of potential Covid immunizations, according to London-based analytics firm Airfinity.",SAN,en,Economic Times India
2020-08-02 01:00:00-05:00,"When It Comes to Covid Vaccines, Rich Nations Are First in Line","(Bloomberg) -- Wealthy countries have already locked up more than a billion doses of coronavirus vaccines, raising worries that the rest of the world will be at the back of the queue in the global effort to defeat the pathogen.Moves by the U.S. and U.K. to secure supplies from Sanofi and partner GlaxoSmithKline",SAN,en,Yahoo Finance
2020-08-01 16:02:11-05:00,US gov announces $2.1bn deal with pharma companies to make 100 million doses of coronavirus vaccine,"French drug maker Sanofi and British pharmaceutical giant GlaxoSmithKline will be paid up to $2.1 billion to supply the United States with enough vaccines for 50 million people, the government announced.",SAN,en,Daily Mail Online
2020-08-01 14:09:42-05:00,"Banco Santander, cuando la atención digital se hace esencial",Los clientes por internet aumentan en 300.000 en lo que va de 2020 y el 20% tiene más de 70 años. La contratación online se dispara,SAN,es,Cinco Dias El Pais
2020-08-01 13:57:07-05:00,European Commission agrees with Sanofi-GSK to purchase 300 million doses of vaccine for EU needs,Now the EC with partners is discussing the possibility of joint reserving of future vaccines both for their own needs and for low and middle income countries,SAN,en,112 International
2020-08-01 13:01:59-05:00,New Russian COVID-19 Vaccine is Scheduled to Start the Phase 3 Trials Next Week in Russia,"Russia, which has reported more than 822,000 cases of COVID-19 and is currently the world’s fourth most COVID-infested country, has concluded plans to register a coronavirus vaccine between August 10 and August 12 this year. This will make way for what will be regarded as the world’s first official approval of a vaccine against the COVID-19 pandemic. According to a report by Bloomberg, the vaccine is being developed by Russia’s Gamaleya Institute and the Russian Direct Investment Fund. Approval for human use is expected to be within 3 to 7 days after registration by regulators. Back story: Two weeks ago, Nairametrics had reported that the head of the Russian wealth fund (RDIF) hinted that Russia could make available a vaccine for the treatment of Coronavirus as early as September. He said that a deal had been agreed with AstraZeneca to manufacture a COVID-19 vaccine being developed by the pharmaceutical giant and Oxford University. This new Russian vaccine, which is scheduled to start the Phase 3 trials next week in Russia, Saudi Arabia, and the United Arab Emirates, has been adjudged safe and will potentially become the first to reach the public.",SAN,en,Novinite
2020-08-01 11:35:00-05:00,Red Flags Soar As Big Pharma Will Be Exempt from COVID-19 Vaccine Liability Claims,"Red Flags Soar As Big Pharma Will Be Exempt from COVID-19 Vaccine Liability Claims Tyler Durden Sat, 08/01/2020 - 12:35 Last week we warned readers to be cautious about new COVID-19 vaccines, highlighting how key parts of the clinical trials are being skipped as big pharma will not be held accountable for adverse side effects for administering the experimental drugs. A senior executive from AstraZeneca, Britain's second-largest drugmaker, told Reuters that his company was just granted protection from all legal action if the company's vaccine led to damaging side effects. ""This is a unique situation where we as a company simply cannot take the risk if in … four years the vaccine is showing side effects,"" said Ruud Dobber, a top exec at AstraZeneca. ""In the contracts we have in place, we are asking for indemnification. For most countries, it is acceptable to take that risk on their shoulders because it is in their national interest,"" said Dobber, adding that Astra and regulators were making safety and tolerability a top priority.",SAN,en,Zero Hedge
2020-08-01 05:49:04-05:00,La Unión Europea comprará 300 millones de dosis de la vacuna producida por Sanofi,La Unión Europea dispondrá de 300 millones de dosis de la vacuna producida por Sanofi. Bruselas ha llegado a un acuerdo con la farmacéutica francesa.,SAN,es,Business Insider Spain
2020-08-01 00:45:05-05:00,Este es el acuerdo multimillonario al que han llegado EEUU y las farmacéuticas Sanofi y GSK para la compra de 100 millones de vacunas contra el coronavirus,EEUU pagará 2.100 millones de dólares (1.775 millones de euros) a ambas farmacéuticas. Más de la mitad de esa cantidad irá destinada al desarrollo de la vacuna.,SAN,es,Business Insider Spain
2020-07-31 16:27:28-05:00,US government set to pay US$2.1 billion to drug giants Sanofi and GSK in coronavirus vaccine deal,"The US government will pay US$2.1 billion to Sanofi SA and GlaxoSmithKline Plc for Covid-19 vaccines to cover 50 million people and to underwrite the drug makers’ testing and manufacturing, the companies said on Friday.The drug makers also said they are in advanced discussions to supply up to 300 million doses of the experimental vaccine for the 27-country European Union.The US award is the biggest yet from ‘Operation Warp Speed’, the White House initiative aimed at accelerating access to…",SAN,en,South China Morning Post
2020-07-31 15:58:02-05:00,"U.S. to pay $2.1 bln to Sanofi, GSK, in COVID-19 vaccine deal | MarketScreener","The U.S. government will pay $2.1 billion to Sanofi SA and GlaxoSmithKline Plc for COVID-19 vaccines to cover 50 million people and to underwrite the drugmakers' testing and manufacturing, the… | July 31, 2020",SAN,en,MarketScreener
2020-07-31 14:18:00-05:00,"Sanofi, GlaxoSmithKline Ink Coronavirus Vaccine Deal With U.S. -- Update",By Joseph Walker The U.S. government will pay up to $2.1 billion to Sanofi SA and GlaxoSmithKline PLC to fund the development of a…,SAN,en,ADVFN UK
2020-07-31 13:30:20-05:00,EU reserves 300 mn doses of potential Sanofi virus vaccine,The EU announced Friday that it had struck a deal with French pharmaceutical giant Sanofi for 300 million doses of a potential coronavirus vaccine.,SAN,en,Digital Journal
2020-07-31 12:30:57-05:00,Bruselas acuerda con Sanofi la compra de 300 millones de dosis si logra una vacuna fiable,La Comisión Europea está en contacto con otras farmacéuticas para realizar nuevas adquisiciones,SAN,es,El Pais
2020-07-31 11:19:22-05:00,Sanofi : EU wraps up Sanofi talks aimed at securing coronavirus vaccine | MarketScreener,"The European Union's executive on Friday wrapped up talks with French drugmaker Sanofi aimed at securing its COVID-19 vaccine for the 27-country EU bloc. The envisaged contract with… | July 31, 2020",SAN,en,MarketScreener
2020-07-31 10:11:35-05:00,We just got one step closer to finding out whether leading coronavirus vaccines work,"Hello, Somehow, we've made it to the end of July. If you can believe it, that means we here in the US have been in this pandemic for five months. Is anyone keeping up with the hobbies they picked up in March? This week in healthcare news, vaccine candidates moved into late-stage trials that should tell us whether the shots work, Republicans and Democrats haven't come to a consensus on the next stimulus bill, and a receipt for $18,000 worth of fertility medications that's been stumping me since May. As a reminder: We now have a daily version of Dispensed! Subscribe here to get updates from the healthcare team in your inbox every day, not just Friday. New to Business Insider's paywall? Use my link here to get 20% off your subscription. Leading coronavirus vaccines have made it into trials that should tell us whether the shots work It was a big week in the race to develop a coronavirus vaccine (I probably write this sentence every week, which feels on par for all the vaccine developments happening).",SAN,en,Business Insider
2020-07-31 09:38:45.441000-05:00,GlaxoSmithKline and Sanofi strike massive deal with HHS for coronavirus vaccine development,The U.S. government pledged $2.1 billion to pharmaceutical companies GlaxoSmithKline and Sanofi Pasteur for the production of up to 100 million doses of COVID-19 vaccines as well as tests and treatments.,SAN,en,Washington Examiner
2020-07-31 09:16:03-05:00,"Banco Santander S A : Santander Holdings USA, Inc. and Santander Consumer USA Holdings Inc. Provide Statement on Capital Actions | MarketScreener","BOSTON and DALLAS, July 31, 2020 /PRNewswire/ -- Santander Holdings USA, Inc. and its publicly held subsidiary, Santander Consumer USA Holdings Inc. announced that SHUSA's request for… | July 31, 2020","SAN,SC",en,MarketScreener
2020-07-31 08:25:33-05:00,"Sanofi, GSK get $2.1B in government money for coronavirus vaccine",Drug makers Sanofi and GlaxoSmithKline are getting up to $2.1B from the government to develop a coronavirus vaccine. Yahoo Finance’s Anjalee Khemlani has the latest with Alexis Christoforous and Brian Sozzi.,SAN,en,Yahoo Finance
2020-07-31 08:24:09-05:00,"Glaxo, Sanofi to partner on $2 billion Operation Warp Speed coronavirus vaccine contract",Drug giants GlaxoSmithKline and Sanofi Pasteur said Friday they had won a commitment from the US federal government to pay up to $2.1 billion to help the two companies move forward with their proposed joint coronavirus vaccine as part of Operation Warp Speed.,SAN,en,CNN
2020-07-31 08:22:24-05:00,"Feds pledge up to $2.1B to COVID-19 vaccine from Sanofi, GlaxoSmithKline","The feds will give Sanofi and GlaxoSmithKline up to $2.1 billion to churn out a coronavirus vaccine in the Trump administration’s latest and largest bet on an experimental inoculation. More than half the award announced Friday will help the European drugmakers develop and test their vaccine, while the rest will be used to support manufacturing…",SAN,en,New York Post
2020-07-31 08:19:23-05:00,U.S. government awards $2.1B to Sanofi-GSK coronavirus vaccine,The government initiative aims to provide 300 million doses of a Covid-19 vaccine by January 2021.,SAN,en,POLITICO
2020-07-31 07:52:31-05:00,US sinks another $2.1 billion into a potential vaccine,"LONDON --- Pharma giants GlaxoSmithKline and Sanofi Pasteur have announced they will supply 100 million doses of its experimental COVID-19 vaccine to the United States as governments buy up supplies in hopes something will work. The United States will pay up to $2.1 billion ""for development including clinical trials, manufacturing, scale-up, and delivery of its vaccine,'' the companies said in a statement. Sanofi will get the bulk of the funds. The U.S. government has a further option for the supply of an additional 500 million doses longer term as part of its Operation Warp Speed program. ""The portfolio of vaccines being assembled for Operation Warp Speed increases the odds tha… Keep on reading: US sinks another $2.1 billion into a potential vaccine",SAN,en,Inquirer News Info
2020-07-31 07:49:55-05:00,"'Partial' Lockdowns Expand In Europe, New COVID-19 Cases Climb In China, Hong Kong: Live Updates","'Partial' Lockdowns Expand In Europe, New COVID-19 Cases Climb In China, Hong Kong: Live Updates Tyler Durden Fri, 07/31/2020 - 08:49 US markets are buzzed off last night's quartet of big-tech earnings reports that absolutely demolished Wall Street projections (is that really such a surprise?), but signs that the virus is reemerging in Europe and Asia have continued to hector investors, politicians, business-owners and taxpayers alike. Last night, we reported that UK PM Boris Johnson had ordered a large swath of northern England to return to 'partial' lockdown status. These new 'partial' lockdown rules affect 4 million people across the region. If the UK seems a little trigger happy, it's not without reason: Catalonia is seeing a serious resurgence of COVID-19, prompting local officials to issue new lockdown orders, while several European states issue travel restrictions or advisories targeting Spain, which has prompted the country to grouse about the damage to its tourism industry. Bloomberg reported Friday that NYC is doomed for a resurgence of the virus in the fall, even as its infection rates continue to fall.",SAN,en,Zero Hedge
2020-07-31 07:10:35-05:00,"US promises $2.1 billion for Sanofi, GSK coronavirus vaccine","Pharma giants Sanofi and GSK are to receive up to $2.1 billion from the US government for the development of a COVID-19 vaccine, the companies said Friday, as the world continues to be ravaged by the coronavirus epidemic. The United States had identified a vaccine candidate under investigation by Sanofi and GSK for its ""Operation Warp Speed,"" which aims to speedily secure millions of doses of a safe and effective COVID-19 vaccine. The vaccine will combine a Sanofi-developed antigen, which stimulates the production of germ-killing antibodies, with GSK's adjuvant technology, a substance that bolsters the immune response triggered by a vaccine, they said in a statement. The Ame… Keep on reading: US promises $2.1 billion for Sanofi, GSK coronavirus vaccine",SAN,en,Inquirer News Info
2020-07-31 06:56:27-05:00,"US to pay US$2.1 billion to Sanofi, GSK, in COVID-19 vaccine deal","The U.S. government will pay US$2.1 billion to Sanofi SA and GlaxoSmithKline Plc for COVID-19 vaccines to cover 50 million people and to underwrite the drug makers' testing and manufacturing, the companies said on Friday.",SAN,en,Channel NewsAsia
2020-07-31 06:55:41-05:00,"Coronavirus live updates: U.S. cases jump by 67,000; Sanofi, GSK nab $2.1 billion in vaccine deal","The coronavirus has infected more than 17.3 million people around the world as of Friday, killing at least 673,822 people.",SAN,en,CNBC
2020-07-31 06:29:00-05:00,"Sanofi, GlaxoSmithKline Ink Coronavirus Vaccine Deal With U.S.",By Joseph Walker The U.S. government will pay up to $2.1 billion to Sanofi SA and GlaxoSmithKline PLC to fund the development of a…,SAN,en,ADVFN UK
2020-07-31 06:13:14-05:00,Sanofi and GlaxoSmithKline Snag $2.1 Billion Government Deal — the Biggest Yet — for Coronavirus Vaccine,"The head of Operation Warp Speed, Moncef Slaoui, is a former GSK executive who as of May held just under $10 million in its stock.",SAN,en,New York Times
2020-07-31 06:00:36-05:00,U.S. agrees to pay Sanofi and GSK $2.1 billion for 100 million doses of coronavirus vaccine,The agreement with Sanofi and GlaxoSmithKelin is the government's second in less than two weeks for 100 million doses of vaccine.,SAN,en,CNBC
2020-07-31 06:00:00-05:00,GlaxoSmithKline PLC Sanofi & GSK picked for Op. Warp Speed by US Gov.,"GlaxoSmithKline PLC 31 July 2020 Issued: 31 July 2020, London, UK and Paris, France - LSE announcement GlaxoSmithKline plc Sanofi and…",SAN,en,ADVFN UK
2020-07-31 03:34:46-05:00,Banco Santander pierde 10.798 millones por el ajuste contable provocado por el coronavirus,"La entidad asume que cerrará el año con un resultado neto negativo tras ese deterioro y registrará las primeras pérdidas de su historia, pero anuncia el pago de un dividendo en acciones.",SAN,es,Heraldo
2020-07-30 15:11:50-05:00,"Sanofi, GSK face U.S. investigation over potential Zantac carcinogen link",The U.S. Department of Justice has opened an investigation into whether drugmakers including Sanofi SA failed to disclose to the federal government information about the potential presence of a probable carcinogen in the heartburn drug Zantac.,SAN,en,Reuters
2020-07-30 12:41:21-05:00,Nuveen compra un local en Canalejas y alojará una megaoficina de Banco Santander,La entidad volverá así a tener presencia en complejo donde tuvo su sede histórica de Madrid,SAN,es,Cinco Dias El Pais
2020-07-30 09:42:07-05:00,"Los malos resultados empresariales y el desplome del PIB de EE.UU hunden al Ibex, que cae más de un 3%","Otro jueves negro para el selectivo español, a quien le está costando digerir la tanda de resultados empresariales que blanco sobre negro dejan al descubierto las consecuencias más dañinas del Covid-19 y de la incertidumbre reinante a nivel internacional. Hoy mismo el BBVA informaba de que entre enero y junio de este año había incurrido en pérdidas de 1.157 millones, sumándose a un desfile que no está gustando nada a los inversores: Santander, Acciona, Red Eléctrica, Airbus, Boeing… A este mal desempeño de importantes empresas, muchas cotizadas en el índice, se le suma una mala referencia macro desde Estados Unidos: el desplome de un 32,9% del PIB en el segundo trimestre, la mayor caída de la historia (la anterior data de 1958 y «solo» supuso un retroceso del 10%). En este contexto, el Ibex 35 ha perdido ya la cota de los 7.000 puntos y registra fuertes retrocesos superiores al 3%. Con un selectivo prácticamente teñido de rojo, solo se salva de la quema un par de valores: Siemens Gamesa que rebota un 4,99% y un plano Meliá Hotels que subía un ligero 0,38%.",SAN,es,ABC Spain
2020-07-30 06:40:00-05:00,BBVA descarta pagar dividendo en acciones y espera acabar 2020 con beneficios,"BBVA se desmarca de la estrategia de Banco Santander . La entidad presidida por Carlos Torres ha anunciado este jueves que no repartirá dividendo en acciones (scrip) durante 2020. De hecho descarta radicalmente volver a esta remuneración al accionista, a la que renunció hace años. En cambio, el segundo banco español tiene el objetivo de volver a su polítca de dividendos en 2021 —también con cargo a las cuentas de 2020— y estudiará si puede recompensar a sus inversores con un pago extraordinario vía recompra de acciones. La otra gran diferencia frente a Santander, es que al contrario que la entidad presidida por Ana Botín, BBVA mantiene la previsión de acabar 2020 en beneficios , incluidos impactos contables por fondos de comercio. El banco vasco perdió 1.157 millones en los seis primeros meses del año , aunque la dinámica mejoró en el segundo trimestre, con un beneficio de 636 millones. Con este ritmo de resultados, y teniendo en cuenta que BBVA prevé que las provisiones bajen en la segunda parte del año, entraría en beneficio.",SAN,es,El Confidencial
2020-07-30 05:15:37-05:00,La recuperación de la economía pasa por la banca,"En esta nueva era poscovid, la colaboración público-privada es clave para relanzar la economía. Y el papel de las entidades financieras es fundamental. Banco Santander lo ha demostrado con la activación de distintas medidas dirigidas a mitigar el impacto de la pandemia en la sociedad",SAN,es,El Pais
2020-07-30 02:39:03-05:00,SANOFI : Goldman Sachs maintains a Buy rating | MarketScreener,"In a research note, Goldman Sachs analyst Keyur Parekh has maintained his recommendation on the stock with a Buy rating.. The target price has been revised downwards and is now set at EUR 103 as… | July 30, 2020",SAN,en,MarketScreener
2020-07-30 01:00:00-05:00,"Santander eleva reserva de calote e lucro cai 41,2%","Sem elevao das provises, ganho do banco teria aumentado 7,2% no perodo",SAN,pt,Jornal do Comercio
2020-07-29 21:00:00-05:00,COVID-19 Impacts: Allergy Rhinitis Drugs Market will Accelerate at a CAGR of almost 4% through 2020-2024 | Increasing Prevalence Of Allergic Rhinitis to Boost Growth | Technavio,"Technavio has been monitoring the allergy rhinitis drugs market and it is poised to grow by USD 2.4 bn during 2020-2024, progressing at a CAGR of almost 4% during the forecast period. The report offers an up-to-date analysis regarding the current market scenario, latest trends and drivers, and the overall market environment. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200729005699/en/ Technavio has announced its latest market research report titled Global Allergy Rhinitis Drugs Market 2020-2024 (Graphic: Business Wire). Technavio suggests three forecast scenarios (optimistic, probable, and pessimistic) considering the impact of COVID-19. Please Request Latest Free Sample Report on COVID-19 Impact The market is fragmented, and the degree of fragmentation will accelerate during the forecast period. Alcon Inc., ALK-Abello AS, Dr. Reddy's Laboratories Ltd., GlaxoSmithKline Plc, Glenmark Pharmaceuticals Ltd., Merck & Co. Inc., Novartis AG, Pfizer Inc., Sanofi, and Stallergenes Greer Ltd. are some of the major market participants.",SAN,en,Benzinga
2020-07-29 19:44:19-05:00,Banco Santander Brasil S A : 07/29/2020 – Protocol and justification of merger of Bosan Participações | MarketScreener,"PRIVATE INSTRUMENT OF PROTOCOL AND JUSTIFICATION OF MERGER OF BOSAN PARTICIPAÇÕES S.A. BY BANCO SANTANDER S.A. By this private instrument, the… | July 30, 2020",SAN,en,MarketScreener
2020-07-29 15:57:14-05:00,Are pharmaceutical firms going to profit from coronavirus vaccines?,The UK government announced on Wednesday that it has signed an agreement with GlaxoSmithKline (GSK) and Sanofi under which the two pharmaceutical companies will provide millions of doses of their experimental coronavirus vaccines to Britain if they prove viable. This is the fourth such agreement ministers have signed with multinational pharma companies.,SAN,en,The Independent
2020-07-29 13:19:30-05:00,Santander no Brasil tem lucro líquido de R$ 6 bilhões no 1º semestre de 2020,"O Banco Santander obteve um lucro líquido no Brasil, entre janeiro e junho de 2020, de R$ 6 bilhões, 33% a menos do que o registrado no mesmo período do ano passado, devido ao impacto da pandemia da C. Santander no Brasil tem lucro líquido de R$ 6 bilhões no 1º semestre de 2020 | Economia | Edição Brasil | Agencia EFE",SAN,pt,EFE News Service
2020-07-29 09:41:36-05:00,Lucro do Santander Brasil cai 41% no 2º trimestre,"Banco espanhol registrou queda recorde de € 11,1 bilhões no período na Europa",SAN,pt,Forbes Brasil
2020-07-29 09:17:50-05:00,Coronavirus vaccine: why the UK has signed a fourth Covid-19 vaccine deal with GSK and Sanofi for 60 million doses - and when it could be available,The new vaccine is being developed by drug companies GSK and Sanofi,SAN,en,The Scotsman
2020-07-29 08:42:00-05:00,El Banco Santander confía en pagar dividendo pese a las pérdidas contables,https://es.investing.com/news/stock-market-news/el-banco-santander-confia-en-pagar-dividendo-pese-a-las-perdidas-contables-2023524,SAN,es,Investing.com Spain
2020-07-29 07:27:00-05:00,"Santander pide que los bancos ""decidan sobre dividendos"" en función del beneficio","El consejero delegado de Banco Santander , José Antonio Álvarez , ha señalado este miércoles tras la publicación de los resultados semestrales, con pérdidas pronunciadas por un ajuste contable , que tendría lógica que el Banco Central Europeo (BCE) “cribe” a los bancos según su capacidad de generar beneficios recurrentes respecto a la posibilidad de repartir dividendos . El ejecutivo ha expresado así su deseo de que el veto sea sólo temporal, ya que afecta a la prima de riesgo o coste del capital que percibe el mercado en la banca. ""Como no puede ser de otra forma, el BCE debería decidir en el futuro el dividendo en función de la capacidad de generación de resultados de las entidades"". Sobre las cifras, “hemos crecido en stocks en todos los mercados, los ingresos se han comportado bien y se han reducido los costes”, ha señalado el consejero delegado, que ha apostillado que los históricos números rojos del banco se deben a ajustes “no recurrentes” . En concreto, la entidad ha publicado pérdidas por valor de 10.798 millones, que llevará a cerrar 2020 en números rojos, las primeras pérdidas de su historia. “Es una crisis de naturaleza diferente a las otras, normalmente focalizadas en algún sector o país, aquí afecta de forma global y ha llevado a situaciones que no tienen precedentes, como el cierre de la economía y que la gente no pueda salir de sus casas.",SAN,es,El Confidencial
2020-07-29 07:20:00-05:00,"Santander Brasil: lucro líquido gerencial é de R$ 2,136 bilhões no 2º tri (-41%) - RIC Mais","O Santander Brasil apresentou lucro líquido gerencial, que não considera ágio de aquisições, de R$ 2,136 bilhões no segundo trimestre, cifra 41,2% menor que a vista um ano antes, de R$ 3,635 bilhões. No comparativo trimestral, houve declínio de 44,6%. Os resultados do banco espanhol no País foram impactados pelo reforço de provisões para devedores […]",SAN,pt,RIC Mais
2020-07-29 07:15:00-05:00,Sanofi pulls out of late-phase Daiichi vaccine collaboration,"Sanofi has pulled out of a pediatric pentavalent vaccine collaboration with Daiichi Sankyo in Japan. The action, which Sanofi disclosed alongside other pipeline updates, follows a multiyear effort to get phase 3 data on the vaccine candidate.",SAN,en,FierceBiotech
2020-07-29 06:55:00-05:00,"Santander tem prejuízo inesperado de 11,1 bilhões de euros no 2º trimestre - RIC Mais","O Grupo Santander registrou um prejuízo inesperado de 11,13 bilhões de euros no segundo trimestre deste ano. De acordo com projeções levantadas pela FactSet e publicadas pela Dow Jones Newswires, o conglomerado espanhol deveria ter registrado um lucro líquido de 838 milhões de euros no período. De janeiro a junho, o resultado ficou negativo em […]",SAN,pt,RIC Mais
2020-07-29 06:32:01-05:00,"The Daily Biotech Pulse: Merck's Breakthrough Therapy Designation, Sonoma Surges On Sanitizer News, Sanofi-Glaxo And More","Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 28) Axonics Modulation Technologies Inc (NASDAQ: AXNX ) Capricor Therapeutics Inc (NASDAQ: CAPR ) Fulgent Genetics Inc (NASDAQ: FLGT ) ITAMAR MED LTD/S ADR (NASDAQ: ITMR ) Medpace Holdings Inc (NASDAQ: MEDP ) (saw an extension of its earnings-induced momentum) NeoGenomics, Inc. (NASDAQ: NEO )(reacted to its second-quarter results) OncoSec Medical Inc (NASDAQ: ONCS ) Penumbra Inc (NYSE: PEN ) Qiagen NV (NYSE: QGEN ) TFF Pharmaceuticals Inc (NASDAQ: TFFP ) Trevena Inc (NASDAQ: TRVN ) X T L Biopharmaceuticals Ltd (NASDAQ: XTLB ) Zoetis Inc (NYSE: ZTS ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows July 28) Nkarta Inc (NASDAQ: NKTX ) Nurix Therapeutics Inc (NASDAQ: NRIX )(IPOed Friday) Verrica Pharmaceuticals Inc (NASDAQ: VRCA ) Sonnet BioTherapeutics Holdings, Inc. (NASDAQ: SONN ) Stocks In Focus Alector Slips After Presenting Dementia Drug Trial Results Alector Inc (NASDAQ: ALEC ) announced at the virtual 2020 Alzheimer's Association International Conference, or AAIC, preliminary results from a Phase 1b and open-label Phase 2 studies of AL001 for the treatment of people with frontotemporal dementia with a progranulin gene mutation, or FTD-GRN, with the Phase 1 study showing AL001 was generally safe and well-tolerated.",SAN,en,Benzinga
2020-07-29 05:19:01-05:00,Banco Santander S A : Santander Posts Massive 2Q Loss on Coronavirus Impairments -- Earnings Review | MarketScreener,"By Pietro Lombardi Banco Santander SA posted an unexpected massive loss in the second quarter after it booked impairments related to the impact of the coronavirus pandemic on the economic… | July 29, 2020",SAN,en,MarketScreener
2020-07-29 04:23:03-05:00,"GlaxoSmithKline, Sanofi Ink Deal With UK To Supply Up To 60M Doses of COVID-19 Vaccine","Sanofi SA (NASDAQ: SNY ) and GlaxoSmithKline plc (NYSE: GSK ) have reached an agreement with the United Kingdom to supply up to 60 million doses of their jointly-developed coronavirus vaccine, the two drugmakers announced Wednesday. What Happened A regulatory approval for the vaccine candidate is expected by the first-half of 2021, if data from clinical trials is positive, according to Sanofi. Both the drugmakers are heightening the pace of manufacture of the antigen and adjuvant to manufacture one billion doses per year. Phase 1 and 2 studies are expected to begin in September and Phase … Full story available on Benzinga.com",SAN,en,Benzinga
2020-07-29 02:59:30-05:00,"Sanofi, Glaxo confirm 60M Covid vaccine dose deal with the U.K. (NASDAQ:SNY)","Following the release of its Q2 results, Sanofi (NASDAQ:SNY), as well as GlaxoSmithKline (NYSE:GSK), confirmed that they would supply the U.K. with up to 6",SAN,en,Seeking Alpha
2020-07-29 02:54:44-05:00,"Britain secures 60 million doses of Sanofi, GSK COVID-19 vaccine","LONDON/PARIS -- Britain has signed a deal for up to 60 million doses of a possible COVID-19 vaccine being developed by Sanofi and GlaxoSmithKline, it said on Wednesday, its fourth such arrangement as the race to tame the pandemic heats up. No vaccine has yet been approved for COVID-19, the respiratory disease caused by the new coronavirus that has killed more than 659,000 people and unleashed economic havoc worldwide. Financial terms of the agreement were not disclosed. Sanofi and GSK confirmed in a statement that regulatory approval for their vaccine could be achieved by the first half of 2021 if clinical data was positive. It is Sanofi and GSK's first deal to supply their … Keep on reading: Britain secures 60 million doses of Sanofi, GSK COVID-19 vaccine",SAN,en,Inquirer News Info
2020-07-29 02:43:00-05:00,"La Bolsa española se da la vuelta y cae el 0,97 % por el Banco Santander",https://es.investing.com/news/stock-market-news/la-bolsa-espanola-se-da-la-vuelta-y-cae-el-097--por-el-banco-santander-2023338,SAN,es,Investing.com Spain
2020-07-29 02:20:32-05:00,El Santande registra pérdidas contables en el primer semestre,"El Banco Santander obtuvo un beneficio ordinario de 1.908 millones de euros en el primer semestre de 2020, un 48% menos que en el mismo periodo del año anterior, por las mayores provisiones relacionadas con la pandemia de la covid-19 . La entidad destaca en un comunicado a la CNMV que aunque la pandemia ha afectado a la actividad, se mantiene un buen resultado ordinario gracias a los ingresos de clientes, una reducción de costes por encima de lo esperado, una sólida calidad crediticia y la generación orgánica de capital. Seguir leyendo… .",SAN,es,El Periodico
2020-07-29 02:09:19-05:00,UK govt signs deal with GSK and Sanofi for 60 million doses of potential Covid-19 vaccine,UK government agreements are now in place for 250 million doses of potential vaccines.,SAN,en,TheJournal IE
2020-07-29 01:56:00-05:00,"Sanofi logró 9.281 millones de euros de beneficio semestral, casi 9 veces más",https://es.investing.com/news/stock-market-news/sanofi-logro-9281-millones-de-euros-de-beneficio-semestral-casi-9-veces-mas-2023313,SAN,es,Investing.com Spain
2020-07-29 01:35:36-05:00,UK signs deal for 60 million virus vaccine doses,"The government signs its fourth vaccine deal, securing doses of a treatment being developed by GSK and Sanofi.",SAN,en,BBC
2020-07-29 01:34:35-05:00,Sanofi lifts earnings view as Regeneron stake sale boosts Q2,Sanofi raised its 2020 earnings forecast on Wednesday after its second-quarter results were boosted by cost cuts.,SAN,en,CNBC
2020-07-29 01:13:39-05:00,Coronavirus: UK signs deal for 60 million doses of Sanofi/GSK COVID-19 vaccine,"Britain has signed a supply deal for up to 60 million doses of a possible COVID-19 vaccine being developed by Sanofi and GlaxoSmithKline, it said on Wednesday, its fourth such arrangement.",SAN,en,Al Arabiya (English)
2020-07-29 01:00:00-05:00,GlaxoSmithKline PLC Sanofi and GSK agree UK doses of COVID-19 vaccine,"GlaxoSmithKline PLC 29 July 2020 Issued: 29(th) July 2020, London, UK and Paris, France GlaxoSmithKline plc (""GSK"") Sanofi…",SAN,en,ADVFN UK
2020-07-29 00:54:00-05:00,"Sanofi, GSK Agree With UK Government to Supply Up to 60 Million Doses of Covid-19 Vaccine",By Ian Walker Sanofi S.A. and GlaxoSmithKline PLC said Wednesday that they have reached an agreement with the U.K. government to supply…,SAN,en,ADVFN UK
2020-07-28 23:40:00-05:00,Government signs deal with GSK and Sanofi for 60m doses of potential coronavirus vaccine,The Government has signed a deal with pharmaceutical giants GlaxoSmithKline (GSK) and Sanofi Pasteur for 60 million doses of a potential Covid-19 vaccine.,SAN,en,Evening Standard
2020-07-27 12:08:16-05:00,"EU talks with Pfizer, Sanofi, J&J on COVID vaccines hit snags: Sources","European efforts to secure potential COVID-19 vaccines from Pfizer, Sanofi and Johnson & Johnson are mired in wrangles over price, payment method and potential liability costs, three EU officials told Reuters.",SAN,en,Channel NewsAsia
2020-07-27 10:50:04-05:00,EU talks to procure COVID-19 supply stalled over financial issues (NYSE:PFE),"Reuters reports that negotiations between the Europe Union (EU) and COVID-19 vaccine developers Pfizer (PFE -0.8%), Sanofi (SNY +2.0%) and Johnson & Johnso",SAN,en,Seeking Alpha
2020-07-27 10:21:08-05:00,"Exclusive: EU talks with Pfizer, Sanofi, J&J on COVID vaccines hit snags - sources",https://www.investing.com/news/stock-market-news/exclusive-eu-talks-with-pfizer-sanofi-jj-on-covid-vaccines-hit-snags--sources-2242131,SAN,en,Investing.com
2020-07-27 05:55:45-05:00,Los ejecutivos del Ibex recortaron su remuneración un 21% y los consejos un 12% en 2018,"La remuneración conjunta de los primeros ejecutivos del Ibex 35 se redujo un 20,8% y la retribución agregada de los consejos de administración disminuyó un 12,3% en el año 2018, debido principalmente a las remuneraciones extraordinarias que se pagaron el año anterior, según recoge el informe 'Evolución de indicadores de buen gobierno en las empresas del Ibex 35 durante el ejercicio 2018' elaborado por CC.OO. La remuneración conjunta de los primeros ejecutivos del Ibex alcanzó los 137 millones de euros (-20,8%) en 2018, lo que supone el 44,6% de la remuneración agregada de los consejos de administración. Las empresas que pagaron mayores remuneraciones a sus primeros ejecutivos en 2018 fueron Naturgy, ACS y Banco Santander, con importes que superaron los 10 millones de euros. En el lado contrario, se colocaron Aena (105.000 euros) y Bankia (800.000 euros). Las empresas que más aumentaron en 2018 la remuneración de sus primeros ejecutivos fueron Naturgy, con 12 millones más por la indemnización por cese del consejero delegado saliente Rafael Villaseca, valorada en 14 millones de euros, y Bankinter, con 2 millones de aumento por el incremento de la remuneración en metálico de la consejera delegada, María Dolores Dancausa, según el informe de CCOO.",SAN,es,ABC Spain
2020-07-27 02:35:31-05:00,Sanofi : Back towards the lower end of the range | MarketScreener,"The fact that share price is returning to the lower bounds of the trading range offers a good timing to enter into new long positions in Sanofi. | July 27, 2020",SAN,en,MarketScreener
2020-07-24 14:44:06-05:00,El Covid acelera un modelo de banca digital que deja las plantillas en el aire,"«La implementación de nuestros planes de transformación digital es crítica porque, cuando pase la crisis del coronavirus, el ritmo de transformación se recuperará una vez más. Y dado que muchos clientes están confiando en la banca digital durante la crisis, es probable que el cambio se acelere». En estos términos se pronunció la presidenta de Banco Santander, Ana Botín, en la junta de accionistas de abril. Ocurrió en lo peor de la pandemia y ya entonces era consciente del avance en las estrategias que estaba por venir. No solo esta entidad está echando ahora el resto por la digitalización; el sector en su conjunto ha aprovechado el último mes y medio de desescalada para implementar y/o reforzar su apuesta tecnológica…. Ver Más",SAN,es,ABC Spain
2020-07-24 13:15:00-05:00,COVID-19 Impacts: Non-Tumorous Skin Diseases Therapeutics Market will Accelerate at a CAGR of over 9% through 2020-2024 | Misdiagnosis of Skin Diseases to Boost Growth | Technavio,"Technavio has been monitoring the non-tumorous skin diseases therapeutics market and it is poised to grow by USD 12.93 billion during 2020-2024, progressing at a CAGR of over 9% during the forecast period. The report offers an up-to-date analysis regarding the current market scenario, latest trends and drivers, and the overall market environment. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200724005304/en/ Technavio has announced its latest market research report titled Global Non-Tumorous Skin Diseases Therapeutics Market 2020-2024 (Graphic: Business Wire) Technavio suggests three forecast scenarios (optimistic, probable, and pessimistic) considering the impact of COVID-19. Please Request the Latest Free Sample Report on COVID-19 Impact Frequently Asked Questions- What is the year-over-year growth of the non-tumorous skin diseases therapeutics market in 2020? Technavio says that the year-over-year growth of the market is 7.19% in 2020.",SAN,en,Benzinga Feeds
2020-07-24 12:52:11-05:00,Banco Santander toma el control de Uro Property y recompra 650 sucursales por 152 millones,"El Banco Santander ha anunciado su intención de recomprar 650 de sus sucursales para ahorrarse el alquiler de las mismas y por esa razón ha decidido tomar el control de la socimi Uro Property, propietaria actualmente de esos locales, por 152 millones de euros, según han informado este viernes fuentes de la entidad. La socimi adquirió en 2007 los locales al Banco Santander y firmó un contrato con el grupo por el se comprometía a seguir en ellos en régimen de alquiler, pero la entidad financiera ha llegado a la conclusión de que le interesa más tenerlas bajo su propiedad. Se trata de una operación financiera con la que el grupo presidido por Ana Botín trata de generar ahorros, considerando que el coste de la compra de los inmuebles es menor a las obligaciones futuras de rentas de alquiler, explican las mismas fuentes. La operación tiene un efecto neutro en capital y en la cuenta de resultados, han apuntado desde la entidad. Desde la entrada en vigor en 2019 de la normativa internacional IFRS16, el tratamiento contable de los arrendamientos cambió y las empresas tienen que recoger en su contabilidad sus obligaciones (deuda) por el pago de alquileres, lo que incentiva la recompra de este tipo de activos, explican expertos del sector.",SAN,es,ABC Spain
2020-07-23 02:38:26-05:00,La recuperación económica pasa por la empresa,"Activar la recuperación económica tras la crisis de la covid-19 es una tarea prioritaria, en la que deben colaborar estrechamente administraciones públicas e iniciativas privadas. Para Banco Santander, es esencial ayudar a empresas y empresarios para garantizar el crecimiento",SAN,es,El Pais
2020-07-22 08:41:10-05:00,Banco Santander S A : Santander launches 2020 edition of its Trainee programme | MarketScreener,"Registration is from 27 July to 8 September, and young people from all over Brazil are expected to take part in the selection process. Madrid, 20th de… | July 22, 2020",SAN,en,MarketScreener
2020-07-22 04:17:36-05:00,Euromoney premia a Santander como mejor banco de España por su gestión durante la Covid-19,"Euromoney ha premiado la gestión de Banco Santander durante la crisis sanitaria de la Covid-19 en Europa Occidental, Europa Central y del Este. La publicación ha distinguido a la entidad bancaria con el premio ‘Excellence in Leadership’ por su…",SAN,es,La Vanguardia
2020-07-21 14:38:43-05:00,Rio Bravo reverte decisão liminar do Santander (SANB11) contra RBVA11,"O Rio Bravo anunciou nesta terça-feira (21) que conseguiu reverter a decisão liminar do Santader (SANB11) contra o fundo Rio Bravo Renda Varejo (RBVA11). Há pouco mais de uma semana, o banco espanh…",SAN,pt,Suno Research
2020-07-21 10:11:00-05:00,Moderna and other top coronavirus drugmakers are boosting their lobbying as they compete for government cash to fuel vaccine work,"The biotech Moderna increased its lobbying spending seven-fold as it races to develop a coronavirus vaccine. Moderna spent $70,000 on lobbying in Washington in the second quarter of this year, up from $10,000 over the same period last year. Business Insider combed through lobbying records companies working on coronavirus vaccines and treatments, including AstraZeneca, Merck, GlaxoSmithKline, and Sanofi. Some other drugmakers also boosted their lobbying spending, while others spent less this quarter. For more stories like this, sign up here for our healthcare newsletter, Dispensed . Moderna , the small biotech whose coronavirus shot was first to get tested in people, is boosting its lobbying as the race to create a vaccine accelerates. The biotech spent a total of $70,000 in the second quarter of 2020, up from $10,000 in the same period of 2019. Moderna hired Avenue Solutions for $20,000 to lobby on ""education around potential COVID-19 vaccines and related issues"" during the second quarter.",SAN,en,Business Insider
2020-07-21 07:44:08-05:00,"Amancio Ortega y Juan Roig, los empresarios que más confianza generan en España","El empresario valenciano Juan Roig, presidente de Mercadona, se sitúa como el líder empresarial de la Comunitat Valenciana que mayor confianza genera en el panorama empresarial español, según datos del estudio 'iTRUST Business Leaders Ranking', elaborado por el think tank MESIAS - Inteligencia de Marca España en colaboración con iTRUST Country Brand Intelligence y la Universidad CEU San Pablo. Según la investigación, realizada sobre una muestra constituida por más de 1.000 directivos, expertos en empresa e investigadores universitarios, el fundador y presidente ejecutivo de Mercadona, Juan Roig, encabeza, asimismo, el ranking de los líderes empresariales que más confianza generan en el mundo empresarial, ocupando la segunda posición del ranking, con más de 80 puntos de confianza, junto con Amancio Ortega, fundador de Inditex y Ana Botín, presidenta de Banco Santander. Asimismo, entre los 20 líderes empresariales que mayor confianza generan en España figura otro empresario valenciano, Manuel Colonques, presidente de Porcelanosa Corporación, quien se sitúa en el puesto 19 del ranking, detallan los impulsores del estudio en un comunicado.",SAN,es,ABC Spain
2020-07-20 02:25:28-05:00,El Corte Inglés quiere crear una gestora de patrimonios y busca socios: negocia con Abante Asesores y Banco Santander,El Corte Inglés quiere crear una gestora de patrimonios y lo hará en colaboración con otras empresas especializadas y negocia con Abante Asesores.,SAN,es,Business Insider Spain
2020-07-19 07:37:22-05:00,"EU In Talks With Moderna, BioNtech, CureVac For Potential Covid-19 Vaccine Deals","The European Union is reportedly in talks to make advance purchase deals of potential COVID-19 vaccines with drugmakers Moderna (MRNA), Sanofi (SNY) and … The post EU In Talks With Moderna, BioNtech, CureVac For Potential Covid-19 Vaccine Deals appeared first on Smarter Analyst .",SAN,en,Smarter Analyst
2020-07-18 17:01:09-05:00,José Palma: “No es momento de estar infraponderados en banca”,"Las caídas de marzo sorprendieron a la gestora poco invertida y fue la ocasión para adquirir compañías como Enagás, Sanofi o Deutsche Bank",SAN,es,Cinco Dias El Pais
2020-07-17 10:03:40-05:00,PRNB Stock Up 1% as Sanofi Mulls Buying Principia Biopharma for $50B,Sanofi is looking at potential acquisitions of U.S. biotechnology companies including Principia Biopharma. PRNB stock is 1% up.,SAN,en,Coinspeaker
2020-07-17 08:06:17-05:00,EU in talks with Moderna and others for COVID-19 vaccine supply (NASDAQ:MRNA),"Reuters reports that the European Union (EU) is negotiating with Moderna (NASDAQ:MRNA), Sanofi (NASDAQ:SNY), Johnson & Johnson (NYSE:JNJ), BioNTech (NASDAQ",SAN,en,Seeking Alpha
2020-07-17 07:00:38-05:00,"EXCLUSIVA-UE negocia con Moderna, BioNtech y CureVac para asegurar acceso a vacunas: fuentes","La Unión Europea está negociando compras anticipadas de posibles vacunas contra el COVID-19 desarrolladas por las farmacéuticas Moderna, Sanofi y Johnson & Johnson, y por las firmas de biotecnología BioNtech y CureVac, dijeron dos fuentes a Reuters.",SAN,es,Reuters Latin America
2020-07-17 06:41:01-05:00,"The Daily Biotech Pulse: 2 IPOs, Nabriva Pneumonia Drug Gets Canadian Regulatory Nod, PhaseBio Doses First COVID-19 Trial Patient","Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 16) AC Immune SA (NASDAQ: ACIU ) ( announced clinical trial update for its Alzheimer's vaccine candidate) argenx SE – ADR (NASDAQ: ARGX ) Bio-Rad Laboratories, Inc. Class A Common Stock (NYSE: BIO ) Castle Biosciences Inc (NASDAQ: CSTL ) Dynavax Technologies Corporation (NASDAQ: DVAX )(announced a collaboration with Mt. Sinai to develop a universal influenza vaccine candidate with CpG1018 adjuvant) Heat Biologics Inc (NASDAQ: HTBX ) Novavax, Inc. (NASDAQ: NVAX ) Qiagen NV (NYSE: QGEN )( Thermo Fisher Scientific Inc. (NYSE: TMO ) announced a sweetened offer to buy the company) Quest Diagnostics Inc (NYSE: DGX ) Otonomy Inc (NASDAQ: OTIC ) Principia Biopharma Inc (NASDAQ: PRNB )(reacted to buyout rumors) Relay Therapeutics Inc (NASDAQ: RLAY ) (jumped 75.25% on its debut) Sanofi SA (NASDAQ: SNY ) (Bloomberg reported the French biotech is on a lookout to buy biotech companies, including Principia) TIZIANA LF SCIE/S ADR (NASDAQ: TLSA ) West Pharmaceutical Services Inc. (NYSE: WST ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows July 16) Avidity Biosciences Inc (NASDAQ: RNA ) Legend Biotech Corp (NASDAQ: LEGN ) Nkarta Inc (NASDAQ: NKTX ) (IPOed last Friday) Repare Therapeutics Inc (NASDAQ: RPTX ) Tricida Inc (NASDAQ: TCDA ) ( received a letter from FDA citing deficiencies in its NDA for the approval of metabolic …",SAN,en,Benzinga Feeds
2020-07-17 00:00:00-05:00,Banco Santander multiplica sus esfuerzos para hacer realidad la remontada de una economía afectada por la pandemia,"Una vez superada la emergencia sanitaria es el momento de centrar todos los esfuerzos en la remontada económica, ya que las consecuencias de la COVID-19 no se han hecho esperar. Entidades como Banco Santander, gobiernos, empresas y otros agentes…",SAN,es,La Vanguardia
2020-07-16 22:33:43-05:00,The vaccine story that's got everyone hooked,"By Katie Thomas and Megan TwoheyIn late February, as the coronavirus spread around the world, Dr. Richard Hatchett, head of an international nonprofit that gives money to vaccine developers, got on an important call to discuss vaccine candidates after his plane touched down at London’s Heathrow Airport.Executives from the Bill & Melinda Gates Foundation, which helped found and finance the nonprofit, were on the line, enthusiastic about Novavax, a small biotech company they thought had the potential to develop a vaccine against the virus — fast.Although the company, based in Gaithersburg, Maryland, had never brought a vaccine to market in its 33-year history, these experts were optimistic about its technology, which uses moth cells to pump out crucial molecules at a much faster rate than typical vaccines — a major advantage in a pandemic.Hatchett’s organization, the Coalition for Epidemic Preparedness Innovations, would go on to invest $388 million in the company’s coronavirus vaccine. ",SAN,en,Economic Times India
2020-07-16 13:13:02-05:00,Principia Biopharma up 12% on rumored Sanofi interest (NASDAQ:PRNB),Principia Biopharma (PRNB +11.9%) perks up on almost an 8x surge in volume in apparent response to rumblings that Sanofi (SNY -0.8%) is eyeing the immune d,SAN,en,Seeking Alpha
2020-07-16 09:45:57-05:00,Banco Santander S A : Santander is one of the five best companies to work for women in Argentina | MarketScreener,"Buenos Aires, 14 July 2020 - PRESS RELEASE Santander was distinguished by Great Place to Work as one of the five 'Best Workplaces for Women' in Argentina among companies with… | July 16, 2020",SAN,en,MarketScreener
2020-07-16 07:31:22-05:00,"The Daily Biotech Pulse: Mallinckrodt Gets FDA Panel Backing, Regulatory Setback For Tricida, Relay Therapeutics IPO","Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 15) Atossa Therapeutics Inc (NASDAQ: ATOS ) (announced results from lab studies of AT-301, its COVID-19 nasal spray drug candidate) AstraZeneca plc (NYSE: AZN ) (moved on reports that it could issue an update on its coronavirus vaccine program soon) Beigene Ltd (NASDAQ: BGNE ) Bio-Rad Laboratories, Inc. Class A Common Stock (NYSE: BIO ) Bio-Rad Laboratories, Inc. Class B Common Stock (NYSE: BIO ) Castle Biosciences Inc (NASDAQ: CSTL ) (announced publication of a study demonstrating its DecisionDx-UM test results significantly impacted treatment plan recommendations for patients with uveal melanoma) Catalent Inc (NYSE: CTLT ) Cytokinetics, Inc. (NASDAQ: CYTK ) (issued an investor update on its cardiovascular pipeline) ESSA Pharma Inc (NASDAQ: EPIX ) (announced enrollment of first patient in Phase 1 study of its prostate cancer drug) Genetic Technologies Limited (NASDAQ: GENE ) (issued an update on its COVID-19 Severity Risk Test) GENMAB A/S/S ADR (NASDAQ: GMAB ) Heat Biologics Inc (NASDAQ: HTBX ) Hologic, Inc.",SAN,en,Benzinga
2020-07-16 03:27:00-05:00,Banco Santander canalizará 800 millones del BEI para ayudas urgentes a pymes españolas,"Empresas agroalimentarias y renovación de flotas de transporte, con 100 millones cada una, serán la primera prioridad.",SAN,es,Publico
2020-07-15 22:00:00-05:00,Las medidas económicas y sociales de Banco Santander para luchar contra el covid,"La entidad ha puesto en marcha préstamos para pymes, apoya investigaciones lideradas por las universidades y ha reforzado la atención digital para sus clientes",SAN,es,El Confidencial
2020-07-15 11:49:29-05:00,"Banco Santander y CaixaBank, premiados por la revista Euromoney - Republica.com","En concreto, Santander ha sido premiado por su gestión ante la crisis del coronavirus en Europa de cara a sus empleados, clientes, accionistas y sociedad en general con el premio 'Excelencia en liderazgo 2020' en Europa Occidental y Europa Central y del Este. Igualmente, Euromoney también ha valorado el apoyo que Banco Santander está dando […]",SAN,es,Republica.com
2020-07-15 10:36:10-05:00,"Banco Santander, CaixaBank y BBVA, premiados por la revista 'Euromoney'","Banco Santander, BBVA y CaixaBank han resultado galardonados por la revista británica ' Euromoney ' en diversas categorías de premios, según se ha publicado este miércoles. Seguir leyendo… .",SAN,es,El Periodico
2020-07-14 08:50:09-05:00,"Banco Santander entrega más de 1,6 millones a proyectos de inserción socio-laboral a través de un fondo solidario - Republica.com","El evento, celebrado en la nueva sede de Santander España, contó con la asistencia del cardenal D. Carlos Osoro, arzobispo de Madrid; el presidente de Santander España, Luis Isasi, el consejero delegado de Santander España, Rami Aboukhair; el consejero delegado de SAM España, Miguel Ángel Sánchez Lozano, y los máximos responsables de Cáritas, Manos Unidas […]",SAN,es,Republica.com
2020-07-14 06:11:57-05:00,Sanofi and MD Anderson collaborate to expedite oncology research (NASDAQ:SNY),Sanofi (NASDAQ:SNY) and The University of Texas MD Anderson Cancer Center announce a five-year strategic collaboration to accelerate the development of inv,SAN,en,Seeking Alpha
2020-07-13 12:40:33-05:00,El grupo farmacéutico alemán Merck asciende a viceconsejera delegada a la española Marta Garijo,"El grupo farmacéutico alemán Merck ha nombrado a la española Belén Garijo vicepresidenta del comité ejecutivo y subconsejera delegada de toda la compañía con efectos a partir de hoy. Garijo, que es médica, especialista en farmacología clínica, ha sido hasta ahora consejera delegada del área de Salud y Medicina de Merck, responsabilidades que mantiene. Adicionalmente y en nombre del comité ejecutivo, es responsable de las funciones de Recursos Humanos y de Medioambiente, Calidad, Salud y Seguridad. El nombramiento de Garijo «reconoce sus espectaculares logros para nuestro negocio de Salud y su fuerte liderazgo en las funciones corporativas críticas», ha afirmado el presidente del consejo de socios de Merck, Johannes Baillou. Garijo entró en Merck en 2011 como directora de Operaciones del negocio de biofarma y fue nombrada miembro del comité ejecutivo en 2015. El año pasado recibió el Premio de la Asociación Española de Directivos 2019 en la categoría Gran Empresa. Antes de incorporarse a Merck, Garijo desempeñó el cargo de vicepresidenta senior de Operaciones Globales para Europa en Sanofi-Aventis, donde también fue miembro del comité ejecutivo del grupo y del consejo de la sociedad de riesgo compartido de Sanofi-Pasteur Vacunas con MSD.",SAN,es,ABC Spain
2020-07-13 07:15:55-05:00,Valencia estrena nuevos «robots» que permitirán hacer dos mil pruebas más al día para detectar el Covid-19,"El Servicio de Microbiología del Hospital La Fe de Valencia ha incorporado una estación robotizada con la que se podrán realizar hasta 2.000 pruebas PCR de diagnóstico del Covid-19 más. Así lo ha anunciado este lunes el presidente de la Generalitat, Ximo Puig, en su visita a los laboratorios que albergan los CovidRobots, fruto de una iniciativa público-privada, a cuyos promotores y empresas participantes ha mostrado su agradecimiento por «ayudar a mejorar la sanidad pública». «Hasta este momento La Fe tenía capacidad para hacer 1.500 PCR», de las que actualmente, «dada la situación de menor intensidad» en la Comunidad Valenciana se realizan alrededor de 500, ha explicado Puig, quien ha confirmado que con los nuevos robots «se podría llegar a hacer 3.500 PCR al día». Según el máximo responsable del Gobierno autonómico, con estos equipamientos «se dará más seguridad» a la ciudadanía gracias a una detección «rápida» y control de la trazabilidad de los eventuales brotes. Imagen de la visita del presidente Ximo Puig al laboratorio del Hospital La Fe - ABC Capacidad para 14.000 PCR diarias Esta línea robotizada de realización masiva de pruebas PCR, instalada en la torre A del Hospital La Fe, permite incrementar la capacidad de realización de test de la Comunitat Valenciana hasta casi 14.000 pruebas diarias entre los laboratorios de microbiología de los hospitales y los centros de investigación médica y universitarios. «A pleno rendimiento, estos Covidrobots permiten realizar 2.000 pruebas de PCR al día porque se adaptan a los protocolos del laboratorio y pueden utilizar reactivos de cualquier marca comercial», según ha explicado Jose Luis López Hontangas, jefe de Servicio Microbiología en La Fe.",SAN,es,ABC Spain
2020-07-13 04:26:06-05:00,Banco Santander S A : Santander and EIB Group provide almost 760 million for SMEs affected by covid-19 | MarketScreener,"The EIB is providing this loan as part of its initial package of emergency measures to support European companies. Some of the funds will go to businesses… | July 13, 2020",SAN,en,MarketScreener
2020-07-13 04:02:00-05:00,El BEI facilita 757 M al Banco Santander para financiar pymes españolas,"Será posible ofrecerles financiación en condiciones ventajosas, tanto en tipos de interés como en plazos de amortización, para impulsar la recuperación del tejido productivo",SAN,es,El Confidencial
2020-07-12 22:00:00-05:00,Una consultora 'tech' del Ibex ficha a seis vips para crecer a nivel internacional,"Netboss Comunicaciones , una consultora tecnológica que presta servicios para los primeros espadas del Ibex 35 , ha creado un consejo asesor para tratar de consolidar su posición a nivel internacional. Tras más de 20 años de recorrido, donde ha trabajado para firmas como Banco Santander , Telefónica , MásMóvil u Orange , la compañía ha cerrado el fichaje de siete destacadas figuras del mundo de la política y los negocios. El consejo asesor estará presidido por Modesto García Piñeiro (quien ha sido vicepresidente de la Cámara de Comercio en España en la anterior legislatura y en la actualidad es presidente de la Cámara de Comercio de Cantabria) y le acompañarán inicialmente Roberto de Diego (que ha ocupado responsabilidades como presidente de British Telecom Europa o CEO de Jazztel y que acaba de ser nombrado presidente no ejecutivo de Capital Energy), Laureano Cabrero (socio de PwC especializado en gestión de Impuestos y 'compliance' societario), así como Soledad Rojo (experta en tecnologías de la información y directora general de la propia Netboss), Jordi Xuclà (exdiputado y exportavoz en el Consejo de Europa ), el conocido empresario Antonio Fournier y Adrian Jofre Bosch , experto en negociación internacional y socio-director de beBartlet .",SAN,es,El Confidencial
2020-07-10 07:36:07-05:00,Banco Santander S A : and IE Foundation offer 100 scholarships for technological innovation applied to the financial sector | MarketScreener,"The Santander Tech Revolution in Finance - IE University Scholarships are aimed at STEM undergraduates and graduates in nine countries. Applications may be… | July 10, 2020",SAN,en,MarketScreener
2020-07-10 07:01:09.037000-05:00,Sanofi's Latest Collaboration Deal,The French drugmaker's latest collaboration deal is with Cambridge MA based Kymera. It provides for…,SAN,en,The Street
2020-07-09 06:27:28-05:00,Sanofi to collaborate with Kymera Therapeutics in immune-inflammatory diseases (NASDAQ:SNY),Sanofi (NASDAQ:SNY) inks an agreement with privately held Kymera Therapeutics aimed at developing and commercializing protein degrader therapies targeting,SAN,en,Seeking Alpha
2020-07-09 06:00:00-05:00,Kymera Therapeutics And Sanofi Enter Into Strategic Partnership To Advance Novel Protein Degrader Therapies To Patients,/PRNewswire/ -- Kymera Therapeutics Inc. today announced the company has entered into a multi-program strategic collaboration with Sanofi (NASDAQ: SNY) to…,SAN,en,PR Newswire
2020-07-08 06:22:55-05:00,Sanofi's Sarclisa OK'd in Canada (NASDAQ:SNY),Health Canada has approved Sanofi's (NASDAQ:SNY) Sarclisa (isatuximab-irfc) for the treatment of adults with relapsed/refractory multiple myeloma who have,SAN,en,Seeking Alpha
2020-07-08 06:13:56-05:00,Kiadis inks license deal with Sanofi valued as high as €875M (OTCMKTS:KIADF),"Kiadis Pharma N.V. (OTC:KIADF) has granted an exclusive global license to its K-NK004 cell program to Sanofi (NASDAQ:SNY), including exclusive rights to it",SAN,en,Seeking Alpha
2020-07-07 11:55:08-05:00,"Sanofi halts trials of IL-6 drug for Covid-19, India to continue with trial of another drug of similar class","Mumbai: French drugmaker Sanofi and Regeneron of the US halted their clinical trials of rheumatoid arthritis drug Sarilumab after finding it did not improve the conditions of severely ill Covid-19 patients.The decision casts a shadow on other similar classes of drugs such as Tocilizumab by Swiss drug maker Roche pharma, that are under trial for treating Covid-19 in countries including India. However, the investigator leading the Tocilizumab trial in India told ET that the efficacy of these drugs on moderate Covid-19 patients still needs to be studied. In India, there is a multi-centre, randomised, controlled study to evaluate the clinical outcome and safety of Tocilizumab with 180 participants.The trials for this class of drug for Covid-19 started after some patients in China who were administered drugs such as Tocilizumab showed improvement in their oxygen levels and were discharged from hospital.This class of drugs is called interleukin-6 (IL-6) receptor blockers. IL-6 is a protein that mounts an immune response to infections.",SAN,en,Economic Times India
2020-07-07 06:03:26-05:00,"Pandora's Scary Box, Apple Optimism, Regeneron, Trading Sanofi","Pandora's Scary Box, Apple Optimism?, Regeneron, Trading Sanofi…PAYX",SAN,en,The Street RealMoney
2020-07-06 05:58:49-05:00,"GlaxoSmithKline, Sanofi to Supply UK Government with 60M COVID-19 Vaccine Doses",The UK government is in talks with Sanofi and GlaxoSmithKline to buy 60 million doses of COVID-19 vaccine. The deal would total $624 million.,SAN,en,Coinspeaker
2020-07-05 09:37:02-05:00,"UK to secure 60 million doses of virus vaccine from Sanofi, GSK","According to a newspaper report, Britain was considering taking an option to buy the vaccine should it work in human trials.",SAN,en,South China Morning Post
2020-07-05 09:06:03-05:00,Britain nears $625 million Sanofi/GSK COVID-19 vaccine deal: report,"Britain is close to a 500 million pound ($624 million) supply deal with Sanofi and GlaxoSmithKline for 60 million doses of a potential COVID-19 vaccine, the Sunday Times reported.",SAN,en,Reuters India
2020-07-05 08:42:00-05:00,"COVID-19 vaccine: Britain nears deal for 60 million vaccine doses from Sanofi/GSK, says report","COVID-19 vaccine: A spokeswoman for Britain’s business ministry, which is handling Britain’s supply of potential COVID-19 vaccines, said talks were ongoing with different parties about access but did not confirm if the Sanofi/GSK project was among them.",SAN,en,The Financial Express
2020-07-05 08:16:55-05:00,Glaxosmithkline set to bag £500m UK deal for coronavirus vaccine - CityAM,Pharmaceuticals giants Glaxosmithkline (GSK) and Sanofi are close to securing a £500m deal to supply the UK government 60m doses,SAN,en,City AM
2020-07-05 08:16:55-05:00,Glaxosmithkline set to bag £500m UK deal for coronavirus vaccine,Pharmaceuticals giants Glaxosmithkline (GSK) and Sanofi are close to securing a £500m deal to supply the UK government 60m doses The post Glaxosmithkline set to bag £500m UK deal for coronavirus vaccine appeared first on CityAM .,SAN,en,City AM
2020-07-05 07:37:30-05:00,"Britain Nears 500 Million Pound Deal For Sanofi, GSK COVID-19 Vaccine: Report","Britain is close to agreeing a 500 million pound ($624 million) supply deal with Sanofi and GlaxoSmithKline for 60 million doses of their potential COVID-19 vaccine, the Sunday Times reported.",SAN,en,NDTV
2020-07-05 02:10:35-05:00,Britain nears 500 million sterling supply deal for Sanofi/GSK COVID-19 vaccine - Sunday Times,"Britain is close to agreeing a 500 million pound ($624 million) supply deal with Sanofi and GlaxoSmithKline for 60 million doses of their potential COVID-19 vaccine, the Sunday Times reported.",SAN,en,Reuters UK
2020-07-05 01:53:02-05:00,GlaxoSmithKline : Britain nears 500 million pound supply deal for Sanofi/GSK COVID-19 vaccine - Sunday Times | MarketScreener,"Britain is close to agreeing a 500 million pound supply deal with Sanofi and GlaxoSmithKline for 60 million doses of their potential COVID-19 vaccine, the Sunday Times reported. … | July 5, 2020",SAN,en,MarketScreener
2020-07-04 23:22:16-05:00,"Glaxo, Sanofi near 500 million pound UK vaccine deal: Times","Money would be paid in stages as the vaccine progresses, with final payment made on delivery.",SAN,en,Economic Times India
2020-07-03 08:28:00-05:00,"GLOBAL MARKETS LIVE: Fiat Chrysler, Regeneron, Uber",Fiat Chrysler is considering possible asset disposals ahead of its merger with PSA. Sanofi and its U.S. partner Regeneron failed in a phase III trial of Covid-19. Exxon Mobil is forecasting a…,SAN,en,MarketScreener
2020-07-03 03:48:00-05:00,"Coagulation Factor Deficiency Pipeline Insights Report, 2020 Featuring Sanofi, AryoGen Pharmed Co, Biotest, ICON, and Roche - ResearchAndMarkets.com","DUBLIN--(BUSINESS WIRE)--The ""Coagulation Factor Deficiency - Pipeline Insight, 2020"" drug pipelines has been added to ResearchAndMarkets.com's offering. Coagulation Factor Deficiency Pipeline Insight, 2020 report outlays comprehensive insights of present clinical development scenario and growth prospects across the Coagulation Factor Deficiency market. A detailed picture of the Coagulation Factor Deficiency pipeline landscape is provided, which includes the disease overview and Coagulation Fac",SAN,en,Business Wire
2020-07-03 01:32:04-05:00,Sanofi personifies headache as ‘Pain Man’ in Combiflam Plus campaign - ET BrandEquity,"Conceptualised by Ogilvy, the film is a quirky take on the daily struggles face while balancing tasks with kids, for work and at home…",SAN,en,Economic Times India Brand Equity
2020-07-02 16:08:55-05:00,US bought nearly the entire supply of a key coronavirus drug,"Remdesivir is one of the novel coronavirus treatments that has shown some efficacy, but the drug is already in short supply. The Trump administration purchased nearly the entire remdesivir supply that Gilead Science will manufacture over the next three months. The US government purchased 500,000 doses of remdesivir, much to the dismay of critics from the scientific community and other officials involved in the COVID-19 response. Remdesivir is one of the two drugs that have shown some effectiveness against the novel coronavirus, but remdesivir therapy only works for a specific type of patient. The antiviral can reduce recovery time by several days, one recent study showed, but it won't work in severe cases, and it can't prevent deaths . If anything, more research is required to determine whether remdesivir can be paired with a secondary drug to improve its effectiveness. Even so, remdesivir is included in standard COVID-19 care in the US, and the Trump administration just acquired nearly all the available remdesivir supply.",SAN,en,BGR
2020-07-02 15:07:52-05:00,France ordered to pay up after epilepsy drug manufactured by coronavirus vaccine firm Sanofi caused birth defects,"A French court has ordered the state to compensate three families whose children suffered birth defects due to the anti-epilepsy medication Dépakine. The drugmaker, Sanofi, is currently racing to certify a vaccine for Covid-19. Read Full Article at RT.com",SAN,en,Russia Today
2020-07-02 14:51:53-05:00,"French state must pay families over Sanofi drug linked to birth defects, court rules","A court on Thursday ordered the French state to pay tens of thousands of euros in damages after finding it responsible in a case over birth defects linked to an anti-epilepsy drug made by pharmaceutical giant Sanofi.The French court ordered the state to compensate three families who filed complaints after the women took the medicine and gave birth to children with congenital malformations, autism or learning difficulties.The court ruled that Sanofi and doctors who prescribed the drug Depakine…",SAN,en,South China Morning Post
2020-07-02 10:04:00-05:00,A German biotech that's chasing a coronavirus vaccine confirmed it's working with Tesla after Musk tweeted about developing 'RNA microfactories',"Elon Misk, the outspoken Tesla CEO, tweeted Thursday that his company is working with a German biotech company to build ""RNA microfactories."" Musk called it a ""side project"" for Tesla. A CureVac spokesperson confirmed to Business Insider that the company is working with Tesla. The spokesperson said they are developing ""a prototype of an automated manufacturing unit"" related to printing the genetic material needed for its vaccine. The company spokesperson declined to provide more details on the extent of the collaboration. Visit Business Insider's homepage for more stories . Elon Musk says he's getting into biotech. In late-night tweets , Musk said a German subsidiary of Tesla is building ""RNA microfactories"" for a biotech company that's developing a coronavirus vaccine candidate. The German biotech CureVac confirmed that it's working with Tesla, but provided few details. The two companies are developing ""a prototype of an automated manufacturing unit"" that can print messenger RNA, the genetic material that CureVac builds its vaccines around, the spokesperson said.",SAN,en,Business Insider
2020-07-02 08:59:25-05:00,Court finds France responsible over Sanofi drug linked to birth defects,Sanofi is facing separate charges of aggravated fraud and unintentionally causing injury.,SAN,en,Free Malaysia Today
2020-07-02 04:28:00-05:00,"European Antibiotics Market Assessment and Forecast to 2027 with Profiles of GlaxoSmithKline, Sanofi, Novartis, Bayer and Pfizer - ResearchAndMarkets.com","DUBLIN--(BUSINESS WIRE)--The ""Europe Antibiotics Market Forecast to 2027 - COVID-19 Impact and Regional Analysis By Drug Class; Action Mechanism; and Country"" report has been added to ResearchAndMarkets.com's offering. The European antibiotics market is expected to reach US$ 15,569.8 million by 2027 from US$ 12,457.7 million in 2019. The market is estimated to grow with a CAGR of 3.1% from 2020 to 2027. The antibiotics market is growing primarily due to prevalence of infectious diseases and inc",SAN,en,Business Wire
2020-07-01 12:04:29-05:00,Un cliente recibirá 600.000 euros de Banco Santander por colocarle 'Valores Santander',El Juzgado de Primera Instancia número 10 de Santander ha condenado a Banco Santander a devolver 600.000 euros a un cliente al que colocó 'Valores Santander' sin proporcionarle la información pertinente. La entidad deberá reembolsar al…,SAN,es,Publico
2020-07-01 11:35:42-05:00,"El Corte Inglés cierra financiación por 959,9 millones de euros con aval del Instituto de Crédito Oficial (ICO)","El Corte Inglés ha firmado un nuevo contrato de financiación por un importe máximo de 959,9 millones de euros que cuenta con el aval del Instituto de Crédito Oficial (ICO). La operación permitirá trasladar a este nuevo convenio parte de la anterior línea de crédito firmada el pasado 1 de abril por un total de 1.341 millones de euros, según ha informado a Efe la compañía. El nuevo acuerdo, que ha sido suscrito por un total de 9 entidades financieras, es a cinco años. Con esta financiación, el grupo se asegura la liquidez por un periodo superior al año y sin ningún tipo de garantías. Los bancos no participantes en el préstamo ICO permanecen en el revolving (línea de crédito) hasta su vencimiento en marzo 2021. Los bancos que han participado en esta nueva operación dirigida por el consejero delegado de El Corte Inglés, Víctor del Pozo, han sido el Banco Santander, BBVA, Caixabank, Sabadell, Bankia, Crédit Agricole, Ibercaja, Kutxabank y Liberbank.",SAN,es,ABC Spain
2020-07-01 08:45:42-05:00,"The race for coronavirus treatments and vaccines is heating up. Here are the 9 most important events to watch for in July, from new vaccine trials starting to the first sales of a COVID-19 drug","The summer will be a critical time for the race to develop effective coronavirus treatments and vaccines. Business Insider identified the nine most important events expected to happen in July. Expect a flood of data this month from vaccine and drug programs wrapping up clinical trials. Other promising therapeutics and vaccines are aiming to start human testing. And the speediest vaccine programs, like Moderna's, will soon start massive late-stage trials — the crucial test in seeing how well these experimental shots work in humans. Visit Business Insider's homepage for more stories . The dog days of summer are shaping into a critical stretch for developing COVID-19 drugs and vaccines. There are hundreds of research efforts across the world hunting for a potential cure. Business Insider reviewed what's underway and identified the nine most important events slated for July. That includes potential vaccines from drugmakers like Johnson & Johnson starting human testing, while those that are farther along like Moderna's experimental vaccine should be disclosing detailed results and even starting late-stage studies.",SAN,en,Business Insider
2020-07-01 04:53:00-05:00,"Santander, condenado a devolver 600.000 euros a un cliente por los ""valores Santander""","El Juzgado de Primera Instancia número 10 de Santander ha condenado a Banco Santander a devolver 600.000 euros a un cliente al que colocó 'Valores Santander' sin proporcionarle la información pertinente. En concreto, la entidad deverá reembolsar al cliente 466.443 euros más los intereses legales del dinero. El banco incurrió en responsabilidad contractual al incumplir sus obligaciones de información y adecuada comercialización de los 'Valores Santander', un producto en el que el demandante invirtió 1,5 millones de euros, según la sentencia consultada por Europa Press. De este modo, el cliente recibirá una indemnización y, al mismo tiempo, conservará las acciones del Banco Santander en que se transformaron los 'Valores Santander', que actualmente están valoradas en unos 291.000 euros. ""En el caso que nos ocupa la demandada no ha acreditado (como le incumbía) haber prestado a los demandantes una información escrupulosa, detallada y completa de todas las características del contrato y sus eventuales riesgos"", señala el juez.",SAN,es,El Confidencial
2020-07-01 03:51:00-05:00,"'Santander Ayuda', un instrumento más del banco para paliar los efectos del covid-19",Banco Santander ha lanzado una nueva edición del programa ‘Santander Ayuda’ para apoyar a organizaciones sin ánimo de lucro en la puesta en marcha de proyectos dirigidos a atender las necesidades de los colectivos más afectados por la crisis del Covid-19.,SAN,es,Publico
2020-06-30 20:55:14-05:00,"With no tax, MNCs ramp up dividends","Mumbai: The big dividend rush by MNCs is on. Taking advantage of the absence of dividend distribution tax (DDT), many multinational companies have been doling out large dividends over the past two months. Finance minister Nirmala Sitharaman in her budget for 20/21 removed the dividend distribution tax on corporates and transferred it to investors from April 1. The trend of large dividend payouts is expected to continue, say experts.Pharma major Pfizer paid a special dividend of Rs 320 per share, or 3,200 per cent, last month compared to Rs 22.50 last year. Sanofi India paid Rs 106 per share dividend and a one-time special dividend of Rs 243 per share recently. Sanofi’s payout last year was 66 per share compared to this year’s total dividend of Rs 349 per share.“The abolition of DDT augurs well for MNCs as the foreign parent entity can claim credit for the corporate taxes paid in India on dividends in their home jurisdictions,” said Amit Tandon, MD of proxy advisory firm Institutional Investor Advisory Services, (IiAS). “MNCs are likely to pay higher dividends from current fiscal onwards.”Oracle Financial Services paid a dividend of Rs 180 per share.",SAN,en,Economic Times India
2020-06-30 17:04:14-05:00,Banco Santander S A : Santander appoints three leading technologists to support its strategy and digital transformation | MarketScreener,"Mr Chávez, a US citizen, brings extensive experience in the financial sector having worked for 20 years at Goldman Sachs, including as a partner since 2006, and a member of the… | July 1, 2020",SAN,en,MarketScreener
2020-06-30 12:57:00-05:00,Banco Santander reconoce una exposición de 490 M a la aerolínea chilena quebrada Latam,"Banco Santander ha reconocido una exposición de 549 millones de dólares (488 millones de euros) a la aerolínea Latam Airlines, un grupo chileno que se declaró en quiebra el pasado 26 de mayo, según un documento remitido por la entidad española al supervisor estadounidense. El banco presidido por Ana Botín ha señalado que se encuentra entre los principales acreedores sin garantías de Latam, principalmente por el programa de fidelización de viajeros frecuentes que Banco Santander y la compañía ponen a disposición de los clientes a través de las tarjetas de crédito de la entidad, tal y como adelantó 'Expansión'. En cualquier caso, Banco Santander cree que aún no es necesario reconocer ningún deterioro , si bien ha admitido que estos activos ""pueden verse afectados"" en el futuro como consecuencia de la declaración de quiebra y que no puede asegurar que el proceso de reestructuración que llevará a cabo la aerolínea no tendrá un efecto material adverso en su negocio. Santander ultima el fichaje de William Vereker como presidente de UK María Igartua El que fuera enviado comercial de la ex primera ministra Teresa May será el nuevo presidente de Santander Reino Unido ha sido el elegido para sustituir a Shriti Vadera Latam, la mayor aerolínea de Latinoamérica y sus filiales en Chile, Perú, Colombia, Ecuador y Estados Unidos se declararon en bancarrota o concurso de acreedores en un tribunal de Nueva York tras el impacto de la crisis del coronavirus.",SAN,es,El Confidencial
2020-06-30 11:55:37-05:00,Banco Santander ficha a un antiguo directivo de Goldman Sachs para la revolución digital,"Banco Santander prosigue con su transformación digital. Tal como ha comunicado a la Comisión Nacional del Mercado de Valores (CNMV), la entidad ha nombrado a R. Martin Chávez como consejero independiente dentro de su estrategia tecnológica. Así, formará parte de las comisiones de retribuciones; de supervisión de riesgos, regulación y cumplimiento; y de innovación y tecnología. Este se trata de un antiguo directivo de Goldman Sachs. Un banquero de inversión con 20 años de experiencia en esa firma, de la que llegó a ocupar puestos de responsabilidad como Chief Information Officer (CIO) y Chief Financial Officer (CFO). En 2019 ya había abandonado la entidad. «Comenzó su carrera como ingeniero de software y fundó distintas empresas tecnológicas en Silicon Valley y Nueva York, de modo que también aporta experiencia digital al consejo», ha informado el Santander al supervisor español. Chávez sustituirá a Esther Giménez-Salinas, que deja el consejo tras ocho años. La revolución tecnológica del banco no termina aquí.",SAN,es,ABC Spain
2020-06-30 08:40:03-05:00,Banco Santander S A : and Spanish Chamber of Commerce 2019 SME of the Year Award goes to Señorío de Montanera | MarketScreener,"The ceremony also included runner-up awards for Internationalisation, for IDE Electric, from Zaragoza; Digitalisation and Innovation, for Toledo company Zennio Avance y… | June 30, 2020",SAN,en,MarketScreener
2020-06-30 07:22:01-05:00,Banco Santander S A : Santander Close to Naming William Vereker as New UK Chairman -Financial Times | MarketScreener,"--Banco Santander SA is close to naming William Vereker as its new U.K. chairman, the Financial Times reports, citing sources familiar with the matter. --Mr. Vereker, the former business envoy… | June 30, 2020",SAN,en,MarketScreener
2020-06-29 22:00:00-05:00,Paz hasta refinanciar: claves del asalto fallido en la junta de Prisa,"Al final, hubo más ruido que nueces. Convencido por los argumentos de los principales acreedores de Prisa, el fondo Amber Capital convino en resolver la junta de accionistas sin hacer más sangre de la ya vertida durante los últimos meses, cuando trabajó en un plan para cambiar el equilibrio de poderes del consejo de administración a su favor, con tele asistencia incluida de Moncloa, tal como este lunes destacaban medios internacionales. Esta tregua entre Banco Santander y Joseph Oughourlian quedó reflejada en el sentido de los votos, ya que Javier Monzón fue reelegido con amplia mayoría y solo con la abstención del fondo activista. Hasta Telefónica, con su 10%, que jugó a la neutralidad hasta última hora, es decir, abstenerse en caso de conflicto, apoyó la renovación del presidente, aunque en el plan B su sustituto habría sido Manuel Mirat , actual consejero delegado. Mandar en Prisa: entre la soga de Monzón y la tibieza de Pallete Carlos Hernanz El mundo del dinero encierra claves de poder y de intereses que explican el sentido de muchas operaciones, movimientos y desenlaces.",SAN,es,El Confidencial
2020-06-28 13:23:19-05:00,The Week Ahead In Biotech (June 28- July 4): Pending Clinical Readouts In Focus During A Short Holiday Week,"Biotech stocks went on a seesaw ride along with the broader markets in the week ended June 26. Yet there were some encouraging developments on the COVID-19 vaccine development front. Vaccine companies are going all out, forging alliances and adding personnel that could help them be successful in their quest. Translate Bio Inc (NASDAQ: TBIO ) rallied strongly earlier in the week on the back of news concerning an expansion of its vaccine development partnership with Sanofi SA (NASDAQ: SNY ) but eventually gave back some of the gains following a secondary offering. Vaxart Inc (NASDAQ: VXRT ), another COVID-19 vaccine play , rallied during the week. The FDA review machinery worked overtime, ruling on a host of investigational therapies. Three biopharma companies went public this week, raising a combined $485 million in gross proceeds. The following are key catalysts in the unfolding week: Conferences Cantor Fitzgerald's Virtual Symposium: ""Winning Ways to Treat Infections and COVID-19: Tuesday, June …",SAN,en,Benzinga
2020-06-27 07:12:35-05:00,"Sanofi, GSK, AstraZeneca, Moderna: The race towards a covid-19 vaccine","Sanofi, one of the world's main vaccine producers, is working on the development of two vaccines against Covid-19, expected to be produced in 2021.The French",SAN,en,Brussels Times
2020-06-26 15:10:00-05:00,Tiny biotechs are touting ties to Trump's Operation Warp Speed coronavirus program and sending their stocks soaring (VXRT),"The Trump administration's coronavirus vaccine program, called Operation Warp Speed, has been shrouded in secrecy since launching in May. Some tiny biotechs have started to announce they have been selected as part of Operation Warp Speed, sending their stocks soaring. The government has said that Operation Warp Speed selected 14 vaccine research programs, but it has declined to specify which companies are involved. Warp Speed is the federal government's effort to have 300 million doses of a safe and effective vaccine by January 2021. Visit Business Insider's homepage for more stories . On Friday, a tiny San Francisco biotech made a bold claim. The biotech called Vaxart said it was chosen by Operation Warp Speed, an effort from the Trump administration to speed up work on a coronavirus vaccine and make an immunization broadly available by early next year. In reality, its vaccine candidate has just been selected for early research in primates. Other major companies are already testing coronavirus vaccines in people.",SAN,en,Business Insider
2020-06-26 12:09:14-05:00,Banco Santander S A : Financial Times group awards Santander Private Banking's technological innovation | MarketScreener,"Professional Wealth Management magazine, part of Financial Times group, awarded Santander Private Banking with its Wealth Tech award for the best private bank in Latin… | June 26, 2020",SAN,en,MarketScreener
2020-06-26 04:56:46-05:00,"Exclusive: Sanofi considering up to 1,680 job cuts in Europe - sources | MarketScreener","Sanofi is considering cutting up to 1,680 jobs in Europe, two sources familiar with the matter said on Friday, as the French drugmaker outlined plans to reduce costs to staff… | June 26, 2020",SAN,en,MarketScreener
2020-06-25 04:32:00-05:00,"Coronavirus vaccine update: Moderna, AstraZeneca, Sanofi make headway",Coronavirus vaccine news: Johnson and Johnson has expedited its trials for the COVID vaccine. The final stage of the trial expected to begin in September has been pushed up to the second half of July,SAN,en,Business Today
2020-06-24 07:07:18-05:00,"The Daily Biotech Pulse: MediciNova On Track For European Patent Win, Partial Clinical Hold Lifted For Innate Pharma, Tela Bio Details Coronavirus Impact","Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 23) ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD ) Acceleron Pharma Inc (NASDAQ: XLRN ) ADC Therapeutics SA (NYSE: ADCT ) Adverum Biotechnologies Inc (NASDAQ: ADVM ) Aeglea Bio Therapeutics Inc (NASDAQ: AGLE ) Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY ) Amicus Therapeutics, Inc. (NASDAQ: FOLD ) Ascendis Pharma A/S (NASDAQ: ASND ) Avidity Biosciences Inc (NASDAQ: RNA ) (went public June 12) BioXcel Therapeutics Inc (NASDAQ: BTAI ) Burning Rock Biotech Ltd (NASDAQ: BNR ) (went public June 12) Corcept Therapeutics Incorporated (NASDAQ: CORT ) Crispr Therapeutics AG (NASDAQ: CRSP ) (moved on analyst action) Dr.Reddy's Laboratories Ltd (NYSE: RDY ) Dyadic International, Inc. (NASDAQ: DYAI ) Editas Medicine Inc (NASDAQ: EDIT ) GENMAB A/S/S ADR (NASDAQ: GMAB ) Halozyme Therapeutics, Inc. (NASDAQ: HALO ) ) Hologic, Inc. (NASDAQ: HOLX ) Horizon Therapeutics PLC (NASDAQ: HZNP ) Immunomedics, Inc.",SAN,en,Benzinga
2020-06-24 06:22:03-05:00,SANOFI : UBS reiterates its Buy rating | MarketScreener,"UBS is positive on the stock with a Buy rating. The target price continues to be set at EUR 101. | June 24, 2020",SAN,en,MarketScreener
2020-06-23 15:47:41-05:00,Sanofi Accelerates Its Timeline for Coronavirus Vaccine Development,The French drugmaker is testing two types of vaccines in a bid to catch up to competitors.,SAN,en,New York Times
2020-06-23 12:42:36-05:00,"Sanofi Accelerates Coronavirus Vaccine Timeline, Says Approval Could Come In First Half Of 2021","Sanofi SA (NASDAQ: SNY ), which is in the race to develop a vaccine for SARS-CoV-2, which causes COVID-19, is unveiling an accelerated timeline for the vaccine program it is pursuing with GlaxoSmithKline plc (NYSE: GSK ). Sanofi has also expanded its collaboration with mRNA vaccine company Translate Bio Inc (NASDAQ: TBIO ). Sanofi Moves Up Vaccine Rollout Timeline: Sanofi said it expects to begin a Phase 1/2 study of the recombinant protein vaccine candidate it is co-developing with GlaxoSmithKline in September, and full approval is likely … Full story available on Benzinga.com",SAN,en,Benzinga Feeds
2020-06-23 10:59:43-05:00,Sanofi hofft auf COVID-19-Impfstoff bis zum 1. Halbjahr 2021 und kooperiert mit Translate Bio - Aktie dreht ins Plus,"Bislang war von der zweiten Hälfte nächsten Jahres die Rede gewesen. Wie die Sanofi SA mitteilte, arbeite man mit Hochdruck an der Entwicklung eines Impftstoffs. Der französische Pharmariese, der den Impfstoff gemeinsam mit seinem britischen Wettbewerber GlaxoSmithKline …",SAN,de,Finanzen AT
2020-06-23 10:40:31-05:00,Why Shares of Translate Bio Are Surging Higher,"Shares of the small-cap mRNA therapeutics company Translate Bio Inc (NASDAQ: TBIO ) were ripping higher Tuesday. What Happened: Translate Bio and Sanofi SA (NASDAQ: SNY ) announced an expansion to their 2018 collaboration and licensing agreement to develop mRNA vaccines for infectious diseases. The expanded collaboration will draw upon Translate Bio's more than a decade of experience in mRNA R&D and Sanofi's leadership in vaccine R&D, the companies said. The Financials: The agreement provides for Translate Bio receiving a total upfront payment of $425 million, and potential future milestones and other payments … Full story available on Benzinga.com",SAN,en,Benzinga
2020-06-23 09:28:00-05:00,"Translate Bio’s Covid-19 Vaccine Gets $1.9 Billion Backing From Sanofi, Stock Soars",The Translate Bio/Sanofi vaccine against Covid—using messenger RNA technology—could start human trials by this year’s fourth quarter.,SAN,en,Barron's
2020-06-23 09:07:08-05:00,Why the Sanofi and Translate Bio Deal Is Win-Win,No summary available.,SAN,en,24/7 Wall street
2020-06-23 08:07:00-05:00,"World Coronavirus Dispatch: Brazil, India struggle as global cases hit 9 mn","Limited Hajj in Saudi, US economy on recovery path, Sanofi's Covid-19 drug and other global news on the impact of the pandemic",SAN,en,Business Standard
2020-06-23 06:57:59-05:00,"The Daily Biotech Pulse: Sanofi Expedites COVID-19 Vaccine Timeline, Apyx Cleared For Market Expansion, Miragen's Positive Readout","The following is a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 22) ADC Therapeutics SA (NYSE: ADCT ) Adverum Biotechnologies Inc (NASDAQ: ADVM ) Aeglea Bio Therapeutics Inc (NASDAQ: AGLE ) Affimed NV (NASDAQ: AFMD ) - announced presentation at the AACR Virtual Meeting II, data on the Bristol-Myers Squibb Co (NYSE: BMY ) unit Genentech's RO7297089 and AFM24 developed from Affimed's ROCK platform Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY ) Amicus Therapeutics, Inc. (NASDAQ: FOLD ) Ascendis Pharma A/S (NASDAQ: ASND ) (presented at the AACR Virtual Meeting II with pre-clinical data for oncology product candidate) Atossa Therapeutics Inc (NASDAQ: ATOS ) Burning Rock Biotech Ltd (NASDAQ: BNR ) (announced full exercise of over-allotment option in IPO) Cytokinetics, Inc. (NASDAQ: CYTK ) Dyadic International, Inc. (NASDAQ: DYAI ) Evoke Pharma Inc (NASDAQ: EVOK ) ( announced FDA approval for inhaled formulation of its gastroparesis drug) Five Prime Therapeutics Inc (NASDAQ: FPRX ) (moved higher on an analyst upgrade) GENMAB A/S/S ADR (NASDAQ: GMAB ) GenMark Diagnostics, Inc (NASDAQ: GNMK ) Halozyme Therapeutics, Inc.",SAN,en,Benzinga
2020-06-23 06:15:34-05:00,Sanofi clinches US$2 billion vaccines deal with Translate Bio,"French drugmaker Sanofi has agreed a potential US$2 billion deal with U.S. biotech company Translate Bio to make vaccines, expanding their collaboration in development of an inoculation against COVID-19.",SAN,en,Channel NewsAsia
2020-06-23 05:38:02-05:00,Translate Bio : Shares Surge on Expanded Deal With Sanofi | MarketScreener,"By Colin Kellaher Shares of Translate Bio Inc. surged nearly 70% in premarket trading Tuesday after the clinical-stage therapeutics company announced an expanded collaboration and license… | June 23, 2020",SAN,en,MarketScreener
2020-06-23 05:15:03-05:00,Principia : Sanofi Enrolls First Patient in Relapsing Multiple Sclerosis Study | MarketScreener,"By Colin Kellaher Principia Biopharma Inc. on Tuesday said its partner Sanofi SA has enrolled the first patient in a phase 3 study of SAR442168 in relapsing multiple sclerosis. The South… | June 23, 2020",SAN,en,MarketScreener
2020-06-23 04:46:43-05:00,Sanofi hofft auf COVID-19-Impfstoff bis zum 1. Halbjahr 2021 und kooperiert mit Translate Bio - Aktie etwas leichter,"Bislang war von der zweiten Hälfte nächsten Jahres die Rede gewesen. Wie die Sanofi SA mitteilte, arbeite man mit Hochdruck an der Entwicklung eines Impftstoffs. Der französische Pharmariese, der den Impfstoff gemeinsam mit seinem britischen Wettbewerber GlaxoSmithKline …",SAN,de,Finanzen AT
2020-06-23 04:04:06-05:00,Sanofi and Translate Bio expand vaccine collaboration,Sanofi and Translate Bio will expand their vaccines collaboration in a deal that could earn the U.S. biotech company more than $2 billion from the French drugmaker.,SAN,en,Reuters
2020-06-23 03:31:00-05:00,Coronavirus: Sanofi expects approval of potential vaccine by first half of 2021,Sanofi Chief Executive Paul Hudson said the firsts in the race now were not assured of securing victory,SAN,en,Business Today
2020-06-23 02:57:33-05:00,"Sanofi, Translate Bio Ramp Up Billion-Dollar mRNA Vaccine Collaboration","Sanofi (SNY) and Translate Bio (TBIO) have announced that they are expanding their existing 2018 collaboration and license agreement to develop mRNA vaccines … The post Sanofi, Translate Bio Ramp Up Billion-Dollar mRNA Vaccine Collaboration appeared first on Smarter Analyst .",SAN,en,Smarter Analyst
2020-06-23 02:40:52-05:00,Coronavirus: Markets rise on vaccine hopes and lockdown easing in England,French drugmaker Sanofi said it hoped a potential vaccine could be signed off sooner than expected.,SAN,en,Yahoo Finance UK
2020-06-23 00:49:36.902000-05:00,Sanofi and Translate Bio to Expand Vaccine Collaboration,"Healthcare companies Sanofi and Translate Bio said on Tuesday they would expand collaboration on developing vaccines, in a deal which will give Translate Bio $425 million (£340 million) in upfront payments.",SAN,en,New York Times
2020-06-23 00:36:01-05:00,Sanofi : Translate Bio Expand Collaboration to Develop mRNA Vaccines | MarketScreener,"By Jessica Sier Sanofi SA said Tuesday that it will further its investment in U.S.-based Translate Bio Inc. to pursue new mRNA vaccines aimed at broadly addressing infectious diseases. … | June 23, 2020",SAN,en,MarketScreener
2020-06-23 00:15:28-05:00,Translate Bio : Sanofi and Translate Bio to expand vaccine collaboration | MarketScreener,"Healthcare companies Sanofi and Translate Bio said on Tuesday they would expand collaboration on developing vaccines, in a deal which will give Translate Bio $425 million in upfront… | June 23, 2020",SAN,en,MarketScreener
2020-06-23 00:01:48-05:00,"SANOFI RECEVRA LES DROITS MONDIAUX ExclusifS POUR DÉVELOPPER, FABRIQUER ET COMMERCIALISER DES VACCINS CONTRE LES MALADIES INFECTIEUSES GRÂCE À LA TECHNOLOGIE DE TRANSLATE BIO","SANOFI RECEVRA LES DROITS MONDIAUX EXCLUSIFS POUR DÉVELOPPER, FABRIQUER ET COMMERCIALISER DES VACCINS CONTRE LES MALADIES INFECTIEUSES GRÂCE À LA TECHNOLOGIE DE TRANSLATE BIO …",SAN,en,Zonebourse
2020-06-22 06:32:53-05:00,"Sanofi, Regeneron Win China Approval For Dupixent Dermatitis Drug","French drugmaker Sanofi (SNYNF) has received regulatory approval in China for its Dupixent drug, which it is developing together with Regeneron Pharmaceuticals, Inc … The post Sanofi, Regeneron Win China Approval For Dupixent Dermatitis Drug appeared first on Smarter Analyst .",SAN,en,Smarter Analyst
2020-06-22 04:04:48-05:00,What Ambani & RPG boss discuss on video-calls,"NEW DELHI: Two days after Reliance Industries Limited (RIL) announced it became a net-debt free company months ahead of its March 2021 target, Harsh Goenka got on a video-call with Mukesh Ambani on Sunday to discuss the brilliance of India's richest man. The RPG Enterprise Chairman took to Twitter to share a screenshot of the two business tycoons talking on a Zoom video-call during the weekend. The 62-year-old businessman lauded the RIL Chairman for making India’s biggest company net-debt free amidst the global slowdown and the Covid-19 impact on the country's economy. He also praised Ambani for understanding the future of tech and pivoting his 'core business from falling oil & petrochemicals to rising tech'. He further said that this is a feat only one man could achieve, when he got the largest global investors to give their money.Feats only one man could achieve ~Making India’s biggest company totally net-debt free amidst global slowdown & C… https://t.co/3YtuoGf91m— Harsh Goenka (@hvgoenka) 1592733061000The picture of the duo sparked a lot of excitement and discussion on the micro-blogging site amongst Goenka's 1.5 million Twitter followers.",SAN,en,Economic Times India
2020-06-20 01:38:26.459000-05:00,"RIL enters $ 150b club, highest mcap by an Indian company","New Delhi: Reliance Industries Limited (RIL) has become the first Indian company to enter the exclusive club of $150 billion in market capitalisation among the worlds most valuable companies, and is now ranked 58 on the list. RIL now has a market capitalisation of $151.2 billion and this is the highest ever valuation of an Indian company. The major milestone comes on a day when RIL announced it has become a net debt-free company. Shares of Reliance Industries continued its bull run on Friday afternoon to cross the Rs 1,700-mark for the first time. The stock hit a fresh all-time high of Rs 1,706.55 and its market capitalisation crossed Rs 10.81 lakh crore. In the exclusive club of $150 billion mcap companies, RIL is now ahead of global leaders like Vanguard, Unilever, China Mobile, McDonalds, AstraZeneca, T Mobile, Amgen, Costco, Bank of China, Sanofi, Accenture, Royal Dutch Shell, Bristol Myer Squibb, Philip Morris, BHP group, Texas Instruments, Invesco, American Tower, Wells Fargo, Citigroup and IBM, among others.",SAN,en,Sify.com
2020-06-19 13:10:02-05:00,"Regeneron Pharmaceuticals : , Sanofi Dupixent Single-Dose Pen Approved By FDA | MarketScreener","By Chris Wack Regeneron Pharmaceuticals Inc. and Sanofi said Friday the U.S. Food and Drug Administration has approved a 300-mg single-dose pre-filled pen for Dupixent dupilumab. The… | June 19, 2020",SAN,en,MarketScreener
2020-06-17 14:32:06-05:00,"Sanofi : FINANCIAL RESULTS July 29, 2020 | MarketScreener","FINANCIAL RESULTS July 29, 2020 Second quarter 2020 results Attachments Permalink Disclaimer Sanofi SA published… | June 17, 2020",SAN,en,MarketScreener
2020-06-17 13:47:05-05:00,Banco Santander S A : Santander InnoVentures invests in US alternative lender Upgrade | MarketScreener,"London and San Francisco, 17 June 2020 - PRESS RELEASE Santander InnoVentures, Santander Group's venture capital fund, today announces its investment into Upgrade, an… | June 17, 2020",SAN,en,MarketScreener
2020-06-17 09:23:00-05:00,"Global Hydroxychloroquine Drugs Market (2020 to 2025) - Featuring Novartis AG, Sanofi & Amneal Pharmaceuticals Among Others - ResearchAndMarkets.com","DUBLIN--(BUSINESS WIRE)--The ""Global Hydroxychloroquine Drugs Market - Forecasts from 2020 to 2025"" report has been added to ResearchAndMarkets.com's offering. The global hydroxychloroquine drugs market is projected to grow at a CAGR of 3.08% to reach US$1,174.129 million by 2025, from US$978.745 million in 2019. Rising prevalence of chronic rheumatoid conditions, malaria, and lupus among the individuals is pushing the demand for hydroxychloroquine drugs. According to the World Health Organizat",SAN,en,Business Wire
2020-06-17 08:34:03-05:00,Banco Santander S A : Santander Invests in US Alternative Lender Upgrade | MarketScreener,"By Pietro Lombardi Banco Santander SA has invested in Upgrade, a U.S. alternative lender focused on offering affordable credit to mainstream consumers. Santander InnoVentures, the… | June 17, 2020",SAN,en,MarketScreener
2020-06-17 05:52:06-05:00,Banco Santander S A : Santander Green Bond Framework June 2020 | MarketScreener,"Banco Santander, S.A. Green Bonds Framework September 27th, 2019 Table of Contents … | June 17, 2020",SAN,en,MarketScreener
2020-06-17 05:52:05-05:00,Banco Santander S A : Santander Sustainable Framework June 2020 | MarketScreener,"Banco Santander, S.A. Global Sustainable Bonds Framework September 25, 2019 Table of Contents … | June 17, 2020",SAN,en,MarketScreener
2020-06-16 12:55:00-05:00,Macron Announces Pharma Giant Sanofi to Invest $689Mln in Vaccine Research in France,No summary available.,SAN,en,UrduPoint
2020-06-16 08:11:08-05:00,Court confirms groundless of Avista's claims against Sanofi pharma company,The northern business court of appeals has made a decision in favor of Sanofi pharmaceutical company in the dispute with Avista Financial Company LLC.,SAN,en,Interfax Ukraine (in English)
2020-06-16 07:47:49-05:00,UK scientists to start immunizing people to coronavirus with new vaccine this week,"Scientists at Imperial College London will start immunizing people in Britain this week with their experimental coronavirus shot, while pharmaceutical company Sanofi and the French government",SAN,en,Al Arabiya
2020-06-16 06:38:48-05:00,Coronavirus live updates: Sanofi to invest over $600 million in vaccine sites; global cases top 8 million,"The coronavirus has infected more than 8.05 million people around the world as of Tuesday, killing at least 437,283 people.",SAN,en,CNBC
2020-06-14 09:58:00-05:00,Sanofi and Sobi donate up to 500 million additional IUs of clotting factor to WFH Humanitarian Aid Program,"CAMBRIDGE, Mass. , June 14, 2020 /PRNewswire/ -- Sanofi and Sobi™, together with the World Federation of Hemophilia (WFH) and WFH USA , today announced an extension of their support of the WFH Humanitarian Aid Program with an additional donation of up to 500 million IUs of factor therapy for humanitarian use, fulfilling the 2014 pledge to donate up to an unprecedented 1 billion IUs over a ten-year period. Since the initial pledge to donate their medicine to the program, over 450 million IUs have been provided and over 17,200 people with hemophilia have been treated with factor donated by Sanofi and Sobi between 2015 and 2019. Additionally, the companies will continue to provide financial support for initiatives such as treatment, access and education programs for a period up to five years, ""Through this partnership with Sanofi and Sobi, our Founding Visionary Contributors, we have been able to significantly expand the reach of the WFH Humanitarian Aid Program, which is leading to a paradigm shift in the management of hemophilia in areas with limited or no access to treatment and care,"" said Alain Baumann , Chief Executive Officer, World Federation of Hemophilia. ""With their continued support, we are confident that people with hemophilia in these countries will continue to receive much needed treatment that is both predictable and sustainable – the foundation of the WFH Humanitarian Aid Program.",SAN,en,Benzinga Feeds
2020-06-14 06:02:01-05:00,"Coronavirus (Covid-19) vaccines status check: Moderna, Sinovac Biotech gear up for final phase trials","Coronavirus, Covid-19 Vaccine India Latest News Update Today in India and World: Among front runners in human trials are Covid-19 vaccines being developed by AstraZeneca, Pfizer, BioNtech, Johnson & Johnson, Merck, Moderna, Sanofi and China’s CanSino Biologics",SAN,en,The Indian Express
2020-06-12 16:38:09-05:00,Banco Santander Brasil S A : 06/12/2020 - MDB - Risk and Compliance Committee | MarketScreener,"BANCO SANTANDER S.A. Public Company with Authorized Capital Corporate Taxpayer ID No. 90.400.888/0001-42 Company… | June 12, 2020",SAN,en,MarketScreener
2020-06-12 07:01:00-05:00,The top scientist at the world's biggest healthcare company told us the top challenge facing J&J and rivals racing to develop a coronavirus vaccine (JNJ),"The leading coronavirus vaccines will soon face their biggest test yet: seeing if they actually work. Top drugmakers are planning to launch massive clinical trials over the next few months. These studies will each recruit tens of thousands of volunteers. Within the next three months, Moderna, AstraZeneca, Pfizer, and Johnson & Johnson are all aiming to start these critical studies. The biggest challenge in running these trials is enrolling people in areas with high rates of infection, J&J's Chief Scientific Officer Paul Stoffels told Business Insider. Picking the right geographic areas could be the difference between these trials finishing in as little as three months or taking as long as a year, Stoffels said. Visit Business Insider's homepage for more stories . The top coronavirus vaccine programs are entering a new chapter. Governments, nonprofits and pharmaceutical companies around the world have made it clear: it's time to execute on the global stage. A safe and effective vaccine is widely seen as the way to end this pandemic.",SAN,en,Business Insider
2020-06-11 11:58:10-05:00,Banco Santander S A : Santander Spain signs on to the United Nations Global Compact's gender equality programme | MarketScreener,"Madrid, 10 June 2020 - Santander Spain has signed on to the Target Gender Equality programme launched in 19 countries by the United Nations Global Compact with the goal of increasing… | June 11, 2020",SAN,en,MarketScreener
2020-06-11 08:29:26-05:00,Sanofi Seeks Growth Strategy For Dupixent Drug To Meet €10B Peak Sales Target,"French drugmaker Sanofi (SNYNF) said it is exploring additional growth opportunities for its Dupixent drug, which it is developing together with Regeneron Pharmaceuticals, … The post Sanofi Seeks Growth Strategy For Dupixent Drug To Meet €10B Peak Sales Target appeared first on Smarter Analyst .",SAN,en,Smarter Analyst
2020-06-11 00:17:15-05:00,Regeneron Pharmaceuticals : Healthcare group Sanofi upbeat on Dupixent opportunities | MarketScreener,"French healthcare company Sanofi outlined more growth opportunities on Thursday for the Dupixent product it is developing along with partner Regeneron. Dupixent is used to… | June 11, 2020",SAN,en,MarketScreener
2020-06-09 16:45:15-05:00,Sanofi (SNY) Gains As Market Dips: What You Should Know,"Sanofi (SNY) closed at $50.85 in the latest trading session, marking a +0.08% move from the prior day.",SAN,en,Zacks Investment Research
2020-06-09 15:30:00-05:00,Denali Therapeutics Provides Broad Update on Its RIPK1 Program Partnered With Sanofi,Denali and Sanofi pause DNL747(a) clinical activities based on the totality of DNL747 data and a superior profile of backup compound DNL788(b)Denali and…,SAN,en,GlobeNewswire
2020-06-09 09:31:00-05:00,"The Zacks Analyst Blog Highlights: Mastercard, Novartis, Boeing Company, Sanofi and Honeywell International","The Zacks Analyst Blog Highlights: Mastercard, Novartis, Boeing Company, Sanofi and Honeywell International",SAN,en,Zacks Investment Research
2020-06-09 05:27:03-05:00,SANOFI : Gets a Buy rating from Morgan Stanley | MarketScreener,"Mark Purcell from Morgan Stanley retains his positive opinion on the stock with a Buy rating. The target price is reviewed upwards from EUR 101 to EUR 107. | June 9, 2020",SAN,en,MarketScreener
2020-06-08 17:53:02-05:00,Banco Santander Brasil S A : 06/08/2020 - Synthetic voting map received by the Bookkepper - on 06/10/2020 | MarketScreener,"[Free English Translation] BANCO SANTANDER S.A. Public-held Company with Authorized Capital Corporate… | June 9, 2020",SAN,en,MarketScreener
2020-06-08 17:26:07-05:00,4 Analysts On Why The Rumored AstraZeneca-Gilead Deal Is Unlikely To Materialize,"The weekend was abuzz with rumors of U.K. pharma giant AstraZeneca plc's (NYSE: AZN ) reported interest in U.S.-based large-cap biopharma Gilead Sciences, Inc. (NASDAQ: GILD ). The report polarized investors and the sell-side alike as they debated the pros and cons of a potential combination. A report in The London Times suggested a union is unlikely, as AstraZeneca is focused on its promising oncology pipeline and its recent coronavirus vaccine program. An M&A deal at this juncture and at such a scale would serve a distraction from these focus areas, the report said. Investors Skeptical Of Deal: The odds of AstraZeneca buying Gilead over the next 12 months is about 33%, Mizuho Securities analyst Salim Syed said, citing a survey of investors that are predominantly hedge funds. When asked about the maximum price AstraZeneca could pay for Gilead, respondents on average suggested a $102-per-share price could be in offing. An average of $98 was what investors said is the minimum price per share Gilead should accept from AstraZeneca.",SAN,en,Benzinga
2020-06-08 11:57:00-05:00,Here's how 13 top drugmakers are sprinting to develop a coronavirus vaccine or treatment that can halt this pandemic,"Leading drugmakers are researching treatments and vaccines for the novel coronavirus. The small biotech Moderna has leaped to the front of the race, with a vaccine candidate that's already had some results. Pharma giants like Johnson & Johnson, Sanofi, Pfizer, and Merck have also jumped into the vaccine race. There's no assurance the vaccines will work. A vaccine might be available for emergency use by the fall, but likely won't be available widely until 2021 at the earliest, top US health officials have said. In the meantime, treatments are needed for those who have COVID-19, the disease caused by the virus. Drug companies including Gilead Sciences have been looking to repurpose drugs in that effort. Visit Business Insider's homepage for more stories . Drugmakers are racing to find treatments and vaccines to counter the coronavirus pandemic. The companies — including giants like Johnson & Johnson, Sanofi, Merck, and Gilead Sciences — are taking a variety of approaches. Some are hunting for near-term treatment options, either by testing existing drugs or investigating new antivirals or antibodies.",SAN,en,Business Insider
2020-06-08 10:45:03-05:00,This is Why Sanofi (SNY) is a Great Dividend Stock,"Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Sanofi (SNY) have what it takes? Let's find out.",SAN,en,Zacks Investment Research
2020-06-06 15:02:00-05:00,THE DIGITAL THERAPEUTICS EXPLAINER: How digital treatments could be a $9 billion opportunity by 2025,"This is a preview of The Digital Therapeutics research report from Business Insider Intelligence. Purchase this report. Business Insider Intelligence offers even more healthcare coverage with Digital Health Pro. Subscribe today to receive industry-changing digital health news and analysis to your inbox. A new class of medicine — digital therapeutics (DTx) — has emerged, offering a novel means of treating the swelling number of patients with chronic diseases and keeping associated costs down. Digital therapeutics deliver evidence-based therapies via software — often in the form of consumer-facing mobile health apps — that replace or complement the existing treatment of a disease. They diverge from the broader digital health market in that they must be approved by regulatory bodies — and displaying proof-of-concept is at the core of their model. DTx vendors leverage their tech to treat chronic conditions, which gobble up the lion's share of the US' healthcare spending: Business Insider Intelligence estimates that the US shelled out up to $3.3 trillion on chronic disease in 2018.",SAN,en,Business Insider
2020-06-03 09:23:29-05:00,Falhas em linhas de crédito impedem retomada das pequenas empresas,"Bancos até agora só distribuíram 5% dos R$ 40 bilhões da linha de crédito para ajudar no pagamento da folha de pequenas e médias empresas. A maior parte das pequenas e médias empresas brasileiras, que respondem por metade dos empregos e 30% do PIB do país, não estão tendo acesso ao dinheiro prometido pelo governo federal para ajudá-las a atravessar a crise do coronavírus, colocando em risco a retomada econômica. Os bancos até agora só distribuíram 5% dos R$ 40 bilhões da linha de crédito para ajudar no pagamento da folha de pequenas e médias empresas, fortemente afetadas pelas quarentenas. Em crise, pequenas empresas têm dificuldade de acessar linhas de crédito Coronavírus e pequenos negócios: veja o que foi autorizado pelo governo e alternativas para enfrentar a crise José Eutimio Brandão Jr. dispensou 50 dos 170 funcionários que trabalhavam em seus empreendimentos: um bar, restaurante, padaria e uma boate em Alagoas. Brandão tentou tomar um crédito para ajudar a pagar os funcionários que sobraram, mas diz que seu banco rejeitou o pedido porque o faturamento geral do seu grupo supera os R$ 10 milhões de limite máximo. ""A taxa de juros é baixa, próxima à Selic, os bancos não querem emprestar porque não vão ganhar dinheiro"", disse Brandão à Reuters.",SAN,pt,Globo
2020-06-02 15:51:06-05:00,"Sanofi's CEO On Cancer Research, Coronavirus Vaccine Progress","Despite a global pandemic, Sanofi SA (NASDAQ: SNY ) is able to continue its research and development — and it is ""essential"" to continue showing success in trials, CEO Paul Hudson said on CNBC's ""Squawk Box."" Sanofi's Momentum In Oncology Sanofi's existing oncology trials are ongoing, and this helped create some new momentum, Hudson said. Most notably, a trial of Sanofi and Regeneron Pharmaceuticals Inc's (NASDAQ: REGN ) lung cancer drug Libtayo cut the risk of death by more than 30% among certain patients, he said. ""We have a very competitive profile to Keytruda,"" the CEO said. ""We are already ahead … Full story available on Benzinga.com",SAN,en,Benzinga Feeds
2020-06-01 17:51:28-05:00,Santander InnoVentures bets on SME fintech lender,"Santander Group’s venture capital fund, Santander InnoVentures, has deepened its presence in Latin America with its fourth investment in the region, this time funneling $5 million in a Series A funding round into a55, a niche alternative SME lender, the VC firm announced in a release last week. Founded in 2018, a55 offers revenue-backed credit […]",SAN,en,Bank Innovation
2020-06-01 08:57:00-05:00,"The Zacks Analyst Blog Highlights: Merck, Glaxo, Roche, Sanofi and Bristol-Myers","The Zacks Analyst Blog Highlights: Merck, Glaxo, Roche, Sanofi and Bristol-Myers",SAN,en,Zacks Investment Research
2020-06-01 07:25:00-05:00,"The race for coronavirus treatments and vaccines is heating up. Here are the 12 most important events to watch for in June, from fresh vaccine data to new antibody drug trials.","The race for coronavirus treatments and vaccines is expected to maintain its frenetic pace in June. Business Insider identified the 12 top events to watch for this month, including new drugs and vaccines starting human testing and a range of data readouts from ongoing studies. The catalysts will impact drug companies ranging in size from massive to tiny, including biopharma giants like Eli Lilly and Regeneron and small biotechs like NantKwest and Inovio Pharmaceuticals. Visit Business Insider's homepage for more stories . June is shaping up to be a critical month for several coronavirus treatment and vaccine research programs. Some will start human testing for the first time, while others will wrap up and report results from clinical trials. There's no shortage of activity in hunting for pharmaceutical solutions to COVID-19, the disease caused by the novel coronavirus. The World Health Organization has tallied 125 coronavirus vaccine programs. Several hundred experimental drugs are being looked at to treat infected people.",SAN,en,Business Insider
2020-06-01 06:21:08-05:00,Banco Santander S A : 142 teams take part in the second “Ideas X” university entrepreneurship support programme | MarketScreener,"During this first stage, 15 out of all the projects received are on the covid-19 track. All teams are made up of undergraduate students who will access entrepreneurial training online… | June 1, 2020",SAN,en,MarketScreener
2020-06-01 06:21:05-05:00,"Banco Santander S A : Santander pensioners to get a charge-free account, preferential service and discounts at chemists | MarketScreener","Santander launches the 'Seniors Account', which is 100% free of charge for pensioners who deposit their income in the bank. Included is access to services at more than 430 branches… | June 1, 2020",SAN,en,MarketScreener
2020-06-01 00:57:01-05:00,Sanofi : Closes $11.7 Billion Sale of Regeneron Stake | MarketScreener,"By Pietro Lombardi Sanofi SA has closed the $11.7 billion sale of almost its entire 20.6% stake in U.S. biotech company Regeneron Pharmaceuticals Inc. The French pharmaceutical major… | June 1, 2020",SAN,en,MarketScreener
2020-05-29 14:24:00-05:00,Mylan Invalidates Sanofi's Lantus® SoloSTAR® Device Patents in IPR Proceedings,"HERTFORDSHIRE, England and PITTSBURGH, May 29, 2020 /PRNewswire/ -- Mylan N.V. (NASDAQ: MYL) today announced that the U.S. Patent and Trademark Appeal Board (PTAB) has ruled in favor of Mylan in inter partes review (IPR) proceedings finding all challenged claims of Sanofi's Lantus®…",SAN,en,PR Newswire
2020-05-29 11:27:56-05:00,Exclusive: Sanofi stops enrolling COVID-19 patients in hydroxychloroquine trials amid safety concerns,"Sanofi has temporarily stopped recruiting new COVID-19 patients for its two clinical trials on hydroxychloroquine and will not supply the anti-malaria drug to treat COVID-19 until concerns about safety are cleared up, it said on Friday.",SAN,en,Reuters
2020-05-29 00:28:47-05:00,Sanofi : Drugmaker Sanofi appoints four new people to executive committee | MarketScreener,"French drugmaker and healthcare company Sanofi on Friday appointed four new people to its executive committee, including a new head for its Sanofi Pasteur arm. Sanofi… | May 29, 2020",SAN,en,MarketScreener
2020-05-28 10:26:37.804000-05:00,"M&A wrap: Sanofi, PNC Financial, Le Pain Quotidien, Novavax , Accel-KKR, Coinbase, Carnival",Sanofi and PNC sell stakes in other companies. Coronavirus forces bakery chain Le Pain into bankruptcy. Deal news from Accel-KKR and Coinbase.,SAN,en,The Middle Market
2020-05-28 05:19:00-05:00,GlaxoSmithKline aims to produce 1 billion doses of coronavirus vaccine boosters,"GSK is working on its own COVID vaccine with French drugmaker Sanofi, one of the many projects to counter the respiratory illness that currently that has no treatment and has killed about 350,000 people",SAN,en,Business Today
2020-05-28 01:51:00-05:00,GSK to produce 1 billion doses of coronavirus vaccine booster in 2021,The British drugmaker is working on its own COVID vaccine with Sanofi,SAN,en,Business Standard
2020-05-28 01:48:10-05:00,Sanofi : to Offload Stake in Regeneron | MarketScreener,"By Denise Roland Sanofi SA plans to offload most of its long-held stake in Regeneron Pharmaceuticals Inc., giving the company an $11.1 billion war chest to help reshape its drug pipeline as… | May 28, 2020",SAN,en,MarketScreener
2020-05-27 21:48:31-05:00,Australian Government's Claim To Recoup Plavix PBS Losses Unsuccessful - Intellectual Property - Australia,The Federal Court of Australia has rejected the Australian Government's claim for $325 million in damages from Sanofi.,SAN,en,Mondaq
2020-05-27 11:16:00-05:00,Sanofi's Dupixent Gets FDA Approval for Eczema in Children,Sanofi (SNY) secures an FDA nod for Dupixent as the first biologic medicine for children aged from six to 11 years with moderate-to-severe atopic dermatitis.,SAN,en,Zacks Investment Research
2020-05-27 11:02:00-05:00,"Amid the COVID-19 Pandemic, Neurologists in Canada Report Pulling Back from EMD Serono's Mavenclad and Sanofi Genzyme's Lemtrada, While Roche's Ocrevus Stalls, According to Spherix Global Insights","EXTON, Pa. , May 27, 2020 /PRNewswire/ -- The COVID-19 pandemic has (at least temporarily) transformed neurology practices and multiple sclerosis (MS) patient management patterns across Canada , according to the most recent report included in Spherix's RealTime Dynamix™: Multiple Sclerosis ( Canada ) service. The report, which collected the responses of 50 Canadian neurologists surveyed between April 6 th and May 2 nd , found that 90% of respondents indicate the novel coronavirus outbreak has had a high impact on their practice. While preference for induction versus escalation treatment was clearly on the rise prior to the pandemic, new data suggest a potentially transient reversion to more conservative disease-modifying therapy (DMT) treatment patterns. Neurologists express hesitation to prescribe or re-dose patients with immunosuppressive DMTs, namely Roche's Ocrevus, Sanofi Genzyme's Lemtrada, and EMD Serono's Mavenclad, due to increased risk of complications or death among MS patients infected with the novel coronavirus.",SAN,en,Benzinga Feeds
2020-05-27 10:00:00-05:00,"Insulin Market Report 2020: Includes Revenue Data (2013-2022) for Novo Nordisk, Sanofi Aventis, Eli Lilly, Merck & Co, and Beckton Dickinson","DUBLIN, May 27, 2020 /PRNewswire/ -- The ""Global Insulin Market - Focus on Insulin Delivery Devices [By Devices - Vials & Syringes, Insulin Pens, Insulin Pumps, Insulin Jet Injectors; By Region - North America (The US), Europe (The UK, Germany, France & Italy) and Asia Pacific (Japan,…",SAN,en,PR Newswire
2020-05-27 06:28:01-05:00,Sanofi : to Sell Regeneron Shares Worth $11.1 Billion to Fund Overhaul | MarketScreener,"By Denise Roland Sanofi SA is to offload most of its long-held stake in Regeneron Pharmaceuticals Inc., giving the company an $11.1 billion war chest to help reshape its drug pipeline as it… | May 27, 2020",SAN,en,MarketScreener
2020-05-27 06:25:23-05:00,"The Daily Biotech Pulse: Cumberland's Positive Anti-Bacterial Readout, FDA Nods For Bristol-Myers, Astellas","Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 26) ADC Therapeutics SA (NYSE: ADCT ) (IPOed May 15) Aeglea Bio Therapeutics Inc (NASDAQ: AGLE )(announced positive one-year Phase 1/2 study and Phase 2 open-label extension study of pegzilarginase in Arginase 1 Deficiency patients) Allogene Therapeutics Inc (NASDAQ: ALLO ) Altimmune Inc (NASDAQ: ALT ) argenx SE – ADR (NASDAQ: ARGX )( announced positive top-line data from a late-stage study of efgartigimod in patients with generalized Myasthenia Gravis) BioMarin Pharmaceutical Inc. (NASDAQ: BMRN )(gained on sell-side comment on the company being a potential target for Sanofi SA (NASDAQ: SNY ) Bio-Rad Laboratories, Inc. (NYSE: BIO ) Castle Biosciences Inc (NASDAQ: CSTL ) Catalent Inc (NYSE: CTLT ) ChemoCentryx Inc (NASDAQ: CCXI ) Corbus Pharmaceuticals Holdings Inc (NASDAQ: CRBP ) Cue Biopharma Inc (NASDAQ: CUE ) Evoke Pharma Inc (NASDAQ: EVOK ) Fate Therapeutics Inc (NASDAQ: FATE ) GENMAB A/S/S ADR (NASDAQ: GMAB ) Harpoon Therapeutics Inc (NASDAQ: HARP ) Horizon Therapeutics PLC (NASDAQ: HZNP ) Immunomedics, Inc.","SBBP,SAN",en,Benzinga
2020-05-27 01:00:37-05:00,Drugmaker Sanofi to raise over US$11 billion via sale of Regeneron shares,"Sanofi will raise over US$11 billion from the sale of 21.6 million shares in its U.S. partner Regeneron, the French drugmaker said on Wednesday, adding it would use the proceeds for innovation and general growth.",SAN,en,Channel NewsAsia
2020-05-27 00:45:08-05:00,Drugmaker Sanofi to raise over $11 billion via sale of Regeneron shares | MarketScreener,"Sanofi will raise over $11 billion from the sale of 21.6 million shares in its U.S. partner Regeneron, the French drugmaker said on Wednesday, adding it would use the proceeds for… | May 27, 2020",SAN,en,MarketScreener
2020-05-26 09:52:00-05:00,"The Zacks Analyst Blog Highlights: Moderna, Pfizer, BioNTech, Sanofi and GlaxoSmithKline","The Zacks Analyst Blog Highlights: Moderna, Pfizer, BioNTech, Sanofi and GlaxoSmithKline",SAN,en,Zacks Investment Research
2020-05-26 09:41:00-05:00,Regeneron (REGN) to Buy Back Part of Its Stake Held by Sanofi,Regeneron (REGN) commences underwritten public secondary offering of its common stock held by Sanofi and repurchases shares for $5 billion.,SAN,en,Zacks Investment Research
2020-05-26 08:03:00-05:00,"Sanofi to Sell Stake in Regeneron, Existing Deal Unchanged","Sanofi (SNY) intends to sell majority of its shareholding in its collaboration partner, Regeneron. However, there will be no change in the ongoing collaboration terms.",SAN,en,Zacks Investment Research
2020-05-26 07:44:23-05:00,Regeneron to buy back $5 billion in stock as Sanofi sells part of its stake,"Shares of Regeneron Pharmaceuticals Inc. undefined were up 0.4% in premarket trading on Tuesday, the day after the company said it will spend $5 billion to…",SAN,en,MarketWatch
2020-05-26 07:00:22-05:00,Sanofi shares down despite US$13 billion Regeneron payday,Shares in Sanofi fell on Tuesday despite the French drugmaker's impending US$13 billion payday from selling most of its 20.6per cent stake in U.S. partner Regeneron .,SAN,en,Channel NewsAsia
2020-05-26 06:00:00-05:00,Sanofi is selling its stake in high-flying Regeneron to fund new drugs discoveries,Sanofi’s decision to sell comes after Regeneron’s stock surged 57% in the past six months. The stake is valued at $13 billion. The sale is part of CEO Paul Hudson’s revamped strategy.,SAN,en,Fortune
2020-05-26 05:54:07-05:00,Sanofi Selling Long-Standing Stake in Regeneron for $13 Billion,Sanofi will sell its stake in Regeneron to focus its efforts on cancer-fighting treatments.,SAN,en,The Street
2020-05-25 17:52:45.293000-05:00,Sanofi to sell stake in Regeneron worth $13 billion - The Boston Globe,"Sanofi is selling a stake in Regeneron Pharmaceuticals Inc. valued at about $13 billion, giving the French drug giant more firepower to invest in fast-growing fields such as cancer.",SAN,en,The Boston Globe
2020-05-25 12:35:02-05:00,Sanofi : to Sell Equity Investment in Regeneron | MarketScreener,"By Kim Richters Sanofi SA said Monday that it plans to sell its equity investment in Regeneron Pharmaceuticals Inc. via a registered public offering and a related share repurchase by… | May 25, 2020",SAN,en,MarketScreener
2020-05-24 17:01:00-05:00,Oxford University Coronavirus Vaccine Trial Chance Of Success Cut From 80% To Only 50%,"Oxford University Coronavirus Vaccine Trial Chance Of Success Cut From 80% To Only 50% Tyler Durden Sun, 05/24/2020 - 18:01 Following the disappointing late Friday publication of a pivotal study by the New England Journal of Medicine , according to which Gilead's Remdeisivir presented no marked benefit for those Coronavirus patients who were healthier and didn’t need oxygen or those who were sicker, requiring a ventilator or a heart-lung bypass machine , and that the only statistically significant improvement was observed in patients on supplemental oxygen, while also concluding that "" given high mortality despite the use of remdesivir, it is clear that treatment with an antiviral drug alone is not likely to be sufficient"", overnight there was more bad news, this time from the world of potential coronavirus vaccines, after the Telegraph reported that the Oxford University team in charge of developing a vaccine said a recent decline in the infection rate will make it increasingly difficult to prove whether it’s been successful. ""It’s a race against the virus disappearing, and against time,"" Professor Adrian Hill, director of the university’s Jenner Institute, told the newspaper. ""We said earlier in the year that there was an 80% chance of developing an effective vaccine by September.",SAN,en,Zero Hedge
2020-05-23 06:45:00-05:00,The untold story of Moderna as the biotech's coronavirus vaccine faces a test that could make it one of the most consequential startups of all time (MRNA),"The biotech Moderna has skyrocketed to global prominence, leading the world's race for a coronavirus vaccine. The Cambridge, Massachusetts-based biotech was founded in 2010 with the ambitious goal to develop a new type of medicine. While its platform remains unproven, it is now being tested under the brightest possible spotlight of a pandemic. Here's the inside story of Moderna's rise, from an offshoot of stem cell research to routinely shattering funding records on its way to biotech's top ranks. The biotech has spent a decade working to meet this moment, and investors have sent its stock soaring to a valuation of almost $30 billion. The next few months will be a defining period for the future of Moderna. Visit Business Insider's homepage for more stories . In its short corporate history, Moderna has grown accustomed to breaking records. A $450 million funding round in 2015 was a record for the biotech industry. Moderna raised even more the next year. And its 2018 initial public offering was the largest ever for a biotech .",SAN,en,Business Insider
2020-05-22 06:42:00-05:00,"Outlook on the Global Diabetes Disposable Insulin Delivery Pen Industry to 2026 - Major Players Analysed are Novo Nordisk, Eli Lilly & Sanofi Among Others - ResearchAndMarkets.com","DUBLIN--(BUSINESS WIRE)--The ""Worldwide Diabetes Disposable Insulin Delivery Pen Market Prospect, Share, Development, Growth & Demand Forecast to 2026"" report has been added to ResearchAndMarkets.com's offering. The Worldwide Diabetes Disposable Insulin Delivery Pen Market size is anticipated to exceed USD 14 billion by 2026. The objective of this market research report is to provide a comprehensive analysis of the fast-evolving, high-growth worldwide diabetes disposable insulin delivery pe",SAN,en,Business Wire
2020-05-21 23:25:11-05:00,Dr. Fauci says he's 'cautiously optimistic' about COVID-19 vaccine trials,"On Monday, pharmaceutical company Moderna announced encouraging results from its first human trial of a potential coronavirus vaccine. ""The question is: Was it immediately safe? Clearly it was,"" Dr. Anthony Fauci said of the prospective vaccine. ""But, importantly, it induced the kind of response that you would predict would be protective against the virus."" Several companies are working to develop a preventative solution for the coronavirus. On Thursday, the US government agreed to pay British pharmaceutical giant AstraZeneca up to $1.2 billion to secure 300 million doses of its experimental vaccine. Visit Business Insider's homepage for more stories . Researchers developing a vaccine for the novel coronavirus have already achieved a milestone that has eluded colleagues working for decades on a vaccine for HIV, Dr. Anthony Fauci said Thursday. Earlier this week, the biotech company Moderna , which has partnered with the National Institutes of Health, announced early findings from the first phase of trials for a COVID-19 vaccine, which was tested on 45 human volunteers.",SAN,en,Business Insider
2020-05-21 13:42:40-05:00,US secures 300M doses of coronavirus vaccine candidate from Oxford,"The coronavirus vaccine race delivers more promising news, as the US invested $1.2 billion to speed up development and secure 300 million doses for the breakthrough Oxford candidate. The novel coronavirus drug proved in pre-clinical trials that it’s effective and safe, and it’s now in human testing. AstraZeneca has licensed the medicine and is in talks to significantly expand manufacturing capacity. Visit BGR’s homepage for more stories . The novel coronavirus health crisis isn’t going away anytime soon, but we’re getting more and more promising reports about potential treatments that could cure or even prevent COVID-19. Vaccines, as in more than one candidate, are the miracle drugs that can prevent infections with SARS-CoV-2, but they’re up to a year away from reaching the masses. At best, the first candidates will be approved for emergency use as soon as September. But there’s no guarantee these medicines will work on humans despite the promising data coming from pre-clinical and clinical trials.",SAN,en,BGR
2020-05-21 04:19:42-05:00,AstraZeneca obtains $1B from US to help fund coronavirus vaccine,"LONDON --- British pharmaceuticals group AstraZeneca on Thursday said it had obtained more than $1.0 billion (0.9 billion euros) from the United States to help fund the production of a coronavirus vaccine. It comes amid concerns that the US could have a vaccine before other countries thanks to its large-scale funding of pharmaceutical companies around the world. France has already slammed drugs giant Sanofi for suggesting the US would get any eventual vaccine first, as world leaders demand that the science should be shared among nations. ""AstraZeneca today received support of more than $1.0 billion from the US Biomedical Advanced Research and Development Authority (BARDA) for the … Keep on reading: AstraZeneca obtains $1B from US to help fund coronavirus vaccine",SAN,en,Inquirer Net
2020-05-20 21:49:08-05:00,"Add Sanofi Indiaa, target price Rs 7,973: ICICI Securities",ICICI Securities expects Sanofi revenue/EBITDA/PAT to grow 5.2 per cent/ 9.0 per cent/13.3 per cent over CY20E- CY22E with declining export revenue contribution.,SAN,en,Economic Times India
2020-05-20 07:33:49-05:00,Checkpoint Therapeutics CEO On Tapping Into A $25 Billion Cancer Treatment Market,"The following article is sponsored by the clinical communications unit of investor relations firm Redington, Inc. The information contained in this article in no way represents investment advice or opinion on the part of Benzinga or its writers and is intended for informational purposes only. Since its establishment in 2014 by founding company Fortress Biotech, Inc. (NASDAQ: FBIO ), biopharmaceutical company Checkpoint Therapeutics (NASDAQ: CKPT ) has focused its research on the development of clinical-stage immunotherapies and targeted therapies for a variety of solid tumor indications, including skin and lung cancer. In September of last year, Checkpoint announced that its research efforts have yielded promising results for its lead PD-L1 checkpoint inhibitor, cosibelimab, which is actively enrolling a pivotal clinical trial for the treatment of cutaneous squamous cell carcinoma (cSCC), the second most common form of skin cancer. Preliminary clinical results for cosibelimab have shown similar efficacy rates to Libtayo, the only FDA-approved treatment for metastatic or locally advanced cSCC.",SAN,en,Benzinga
2020-05-19 22:53:00-05:00,"Share Market LIVE: Sensex climbs 150 points, Nifty at 8,889; Bajaj Finance, Grasim, Tata Motors top gainers","Dalal Street today: Companies set to announce their earnings are Apollo Tyres, Tata Power, Sanofi, Larsen & Toubro Infotech, Bajaj Finance, Embassy Office Parks REIT.",SAN,en,Business Today
2020-05-19 16:42:01-05:00,Sanofi : Europe Falls Behind U.S. in Funding Coronavirus Vaccine -- and Securing Access | MarketScreener,"By Denise Roland, Noemie Bisserbe and Nick Kostov PARIS -- As pharmaceutical giants edge closer to a potential vaccine for the new coronavirus, governments demanding access to any supplies are… | May 19, 2020",SAN,en,MarketScreener
2020-05-19 13:53:36-05:00,These are the 6 most promising coronavirus vaccine candidates,"Six coronavirus vaccine candidates have been determined to be the likeliest to succeed, a Morgan Stanley analyst said in a recent note to investors. The list of candidates includes a few familiar names, like Moderna, Oxford, and BioNTech. These labs are already conducting promising human trials, and the drugs could be approved later this year. Other vaccine candidates from Johnson & Johnson and Sanofi could be ready by the end of 2021. Visit BGR’s homepage for more stories . There’s no cure for the novel coronavirus right now, but significant progress is being made. Physicians treating COVID-19 patients have been able to discover all sorts of unusual symptoms and come up with treatments that can speed up recovery and reduce complications. Similarly, vaccine research looks incredibly promising. We have no idea if a vaccine will be able to generate the desired immune response and block infection, but more than 100 teams came forward with ideas on how to stop the virus. As many as eight of them are already in various phases of clinical trials, and at least a couple of them could be approved for emergency use as soon as this fall.",SAN,en,BGR
2020-05-19 08:38:09-05:00,China outplayed the world on the day it was meant to face a reckoning over its coronavirus response,"The World Health Assembly began on Monday, with dozens of countries looking to hold China accountable over the coronavirus outbreak. It would likely have embarrassed China on the world stage, casting its response in an unflattering light. But China ended up sidestepping that. President Xi Jinping deftly embraced a watered-down investigation likely to spare China any humiliation. He also made a high-profile pledge of $2 billion to the WHO, plus more aid to countries in need. At the same time, President Donald Trump refused to speak at the assembly and threatened to withdraw totally . US funding for the WHO is already on hold. China moved nimbly on the world stage, and made a show of generosity, while the US appeared small-minded and reluctant to lead. Visit Business Insider's homepage for more stories . China was meant to face a reckoning this week over its early coronavirus response, outnumbered in public by dozens of angry nations at the World Health Assembly. Instead, it ended up outplaying the world.",SAN,en,Business Insider
2020-05-18 22:22:00-05:00,"Share Market LIVE: Sensex pre-opens 500 points higher, Nifty at 8,971 amid positive global cues","Dalal Street today: Companies set to announce their earnings are Apollo Tyres, Tata Power, Sanofi, Larsen & Toubro Infotech, Bajaj Finance, Embassy Office Parks REIT.",SAN,en,Business Today
2020-05-18 19:24:26-05:00,Santander (SANB11) realiza movimento de integração entre fintechs,"As fintechs Superdigital e SIM, do Santander (SANB11), oferecem crédito na primeira integração de plataformas. Clique para saber mais",SAN,pt,Suno Research
2020-05-18 14:03:00-05:00,"Moderna just put out promising early data on a coronavirus vaccine, but the CEO told us the biggest challenge lies ahead: making enough doses to immunize the world","Moderna CEO Stephane Bancel said the company needs more money to ramp up production of its potential coronavirus vaccine. ""We need more,"" Bancel told Business Insider, if Moderna will be able to produce hundreds of millions of doses by year's end. The CEO said he is now talking with foundations and governments to secure more funding. The US government has already committed nearly $500 million to the project, but Bancel said it will likely take several years to vaccinate the world. ""We might have a vaccine approved and people are dying because we didn't make enough product, because nobody helped us,"" he said. On Monday, Moderna released results showing people developed virus-fighting antibodies after receiving its vaccine. Larger studies are needed to determine if the vaccine works, but the results are a promising early sign. Visit Business Insider's homepage for more stories . Determining how many doses of a potential coronavirus vaccine could be available by year's end boils down to one major factor: money. ""It depends on how much help we get now,"" Moderna CEO Stephane Bancel told Business Insider. ""Capital."" On Monday, the Cambridge, Massachusetts-based biotech became the first company in the world to release early human results for its experimental coronavirus vaccine.",SAN,en,Business Insider
2020-05-18 12:59:00-05:00,Morgan Stanley reveals the 6 most promising coronavirus vaccines and a timeline of when each one will be widely available,"There are more than 100 potential coronavirus vaccines in the works. According to analysts at Morgan Stanley, there are six vaccines that have a chance to succeed by being effective and widespread. The groups developing those vaccines are Moderna Therapeutics, Pfizer with BioNTech, AstraZeneca with the University of Oxford, CanSino, as well as Johnson & Johnson and GlaxoSmithKline's work in partnership with Sanofi. The market for the vaccines, the analysts estimated, could be anywhere from $10 billion to $30 billion during the pandemic, and anywhere from $2 to $25 billion when the disease is endemic to the world population. Visit Business Insider's homepage for more stories . Companies are racing to develop potential vaccines to combat the coronavirus pandemic. There are more than 100 vaccines in development, some of which have moved into human trials only months after the virus was identified. The trials are moving at breakneck speed, with experts expecting potential vaccines available for emergency use by the fall .",SAN,en,Business Insider
2020-05-16 03:00:00-05:00,A biotech company is collecting human skin donated from cosmetic surgery and keeping it alive for testing,"Genoskin is a company that takes leftover skin from cosmetic surgeries, keeps it alive, and provides it to the pharmaceutical and biotech industries for testing. The samples are kept in a gel that keeps them alive and nourished for 7 days, during which they behave like skin on the body. The company — which gets permission from its donors — says the process meets international ethical standards and is an alternative to animal testing. The samples can tan, grow hair, and even heal if they are hurt. They can be used to test everything from the effects of UV light on skin, to immune responses, to toxic substances. Visit Business Insider's homepage for more stories . Genoskin is a company that has figured out how to keep human skin alive for up to a week away from the body, and is using their tech to provide testing samples to the biotech, pharmaceutical and cosmetic industries. The company distributes little buttons of skin — kept alive in a cup of secret-recipe gel — that behave a lot like skin on our bodies.",SAN,en,Business Insider
2020-05-15 15:35:00-05:00,Inside the Science and Companies Racing to Develop a Covid-19 Vaccine,"There are two camps in the Covid-19 vaccine development: those using relatively unproven techniques for speed (Pfizer, Moderna, Johnson & Johnson) and those sticking with proven methods that will be slower to come to market (Sanofi and GlaxoSmithKline). What to know.",SAN,en,Barron's
2020-05-15 13:41:38-05:00,Sanofi walks back pledge to grant US first access to coronavirus vaccine,"French pharmaceutical group Sanofi walked back its pledge to grant the US first access to its COVID-19 vaccine once it is ready — hours after that decision stirred anger from the French government. “I am going to be extremely clear: there will be no particular advance for any country,” Serge Weinberg, chairman of the Sanofi…",SAN,en,New York Post
2020-05-15 10:30:00-05:00,Bitfinex 15.5 optimizaciones de rendimiento de WebSocket y datos mejorados de Santiment - ESP BlockBoard,"Bitfinex actualizó su plataforma de negociación y el servicio social Pulse con el lanzamiento de la versión 15.5. La nueva versión incluye algunas mejoras en los servicios y también correcciones de errores como cualquier otra actualización de software. «Con un Bitfinex Pulse más potente y un rendimiento mejorado del selector de datos Santiment, la última […] The post Bitfinex 15.5 optimizaciones de rendimiento de WebSocket y datos mejorados de Santiment appeared first on Crypto Economy.",SAN,es,Blockboard News
2020-05-15 10:03:48-05:00,Macron to Meet Sanofi CEO on Tuesday Amid Coronavirus Vaccine Row,No summary available.,SAN,en,UrduPoint
2020-05-15 06:52:05-05:00,France piles pressure on Sanofi over coronavirus vaccine plans,The French government has summoned Sanofi CEO Paul Hudson to a meeting on Tuesday after he appeared to suggest the United States would be first in line to receive a coronavirus vaccine if the company succeeds in developing one.,SAN,en,CNN RSS
2020-05-15 04:18:34-05:00,"News24.com | Covid-19 wrap: Global vaccine race heats up, US adds 1 754 more deaths and UK to roll out antibody testing","Global tensions are simmering over the race for a coronavirus vaccine, as the United States and China traded jabs, and France slammed pharmaceuticals giant Sanofi for suggesting the US would get any eventual vaccine first.",SAN,en,News24
2020-05-14 22:14:16-05:00,"Neutral on Biocon, target price Rs 320: Motilal Oswal",The company won a patent litigation initiated by Sanofi for the Insulin Glargine device.,SAN,en,Economic Times India
2020-05-14 18:01:41-05:00,France defends equal access to any vaccine as US eyes its own plans,"PARIS: France said on Thursday (May 14) that the world's nations would have equal access to any novel coronavirus vaccine developed by pharmaceuticals giant Sanofi, a day after the CEO suggested that Americans would likely be the first in line. US Secretary of State Mike Pompeo, in an interview …",SAN,en,Channel NewsAsia
2020-05-14 16:14:13-05:00,Chief of French pharma company under fire for saying the US gets priority access to Covid-19 vaccine,President Emmanuel Macron’s office said it would hold talks with Sanofi executives next week.,SAN,en,TheJournal IE
2020-05-14 15:40:02-05:00,Sanofi Irks France by Saying U.S. Would Get Any Covid-19 Vaccine First -- Update | MarketScreener,"By Noemie Bisserbe and Denise Roland PARIS -- The office of President Emmanuel Macron summoned the management of Sanofi SA to a meeting next week, according to a French official, after the… | May 14, 2020",SAN,en,MarketScreener
2020-05-14 15:01:42-05:00,Sanofi : France's Macron to meet Sanofi chief on May 19 - Elysee | MarketScreener,"President Emmanuel Macron will meet the chief executive of French pharmaceutical firm Sanofi on May 19, a presidential official said on Thursday, after Paul Hudson angered the… | May 14, 2020",SAN,en,MarketScreener
2020-05-14 13:55:29-05:00,"Sanofi Stock Down 1.6%, Company Criticized for Giving U.S. Priority Access to Vaccine","After closing yesterday with a slight rise of 0.17%, Sanofi (SNY) stock now is down 1.70% and is trading at around $47.50.",SAN,en,Coinspeaker
2020-05-14 13:02:08-05:00,Macron's office to meet Sanofi executives over vaccine dispute: presidency,No summary available.,SAN,en,UrduPoint
2020-05-14 12:39:15-05:00,Sanofi CEO pledges COVID-19 vaccine for all after French backlash,"PARIS: Sanofi chief executive Paul Hudson said on Thursday (May 14) it was vital that any coronavirus vaccine reach all parts of the world, after angering the French government earlier by saying some countries would get priority access. But the CEO of the French pharmaceutical giant stood firm on …",SAN,en,Channel NewsAsia
2020-05-14 10:28:50-05:00,French pharma giant irks Paris with US first for vaccine comment,"Edouard Philippe, France's prime minister, said ""equal access for everyone to the vaccine is not negotiable"". It came after French pharma giant Sanofi suggested the US would be first in line for any cure.",SAN,en,euronews
2020-05-14 10:07:52-05:00,"Covid-19 vaccine latest updates: Moderna, Novavax to start human trials; Sanofi row and more","From Moderna Therapeutics getting fast-track approval from the US Food and Drug Administration (FDA) for its Covid-19 vaccine to Novavax moving to humans trials, the world is inching closer to lay its hands on a vaccine.",SAN,en,The Indian Express
2020-05-14 09:38:06-05:00,France angered by suggestion U.S. would get first access to coronavirus vaccine by French pharma company Sanofi,The government pushback came after comments by Sanofi chief executive Paul Hudson.,SAN,en,The Washington Post
2020-05-14 09:27:36-05:00,French Gov't Slams Pharma Giant Sanofi For Prioritizing US in Access to COVID-19 Vaccine,No summary available.,SAN,en,UrduPoint
2020-05-14 08:53:11-05:00,French drug giant Sanofi walks back after saying U.S. would get COVID-19 vaccine first,"Sanofi CEO Paul Hudson’s comments prompted angry reaction from the French government, with a junior minister telling Sud Radio “to us, it would be unacceptable that a country would get privileged access under the pretext of money reasons.”",SAN,en,The Star
2020-05-14 07:47:03-05:00,Sanofi CEO Says Americans to Get Potential Virus Vaccine First,French drugmaker Sanofi (SNY) said that the U.S. The post Sanofi CEO Says Americans to Get Potential Virus Vaccine First appeared first on Smarter Analyst .,SAN,en,Smarter Analyst
2020-05-14 06:27:27-05:00,France resists idea of US getting vaccine first,The government says French drug giant Sanofi should not prioritise the US market.,SAN,en,BBC
2020-05-14 05:50:44-05:00,France Says Sanofi Plan to Put US First For COVID Vaccine 'Unacceptable',"Sanofi SA, the french drugmaker that could develop the world's first coronavirus vaccine, was caught in a political maelstrom Thursday as officials spar over who may receive the first doses of any potential treatment.",SAN,en,The Street
2020-05-14 05:34:01-05:00,Sanofi : Sutimlimab Gets FDA Priority Review for Hemolysis in Cold Agglutinin Disease | MarketScreener,"By Colin Kellaher Sanofi S.A. on Thursday said the U.S. Food and Drug Administration granted priority review to its biologics license application for sutimlimab for the treatment of… | May 14, 2020",SAN,en,MarketScreener
2020-05-14 05:32:48-05:00,Sanofi walks back after saying US would get vaccine first,"French pharmaceutical group Sanofi says it will make its COVID-19 vaccine, when ready, available in all countries",SAN,en,ABC News
2020-05-14 03:57:23-05:00,"Your money, your right? France disputes PRIVILEGED ACCESS to Covid-19 vaccine for US","Pharmaceutical giant Sanofi should not give the US first access to its Covid-19 vaccine, Secretary of State for Economy Agnes Pannier-Runacher has said, urging that the firm make the treatment available to all countries. Read Full Article at RT.com",SAN,en,Russia Today
2020-05-14 03:41:34-05:00,France says 'unacceptable' for Sanofi to give coronavirus vaccine to US first,"The French government warned Thursday that it would be ""unacceptable"" for pharmaceutical giant Sanofi to reserve any Covid-19 vaccine for the United States first, after the firm's chief said he would give preference to the American market.",SAN,en,FRANCE 24
2020-05-14 03:40:18-05:00,French fury after Sanofi says US to get virus vaccine first,"The French government cried foul Thursday after pharmaceutical giant Sanofi said it would reserve first shipments of any COVID-19 vaccine for the United States, saying the move would be ""unacceptable"" in a crisis that has killed nearly 300,000 people w…",SAN,en,Digital Journal
2020-05-14 03:20:38-05:00,France says 'unacceptable' for Sanofi to give US virus vaccine first,"PARIS: The French government warned Thursday (May 14) that it would be ""unacceptable"" for pharmaceutical giant Sanofi to reserve any COVID-19 vaccine for the United States first, after the firm's chief said he would give preference to the American market. ""For us, it would be unacceptable for …",SAN,en,Channel NewsAsia
2020-05-14 02:19:00-05:00,France gov't warns Sanofi against prioritizing US on virus vaccine,"The French government warned Thursday that it would be ""unacceptable"" for pharmaceutical giant Sanofi to reserve any COVID-19 vaccine for the United States first, after t…",SAN,en,Daily Sabah
2020-05-13 16:37:15-05:00,Sanofi to accelerate European COVID-19 vaccine access,NEW YORK: French drug manufacturer Sanofi SA said on Wednesday (May 13) that it is working with European regulators to speed up access to a potential coronavirus vaccine in Europe after its chief executive suggested Americans would likely get the vaccine first. The company said in a statement that …,SAN,en,Channel NewsAsia
2020-05-13 15:50:25-05:00,Sanofi to accelerate European COVID-19 vaccine access after CEO prioritizes US preorders,French drugmaker Sanofi SA said on Wednesday that it is working with European regulators to speed up access to a potential coronavirus vaccine in Europe after its chief executive suggested Americans would likely get the vaccine first.,SAN,en,Channel NewsAsia
2020-05-13 13:15:23-05:00,Americans will be first to get French drugmaker's coronavirus vaccine,"Paul Hudson, CEO of Sanofi, told Bloomberg that the US will have privileges to place the first and largest pre-order for its coronavirus vaccine - once one is ready - after giving $30 million in funding.",SAN,en,Daily Mail Online
2020-05-13 11:36:56-05:00,US will likely get French coronavirus vaccine before other countries,"The pharmaceutical giant Sanofi — which has vowed to rapidly create the vaccine — will send doses to the US before the rest of Europe if the firm can successfully deliver it, according to Bloomberg News.",SAN,en,New York Post
2020-05-13 09:57:47-05:00,"The US would be the first to get a potential coronavirus vaccine being created by a French company, its CEO said (SNY)","The US would be first country to get a potential coronavirus vaccine if it's successfully made by French pharmaceutical company Sanofi. Because the US ""invested in taking the risk"" first, it would also be first to receive the vaccine, Sanofi CEO Paul Hudson told Bloomberg News. The comments raise questions about how distribution would be handled once a vaccine is created. Visit Business Insider's homepage for more stories . The US would be the first to receive a potential coronavirus vaccine if French pharmaceutical company Sanofi is able to produce it. Sanofi CEO Paul Hudson told Bloomberg that ""the US government has the right to the largest pre-order because it's invested in taking the risk."" He said that the United States was first to fund the company's research, so it expects ""that if we've helped you manufacture the doses at risk, we expect to get the doses first."" After receiving a boost from the US in February, Sanofi has partnered on the search for a vaccine with British pharmaceutical company GlaxoSmithKline.",SAN,en,Business Insider
2020-05-12 09:45:18-05:00,WHAT'S NEXT: 200 leaders look into the future of business,"Everything's changed. The COVID-19 pandemic has led to a third of the global population being put on lockdown, millions of workers furloughed or laid off, and a historic economic contraction. The coronavirus has affected everything, from how we work and take care of one another, to how we shop, pay, and entertain ourselves. To understand how the pandemic is transforming business, in the last week of April we asked more than 200 CEOs from a variety of industries in the US and beyond a three-part question: How will the way you operate change because of the coronavirus? How will your industry change? And how will the world change? In this feature you'll find answers from the CEOs of Walmart, AB InBev, Duke Energy, ViacomCBS, Sanofi, Zoom, PayPal, and more. Their insights address the rise of remote work and the cost of commercial rents, the role of government in business, how we'll interact with our doctors in the future, and much more. The theme: The coronavirus has hit fast forward on many trends that were already emerging. ""The future we imagined for 2030 has been pulled forward to the present, with everything going digital by default,"" Tobias Lütke, the CEO of Shopify, told us.",SAN,en,Business Insider
2020-05-12 08:34:00-05:00,NIH Director Francis Collins shares his best-case scenario for a coronavirus vaccine: We could have a shot by fall but mass-producing it will be 'a heck of a stretch' by the end of the year.,"A top US public health official told Business Insider it's possible that we'll have not just one but several effective coronavirus vaccines this year. Dr. Francis Collins, director of the National Institutes of Health, said his ""best-case scenario"" is that four or five vaccines will get through clinical trials, and at least one will be ready for emergency use by the fall Collins has led the NIH, the top US agency for biomedical research, since 2009. Previously, the physician-geneticist led the Human Genome Project in the late-1990s, successfully sequencing the human genome for the first time. In a wide-ranging interview on vaccines, Collins discussed how the NIH plans to quickly test candidates, realistic timelines, the ""underappreciated"" manufacturing challenge, and the threat of the antivax movement. Visit Business Insider's homepage for more stories . Having an effective coronavirus vaccine is possible by the end of 2020, but achieving a goal of 300 million doses by January will be ""a heck of a stretch,"" Dr.",SAN,en,Business Insider
2020-05-07 12:08:20-05:00,Lucro dos principais bancos é o mais baixo desde o terceiro trimestre de 2017,"No primeiro trimestre, desempenho dos bancos foi bastante afetado pelas provisões realizadas para cobrir potenciais perdas durante a crise provocada pelo coronavírus. Os quatro maiores bancos dos país registraram no primeiro trimestre deste ano o lucro mais baixo desde o terceiro trimestre de 2017, segundo levantamento realizado pela Economatica. A soma do lucro de Santander, Itaú, Bradesco e Banco do Brasil foi de R$ 13,762 bilhões no primeiro trimestre deste ano. No terceiro trimestre de 2017, o ganho apurado foi de R$ 13,596 bilhões. Lucro dos quatro maiores bancos Economia G1 Em relação ao primeiro trimestre do ano passado, o quatro bancos registraram uma queda de 31% no lucro. Nos primeiros três meses de 2019, o ganho conjunto foi de R$ 19,950 bilhões. A comparação é feita de forma nominal (sem levar em conta a inflação). Neste ano, o desempenho dos bancos tem sido basante afetado pelas provisões realizadas para cobrir potenciais perdas durante a crise provocada pelo coronavírus. ",SAN,pt,Globo
2020-05-07 10:07:00-05:00,"The upstart biotech Moderna just sped up the timeline for crucial human trials of its coronavirus vaccine, readying the shot for potential use this fall (MRNA)","US regulators are allowing Moderna to move forward on testing its experimental coronavirus vaccine in a 600-person study A small trial focused on safety has been running for about two months. The OK to advance into mid-stage testing comes before any results have been made available from this initial study. Moderna is aiming to have its vaccine ready this fall for emergency use authorization. Vaccine supply would still be limited, but emergency authorization could allow for broader use among healthcare workers or other high-risk groups of people. The US government would decide who gets it, Moderna said. Visit Business Insider's homepage for more stories . A leading coronavirus vaccine program is rapidly advancing through clinical testing, despite the absence of any data yet on whether the injection works. The $18 billion biotech Moderna said Thursday that US regulators have OK'd the company's plan for a 600-person mid-stage clincial trial to further test its experimental vaccine. The company also accelerated the timeline for the start of a late-stage trial, designed to tell if the vaccine works.",SAN,en,Business Insider
2020-05-07 05:20:00-05:00,Bilateral deals might not be equitable for Covid-19: MPP executive director Charles Gore,"Countries are waiting for drugs and vaccines to combat Covid-19, which will help them to lift lockdowns and have treatments ready to handle future infection waves. However, access and affordability of such drugs remain a key area of concern. The Medicines Patent Pool is a United Nations-backed public health organisation that helps middle- and low-income countries get access to critical drugs. MPP executive director Charles Gore told ET about the organisation’s plan to ensure equitable access of Covid-19 drugs and vaccines. Edited excerpts:Which are the companies you are negotiating for Covid-19 patents?We are in discussions with Gilead for Remdesivir. I don’t know how this will go, but we are in discussions. We have a confidentiality agreement with them, so can’t share much, but this is the first of the drugs that we are looking at. Besides this, we are watching a few drugs like Favipiravir, Tocilizumab, Sarilumab, Ruxolitinib and Siltuximab.What about vaccines?We are reaching out to GSK-Sanofi, J&J (Janssen), Oxford University and the University of Bern, asking them if we can be of assistance to them – we will see how this goes.",SAN,en,Economic Times India
2020-05-06 16:09:58-05:00,$SAN : Sanofi Shows Monthly Bullish Structure,"Buyers should be waiting at 56.70-47.61 to enter the market. From there, Sanofi should resume the rally or it can see a 3 waves bounce at least.",SAN,en,Elliottwave Forecast
2020-05-06 03:49:39-05:00,French group Sanofi names Romanian at the helm of its operations in Romania and Moldova,No summary available.,SAN,en,Romania Insider
2020-05-06 03:15:00-05:00,Coronavirus COVID 19 vaccine: France-based drugmaker Sanofi to start large scale human trials,"Coronavirus COVID 19 vaccine news, latest update, human trials: Sanofi's Pasteur division has an established track record in influenza vaccines. Last month it had teamed with its British rival GSK to produce a vaccine candidate hoping that it will be ready in 2021.",SAN,en,The Financial Express
2020-05-05 23:47:18-05:00,Drugmaker Sanofi to enroll thousands for its COVID-19 vaccine trials,"PARIS: French drugmaker Sanofi said it plans to enroll thousands of subjects globally for trials of an experimental vaccine for the coronavirus it is developing with GlaxoSmithKline, and that it has started to discuss advanced purchases with several countries. Sanofi is working on two vaccine …",SAN,en,Channel NewsAsia
2020-05-05 10:45:15-05:00,Why Sanofi (SNY) is a Great Dividend Stock Right Now,"Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Sanofi (SNY) have what it takes? Let's find out.",SAN,en,Zacks Investment Research
2020-05-05 06:16:32-05:00,Regeneron to Begin Human Studies of Covid-19 Treatment in June,"Alongside partner Sanofi, Regeneron is prepping to begin human studies of its antibody 'cocktail' treatment for Covid-19 next month.",SAN,en,The Street
2020-05-04 17:08:16-05:00,"Itaú tem lucro de R$ 3,4 bilhões no primeiro trimestre","Houve uma queda de 49,3% na comparação com o mesmo período de 2019. Fachada de agência do banco Itaú no Rio de Janeiro Sergio Moraes/Reuters O banco Itaú informou nesta segunda-feira (4) que registrou lucro líquido contábil de R$ 3,401 bilhões no primeiro trimestre de 2020, uma queda de 49,3% na comparação com o mesmo período do ano anterior. Outros bancos O Bradesco registrou lucro líquido contábil de R$ 3,382 bilhões no 1º trimestre de 2020, uma queda de 41,9% em relação ao mesmo período do ano passado (R$ 5,82 bilhões). Já o Santander Brasil apurou lucro de R$ 3,774 bilhões nos primeiros três meses do ano, crescimento de 10,5%.",SAN,pt,Globo
2020-05-02 15:00:32-05:00,Coronavirus means science is suddenly being done differently – and so is politics | Paul Nurse,"The Nobel prize-winning scientist on how the pandemic is bringing dramatic shifts in medical research See all our coronavirus coverage Coronavirus – latest updates If we are to return to our normal lives, we need answers to many questions and they will only be delivered by science and medicine and their applications. In fact, the speed with which the virus has spread around the globe has been matched by the speed with which many scientists have mobilised themselves to take on this pandemic. The British science community has responded rapidly. The government’s funding agency, UK Research and Innovation-Medical Research Council ( UKRI-MRC ), has created new funding schemes, the Wellcome Trust has partnered with the Gates Foundation to speed up research and Cancer Research UK is supporting work into how Covid-19 is disrupting cancer treatment . In the last weeks, Oxford University and Imperial College London have reported on their plans for new vaccines and on more modelling of the impact of the virus.",SAN,en,The Guardian
2020-05-01 06:24:00-05:00,"The Zacks Analyst Blog Highlights: Gilead Sciences, Pfizer, Sanofi, GlaxoSmithKline and Moderna","The Zacks Analyst Blog Highlights: Gilead Sciences, Pfizer, Sanofi, GlaxoSmithKline and Moderna",SAN,en,Zacks Investment Research
2020-05-01 04:48:00-05:00,"Top 20 Vaccine Companies In-Depth Analysis, 2020 - Featuring Sanofi Pasteur, GlaxoSmithKline & Pfizer Among Others - ResearchAndMarkets.com","DUBLIN--(BUSINESS WIRE)--The ""Top 20 Vaccine Companies In-Depth Analysis 2020: Sanofi, Pfizer, GlaxoSmithKline (GSK), Merck & Co., AstraZeneca, Emergent BioSolutions, Mitsubishi Tanabe Pharma, Seqirus (CSL Limited), Other Companies"" report has been added to ResearchAndMarkets.com's offering. This report presents an in-depth assessment of the top 20 vaccine companies' market dynamics, opportunities, competitive landscape and discusses major trends. The report offers the most up-to-date top 2",SAN,en,Business Wire
2020-04-29 08:23:00-05:00,"The Zacks Analyst Blog Highlights: Moderna, Johnson & Johnson, Sanofi and Novavax","The Zacks Analyst Blog Highlights: Moderna, Johnson & Johnson, Sanofi and Novavax",SAN,en,Zacks Investment Research
2020-04-28 07:04:31-05:00,"Santander concede mais crdito sob coronavrus e lucro cresce 10,5% no 1 trimestre","Banco espanhol fechou o perodo com lucro lquido foi de R$ 3,9 bilhes",SAN,pt,Jornal do Comercio
2020-04-28 06:44:00-05:00,"Santander Brasil vê primeiros sinais da crise, mas bate projeção de lucro","Por Carolina MandlSÃO PAULO (Reuters) - O Banco Santander Brasil divulgou nesta terça-feira lucro líquido acima do esperado por analistas para o primeiro trimestre, impulsionado por outro período de rápido crescimento da… Leia mais",SAN,pt,Extra
2020-04-28 05:28:54-05:00,"Santander Brasil tem lucro de R$ 3,7 bilhões no 1º trimestre, alta de 10,5%","Retorno sobre o patrimônio líquido, um indicador da lucratividade dos bancos, cresceu e atingiu 22,3%. Agência do banco Santander no Rio de Janeiro Ricardo Moraes/Reuters O Santander Brasil registrou lucro líquido de R$ 3,774 bilhões no 1º trimestre, o que representa um crescimento de 10,5% na comparação com o mesmo período do ano passado (R$ 3,415 bilhões). Na comparação com o 4º trimestre (R$ 3,748 bilhões), houve alta de 0,7% nos ganhos. Já o lucro gerencial, que exclui fatores extraordinários, alcançou R$ 3,853 bilhões nos primeiros 3 meses do ano, alta de 10,5% na comparação anual e de 3,4% em relação ao trimestre anterior, segundo balanço divulgado nesta terça-feira (28). O retorno sobre o patrimônio líquido médio, um indicador da lucratividade dos bancos, atingiu 22,3% no 1º trimestre, alta de 1,2 ponto percentual na comparação anual e de 1 ponto em três meses.",SAN,pt,Globo
2020-04-28 00:18:28-05:00,Banco Santander S A : Argentina | MarketScreener,"28 April 2020 Argentina Q1'20 Earnings Presentation Important Information … | April 28, 2020",SAN,en,MarketScreener
2020-04-28 00:18:21-05:00,Banco Santander S A : Spain | MarketScreener,"28 April 2020 Spain Q1'20 Earnings Presentation Important Information … | April 28, 2020",SAN,en,MarketScreener
2020-04-28 00:18:19-05:00,Banco Santander S A : United States | MarketScreener,"28 April 2020 US Q1'20 Earnings Presentation Important Information … | April 28, 2020",SAN,en,MarketScreener
2020-04-28 00:18:15-05:00,Banco Santander S A : Mexico | MarketScreener,"28 April 2020 Mexico Q1'20 Earnings Presentation Important Information … | April 28, 2020",SAN,en,MarketScreener
2020-04-28 00:18:12-05:00,Banco Santander S A : Poland | MarketScreener,"28 April 2020 Poland Q1'20 Earnings Presentation Important Information … | April 28, 2020",SAN,en,MarketScreener
2020-04-28 00:18:10-05:00,Banco Santander S A : Portugal | MarketScreener,"28 April 2020 Portugal Q1'20 Earnings Presentation Important Information … | April 28, 2020",SAN,en,MarketScreener
2020-04-28 00:18:08-05:00,Banco Santander S A : United Kingdom | MarketScreener,"28 April 2020 United Kingdom Q1'20 Earnings Presentation Important Information … | April 28, 2020",SAN,en,MarketScreener
2020-04-27 06:44:05-05:00,Regeneron and Sanofi Drug Shows Promise Treating Sickest Coronavirus Patients,A drug co-produced by Regeneron and Sanofi used to treat rheumatoid arthritis has shown potential to treat patients most stricken with Covid-19.,SAN,en,The Street
2020-04-27 06:15:05-05:00,Regeneron Pharmaceuticals : Drug Study Halted Early for Certain Covid-19 Patients After No Benefit Seen | MarketScreener,"By Joseph Walker Regeneron Pharmaceuticals Inc. and Sanofi SA said Monday they will shut down part of a study exploring whether their arthritis therapy could treat certain hospitalized… | April 27, 2020",SAN,en,MarketScreener
2020-04-27 06:01:01-05:00,"Regeneron, Sanofi arthritis drug shows benefit for sickest coronavirus patients, but not for less- advanced cases","The drug, Kevzara, inhibits a pathway thought to contribute to the lung inflammation in patients with the most severe forms of Covid-19.",SAN,en,CNBC
2020-04-27 05:58:00-05:00,Regeneron and Sanofi Provide Update on U.S. Phase 2/3 Adaptive-Designed Trial of Kevzara® (sarilumab) in Hospitalized COVID-19 Patients,"/PRNewswire/ -- Independent Data Monitoring Committee recommended continuing ongoing Phase 3 trial only in the more advanced ""critical"" group with Kevzara…",SAN,en,PR Newswire
2020-04-24 11:23:00-05:00,"Insights on the Worldwide Pediatric Vaccines Industry to 2030 - Featuring GlaxoSmithKline, Pfizer & Sanofi Among Others - ResearchAndMarkets.com","DUBLIN--(BUSINESS WIRE)--The ""Pediatric Vaccines Global Market Report 2020-30: Covid 19 Impact and Recovery"" report has been added to ResearchAndMarkets.com's offering. The global pediatric vaccines is expected to decline from $30.4 billion in 2019 to $28.9 billion in 2020 at a compound annual growth rate (CAGR) of -5%. The decline is mainly due to the focus on Covid-19 outbreak and its treatment across the globe and non-availability of vaccines or delay of immunizations in pediatrics. This rep",SAN,en,Business Wire
2020-04-24 09:00:00-05:00,"Global OTC Analgesics Market Report 2020, Featuring Company Profiles of Bayer, Sanofi and Sun Pharmaceuticals","DUBLIN, April 24, 2020 /PRNewswire/ -- The ""Over the Counter (OTC) Analgesics Market - Growth, Trends, and Forecast (2020 - 2025)"" report has been added to ResearchAndMarkets.com's offering. The over the counter (OTC) analgesics market is facing increased demand due to the increasing…",SAN,en,PR Newswire
2020-04-24 04:59:09-05:00,"Sanofi confirms targets, strong demand for painkillers lifts first-quarter | MarketScreener","Sanofi confirmed its 2020 outlook on Friday after posting stronger first-quarter results led by its specialty care unit and demand for over-the-counter medicines to treat pain and fever amid the… | April 24, 2020",SAN,en,MarketScreener
2020-04-24 04:33:49-05:00,COVID-19 boosts sales for French pharma giant Sanofi,"French pharmaceutical giant Sanofi said Friday that its first quarter sales surged in part due to stockpiling of the painkiller Doliprane, as other companies around the world struggle during the coronavirus pandemic.",SAN,en,Channel NewsAsia
2020-04-20 08:27:00-05:00,"The Zacks Analyst Blog Highlights: Regeneron Pharmaceuticals, Moderna, Sanofi, Vaxart and Eli Lilly","The Zacks Analyst Blog Highlights: Regeneron Pharmaceuticals, Moderna, Sanofi, Vaxart and Eli Lilly",SAN,en,Zacks Investment Research
2020-04-19 16:22:22-05:00,"The Week Ahead In Biotech (April 19-25): Eli Lilly, Biogen Earnings On Tap, Sanofi Awaits FDA Decision","Biotech stocks staged a nice recovery along with the broader markets in the week ended April 17. Apart from the broader market sentiment, big moves in biopharma companies such as Johnson & Johnson (NYSE: JNJ ) and Gilead Sciences, Inc. (NASDAQ: GILD ) also supported sentiment. The former reported strongly quarterly results and the latter benefited from reports of positive efficacy data on its COVID-19 treatment candidate remdesivir. Urogen Pharma Ltd (NASDAQ: URGN ) gained approval for its low-grade bladder cancer drug. News flow concerning the … Full story available on Benzinga.com",SAN,en,Benzinga Feeds
2020-04-18 08:00:08-05:00,Sanofi partners with GlaxoSmithKline to develop COVID-19 vaccine,"Kampala, Uganda | THE INDEPENDENT | Leading drug manufacturing firms, Sanofi and GlaxoSmithKline, have entered into an agreement to develop an adjuvanted vaccine for COVID-19, using innovative technology from both companies to help address the ongoing pandemic. Sanofi will contribute its S-protein COVID-19 antigen, which is based on recombinant DNA technology. This technology has produced an …",SAN,en,The Independent Uganda
2020-04-17 10:53:00-05:00,"Global Multiple Sclerosis Drugs Market Study, 2020 - Leading Players are Biogen, Novartis, Roche, Bayer HealthCare, Pfizer, Merck & Co, Sanofi, Teva Pharma, GlaxoSmithKline and Acorda Therapeutics - ResearchAndMarkets.com","DUBLIN--(BUSINESS WIRE)--The ""Multiple Sclerosis Drugs Market Global Report 2020"" report has been added to ResearchAndMarkets.com's offering. The global multiple sclerosis drugs market was worth $20.83 billion in 2019. North America is expected to be the largest region in the forecast period. Major players in the market are Biogen, Novartis, Roche, Bayer HealthCare, Pfizer, Merck & Co, Sanofi, Teva Pharmaceutical Industries, GlaxoSmithKline and Acorda Therapeutics. The growth of multiple sc",SAN,en,Business Wire
2020-04-17 09:40:00-05:00,Sanofi/Luminostics to Make Self-Testing Solution for Coronavirus,"Sanofi (SNY) partners with Luminostics to make a COVID-19 smartphone-based self-testing solution, which will be based on the latter's proprietary technology.",SAN,en,Zacks Investment Research
2020-04-17 08:57:03-05:00,Sanofi Ready To Produce Up To 600M COVID-19 Vaccine Doses,French multinational pharma Sanofi (SNYNF) can produce as many as 600 million doses of its coronavirus vaccine next year if everything goes to … The post Sanofi Ready To Produce Up To 600M COVID-19 Vaccine Doses appeared first on Smarter Analyst .,SAN,en,Smarter Analyst
2020-04-16 10:50:00-05:00,"Outlook on the Global Neurodegenerative Disorder Therapeutics Industry to 2030 - Featuring Biogen, Pfizer, Novartis & Sanofi Among Others - ResearchAndMarkets.com","DUBLIN--(BUSINESS WIRE)--The ""Neurodegenerative Disorder Therapeutics Market Global Report 2020-30"" report has been added to ResearchAndMarkets.com's offering. The global neurodegenerative disorder therapeutics market was worth $13.35 billion in 2019. It is expected to grow at a compound annual growth rate (CAGR) of 8.12% and reach $18.23 billion by 2023. The neurodegenerative disorder therapeutics market has been geographically segmented into North America, Western Europe, Asia-Pacific, Easter",SAN,en,Business Wire
2020-04-16 07:25:26-05:00,Sanofi teams up with U.S. firm Luminostics on developing COVID-19 testing app,https://www.investing.com/news/coronavirus/sanofi-teams-up-with-us-firm-luminostics-on-developing-covid19-testing-app-2142021,SAN,en,Investing.com
2020-04-16 07:24:17-05:00,Sanofi : teams up with U.S. firm Luminostics on developing COVID-19 testing app | MarketScreener,"French healthcare company Sanofi and U.S. start-up technology company Luminostics said they were joining up to work on developing a smartphone-based self-testing solution to see if someone has the… | April 16, 2020",SAN,en,MarketScreener
2020-04-15 10:09:48-05:00,GlaxoSmithKline teams up with Sanofi for a Covid-19 vaccine. Are its shares worth considering?,"GlaxoSmithKline has teamed up with Sanofi to develop a vaccine for Covid-19. It’s good news for everyone, but will it be good news for the GSK share price? The post GlaxoSmithKline teams up with Sanofi for a Covid-19 vaccine. Are its shares worth considering? appeared first on The Motley Fool UK .",SAN,en,The Motley Fool UK
2020-04-15 08:04:00-05:00,A top executive at one of America's largest healthcare companies is leaving for the rest of the year to go help the WHO develop a coronavirus vaccine,"Andrew Witty, the president of health giant UnitedHealth Group and CEO of its Optum unit, is taking a leave of absense to lead the World Health Organization's efforts to develop a coronavirus vaccine, UnitedHealth said on Wednesday. Prior to running Optum, Witty was CEO of pharma company GlaxoSmithKline, which has a major vaccines business. Witty's expected to return to the company by the end of 2020. Visit Business Insider's homepage for more stories . Andrew Witty, a top executive at UnitedHealth Group, is taking a leave of absence to work on a coronavirus vaccine. Witty, who serves as the president of UnitedHealth and as CEO of the company's Optum business arm, will be co-leading the World Health Organization's efforts to develop a vaccine for COVID-19, the disease caused by the novel coronavirus, UnitedHealth said on Wednesday morning. ""I am deeply honored to help lead this mission to seek a COVID-19 vaccine,"" Witty said in a news release on Wednesday . Prior to joining UnitedHealth in 2018, Witty was CEO of vaccine-maker GlaxoSmithKline.",SAN,en,Business Insider
2020-04-15 07:26:00-05:00,"Pharma Stocks Rally on Sanofi, GSK Coronavirus Vaccine Tie-Up","If successful, the Sanofi (SNY) and GlaxoSmithKline plc (GSK) vaccine would be available in the second half of 2021. Shares of drugmakers jumped on the news.",SAN,en,Zacks Investment Research
2020-04-15 04:22:00-05:00,Two of world's biggest pharmaceutical giants join forces to create coronavirus vaccine,Two of the world’s largest pharmaceutical companies are joining forces to create a coronavirus vaccine – although it may not be available until the end of 2021. British firm GSK and French multinational Sanofi announced the collaboration in the hope of providing long-lasting immunity to Covid-19 cheaply and on a mass scale.,SAN,en,The Independent
2020-04-15 03:43:00-05:00,"The world will need more than one COVID-19 vaccine, says GSK CEO Emma Walmsley",Walmsley said GSK's partnership with Sanofi brings scale to the attempt to get a covid-19 vaccine but that there was still an enormous amount of work to do.,SAN,en,The Financial Express
2020-04-14 18:01:00-05:00,GlaxoSmithKline in deal with rival Sanofi to make coronavirus vaccine on huge scale,One of Britain’s biggest drug companies is teaming up with a French rival to develop a coronavirus vaccine and manufacture hundreds of millions of doses.GlaxoSmithKline is to work with Sanofi on a,SAN,en,The Times
2020-04-14 16:45:53-05:00,British drug firms fight to be first in race to beat Covid,Glaxosmithkline shares rose 1.7 per cent after its announcement with Sanofi. Astrazeneca says it is investigating whether one of its cancer drugs could be adapted to treat virus victims.,SAN,en,Daily Mail Online
2020-04-14 11:02:00-05:00,"GlaxoSmithKline, Sanofi strike deal to develop coronavirus vaccine",The drugmakers said they expect to start clinical trials for the vaccine in the second half of this year.,SAN,en,Business Standard
2020-04-14 10:54:31-05:00,GSK partners with Sanofi to develop coronavirus vaccine,CityAM - Pharmaceuticals giant Glaxosmithkline (GSK) has joined forces with French drugmaker Sanofi to develop a vaccine for the coronavirus disease.,SAN,en,City AM
2020-04-14 09:48:00-05:00,GlaxoSmithKline and Sanofi Announce Joint Coronavirus Vaccine Program,"The new collaboration may be the most significant Covid-19 vaccine project yet announced. It not only takes advantage of the expertise of two of the world’s largest vaccine makers, but also of their manufacturing prowess.",SAN,en,Barron's
2020-04-14 09:30:44-05:00,"Pharma giants Sanofi, GSK working on COVID vaccine for 2021",No summary available.,SAN,en,UrduPoint
2020-04-14 08:31:24-05:00,"GlaxoSmithKline, Sanofi Collaborate On COVID-19 Vaccine Development: What You Should Know","COVID-19 vaccine development has become a crowded field, with about 70 players working for a breakthrough, according to the latest estimates by the World Health Organization. Sanofi SA (NASDAQ: SNY ) and GlaxoSmithKline plc (NYSE: GSK ) announced a collaboration Tuesday to develop an adjuvanted vaccine for the SARS-CoV-2 virus. The companies said a letter of intent has been signed. Sanofi To Contribute S-Protein Sanofi, which is already working on an S-protein vaccine in preclinical studies, will contribute its S-protein COVID-19 antigen based on recombinant DNA technology, according to the companies. This technology has already produced an exact genetic match to proteins found on the surface of the virus, and … Full story available on Benzinga.com",SAN,en,Benzinga
2020-04-14 07:53:28-05:00,The Promise of Ifenprodil – A Repurposed Drug Race for COVID-19,"Developed in the 1970’s, Ifenprodil, a drug originally developed by Sanofi, has been sitting quietly on the approved drug list in Japan for over 45 years. Treating neurological conditions like vertigo and dizziness, it’s real potential …",SAN,en,Baystreet.ca
2020-04-14 07:10:34-05:00,Sanofi and GSK to join forces in Covid-19 vaccine collaboration | London Business News | Londonlovesbusiness.com,"Sanofi and GSK have announced that they have signed a letter of intent to develop an adjuvanted vaccine for coronavirus, using innovative technology",SAN,en,London Loves Business
2020-04-14 07:03:33-05:00,GSK and Sanofi join forces to work on coronavirus vaccine,Two companies jointly have capacity to manufacture hundreds of millions of doses Coronavirus – latest updates See all our coronavirus coverage Two of the world’s biggest vaccine companies have joined forces in an unprecedented effort to develop a Covid-19 vaccine. What is Covid-19? Continue reading…,SAN,en,The Guardian
2020-04-14 06:38:19-05:00,Sanofi partners with GSK for developing coronavirus vaccine,"Clinical trials of the vaccine will start this year, Sanofi CEO Paul Hudson said.",SAN,en,CNBC
2020-04-14 06:35:00-05:00,GSK and Sanofi join forces to develop Covid-19 vaccine,The two companies plan to have a vaccine ready for testing by the second half of 2020,SAN,en,The Telegraph
2020-04-14 06:15:08-05:00,GlaxoSmithKline : Sanofi Join Forces to Develop Coronavirus Vaccine | MarketScreener,"By Ian Walker GlaxoSmithKline PLC and Sanofi SA said Tuesday that they have signed a preliminary agreement to develop an adjuvanted vaccine for the new coronavirus, or Covid-19. The… | April 14, 2020",SAN,en,MarketScreener
2020-04-14 06:07:08-05:00,"GSK, Sanofi strike deal to develop COVID-19 vaccine",GlaxoSmithKline Plc and Sanofi SA said on Tuesday they would develop a vaccine to fight the fast-spreading coronavirus.,SAN,en,Reuters
2020-04-13 16:46:00-05:00,70 potential coronavirus vaccines are in the works globally and trials are moving forward at an unprecedented speed,"70 potential coronavirus vaccines are in development globally, according to a World Health Organization report . Three drugmakers — CanSino, Moderna, and Inovio — are already running human trials . Vaccines typically take multiple years to develop, but researchers racing against the coronavirus pandemic are hoping to drastically speed up that timeline. Still, public health experts say it could take 12 to 18 months to determine whether a vaccine is safe and effective, and some experts have said a rushed rollout could backfire . Visit Business Insider's homepage for more stories . At least 70 potential coronavirus vaccines are currently in development, with 3 already in clinical trials, according to the World Health Organization . WHO published an updated list of vaccine efforts on April 11, showing a vast array of companies pursuing shots that could halt the coronavirus. Bloomberg News reported on the document earlier. As the virus continues to spread, infecting more than 1.9 million people and killing more than 110,000 worldwide, researchers have been racing to develop vaccines.",SAN,en,Business Insider
2020-04-12 16:10:11-05:00,"This Is Where The World Is On The ""Corona Curve"" At This Moment: An Update","This Is Where The World Is On The ""Corona Curve"" At This Moment: An Update Last week, when we looked at the latest shape of the Coronavirus curve, we said that even as US cases continue to soar, ""the light at the end of the tunnel is now visible"" and indeed as JPMorgan's MW Kim writes in his latest Covid-19 update note published late last week, the global infection growth is showing early signs of slowing (53% W/W vs. 95% W/W two weeks ago), according to Johns Hopkins data , according to which the number of global confirmed cases is set to surpass 2 million in the coming days. This reduction in new cases is the result of a sharp drop in the number of susceptible targets (i.e., cutting new contacts), which means that curve control is working with both China and Korea now well into the recovery stage, while Germany, Spain and Italy are at or near the curve peak, with US, France, the UK and several other nations close behind. This is certainly impressive considering what the curve looked like just two weeks ago : In other words, the first wave of coronavirus infections appears to be plateauing as a result of a sharp, forced reduction in secondary infection rates, or R-0 .",SAN,en,Zero Hedge
2020-04-10 08:29:25-05:00,Sanofi donating 100 million doses of hydroxychloroquine to 50 countries,French pharmaceutical giant Sanofi has committed to donating 100 million doses of the decades-old anti-malarial drug hydroxychloroquine — a potential but unproven weapon against COVID-19 — to 50 countries across the world. The company has already doubled its production capacity of the drug across its eight hydroxychloroquine manufacturing sites worldwide and is on track to…,SAN,en,New York Post
2020-04-10 04:30:10-05:00,Sanofi offers 100 mln doses of hydroxychloroquine in COVID-19 fight,No summary available.,SAN,en,UrduPoint
2020-04-09 11:52:29-05:00,Sanofi SA (NASDAQ: SNY) Q4 2019 Earnings Call Transcript,"Sanofi SA (SNY) Q4 2019 earnings call dated Feb. 06, 2020 Corporate Participants: Felix Lauscher — Head of Investor Relations Paul Hudson — Chief Executive Officer John Reed, MD, PhD — Executive Vice President, Global Head of Research & Development Jean-Baptiste Chasseloup de Chatillon — Executive Vice President, Chief Financial Officer Bill Sibold — Executive Vice President, Sanofi Genzyme Olivier Charmeil — Executive Vice President, China & […]",SAN,en,news.alphastreet.com
2020-04-08 16:50:09-05:00,Sanofi (SNY) Gains But Lags Market: What You Should Know,"In the latest trading session, Sanofi (SNY) closed at $45.18, marking a +1.3% move from the previous day.",SAN,en,Zacks Investment Research
2020-04-08 14:07:02-05:00,"Sanofi CEO Talks Coronavirus Vaccine Development, Potential Treatment","France-based global drugmaker Sanofi SA (NYSE: SNY ) is working on developing a coronavirus vaccine under the assumption the pandemic will resume ""in some form"" into 2021, CEO Paul Hudson said Wednesday in a Fox Business interview. Coronavirus Vaccine By Mid-2021? Sanofi's potential vaccine against the coronavirus is unlikely to be made available until mid-2021, Hudson said. This timeline represents ""unprecedented speed,"" as it typically takes 10 years to develop a vaccine from start to finish, the CEO said. The problem with creating a coronavirus vaccine is that it will be administered to already healthy people, so an 18-month timeline ensures the company is ""doing it the right way,"" he said. ""We are confident we will get there,"" Hudson said. ""I think people need to know we will get there and we are … Full story available on Benzinga.com",SAN,en,Benzinga Feeds
2020-04-08 13:39:00-05:00,Alphabet's life sciences firm Verily may use its its giant patient registry to help sign people up to test coronavirus treatments,"Verily, the life-sciences arm of Google's parent company Alphabet, could soon connect patients to clinical trials for coronavirus treatments. Verily has a massive collection of patient data called Project Baseline that already helps drugmakers run studies by connecting them to participants. With so many drugs on the way that could help treat the virus, widespread participation in trials could be an important project for Verily, according to Vivian Lee, president of health platforms. Visit Business Insider's homepage for more stories . Verily, the health wing of Google parent company Alphabet, could soon connect patients to clinical trials for coronavirus treatments. Through its massive patient registry, Project Baseline , Verily helps drugmakers run studies by connecting them to participants. It's currently enrolling people in research on topics including depression, heart disease, and sleep. With many drugs on the way that could help treat the coronavirus, ensuring widespread participation in trials could be an essential function of the Baseline technology, according to Dr.",SAN,en,Business Insider
2020-04-07 16:21:09-05:00,Coronavirus vaccines: What we know about testing and availability,"The World Health Organization says that there are more than 40 research effort to develop a coronavirus vaccine. Two vaccine candidates are already undergoing human testing that could produce a coronavirus vaccine by as early as this fall. Business Insider compiled a list of all the coronavirus vaccine candidates that are undergoing research or human trials. Visit Business Insider's homepage for more stories . The drug industry and health officials are now racing to respond to the coronavirus outbreak as cases of COVID-19 mount, and the World Health Organization has declared it a pandemic. There are more than 40 ongoing research efforts across the globe to develop a coronavirus vaccine, according to the World Health Organization . Two vaccine candidates, for instance, have already started human testing in record timing. But it will still take at least a year to determine if any vaccine works against this virus. Here's is our list of the few vaccines that are undergoing human testing as well as other vaccine candidates that could become available in 2021.",SAN,en,Business Insider
2020-04-07 09:08:53-05:00,Coronavirus treatments: A list of the most promising medical treatments for COVID-19,"There are no medical treatments for patients infected with the novel COVID-19 virus. Some of the world's leading drugmakers are conducting trials on candidate drugs like remdesivir and Actemra . Business Insider has compiled a list of the most promising coronavirus medical treatments undergoing clinical testing. Visit Business Insider's homepage for more stories . A novel coronavirus has infected more than 1.2 million people worldwide and killed more than 70,000. There is no medical treatment that cures patients with COVID-19. However, some of the world's leading drugmakers are testing hundreds of existing drugs and investigating new ones to produce a treatment for those already infected. Here's our list of some of the most promising medical treatments undergoing clinical trial testing right now. Remdesivir: The California biotech Gilead is repurposing a drug called remdesivir that was previously tested against Ebola. The WHO has called the antiviral remdesivir "" the most promising candidate "" for treatment against COVID-19, the disease caused by the coronavirus.",SAN,en,Business Insider
2020-04-07 06:55:37-05:00,"The Daily Biotech Pulse: Sanofi, Regeneron Finalize Praluent Restructuring, Natus Pre-Announces Q1 Shortfall, Alcon To Delay Dividend Initiation","Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs April 6.) Forty Seven Inc (NASDAQ: FTSV ) Masimo Corporation (NASDAQ: MASI ) Seattle Genetics, Inc. (NASDAQ: SGEN ) Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX ) Down In The Dumps (Biotech stocks that hit 52-week lows April 6) BIOLASE Inc (NASDAQ: BIOL ) China SXT Pharmaceuticals Inc (NASDAQ: SXTC ) ENDRA Life Sciences Inc (NASDAQ: NDRA ) Global Cord Blood Corp (NYSE: CO ) ImmuCell Corporation (NASDAQ: ICCC ) IMMURON LTD/S ADR (NASDAQ: IMRN ) Menlo Therapeutics Inc (NASDAQ: MNLO ) (flunked two late-stage studies that evaluated oral serlopitant for treating pruritus associated with prurigo nodularis) Merus NV (NASDAQ: MRUS ) Millendo Therapeutics Inc (NASDAQ: MLND ) (said it is discontinuing development of livoletide as a potential treatment for Prader-Willi syndrome following failed Phase 2b study) Obalon Therapeutics Inc (NASDAQ: OBLN ) Quest Diagnostics Inc (NYSE: DGX ) (said it has performed 550,000 COVID-19 tests) Second Sight Medical Products Inc (NASDAQ: EYES ) Stocks In Focus Sanofi, Regeneron Finalize Previously Announced Praluent Restructuring Sanofi SA (NASDAQ: SNY ) and Regeneron Pharmaceuticals Inc (NASDAQ: REGN ) announced they have finalized the planned restructuring related to cholesterol drug Praluent.",SAN,en,Benzinga
2020-04-07 06:06:39-05:00,"Trump has a distant financial link to a pharma giant that makes the drug he's been pushing to fight COVID-19 — but it's probably worth less than $1,000","President Donald Trump has a distant financial link to Sanofi, the French pharmaceutical company that produces a drug that is being trialed as a possible coronavirus treatment The link was first highlighted by The New York Times , which described it as ""small."" Calculations by Business Insider suggest the stake — held via a trust and a mutual fund — is worth no more than $1,305. President Donald Trump has repeatedly endorsed chloroquine and hydroxychloroquine at his press briefings as an experimental treatment to fight COVID-19, the disease caused by the new coronavirus. Some of Trump's associates also have financial ties to Sanofi, according to The Times. Visit Business Insider's homepage for more stories . President Donald Trump reportedly has a ""small personal financial interest"" in a drugmaker that produces hydroxychloroquine, a drug he has been enthusiastically touting as a possible treatment for the new coronavirus, according to a Monday New York Times report. ""As of last year, Mr.",SAN,en,Business Insider
2020-04-07 03:13:02-05:00,Sanofi : Correction to Sanofi Article | MarketScreener,"Sanofi has finalized the restructuring related to Praluent with Regeneron. Sanofi Finalizes Praulent Restructuring With Regeneron, at 0539 GMT, misstated the name of the drug in the headline. The… | April 7, 2020",SAN,en,MarketScreener
2020-04-06 22:33:56-05:00,"ITC, Britannia, Torrent, Abbott, Sanofi, Lupin better choices now","For traders, there will be plenty of opportunities with low risk-reward ratio due to higher stop-loss.",SAN,en,Economic Times India
2020-04-06 08:48:00-05:00,"The Zacks Analyst Blog Highlights: J&J, Sanofi, AstraZeneca, Lilly and Merck","The Zacks Analyst Blog Highlights: J&J, Sanofi, AstraZeneca, Lilly and Merck",SAN,en,Zacks Investment Research
2020-04-03 08:26:47-05:00,Sanofi CEO : 'The One-Meeting Trip Will Disappear' | MarketScreener,"By Denise Roland Paul Hudson had a lot on his plate as the new boss of French health-care giant Sanofi SA: radically pruning its drug pipeline, cutting EUR2 billion in costs by 2022 and… | April 3, 2020",SAN,en,MarketScreener
2020-04-03 00:38:03-05:00,Banco Santander S A : Cancels 2019 Final Dividend | MarketScreener,"By Olivia Bugault Banco Santander SA said late Thursday that it is scrapping its final dividend for 2019 after the European Central Bank asked banks not to pay dividends until October. … | April 3, 2020",SAN,en,MarketScreener
2020-04-02 16:00:58-05:00,"Michigan Physician On 'Out-Of-Control' Coronavirus, How Trump's Tweets Drove Shortage Of Rheumatological Drug","President Donald Trump found a cure for the coronavirus — or so he thought. On March 21, Trump tweeted praise for a combo treatment of hydroxychloroquine and azithromycin and urged that they “be put in use IMMEDIATELY.” Doctors and patients listened. “There has been some use of it in the hospital,” Dr. Lisa Elconin, an internist through the Henry Ford Health System, said Friday on Benzinga’s PreMarket Prep . Elconin is the wife of PreMarket Prep co-host Joel Elconin. “Whether it should be used earlier as an outpatient, there hasn’t been enough studies to show that, and there has been some harm from it, but the supplies actually have unfortunately been depleted.” Trump’s ad triggered a shortage for patients routinely prescribed these drugs. “After the president tweeted about the plaquenil and zithromax [the brand names], people were getting prescriptions from their doctors,” Elconin said of the drugs made by Sanofi SA (NASDAQ: SNY ) and Pfizer Inc. (NYSE: PFE ), respectively. ""Doctors were giving it to friends, so then what happened was the state of Michigan was almost out of plaquenil."" It's a drug that's used for lupus and rheumatoid arthritis patients as a maintenance drug, and those patients …",SAN,en,Benzinga
2020-04-02 10:25:42-05:00,"Everything we know about the coronavirus, from who's most at risk to where new cases are spreading","A third of the world is now under some form of lockdown due to the coronavirus pandemic. The US has the largest reported outbreak, representing more than one fifth of all cases worldwide, with New York at its epicenter. Italy has the world's highest reported death count. Here's everything we know about COVID-19. Read Business Insider's live coronavirus updates here , and visit the homepage for more stories . As the coronavirus pandemic continues to grow and evolve — the US has the world's largest outbreak , with more than 200,000 people infected, while Italy has recorded more deaths than any other country — researchers are scrambling to learn about the virus and recommend effective responses. Typical coronavirus patients develop a fever, dry cough, or shortness of breath, but these symptoms may appear at different times — or not at all. Severe cases tend to worsen about five to 10 days after symptoms start. The virus' average incubation period is about five days, but can range anywhere from two to 14 days, according to the CDC.",SAN,en,Business Insider
2020-04-01 11:52:35-05:00,Bolsas da Europa fecham em queda com piora da indústria,"Pesquisa mostrou que a atividade industrial da zona do euro entrou em colapso em março, com analistas prevendo que interrupções prolongadas no setor podem ter impacto duradouro na economia. As ações europeias encerraram em baixa nesta quarta-feira (1º), em meio a dados econômicos cada vez mais terríveis devido ao coronavírus, enquanto os papéis de bancos despencaram conforme várias grandes instituições do setor suspenderam o pagamento de dividendos. O índice FTSEurofirst 300 caiu 2,92%, a 1.224 pontos, enquanto o índice pan-europeu STOXX 600 perdeu 2,9%, a 311 pontos. Na terça-feira, o STOXX encerrou os primeiros três meses do ano com a maior perda trimestral em quase 18 anos. No período de janeiro a março o valor de mercado das companhias que compõem o índice despencou cerca de US$ 2,8 trilhões. A Bolsa de Frankfurt, na Alemanha, cujo índice acionário DAX é o mais importante da Europa continental Reuters Uma pesquisa mostrou que a atividade industrial da zona do euro entrou em colapso em março, com analistas prevendo que interrupções prolongadas no setor podem ter um impacto duradouro e profundo na economia. ""Com a produção e a atividade empresarial reduzidas a níveis extremamente baixos e já que as medidas de contenção ainda precisam provar sua eficácia, a maioria das empresas é confrontada com uma queda drástica nas receitas, o que provavelmente levará a um rápido aumento do desemprego"", disse Davide Oneglia, economista da TS Lombard. ""Esperamos uma recessão severa na zona do euro no primeiro semestre e apenas uma recuperação modesta depois disso."" A expectativa é que o lucro das empresas listadas no STOXX 600 caia em um quinto no segundo trimestre, aprofundando a recessão europeia no setor corporativo, enquanto os dividendos pagos por essas empresas provavelmente devem cair cerca de 40%.",SAN,pt,Globo
2020-03-31 00:44:45-05:00,Covid vaccine in 18 mths? Experts urge reality check,"By James PatonAs a young researcher in the late 1980s, Michael Kinch wanted to solve the biggest medical puzzle of the day: how to design an HIV vaccine. But dozens of well-funded labs were attacking the problem, a solution seemed easily within reach, and Kinch moved on.More than 30 years and 30 million deaths later, there’s still no approved HIV vaccine -- a cautionary tale for anyone expecting a coronavirus vaccine within the next year, according to Kinch, a former drug developer who’s now associate vice chancellor at Washington University in St. Louis.“There’s a built-in assumption that there will be a vaccine,” Kinch said. “We just have to go into it very sober.”As worldwide cases surge past 750,000, governments, investors and the public are keenly watching the breakneck race to deliver coronavirus vaccines that could prevent future infections. Researchers are seen as the saviors who will deliver therapies and vaccines needed to defeat the coronavirus, and President Donald Trump has urged drugmakers to “get it done.”Among the majority of the public, vaccines are embraced as safe and straightforward: show the virus or a key piece of it to the immune system to remember so that it’s ready when a real infection occurs.",SAN,en,Economic Times India
2020-03-30 15:48:00-05:00,"The coronavirus has thick spikes that seem to latch more easily onto human cells than other viruses, according to a 3D map of its structure","A new study from the University of Minnesota created a 3D model of the new coronavirus and found that it could bind far more efficiently to human cell receptors than the SARS virus. This might explain how the new coronavirus could spread across the globe at such a dizzying speed. This 3D map could help scientists create vaccines that block these cell receptors, stopping the new coronavirus before it can replicate. Visit Business Insider's homepage for more stories . A new study offers fresh insight into the unique structure of the novel coronavirus that makes it so infectious. Researchers at the University of Minnesota created a 3D map of the virus, known technically as Sars-CoV-2. They found that it has a shell of thick spikes that latch onto human cell receptors much more efficiently than Sars, another type of coronavirus that caused a smaller-scale but devastating pandemic in Asia in 2002. Health officials around the world are already recommending social distancing to combat the pandemic because it's clear that infection is spread by coronavirus droplets produced when infected people cough or sneeze.",SAN,en,Business Insider
2020-03-30 07:00:56-05:00,"First patient treated in Regeneron, Sanofi trial for COVID-19 treatment",Regeneron Pharmaceuticals Inc. and Sanofi SA said Monday that the first patient in a global clinical trial testing Kevzara as a therapy for patients…,SAN,en,MarketWatch
2020-03-30 06:58:12-05:00,"Stocks making the biggest moves in the premarket: J&J, Sanofi, Regeneron, La-Z-Boy, Apple & more","The stocks making the biggest moves in premarket trading include J&J, Sanofi, Regeneron, La-Z-Boy, Apple, and more.",SAN,en,CNBC
2020-03-30 05:52:23-05:00,Covid 19 vaccine race develops at speed,"Originally written by Anthony Ginsberg on What Investment Currently, at least 30 companies and academic institutions, biotech startups and big pharma giants including Johnson & Johnson and Sanofi are working on vaccines. Scientists have already studied the full genome of the virus and found the proteins that cause the infection. A number of Biotech companies including Gilead Sciences and Moderna are advanced in",SAN,en,whatinvestment.co.uk
2020-03-29 06:42:14-05:00,2 Biotech Giants in the Hunt for New Coronavirus Drugs,"With the number of confirmed COVID-19 cases rising despite worldwide lockdowns and social distancing efforts, the biotech industry is taking action. In just two months since the first infection was reported in the U.S., the country’s total number of cases has surpassed both that of Italy and China, and the Trump administration is calling on names in the space to step in. The sector’s response? Challenge accepted. As the U.S. government pumped $8.3 billion into research as well as prevention efforts, several biotech companies have joined the fight against COVID-19. Among those battling the virus, one of TipRanks’ top five rated investing firms , Oppenheimer, recently highlighted two biotech heavyweights that have made notable strides in developing COVID-19 drugs. Bearing this in mind, we used TipRanks’ database to learn more about Oppenheimer’s picks. It turns out that each Buy-rated ticker has also received substantial support from other Wall Street analysts. Here’s the full rundown. Gilead Sciences ( GILD ) First up we have healthcare giant Gilead Sciences.",SAN,en,Nasdaq
2020-03-28 08:35:00-05:00,Escobar: Why Is France Hiding A Cheap And Tested Virus Cure?,"Escobar: Why Is France Hiding A Cheap And Tested Virus Cure? Authored by Pepe Escobar via The Asia Times, The French government is arguably helping Big Pharma profit from the Covid-19 pandemic… What’s going on in the fifth largest economy in the world arguably points to a major collusion scandal in which the French government is helping Big Pharma to profit from the expansion of Covid-19. Informed French citizens are absolutely furious about it. My initial question to a serious, unimpeachable Paris source, jurist Valerie Bugault, was about the liaisons dangereuses between Macronism and Big Pharma and especially about the mysterious “disappearance” – more likely outright theft – of all the stocks of chloroquine in possession of the French government. Respected Professor Christian Perronne talked about the theft live in one of France’s 24/7 info channels: “The central pharmacy for the hospitals announced today that they were facing a total rupture of stocks, that they were pillaged.” With input from another, anonymous source, it’s now possible to establish a timeline that puts in much-needed perspective the recent actions of the French government.",SAN,en,Zero Hedge
2020-03-27 16:58:05-05:00,Banco Santander S A : Revision of the rating granted to Banco Santander by Fitch Ratings | MarketScreener,"Banco Santander, S.A. , pursuant to the provisions of the Spanish Securities Market Act , hereby announces the following: INSIDE INFORMATION … | March 27, 2020",SAN,en,MarketScreener
2020-03-27 15:33:00-05:00,Another mRNA Company Announced a Covid-19 Vaccine Program,"Sanofi announced a new effort to develop a vaccine to prevent the novel coronavirus, Covid-19, using messenger RNA, in a collaboration with the biotech firm Translate Bio.",SAN,en,Barron's
2020-03-27 13:38:04-05:00,Banco Santander S A : Santander Brasil offers exclusive in-branch service for the elderly and a 12% discount on online purchases in pharmacies | MarketScreener,"These new measures aim to reduce the risk for the most vulnerable members of the community and encourage fewer people to go out into the streets during the quarantine period … | March 27, 2020",SAN,en,MarketScreener
2020-03-27 13:02:14-05:00,Companies that are working on the coronavirus vaccine,"The coronavirus pandemic continues to plague the world with over 500,000 cases reported globally and over 82,000 cases in the US alone. As the world grapples with the outbreak, several healthcare companies are working to develop a vaccine against COVID-19. Let’s take a look at some of them: Sanofi and Translate Bio The latest to […]",SAN,en,news.alphastreet.com
2020-03-27 07:02:53-05:00,"The Daily Biotech Pulse: Sanofi-Translate Bio Join Hands For Coronavirus Vaccine, TherapeuticsMD Suspends Guidance",Here's a roundup of top developments in the biotech space over the … Full story available on Benzinga.com,SAN,en,Benzinga Feeds
2020-03-27 01:54:03-05:00,Sanofi : Translate Bio to Develop Covid-19 Vaccine Candidate | MarketScreener,"By Kim Richters The French pharmaceutical major Sanofi SA said Friday that it is collaborating with Translate Bio Inc. to develop a new mRNA vaccine candidate against Covid-19. The U.S…. | March 27, 2020",SAN,en,MarketScreener
2020-03-24 13:52:00-05:00,Drugmakers are developing coronavirus vaccines in record time — but it will still be months before one is available,"Drug companies are working on developing a coronavirus vaccine at record speed. But a safe, FDA-approved solution may still be several months away. US health officials have said it will take at least 12 months to know if any vaccine works. And the question of who will pay for vaccine development is still unanswered. View more episodes of Business Insider Today on Facebook. Vaccines typically take multiple years to develop. But when it comes to the rapidly escalating coronavirus pandemic , drug companies don't have that kind of time. Luckily, there are reasons to be hopeful that a vaccine against the coronavirus could be developed in record time. Leading the way is Moderna, which is developing a vaccine at a record pace. According to the World Health Organization, there are about 40 coronavirus vaccines being developed right now. Leading the way is Moderna, a biotechnology company from Massachussetts that has managed to bring a vaccine candidate into a clinical trial in about two months.",SAN,en,Business Insider
2020-03-24 08:48:00-05:00,Hospitals and pharmacies risk running out of inhalers as the coronavirus strains supplies,"Metered dose inhalers (MDIs) filled with the medicine albuterol are in short supply, as hospitals need them to treat patients infected by the novel coronavirus . Albuterol is a medication that helps with respiratory issues, such as asthma and chronic obstructive pulmonary disease. Alternatives to metered dose inhalers, like nebulizers, aren't as safe to use for people who might have the coronavirus, because they can help spread the virus and expose healthcare workers. Visit Business Insider's homepage for more stories . A common type of inhalers is joining a running list of potential shortages straining the US healthcare system as it gears up to fight the novel coronavirus . Hospitals are using inhalers filled with albuterol to treat a growing number of patients with respiratory issues caused by the new coronavirus. In the first two weeks of March, hospitals ordered more than twice as many metered-dose inhalers (MDIs) as they did over comparable periods in January and February, according to data compiled by Premier, a healthcare-supply company.",SAN,en,Business Insider
2020-03-24 08:30:40-05:00,Novavax Shares Rally On Flu Vaccine Study Results: What You Need To Know,"Novavax, Inc. (NASDAQ: NVAX ), which was in the news recently on account of its COVID-19 vaccine development program, is in the spotlight yet again Tuesday. Flu Vaccine Candidate Aces Study The small-cap late-stage biotech announced positive top-line results Tuesday for its pivotal late-stage study of its influenza vaccine candidate NanoFlu, which is being evaluated in adults 65 and older. NanoFlu is Novavax's recombinant quadrivalent seasonal flu vaccine with the company's proprietary Matrix-M adjuvant. The late-stage study evaluated the immunogenicity and safety of NanoFlu Quadrivalent compared to Fluzone Quadrivalent, a U.S.-licensed quadrivalent influenza vaccine marketed by Sanofi SA (NASDAQ: SNY ). The primary objectives … Full story available on Benzinga.com",SAN,en,Benzinga
2020-03-23 08:15:00-05:00,"The Zacks Analyst Blog Highlights: Pfizer, Roche, Sanofi, Lilly and Merck","The Zacks Analyst Blog Highlights: Pfizer, Roche, Sanofi, Lilly and Merck",SAN,en,Zacks Investment Research
2020-03-22 05:24:01-05:00,"'We hope Plaquenil will save some people,' says Sanofi's Olivier Bogillot","As the world faces the biggest public health crisis in a century, researchers are exploring whether the drugs chloroquine and hydroxychloroquine could be used effectively to treat the symptoms of the coronavirus. This follows encouraging early results in both France and China. French pharmaceutical company Sanofi said it was ready to offer the French government millions of doses of hydroxychoroquine, sold under its brand name Plaquenil. FRANCE 24 Annette Young speaks to Olivier Bogillot, president of Sanofi France.",SAN,en,FRANCE 24
2020-03-20 09:33:00-05:00,Feinstein Institutes begins enrolling patients in multiple COVID-19 clinical trials,"MANHASSET, N.Y.--(BUSINESS WIRE)--The Feinstein Institutes for Medical Research, the research arm of Northwell Health, announced today the enrollment of three clinical trials in the ongoing effort to combat COVID-19, the novel coronavirus. Feinstein Institutes researchers are teaming up with Gilead Sciences, Regeneron Pharmaceuticals and Sanofi to identify effective treatments for patients currently hospitalized in moderate and severe conditions with COVID-19. The goal is to improve recovery an",SAN,en,Business Wire
2020-03-20 06:26:21-05:00,Coronavirus treatment: Ibuprofen may worsen effects of COVID-19? Sanofi counters WHO statement,"Countering it, Sanofi said the WHO has stated they are not aware of published clinical or population-based data on ibuprofen and the worsening of COVID-19 and based on currently available information, do not recommend against the use of ibuprofen.",SAN,en,The Financial Express
2020-03-19 09:04:00-05:00,Santander Bank Portugal chairman become's country's second Covid-19 fatality,"Following Santander Portugal’s announcement of the passing of its chairman, Antonio Vieira, Santander Group executive chairman, Ana Botín, has issu…",SAN,en,Finextra Research
2020-03-18 20:11:37-05:00,France cautiously exploring coronavirus treatment based on anti-malaria drug,"French pharmaceutical company Sanofi said it's ready to assist the government with millions of doses of a drug that could help treat 300,000 coronavirus patients. Test with anti-malaria Plaquenil showed that the COVID-19 virus disappeared after six days in 75% of patients in a limited study. The government said the results were promising, but they need to be validated by more extended, independent trials before going forward. Visit BGR's homepage for more stories . Staying home and washing our hands are two simple things we all can do to give hospitals the time they need to treat severe coronavirus cases and authorities the time they need to procure critical medical supplies (ventilators and COVID-19 test kits) and come up with measures that will prop up the economy when this is over. At the same time, researchers need time to study the virus closely, to understand how it works and how it can be defeated. Doctors in Australia have published a study that shows how the immune system kills the infections, while several laboratories around the world are working on vaccines.",SAN,en,BGR.com
2020-03-18 11:43:33-05:00,"Banco Santander S A : Ana Botín statement, following Santander Portugal's announcement of the passing of its chairman, Antonio Vieira | MarketScreener","This morning when I was speaking to Pedro, our Portugal CEO and later to Rita, Antonio's daughter I felt very personally the true dimension of this crisis. It was one of the saddest… | March 18, 2020",SAN,en,MarketScreener
2020-03-17 03:22:01-05:00,Banco Santander S A : Warns of Possible Coronavirus Hit on Earnings | MarketScreener,"By Pietro Lombardi Banco Santander SA said Tuesday that it is too early to forecast the impact of the coronavirus pandemic but that it might cause a 5% hit on earnings for this year. At… | March 17, 2020",SAN,en,MarketScreener
2020-03-17 02:56:10-05:00,Banco Santander S A : Santander Group Chairman presentation at MS EFC | MarketScreener,"Regulatory Story Go to market news section … | March 17, 2020",SAN,en,MarketScreener
2020-03-16 10:10:11-05:00,"Sanofi, Regeneron begin testing coronavirus treatment with arthritis drug","In February, Regeneron announced a partnership with the U.S. Department of Health and Human Services to develop a coronavirus treatment.",SAN,en,Fox Business
2020-03-16 08:56:00-05:00,"Sanofi, Regeneron start testing arthritis drug to fight coronavirus","Sanofi SA and partner Regeneron Pharmaceuticals Inc have started a clinical trial of their rheumatoid arthritis drug Kevzara as a treatment for the coronavirus, the companies said on Monday.",SAN,en,FRANCE 24
2020-03-16 08:09:00-05:00,"Pharma giants Sanofi and Regeneron are now testing out an arthritis drug to fight the coronavirus, starting in New York","Drugmakers are testing a drug that's currently used to treat arthritis against the novel coronavirus. Pharma companies Sanofi and Regeneron said Monday that they started a trial, and are looking to enroll 400 patients in New York. They eventually plans to test the drug, called Kevzara, across the globe. There are no approved treatments or vaccines for the coronavirus. Many pharma and biotech companies have started research programs in the last few weeks as the outbreak has worsened into an official pandemic. Visit Business Insider's homepage for more stories . A new coronavirus clinical trial is now seeking patients in the US, starting in New York. The French pharma giant Sanofi and New York biotech company Regeneron said Monday they have kicked off a global testing program for Kevzara as a treatment for severe cases of COVID-19, the disease caused by the coronavirus pandemic. Currently, there are no approved treatments or vaccines for the coronavirus. Kevzara was approved in the US in 2017 to treat rheumatoid arthritis.",SAN,en,Business Insider
2020-03-16 07:14:00-05:00,Testing underway to determine effectiveness of arthritis drug as coronavirus treatment,Sanofi SA and partner Regeneron Pharmaceuticals Inc have started a clinical trial of their rheumatoid arthritis drug Kevzara as a treatment for the coronavirus.,SAN,en,Independent on Saturday
2020-03-16 07:09:00-05:00,Regeneron and Sanofi Begin Global Kevzara® (sarilumab) Clinical Trial Program in Patients with Severe COVID-19,"/PRNewswire/ -- U.S. Phase 2/3 trial initiated and will begin enrolling patients immediately Regeneron is leading U.S. trials, Sanofi will lead upcoming ex-U.S….",SAN,en,PR Newswire
2020-03-12 07:00:00-05:00,VBI Vaccines Appoints Damian Braga to Board of Directors,"CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $VBIV--VBI Vaccines Inc. (NASDAQ: VBIV) (“VBI”), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, today announced that Damian Braga has joined its Board of Directors. Mr. Braga spent 27 years at Sanofi Pasteur, the human vaccines business of Sanofi Group, retiring in 2015 as the Senior Vice President, Global Commercial Operations & President, U.S. and the Americas, where he was responsible fo",SAN,en,Business Wire
2020-03-12 05:55:19-05:00,Banco Santander S A : Deutsche Bank opts not to redeem $1.25 billion of debt next month | MarketScreener,"… | March 12, 2020",SAN,en,MarketScreener
2020-03-11 19:36:00-05:00,Biocon: Insulin drug's patent hurdle cleared,"Shares of Biocon may see buying interest, as the company won a major ruling for insulin drug in the US. According to Biocon, the US District Court of New Jersey invalidated Sanofi’s patent suit again",SAN,en,The Hindu BusinessLine
2020-03-11 09:16:53-05:00,"Biocon, Mylan win US court ruling that nullifies Sanofi’s patent","Bengaluru: Biocon, with its partner Mylan, has won a US court ruling that invalidated rival Sanofi’s patent on the insulin Glargine device, removing a key legal hurdle for the biotech major to commercialize Semglee. The US District Court of New Jersey found the device patent claims (US Patent No. 9526844) asserted by Sanofi against Biocon and Mylan’s insulin Glargine product ‘not infringed’ and ‘invalid’ for lack of written description, said Biocon in a press statement. Semglee is co-developed with Mylan in the US. The 505(b)(2) New Drug Application (NDA) for Semglee is under active review by the US Food and Drug Administration (USFDA). The USFDA has set a target action date for our Insulin Glargine application in June 2020, said the company. In October 2017, Sanofi had initiated patent infringement litigation against Biocon and Mylan’s NDA in the US District Court of New Jersey that included the formulation patents covering insulin Glargine as well as patent covering the Insulin Glargine injection pen, triggering a 30-month stay on the product’s approval.",SAN,en,The Economic Times India
2020-03-10 15:41:00-05:00,"WSJ News Exclusive | Regeneron, Sanofi to Test Arthritis Drug as Coronavirus Treatment",Drugmakers Regeneron Pharmaceuticals Inc. and Sanofi SA are racing to launch clinical trials exploring whether their arthritis drug could treat symptoms of novel coronavirus infections.,SAN,en,The Wall Street Journal
2020-03-09 09:00:58-05:00,Telehealth unicorn Babylon signed a decade-long deal with the Rwandan government to give consumers free access to its services,"This story was delivered to Business Insider Intelligence Digital Health Pro subscribers earlier this morning. To get this story plus others to your inbox each day, hours before they're published on Business Insider, click here. The UK-based telehealth unicorn's deal in Rwanda will grant all citizens over age 12 free access to digital services from Babylon's Rwanda-focused subsidiary Babyl, per MobiHealthNews. For context, Babyl connects patients to remote Rwanda-based general practitioners, flaunts triage and symptom checker tools, and enables electronic prescription services. And it's seen success in region, counting over 2 million subscribers since launching in 2016. Despite coming under fire from the public lately, Babylon seems to be blazing forward with its global expansion efforts. Babylon recently drummed up scrutiny over the caliber of advice its AI-enabled chatbot is churning out and how it's handling customer data. For instance, Babylon-employed physicians have expressed worry that Babylon's software was advising patients to head into emergency rooms who might not actually need emergency services — and UK doctors have denounced Babylon's relationship with the NHS.",SAN,en,Business Insider
2020-03-06 17:04:20-05:00,Banco Santander S A : SEC Filing (20-F) | MarketScreener,"Exhibit Exhibit 1.1 BYLAWS OF BANCO SANTANDER, S.A. … | March 6, 2020",SAN,en,MarketScreener
2020-03-06 11:43:10-05:00,Banco Santander S A : Santander Global Sustainable Bond Framework March 2020 | MarketScreener,"Banco Santander, S.A. Global Sustainable Bond Framework September 25, 2019 1 … | March 6, 2020",SAN,en,MarketScreener
2020-03-06 11:15:00-05:00,"'Crazy hours, short nights': The inside story of how a buzzy biotech upstart developed a potential coronavirus vaccine in record time (MRNA)","The $10 billion biotech Moderna developed a potential coronavirus vaccine in record time, zooming past Big Pharma competitors. The company's CEO Stephane Bancel sat down with Business Insider to discuss the technology platform that drove its speed, and how the company hopes to pioneer a new way of developing vaccines. ""The speed is one dimension, but the piece that excites me the most about this technology is we can do vaccines that cannot be done using traditional technology,"" Bancel said. The potential coronavirus vaccine will still require at least 12 to 18 months of testing in humans to determine if it's safe and works to prevent the virus, according to a top US health official. Here's the inside story of how Moderna went from the virus being sequenced to a vaccine being shipped in 42 days. Visit Business Insider's homepage for more stories . NORWOOD, Massachusetts — Stephane Bancel was vacationing in the south of France with his family when he first read about the virus. It was early January when the biotech executive saw a Wall Street Journal article describing a ""mystery virus outbreak"" in central China.",SAN,en,Business Insider
2020-03-06 09:54:00-05:00,"Global Biologics Market: Insight, Competition and Forecast (2020-2025) Featuring Eli Lilly, Sanofi, Pfizer, Roche, AbbVie, Amgen, Merck & Co, Novo Nordisk, BMS, and Johnson & Johnson - ResearchAndMarkets.com","DUBLIN--(BUSINESS WIRE)--The ""Global Biologics Market: Analysis By Product Type, Application Type, Product Pipeline, End User, By Region, By Country (2020 Edition): Market Insight, Competition and Forecast (2020-2025)"" report has been added to ResearchAndMarkets.com's offering. The Global Biologics Market was valued at USD 281.69 billion in the year 2019. Growing development of pipeline products and rapid economic growth with rising prevalence of chronic diseases and surging demand for low cost",SAN,en,Business Wire
2020-03-05 03:21:00-05:00,J&J Files MAA for Multiple Sclerosis Drug Ponesimod in Europe,"Ponesimod's regulatory application in Europe is based on data from the head-to-head OPTIMUM phase III study comparing it to Sanofi's (SNY) MS drug, Aubagio",SAN,en,Zacks Investment Research
2020-03-04 15:53:01-05:00,Sanofi : Correction to Sanofi Insulin Price Story | MarketScreener,"CVS Caremark is the pharmacy-benefit manager arm of CVS Health Corp., which acquired health insurer Aetna in 2018. Sanofi, Fighting Back in Insulin Price Debate, Says Its Net Prices Fell 11%, at… | March 4, 2020",SAN,en,MarketScreener
2020-03-03 16:45:00-05:00,Sanofi's Sarclisa Gets FDA Nod for Third-Line Multiple Myeloma,The FDA approves Sanofi's (SNY) Sarclisa (isatuximab) combo for the treatment of adult patients with relapsed refractory multiple myeloma in the third-line setting.,SAN,en,Zacks Investment Research
2020-03-03 12:51:00-05:00,Sanofi just got its first cancer drug approved in a decade. Here's the pharma giant's plan to rejoin the fight against cancer under new CEO Paul Hudson.,"The French drugmaker Sanofi has officially re-entered oncology, as the Food and Drug Administration approved the multiple myeloma treatment Sarclisa on Monday. Sanofi's last new cancer drug was a chemotherapy approved a decade ago. Under new leadership, the company plans to advance several more cancer therapies, a top Sanofi executive told Business Insider. ""Sarclisa is our re-entry into oncology,"" Sanofi's development leader Dietmar Berger said in an interview. ""You see a very meaningful pipeline behind that."" In his first few months as CEO, Paul Hudson has begun shaking up the $120 billion pharma giant. In December, he announced Sanofi will stop diabetes and cardiovascular research , while inking a $2.5 billion deal to acquire Synthorx and expand its immuno-oncology pipeline. Click here for more BI Prime stories . Sanofi is back in the fight against cancer. On Monday, the French pharmaceutical giant won US approval for Sarclisa, a therapy for a type of blood cancer called multiple myeloma.",SAN,en,Business Insider
2020-03-02 13:52:50-05:00,SANOFI-LA FDA AMÉRICAINE APPROUVE SARCLISA POUR LE TRAITEMENT DU MYÉLOME MULTIPLE EN RECHUTE OU RÉFRACTAIRE | Zone bourse,SANOFI-LA FDA AMÉRICAINE APPROUVE SARCLISA POUR LE TRAITEMENT DU MYÉLOME MULTIPLE EN RECHUTE OU RÉFRACTAIRE … | 2 mars 2020,SAN,en,Zonebourse
2020-03-02 13:51:16-05:00,Sanofi : FDA approves Sarclisa® (isatuximab-irfc) for patients with relapsed refractory multiple myeloma,FDA approves Sarclisa® (isatuximab-irfc) for patients with relapsed refractory multiple myeloma Sarclisa in combination with pomalidomide and…,SAN,en,GlobeNewswire
2020-03-02 13:14:10-05:00,Sanofi : FDA Approves Sanofi-Aventis Therapy for Multiple Myeloma | MarketScreener,"By Stephen Nakrosis The U.S. Food and Drug Administration on Monday said it approved Sarclia, or isatuximab-irfc, in combination to treat certain adult patients with multiple myeloma. … | March 2, 2020",SAN,en,MarketScreener
2020-02-28 16:13:00-05:00,Sanofi to pay $11.9 million to resolve U.S. drug kickback probe,https://www.investing.com/news/stock-market-news/sanofi-to-pay-119-million-to-resolve-us-drug-kickback-probe-2097591,SAN,en,Investing.com
2020-02-28 15:59:00-05:00,"Baron & Budd Obtains $11,850,000 Settlement in False Claims Act Case Against Sanofi-Aventis U.S., LLC","WASHINGTON--(BUSINESS WIRE)-- #becomeawhistleblower--Today, the nationally recognized attorneys from Baron & Budd obtained an $11,850,000 settlement in a case against pharmaceutical marketing company, Sanofi-Aventis U.S., LLC. The company markets drugs, including Lemtrada, a treatment for patients with multiple sclerosis (MS). In this case, a whistleblower came forward with information alleging that Sanofi was paying kickbacks to physicians and patients. The scheme was allegedly perpetrated by making the cost of L",SAN,en,Business Wire
2020-02-27 16:00:00-05:00,Alnylam Announces Changes to its Board of Directors,"CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced the appointment of Dr. Olivier Brandicourt to its Board of Directors effective March 2, 2020. Dr. Brandicourt served as Chief Executive Officer and a member of the Board of Directors of Sanofi from 2015 to 2019. Prior to that he was CEO and chair of Bayer HealthCare from 2013 to 2015, and spent 13 years at Pfizer, including as a member of its Executive Leadership Tea",SAN,en,Business Wire
2020-02-27 14:59:00-05:00,How the buzzy biotech Moderna sped past Big Pharma to develop the first potential coronavirus vaccine in just 42 days,"In the sprint to develop vaccines for the coronavirus outbreak , the world's largest drugmakers have been lapped by a startup biotech. It took 42 days for Moderna to turn the genomic sequence of the virus into a vaccine candidate and ship it to US health officials. The National Institutes of Health will now start the first human trial in a matter of weeks, focused on safety. It will require months of additional study to know if the vaccine is safe and effective in protecting people against this novel coronavirus. Moderna showed how its novel genetic technology can speed up vaccine development. The Cambridge, Massachusetts-based biotech is also testing vaccines for infectious diseases like the Zika virus, respiratory syncytial virus, and cytomegalovirus, or CMV. Click here for more BI Prime articles . Scrambling to respond to the growing coronavirus outbreak, some of the world's largest drugmakers have begun researching vaccines to prevent the deadly virus. But a small, startup biotech has sped past them, becoming the first company to produce a potential vaccine ready to be tested in humans.",SAN,en,Business Insider
2020-02-26 09:57:00-05:00,Buzzy biotech Moderna is 'looking at all options' to ramp up production just days after shipping the first potential coronavirus vaccine (MRNA),"A startup biotech is leading the race to develop a coronavirus vaccine, as the scientific community and drug industry scramble to identify treatments to halt the outbreak. On Tuesday, Moderna shipped the first batches of its experimental vaccine to the National Institutes of Health. US health officials will lead the first clinical trial, planning to test the vaccine for safety in healthy adults. While the NIH prepares to start that study, Moderna executives said they are ""looking at all options"" to boost manufacturing capabilities. The buzzy biotech, which went public in 2018, has been solely focused on research. A sense of urgency has been placed on the drug industry to identify and develop vaccines and treatments to halt the coronavirus outbreak, which is causing the disease called COVID-19. The virus has killed more than 2,700 people and sickened more than 81,000. Visit Business Insider's homepage for more stories . A small, buzzy biotech is leading the race to develop a vaccine against the coronavirus, outpacing some of the world's largest pharmaceutical companies like Johnson & Johnson and Sanofi in the process.",SAN,en,Business Insider
2020-02-25 10:28:00-05:00,Sanofi Plans Spin-Off of API Unit Into a European Company,Sanofi (SNY) plans to combine its API commercial activities with six of its European API production sites and spin-off the same into an independent European API company.,SAN,en,Zacks Investment Research
2020-02-24 22:23:40-05:00,"Board Meetings Today: Asian Paints, Dr Lal Pathlabs, Navin Fluorine, Sanofi India and Wonderla Holidays",It makes sense to have a look at the corporate agendas for the day’s as announced to the stock exchanges.,SAN,en,The Economic Times India
2020-02-24 16:22:00-05:00,"J&J, Sanofi, Inovio Hunt for Coronavirus Vaccines","Johnson & Johnson, Sanofi and Inovio Pharmaceuticals have started to develop coronavirus vaccines. The efforts come as Moderna has shipped a batch of its coronavirus vaccine to U.S. researchers for human testing.",SAN,en,The Wall Street Journal
2020-02-24 11:12:57-05:00,Sanofi creating pharma ingredient company to IPO,"Sanofi (SNY -1.9%) plans to create a company from six of its production sites in Europe, which would rank as the world's second largest API (active pharmac",SAN,en,Seeking Alpha
2020-02-24 10:39:01-05:00,Sanofi : to Create Pharmaceutical Ingredients Leader With Eyes to Spinoff | MarketScreener,"By Carlo Martuscelli France's Sanofi SA said Monday that it will consolidate its six active pharmaceutical ingredient production sites into a new market-leading company which it will… | February 24, 2020",SAN,en,MarketScreener
2020-02-24 10:23:00-05:00,Sanofi says it's considering IPO of pharmaceutical-ingredients arm,French drugmaker Sanofi announced plans to split off its unit producing and marketing active pharmaceutical ingredients for a possible IPO in 2022. Sanofi…,SAN,en,MarketWatch
2020-02-24 09:00:56-05:00,"Pharma Giants Pfizer, GlaxoSmithKline, Eli Lilly Utilize Tech Underlying Bitcoin to Track Fake Drugs","Roughly two dozen pharmaceutical companies, including Pfizer, GlaxoSmithKline, Eli Lilly, Sanofi and Roche, have come together to develop a blockchain-based system that secures the supply chain of prescription drugs and tracks counterfeit medicines, reports Reuters.",SAN,en,The Daily Hodl
2020-02-21 15:48:52-05:00,A tiny biotech's huge bet on a heart pill abandoned by Big Pharma just paid off. Esperion's CEO shares the old-school sales strategy he's planning for the drug. (ESPR),"Esperion Therapeutics just got its first heart drug approved in the US, and the CEO told Business Insider the company is pricing the cholesterol-lowering medication at around $10 per day. ""Our industry was built on once-a-day pills for chronic disease,"" Esperion CEO Tim Mayleben said in an interview. It's an old-school approach that supports blockbuster hopes for Esperion's pill. Other companies that have set higher prices for their heart drugs have fallen short in recent years. Visit Business Insider's homepage for more stories . Esperion Therapeutics just received its first US approval on Friday, clearing the way to launch its first heart drug. The approval wraps a long, strange journey for the Ann Arbor, Michigan-based biotech and its cholesterol-lowering pill, Nexletol. Esperion was acquired by pharma giant Pfizer in 2003 for $1.3 billion. A few years later, Pfizer ditched the business as part of a massive restructuring. But Esperion's original founder and CEO, Roger Newton, wasn't done.",SAN,en,Business Insider
2020-02-21 11:00:00-05:00,"Global Bispecific Antibody Therapeutics Market (2019 to 2030) - In-depth Analysis, Highlighting the Capabilities of Various Stakeholders Engaged in this Domain","DUBLIN , Feb. 21, 2020 /PRNewswire/ -- The ""Bispecific Antibody Therapeutics Market (4th Edition), 2019-2030"" report has been added to ResearchAndMarkets.com's offering. The Bispecific Antibody Therapeutics Market (4th Edition), 2019-2030 report features an extensive study of the current market landscape, offering an informed opinion on the likely adoption of these therapeutics over the next decade. The study features an in-depth analysis, highlighting the capabilities of various stakeholders engaged in this domain. The report also features the likely distribution of the current and forecasted opportunity across [A] key therapeutic areas (genetic disorders, hematological malignancies, autoimmune disorders, infectious diseases, inflammatory disorders, eye disorders and skin disorders), [B] different mechanisms of action (T-cell retargeting / activation, cytokines retargeting / neutralization, dual ligands blocking and others), [C] key targets (CD3 x CD19, CD30 x CD16A, Factor IXa x Factor X, IL-13 x IL-4, IL-17A x Albumin, IL-17A x IL-17F, IL-1 x IL-1, Psl x PcrV, TNF- x HSA and VEGF-A x ANG-2), [D] type of antibody formats (asymmetric, fragments, symmetric and others), [E] key players (AbbVie, Affibody, Affimed, Amgen, AstraZeneca, Merck, Roche, Sanofi and Taisho Pharmaceutical) and [F] key geographical regions ( North America , Europe and Asia Pacific ).",SAN,en,Benzinga Feeds
2020-02-21 10:48:27-05:00,"Dispensed: Big Pharma's plans to compete with buzzy startups, Sanofi's entrance to the coronavirus vaccine race, and a Medicare Advantage pitch deck","Hello, Welcome to Dispensed, Business Insider's weekly healthcare newsletter. This week's edition is being written in sunny Palm Springs, California, though regrettably sent out back in chilly New York. Are you new to the newsletter ? You can sign up here. The big story I want to highlight this week came from a tag-team between Andrew Dunn and me . We got the scoop on Dermatology.com, the website pharmaceutical company Bausch Health (remember Valeant Pharmaceuticals?) is using to get in on the trend of startups that are prescribing and shipping medication straight to your door. Ever since I first started hearing about companies like Roman, Hims, or Nurx, I've been thinking it'd only be a matter of time before drugmakers themselves see this as a new way to reach patients. And when they do get interested, who are the companies they'll need to work with to pull that off? What Bausch is doing with its dermatology drugs gives us a good idea of what we might expect. Big Pharma just started copying the buzzy startups that ship Viagra and hair-loss pills to your door, and it could be the start of a 'mega-trend' The pharmaceutical company Bausch Health is now selling prescription drugs online to treat conditions like acne, wrinkles, and eczema.",SAN,en,Business Insider
2020-02-19 10:50:00-05:00,"Global Immunosuppressant Drugs Market (2020 to 2025) - Featuring Astellas Pharma, Sanofi (Genzyme) & Bristol-Myers Squibb Among Others - ResearchAndMarkets.com","DUBLIN--(BUSINESS WIRE)--The ""Immunosuppressant Drugs Market - Growth, Trends, and Forecast (2020 - 2025)"" report has been added to ResearchAndMarkets.com's offering. The Immunosuppressant Drugs Market is expected to register a CAGR of 4.6% during the forecast period. An immunosuppressant is an agent that can suppress or prevent the immune response. Immunosuppressant drugs are used to prevent rejection of a transplanted organ and to treat autoimmune diseases such as type 1 diabetes, rheumatoid",SAN,en,Business Wire
2020-02-19 09:42:02-05:00,"Sanofi, J&J Join Forces With BARDA for Coronavirus Vaccine","Sanofi (SNY) and J&J (JNJ) sign deals with BARDA, part of U.S. Department of Health and Human Services, for accelerated development of a vaccine for the newly found coronavirus.",SAN,en,Yahoo Finance
2020-02-19 07:50:54-05:00,The Health 202: Drugmakers are developing a coronavirus vaccine. That’s a sign the disease will be around a long time.,Sanofi and Janssen clearly think it’s worth the financial risk.,SAN,en,The Washington Post
2020-02-19 05:58:08-05:00,Savills : advises Santander on sale of prime Lisbon asset | MarketScreener,"The building, which was formerly occupied by the bank itself and other companies under the Santander Group, comprises nine floors above ground and five underground with a combined… | February 19, 2020",SAN,en,MarketScreener
2020-02-18 13:08:26-05:00,Sanofi to Work on Coronavirus Vaccine | MarketScreener,"By Denise Roland Drug giant Sanofi SA has entered the race to develop a vaccine against the new coronavirus, joining a handful of big and small drug makers, and teams of university… | February 18, 2020",SAN,en,MarketScreener
2020-02-18 11:59:48-05:00,Sanofi Joins Race for Coronavirus Vaccine as Death Toll Mounts,"Sanofi will work with a division of the U.S. Health and Human Services Department, with plans to revive work on an advanced prevaccine drug that more than a decade ago it started to develop to combat SARS.",SAN,en,The Street
2020-02-18 10:41:00-05:00,Sanofi to work on coronavirus vaccine,"Shares of Sanofi ADR were up 1% in trading on Monday after the French drugmaker announced plans to work on a vaccine for COVID-19, the new coronavirus that…",SAN,en,MarketWatch
2020-02-18 07:00:00-05:00,Baxter Completes Acquisition of Seprafilm Adhesion Barrier,"DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX), a leading global medical products company, has completed its previously announced acquisition of Seprafilm Adhesion Barrier and related assets from Sanofi for $350 million. The Seprafilm product family, which is used as an adjunct to reduce the incidence, extent and severity of adhesions in certain pelvic and abdominal surgeries, currently has a global commercial presence in the U.S., Japan, China, South Korea and France, a",SAN,en,Business Wire
2020-02-13 11:50:24-05:00,Is Sanofi (SNY) Stock Undervalued Right Now?,"Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.",SAN,en,Zacks Investment Research
2020-02-13 08:07:00-05:00,"One Drop Expands Team To Include Former Sanofi Head of US Diabetes Integrated Care, Rachel Y. Martens, And Behavioral Science Expert, Dr. Gina Merchant","NEW YORK, Feb. 13, 2020 /PRNewswire/ -- One Drop, a leader in digital therapeutics solutions for people living with diabetes and other chronic conditions, today announced the additions of Rachel Yap Martens, former Head of US Diabetes Integrated Care at Sanofi, and Dr. Gina Merchant,…",SAN,en,PR Newswire
2020-02-11 09:17:10-05:00,Lucro do Itaú em 2019 é o maior da história dos bancos do país,"Banco teve lucro de R$ 26,583 bilhões no ano passado. Marca anterior havia sido registrada pelo próprio Itaú em 2018. O lucro líquido de R$ 26,583 bilhões reportado pelo Itaú na segunda-feira (11) é o maior resultado anual nominal (não ajustado pela inflação) já registrado por bancos brasileiros de capital aberto, segundo dados da provedora de informações financeiras Economatica. A marca anterior havia sido registrada pelo próprio Itaú em 2018, quando o banco teve um lucro líquido de R$ 24,977 bilhões. Maiores lucros anuais de bancos brasileiros Economia G1 No quarto trimestre de 2019, o lucro líquido foi de R$ 7,482 bilhões, alta de 20,6% ante o mesmo período de 2018. Já o retorno sobre o patrimônio líquido anualizado, indicador que mede como o banco remunera os seus acionistas, chegou a 23,7% no ano passado, um avanço de 1,7 ponto percentual contra 2018. Últimos resultados do Itaú Arte/G1 Lucros dos outros bancos Bradesco e Santander também já divulgaram seus resultados consolidados de 2019.",SAN,pt,Globo
2020-02-10 17:30:37-05:00,Sanofi urges SCOTUS to stay Lantus patent fight with Mylan,Pharmaceutical company Sanofi has asked the U.S. Supreme Court to halt its patent litigation with Mylan NV over the diabetes drug Lantus while the justices mull whether to weigh in on constitutional questions raised by the case.,SAN,en,Reuters
2020-02-07 04:24:00-05:00,"Pharma Stock Roundup: BMY, GSK, SNY Q4 Results, MRK Earnings & Split","Merck (MRK), Bristol Myers (BMY), Sanofi (SNY), Glaxo (GSK) and Novo Nordisk (NVO) announce Q4 results.",SAN,en,Zacks Investment Research
2020-02-06 06:23:22-05:00,"Banco Santander S A : Santander Private Banking, named Best Private Bank in Spain, Portugal, Chile and Mexico by Euromoney | MarketScreener","Santander achieved a record number of awards including Best Private Bank in ESG & Impact Investing and Best Private Banking for Technology in several of its core markets. … | February 6, 2020",SAN,en,MarketScreener
2020-02-06 05:38:02-05:00,Sanofi : Zantac Recall Weighs on Sanofi's Earnings -- Update | MarketScreener,"By Denise Roland Sanofi SA swung to a loss in the fourth quarter as the recall of heartburn drug Zantac over cancer concerns offset strong sales of newer treatments. The French… | February 6, 2020",SAN,en,MarketScreener
2020-02-06 02:13:00-05:00,Sanofi swings to loss as dupixent drives sales higher,"Sanofi SA swung to a net loss in its fourth quarter results Thursday after booking impairment charges on a number of its assets, but reported rising sales on…",SAN,en,MarketWatch
2020-02-06 02:03:50-05:00,"Sanofi EPS beats by €0.06, misses on revenue",Sanofi (NASDAQ:SNY): Q4 Non-GAAP EPS of €1.34 beats by €0.06; GAAP EPS of -€0.01. Revenue of €9.61B (+6.8% Y/Y) misses by €40M. Press Release,SAN,en,Seeking Alpha
2020-02-06 01:51:10-05:00,Sanofi : eyes more growth this year as it narrows focus | MarketScreener,"Sanofi on Thursday said it was expecting earnings per share to grow around 5 percent at constant exchange rates in 2020, weeks after pledging to focus on vaccines and key treatments like its eczema… | February 6, 2020",SAN,en,MarketScreener
2020-02-06 01:45:02-05:00,Sanofi : Swung to 4Q Loss; Dupixent Drives Sales Higher | MarketScreener,"By Carlo Martuscelli Sanofi SA swung to a net loss in its fourth quarter results Thursday after booking impairment charges on a number of its assets, but reported rising sales on the back… | February 6, 2020",SAN,en,MarketScreener
2020-02-05 10:05:00-05:00,Banco Santander S.A. declares quarterly dividend on preferred stock,"MADRID, Feb. 5, 2020 /PRNewswire/ -- Banco Santander, S.A. will pay distributions for the 4.00% Non-Cumulative Guaranteed Series 6 Preferred Securities to holders of record as of February 18, 2020 and such distribution will be paid on March 5, 2020 as per the following details: Nº of…",SAN,en,PR Newswire
2020-02-04 07:07:52-05:00,French company Sanofi investigated over epilepsy drug linked to birth defects,"French healthcare company Sanofi said on Tuesday it was being investigated over Depakine, an epilepsy drug which caused birth malfunctions and slow neurological development when taken during pregnancy.",SAN,en,FRANCE 24
2020-02-04 05:57:08-05:00,French pharmaceutical giant Sanofi charged in birth defects case,It is accused of failing to warn about side effects of its anti-epilepsy drug.,SAN,en,Free Malaysia Today
2020-02-04 04:54:16-05:00,Banco Santander S A : has launched the first numberless credit card in Mexico | MarketScreener,"Santander Mexico has launched a credit card for its customers that has no visible numbers or codes. The numberless card increases customer security for online and mobile shopping,… | February 4, 2020",SAN,en,MarketScreener
2020-02-04 04:08:44-05:00,Sanofi says charged in birth defects case,No summary available.,SAN,en,UrduPoint
2020-02-04 01:57:39-05:00,Sanofi : France's Sanofi under investigation in Depakine birth defects case | MarketScreener,"French healthcare company Sanofi said it had been put under investigation over a legal case relating to Depakine, a medication known to have caused birth malfunctions and slow neurological development… | February 4, 2020",SAN,en,MarketScreener
2020-02-02 23:15:00-05:00,"Global Anti-Fungal Agents Market 2020-Novartis AG,Pfizer,Sanofi-Aventis","Feb 02, 2020 (Eon Market Research via COMTEX) -- Eon Market Research announces the addition of a new research report, titled ""Global Anti-Fungal Agents…",SAN,en,MarketWatch
2020-01-30 09:26:49-05:00,"The Daily Biotech Pulse: Sanofi Reports Positive Readout, Tonix Vaccine Candidate Aces Animal Study, Hologix's Weak Guidance","Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on Jan. 29) 10X Genomics Inc (NASDAQ: TXG ) Agile Therapeutics Inc (NASDAQ: AGRX ) Aptose Biosciences Inc (NASDAQ: APTO ) Catalent Inc (NYSE: CTLT ) Cabaletta Bio Inc (NASDAQ: CABA )(announced grant of orphan drug designation for its DSG3-CAART for the treatment of pemphigus vulgaris) AtriCure Inc. (NASDAQ: ATRC ) Dr.Reddy's Laboratories Ltd (NYSE: RDY ) Fate Therapeutics Inc (NASDAQ: FATE ) Hologic, Inc. (NASDAQ: HOLX ) Insulet Corporation (NASDAQ: PODD ) Johnson & Johnson (NYSE: JNJ )(confirmed it is working on treatment/vaccines for coronavirus) Nevro Corp (NYSE: NVRO ) Profound Medical Corp (NASDAQ: PROF ) Quest Diagnostics Inc (NYSE: DGX ) ResMed Inc. (NYSE: RMD ) Satsuma Pharmaceuticals Inc (NASDAQ: STSA )(reacted to publication of positive data readout for its lead drug candidate) Tandem Diabetes Care Inc (NASDAQ: TNDM ) West Pharmaceutical Services Inc. (NYSE: WST ) Zimmer Biomet Holdings Inc (NYSE: ZBH ) Down In The Dumps (Biotech Stocks Hitting 52-week lows on Jan. 29) Avanos Medical Inc (NYSE: AVNS ) Enanta Pharmaceuticals Inc (NASDAQ: ENTA ) Endologix, Inc. (NASDAQ: ELGX ) Galectin Therapeutics Inc.",SAN,en,Benzinga
2020-01-29 10:00:38-05:00,"Santander Brasil tem lucro de R$ 14,18 bilhões em 2019; governo indica conselheira para Petrobras e mais destaques",Confira os destaques do noticiário corporativo na sessão desta quarta-feira (29),SAN,pt,InfoMoney
2020-01-29 09:25:55-05:00,"Santander Brasil tem lucro de R$ 14,2 bi em 2019; FUP anuncia greve na Petrobras no sábado e mais destaques",Confira os destaques do noticiário corporativo na sessão desta quarta-feira (29),SAN,pt,InfoMoney
2020-01-29 08:06:31-05:00,"Santander Brasil reporta alta de 16,6% no lucro de 2019","O Santander Brasil apresentou um lucro líquido de R$ 3,74 bilhões no quatro trimestre do ano passado. Clique aqui e saiba mais.",SAN,pt,Suno Research
2020-01-29 08:05:13-05:00,"Santander Brasil tem lucro lquido gerencial de R$ 3,7 bilhes no 4 trimestre","Em relao aos trs meses imediatamente anteriores, de R$ 3,705 bilhes, foi observada leve alta de 0,6%",SAN,pt,Jornal do Comercio
2020-01-29 07:52:12-05:00,Sanofi : asks employees to stop travel to and from China | MarketScreener,"French drugmaker Sanofi said on Wednesday it was postponing all its events in China and had asked employees to stop all travel to and from Wuhan and Hubei provinces in China…. | January 29, 2020",SAN,en,MarketScreener
2020-01-29 07:10:39-05:00,"Lucro do Santander tem alta 17,4% em 2019 e chega a R$ 14,5 bi - Economia - Estadão",Participação do País no resultado do grupo subiu de 26% para 28%,SAN,pt,Estadao. Economia
2020-01-29 06:40:00-05:00,"Santander Brasil tem alta de 9,4% no lucro líquido recorrente do 4º tri","Por Carolina MandlSÃO PAULO (Reuters) - O Banco Santander Brasil reportou crescimento de 9,4% no lucro líquido recorrente do quarto trimestre de 2019 em relação ao mesmo período do ano anterior, apoiado principalmente nos… Leia mais",SAN,pt,Extra
2020-01-29 03:15:49-05:00,Santander verdient signifikant mehr und stärkt Kapitalquote - Santander-Aktie stärker,"Die spanische Bank stärkte ihre harte Kernkapitalquote und sieht sich auf Kurs für die Mittelfristziele. Die Aktionäre sollen für 2019 eine Dividende von 0,23 Euro je Aktie bekommen, davon 0,20 Euro in bar. Im Schlussquartal steigerte Banco Santander den…",SAN,de,Finanzen CH
2020-01-29 01:53:00-05:00,Santander profit beats expectations as capital increased,"Banco Santander SA’s fourth-quarter net profit rose significantly, beating expectations and helped by one-offs, with the bank strengthening its capital…",SAN,en,MarketWatch
2020-01-29 01:10:11-05:00,Banco Santander S A : 2019 Results | MarketScreener,"Banco Santander achieved an attributable profit of €6,515 million in 2019, 17% less than in 2018, after recording net charges amounting to -€1,737 million. The charges… | January 29, 2020",SAN,en,MarketScreener
2020-01-29 01:05:13-05:00,Banco Santander S A : 2019 financial report | MarketScreener,"intangible assets Underlying RoTE … | January 29, 2020",SAN,en,MarketScreener
2020-01-28 10:39:00-05:00,Regeneron & Sanofi's sBLA for Dupixent Accepted by the FDA,The FDA accepts Regeneron (REGN) and Sanofi's sBLA for Dupixent for Priority Review.,SAN,en,Zacks Investment Research
2020-01-28 09:00:00-05:00,"The president of Google Cloud explains why Accenture's decision to move a key division to its platform is a major blow against Amazon's dominant cloud (GOOG, AMZN, ACN)","IT services giant Accenture has picked Google Cloud as the main platform for its life sciences division. It's a big win for the tech giant, which faces stiff competition in the cloud wars against bigger players led by Amazon and Microsoft. The move is also a blow to Amazon: ""We will be replatforming all of the current applications, which include AWS and a number of other parties onto Google Cloud,"" Simon Eaves, Accenture's group chief executive for products, told Business Insider. Google Cloud's victory is also significant because it involves the life sciences industry, where major players are expected to accelerate their migration to the cloud in the coming years. Click here for more BI Prime stories. Google just notched a win in the cloud wars after Accenture picked Google Cloud as the platform for its life sciences division. Accenture said Tuesday that it has decided to use Google Cloud technology for its life sciences industry platform, which used by major pharmaceutical and biotech clients, such as Bayer and UCB.",SAN,en,Business Insider
2020-01-28 07:41:00-05:00,"The Zacks Analyst Blog Highlights: Merck, Broadcom, Sanofi, Equinix and American Electric Power","The Zacks Analyst Blog Highlights: Merck, Broadcom, Sanofi, Equinix and American Electric Power",SAN,en,Zacks Investment Research
2020-01-24 16:45:00-05:00,"Global Stroke Treatment Market Report 2019-2027 Featuring Bristol-Myers Squibb, Boehringer Ingelheim, Daiichi Sankyo, Roche, Johnson & Johnson Services, Sanofi, Amgen, Biogen, and AstraZeneca","DUBLIN, Jan. 24, 2020 /PRNewswire/ -- The ""Stroke Treatment Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2019 - 2027"" report has been added to ResearchAndMarkets.com's offering. This report on the global stroke treatment market studies the past as well as…",SAN,en,PR Newswire
2020-01-24 07:00:46-05:00,Sanofi Closes Purchase of Synthorx | FinSMEs,"Sanofi completed the acquisition of Synthorx, Inc., La Jolla, CA-based clinical-stage biotechnology company, for $68 per share in cash",SAN,en,FinSMEs
2020-01-23 09:46:44-05:00,Sanofi finalizes Synthorx buy,Sanofi (SNY +0.2%) has completed its $2.5B acquisition of Synthorx (NASDAQ:THOR) announced last month.,SAN,en,Seeking Alpha
2020-01-21 03:35:00-05:00,Should Value Investors Pick Sanofi (SNY) Stock Right Now?,Is Sanofi (SNY) a great pick from the value investor's perspective right now? Read on to know more.,SAN,en,Zacks Investment Research
2020-01-15 05:58:09-05:00,Banco Santander S A : Instructions on how to follow the presentation | MarketScreener,"Santander Investor Relations Full year 2019 financial results Banco Santander's Executive… | January 15, 2020",SAN,en,MarketScreener
2020-01-14 12:00:00-05:00,BIOCORP and SANOFI Strengthen Their Partnership With Mallya Smart Sensors,"ISSOIRE, France--(BUSINESS WIRE)-- #Mallya--BIOCORP and SANOFI strengthen their partnership with Mallya smart sensors.",SAN,en,Business Wire
2020-01-10 07:13:12-05:00,"The Daily Biotech Pulse: Positive Data Readouts To Spur Aclaris, Moderna And Ultragenyx","Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on Jan. 9) Acceleron Pharma Inc (NASDAQ: XLRN ) Allergan plc (NYSE: AGN ) Applied Genetic Technologies Corp (NASDAQ: AGTC ) ( announced positive midstage results for its gene therapy to treat inherited eye disorder) Applied Therapeutics Inc (NASDAQ: APLT ) Bio-Rad Laboratories, Inc. (NYSE: BIO ) Bristol-Myers Squibb Co (NYSE: BMY ) Collegium Pharmaceutical Inc (NASDAQ: COLL ) COLLPLANT BIOTE/S ADR (NASDAQ: CLGN ) DBV TECHNOLOGIE/S ADR (NASDAQ: DBVT ) (reported positive results for a late-stage study of its peanut allergy patch) DexCom, Inc. (NASDAQ: DXCM ) Global Blood Therapeutics Inc (NASDAQ: GBT ) Grifols SA - ADR ADR Class B (NASDAQ: GRFS ) Inspire Medical Systems Inc (NYSE: INSP ) ITAMAR MED LTD/S ADR (NASDAQ: ITMR ) Karyopharm Therapeutics Inc (NASDAQ: KPTI ) LeMaitre Vascular Inc (NASDAQ: LMAT ) Masimo Corporation (NASDAQ: MASI ) Medtronic PLC (NYSE: MDT )(announced the acquisition of Stimgenics) Molecular Templates Inc (NASDAQ: MTEM ) Morphosys Ag (NASDAQ: MOR ) NuVasive, Inc.",SAN,en,Benzinga
2020-01-08 13:18:13-05:00,Sophos : Banco Santander S.A. - Form 8.3 - Sophos Group plc | MarketScreener,"RNS Number : 2135Z Banco Santander S.A. 08 January 2020 FORM 8.3 … | January 8, 2020",SAN,en,MarketScreener
2020-01-08 11:25:00-05:00,"The Zacks Analyst Blog Highlights: JPMorgan, Sanofi, General Electric, American Electric Power and Shopify","The Zacks Analyst Blog Highlights: JPMorgan, Sanofi, General Electric, American Electric Power and Shopify",SAN,en,Zacks Investment Research
2020-01-07 16:24:08-05:00,Santander aumenta limite de financiamento para 90% do valor do imóvel,"O Santander (SANB11) aumentou, nesta terça-feira (7), o limite de financiamento de imóveis para 90% do seu valor. Clique aqui para saber mais.",SAN,pt,Suno Research
2020-01-07 07:57:46-05:00,"The Daily Biotech Pulse: Xeris Jumps On Positive Data, Mixed Results For Merck's Keytruda-Chemo Combo In Lung Cancer, Intra-Cellular Announces Offering","The following is a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs on Jan. 6.) Agile Therapeutics Inc (NASDAQ: AGRX ) Aimmune Therapeutics Inc (NASDAQ: AIMT ) Audentes Therapeutics Inc (NASDAQ: BOLD ) BioNTech SE – ADR (NASDAQ: BNTX ) Esperion Therapeutics Inc (NASDAQ: ESPR ) Inspire Medical Systems Inc (NYSE: INSP ) Nevro Corp (NYSE: NVRO ) Nymox Pharmaceutical Corp (NASDAQ: NYMX ) (announced publication of a peer reviewed research report on the experimental studies for its fexapotide triflutate treatment for prostate enlargement and low-grade prostate cancer) Orthopediatrics Corp (NASDAQ: KIDS ) (announced sale of its adult Vilex business in Tennessee to Squadron Capital and used the proceeds for the repayment of term loan due to Squadron) Oyster Point Pharma Inc (NASDAQ: OYST ) Sanofi SA (NASDAQ: SNY ) (JPMorgan upgraded the shares from Neutral to Overweight, citing an attractive valuation) Soligenix, Inc.",SAN,en,Benzinga
2020-01-06 10:21:00-05:00,"Buy Sanofi Stock Because It’s Undervalued, J.P. Morgan Says","European pharmaceutical and biotech fundamentals will be strong in 2020, according to J.P. Morgan. Sanofi, Novo Nordisk, and Roche are among the firm’s stock picks.",SAN,en,Barron's
2020-01-05 08:41:00-05:00,Swiss parents take French drugmaker to court,"About a dozen Swiss parents have launched a civil action lawsuit over the prescription of the antiepileptic drug Depakine during pregnancy. They accuse their neurologists and the French drug manufacturer Sanofi, which produces Depakine, of failing to warn them about the risks to the fetus, according to reports published on Le Matin Dimanche and SonntagsZeitung. Depakine is still widely used today to treat epilepsy and migraines. Scientists have established that the sodium valproate contained in the drug creates psychomotor, cognitive and mental development disorders in 30 to 40% of cases. The Swiss expecting mothers were not made aware of these dangers. A warning from agency for therapeutic products, Swissmedic, came to late. In Switzerland, 39 children have been born with brain damage in connection to Depakine use, according to a report commissioned by the government. Thierry Buclin, a professor of clinical pharmacology at the University Hospital of Lausanne suspects the …",SAN,en,Swiss Info
2020-01-02 10:41:09-05:00,Drugmakers Kick Off 2020 With Margin-Expanding Price Hikes,"Drug manufacturers across the globe raised the list prices of more than 250 therapies on New Year’s Day, according to aggregate reports from Reuters and research firm 3 Axis Advisors. Biogen, Bristol-Myers, Gilead Drug Prices Increase Biogen Inc (NASDAQ: BIIB ) raised Tecfidera by 6%. Bristol-Myers Squibb Co (NYSE: BMY ) raised Opdivo and Yervoy 1.5% and Eliquis and Revlimid 6%. Gilead Sciences, Inc. (NASDAQ: GILD ) boosted the prices of more than 15 treatments, including Biktarvy and Truvada, by less than 5%. GlaxoSmithKline plc (NYSE: GSK ), Pfizer Inc. (NYSE: PFE ) and Sanofi SA (NASDAQ: SNY ) also increased prices across their expansive portfolios. In keeping with political promises meant to preempt new regulations and penalties, almost all of the price hikes remained under … Full story available on Benzinga.com",SAN,en,Benzinga
2020-01-02 08:00:00-05:00,"Worldwide Insulin Markets, 2015-2018 & 2019-2025 - Key Players are Sanofi, Takeda, Novo Nordisk, Bristol-Myers Squibb, Novartis, Eli Lilly, Oramed, Dongbao Enterprise Group, and Biocon","DUBLIN, Jan. 2, 2020 /PRNewswire/ -- The ""Insulin Market: Global Industry Perspective, Comprehensive Analysis and Forecast, 2018-2025"" report has been added to ResearchAndMarkets.com's offering. The global demand for insulin market was valued at approximately USD 30.3 billion in 2018 and…",SAN,en,PR Newswire
2019-12-31 16:06:03-05:00,Exclusive: Drugmakers from Pfizer to GSK to hike US prices on over 200 drugs,"Drugmakers including Pfizer Inc, GlaxoSmithKline PLC and Sanofi SA are planning to hike prices on more than 200 drugs in the United States on Wednesday, according to drugmakers and data analyzed by healthcare research firm 3 Axis Advisors.",SAN,en,Channel NewsAsia
2019-12-30 08:30:00-05:00,"Global Pediatric Medicines Market Review 2018-2019 & Forecast to 2024 with Profiles of Leading Players Abbott Laboratories, GlaxoSmithKline, Novartis, Sanofi, and Vertex Pharmaceuticals","DUBLIN, Dec. 30, 2019 /PRNewswire/ -- The ""Pediatric Medicines: Global Markets"" report has been added to ResearchAndMarkets.com's offering. This new report on pediatric medicine will provide a brief overview on the current status of the industry and recent developments. It presents the…",SAN,en,PR Newswire
2019-12-20 08:12:05-05:00,"The Daily Biotech Pulse: Axovant Surges On Gene Therapy Study Results, FDA Approves Merck's Ebola Vaccine, Abeona Announces Offering","The following is a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs Dec. 19.) Acceleron Pharma Inc (NASDAQ: XLRN ) Ardelyx Inc (NASDAQ: ARDX ) AstraZeneca plc (NYSE: AZN ) Axsome Therapeutics Inc (NASDAQ: AXSM ) (priced its 2-million-share common stock offering at $87 per share) Clearside Biomedical Inc (NASDAQ: CLSD ) Cortexyme Inc (NASDAQ: CRTX ) Cue Biopharma Inc (NASDAQ: CUE ) Exagen Inc (NASDAQ: XGN ) Globus Medical Inc (NYSE: GMED ) Horizon Therapeutics PLC (NASDAQ: HZNP ) HEALTH SCIENCES/SH (NASDAQ: IMVT ) (The acquisition vehicle announced merger with Immuvant, a clinical-stage biopharma company focusing on autoimmune disorders) IVERIC bio Inc (NASDAQ: ISEE ) Johnson & Johnson (NYSE: JNJ ) (Barclays upgraded shares to Overweight) The Medicines Company (NASDAQ: MDCO ) Merck & Co., Inc. (NYSE: MRK ) Mirum Pharmaceuticals Inc (NASDAQ: MIRM ) Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA ) Monopar Therapeutics Inc. (NASDAQ: MNPR ) (Went public Thursday) Myokardia Inc (NASDAQ: MYOK ) NeoGenomics, Inc. (NASDAQ: NEO ) Novan Inc (NASDAQ: NOVN ) Oramed Pharmaceuticals, Inc. (NASDAQ: ORMP ) Principia Biopharma Inc (NASDAQ: PRNB ) Quest Diagnostics Inc (NYSE: DGX ) Recro Pharma Inc (NASDAQ: REPH ) Sanofi SA (NASDAQ: SNY ) SpringWorks Therapeutics Inc (NASDAQ: SWTX ) Down In The Dumps (Biotech stocks that hit 52-week lows Dec. 19.) Aethlon Medical, Inc. (NASDAQ: AEMD ) Anixa Biosciences Inc (NASDAQ: ANIX ) Aridis Pharmaceuticals Inc (NASDAQ: ARDS ) China SXT Pharmaceuticals Inc (NASDAQ: SXTC ) Correvio Pharma Corp (NASDAQ: …",SAN,en,Benzinga
2019-12-18 02:11:48-05:00,Evotec : expands service agreement with Sanofi to create a centralised global sample management hub in Toulouse | MarketScreener,"Evotec expands service agreement with Sanofi to create a centralised global sample management hub in Toulouse CENTRALISATION OF SAMPLE… | December 18, 2019",SAN,en,MarketScreener
2019-12-16 14:14:00-05:00,"Promising Early Launch Metrics for AbbVie's Rinvoq (upadacitinib) to Help JAK Inhibitors Solidify Their Position as Second-Line Leaders in Rheumatoid Arthritis, According to Spherix Global Insights","EXTON, Pa. , Dec. 16, 2019 /PRNewswire/ -- Spherix examined the charts of 1,021 rheumatoid arthritis (RA) patients recently switched from one biologic/JAK to another agent via the 2019 annual RealWorld Dynamix™: Biologic/JAK Switching in Rheumatoid Arthritis (US) service. The patient chart analysis revealed that TNF inhibitor cycling remains the most common switch pattern among RA patients, though has leveled off over the past year after steady decreases since 2016. Nevertheless, the percent of patients being switched from one TNF inhibitor to another drops with each line of biologic/JAK therapy, as rheumatologists are more inclined to prescribe an alternate mechanism agent in the second- or later-line setting. While the percent of patients being switched to a TNF inhibitor stands unchanged from the prior year, switches to JAK inhibitors have increased in popularity – likely at the expense of the IL-6 inhibitor class, which had been experiencing year over year gains in the switch- to segment up until the current year (reverting back to figures reported in 2016).",SAN,en,Benzinga Feeds
2019-12-15 15:49:18-05:00,"The Week Ahead In Biotech: Avadel, Epizyme In Focus In A Quiet Week","Biotech stocks were seen consolidating last week after advancing in the previous week. The iShares NASDAQ Biotechnology Index (NASDAQ: IBB ) reached a 52-week high of 121.16 Monday, although it has come off this level since then. The week saw huge moves in reaction to presentations at the American Society of Hematology annual meeting. A few M&A announcements were made, including Merck & Co., Inc.'s (NYSE: MRK ) deal to buy ArQule, Inc. (NASDAQ: ARQL ) and Sanofi SA's (NASDAQ: SNY ) proposed purchase of Synthorx Inc (NASDAQ: THOR ). Correvio Pharma Corp (NASDAQ: CORV ) … Full story available on Benzinga.com",SAN,en,Benzinga
2019-12-13 08:10:02-05:00,"The Daily Biotech Pulse: Second Time's The Charm For Sarepta, Pfizer's Xeljanz Snags Third Approval, NewLink Genetics Rejects Competing Offer","The following is a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs on Dec. 12.) Allergan plc (NYSE: AGN ) Amgen, Inc. (NASDAQ: AMGN ) (received approval for its bone-building osteoporosis drug in the U.S.) Aprea Therapeutics Inc (NASDAQ: APRE ) Aptose Biosciences Inc (NASDAQ: APTO ) Aurinia Pharmaceuticals Inc (NASDAQ: AUPH ) Avenue Therapeutics Inc (NASDAQ: ATXI ) (submitted the NDA for intravenous tramadol for the management of moderate to moderately severe pain in adults in a medically supervised health care setting) Bausch Health Companies Inc (NYSE: BHC ) (reacted to upgrade to Overweight rating by JPMorgan) BioNTech SE – ADR (NASDAQ: BNTX ) Bio-Rad Laboratories, Inc. Class A (NYSE: BIO ) Boston Scientific Corporation (NYSE: BSX ) Bristol-Myers Squibb Co (NYSE: BMY ) Deciphera Pharmaceuticals Inc (NASDAQ: DCPH ) Eidos Therapeutics Inc (NASDAQ: EIDX ) ESSA Pharma Inc (NASDAQ: EPIX ) Flexion Therapeutics Inc (NASDAQ: FLXN ) Forty Seven Inc (NASDAQ: FTSV ) Globus Medical Inc (NYSE: GMED ) (reacted to upgrade to Overweight by Wells Fargo Securities) Gossamer Bio Inc (NASDAQ: GOSS ) Hologic, Inc.",SAN,en,Benzinga Feeds
2019-12-12 14:00:00-05:00,Global Osteoarthritis Therapeutics Market 2019-2023 | Evolving Opportunities With Bayer AG and Sanofi | Technavio,LONDON--(BUSINESS WIRE)-- #Biotechnology--Global osteoarthritis therapeutics market is poised to grow by USD 2.56 billion during 2019-2023 at a CAGR of about 8% during the forecast period.,SAN,en,Business Wire
2019-12-12 07:38:44-05:00,"The Daily Biotech Pulse: European Nod For Amgen, miRagen Overhauls Clinical Pipeline, Tonix Snags Patent Win","Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Dec. 11) Acceleron Pharma Inc (NASDAQ: XLRN ) Aimmune Therapeutics Inc (NASDAQ: AIMT ) Aprea Therapeutics Inc (NASDAQ: APRE ) Aptose Biosciences Inc (NASDAQ: APTO ) argenx SE – ADR (NASDAQ: ARGX ) ArQule, Inc. (NASDAQ: ARQL ) Arvinas Inc (NASDAQ: ARVN ) Audentes Therapeutics Inc (NASDAQ: BOLD ) Axsome Therapeutics Inc (NASDAQ: AXSM ) Avadel Pharmaceuticals PLC (NASDAQ: AVDL ) Bausch Health Companies Inc (NYSE: BHC ) BioNTech SE – ADR (NASDAQ: BNTX ) Bio-Rad Laboratories, Inc. (NYSE: BIO ) Bristol-Myers Squibb Co (NYSE: BMY ) Cue Biopharma Inc (NASDAQ: CUE ) Deciphera Pharmaceuticals Inc (NASDAQ: DCPH ) Eidos Therapeutics Inc (NASDAQ: EIDX ) Flexion Therapeutics Inc (NASDAQ: FLXN ) Forty Seven Inc (NASDAQ: FTSV ) GlaxoSmithKline plc (NYSE: GSK ) Gossamer Bio Inc (NASDAQ: GOSS ) Immunomedics, Inc. (NASDAQ: IMMU ) Incyte Corporation (NASDAQ: INCY ) IVERIC bio Inc (NASDAQ: ISEE ) Kadmon Holdings Inc (NYSE: KDMN ) Ra Pharmaceuticals Inc (NASDAQ: RARX ) Repro-Med Systems, Inc.",SAN,en,Benzinga
2019-12-12 04:03:44-05:00,"Biocorp, Sanofi inks insulin delivery tech deal","Mubasher: France’s Biocorp inked a partnership agreement with pharmaceutical giant Sanofi for the use of the medical device maker’s connected device for insulin pens, Mallya.",SAN,en,Mubasher Info
2019-12-11 09:14:00-05:00,Resumen: PSE: Sanofi se une a la Systems-based Pharmaceutics Alliance,LONDRES--(BUSINESS WIRE)--The Systems-based Pharmaceutics Alliance welcomes Sanofi S.A. as its newest member.,SAN,en,Business Wire
2019-12-11 08:30:00-05:00,Sanofi (SNY) Looks Good: Stock Adds 6.2% in Session,"Sanofi (SNY) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.",SAN,en,Zacks Investment Research
2019-12-11 07:40:00-05:00,PSE: Sanofi joins Systems-based Pharmaceutics Alliance,LONDON--(BUSINESS WIRE)-- #AdvancedProcessModelling--The Systems-based Pharmaceutics Alliance welcomes Sanofi S.A. as its newest member.,SAN,en,Business Wire
2019-12-11 07:21:31-05:00,"The Daily Biotech Pulse: Correvio Faces FDA Panel Rejection, Iterum's Antibiotic Trial Narrowly Misses Primary Endpoint","Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Dec. 10) Acceleron Pharma Inc (NASDAQ: XLRN ) Aimmune Therapeutics Inc (NASDAQ: AIMT ) argenx SE – ADR (NASDAQ: ARGX ) ArQule, Inc. (NASDAQ: ARQL )(agreed to be bought by Arvinas Inc (NASDAQ: ARVN ) Audentes Therapeutics Inc (NASDAQ: BOLD ) Aurinia Pharmaceuticals Inc (NASDAQ: AUPH ) Axsome Therapeutics Inc (NASDAQ: AXSM ) Avadel Pharmaceuticals PLC (NASDAQ: AVDL ) Bausch Health Companies Inc (NYSE: BHC ) BridgeBio Pharma Inc (NASDAQ: BBIO ) Bristol-Myers Squibb Co (NYSE: BMY )(reacted to ASH presentation) Deciphera Pharmaceuticals Inc (NASDAQ: DCPH ) Eidos Therapeutics Inc (NASDAQ: EIDX ) Flexion Therapeutics Inc (NASDAQ: FLXN ) Forty Seven Inc (NASDAQ: FTSV ) GALAPAGOS NV/S ADR (NASDAQ: GLPG ) GlaxoSmithKline plc (NYSE: GSK ) Global Blood Therapeutics Inc (NASDAQ: GBT ) Gossamer Bio Inc (NASDAQ: GOSS ) Immunomedics, Inc. (NASDAQ: IMMU ) Incyte Corporation (NASDAQ: INCY ) IVERIC bio Inc (NASDAQ: ISEE ) The Medicines Company (NASDAQ: MDCO ) Merck & Co.",SAN,en,Benzinga
2019-12-10 12:28:09-05:00,"Regeneron Shares Swing On Sanofi's Hint At Sale Of Ownership Stake, Amendments To Drug Collaborations","Regeneron Pharmaceuticals Inc (NASDAQ: REGN ) shares were rebounding Tuesday as investors digested French pharma giant and collaboration partner Sanofi SA's (NASDAQ: SNY ) potential liquidation of its Regeneron stake — and the restructuring of a collaboration agreement between the two. Hints At Regeneron Stake Sale At Sanofi's Capital Markets Day, the company announced a slew of measures intended to drive innovation and growth. Apart from prioritizing key growth drivers — Dupixent and vaccines — and accelerating an R&D focus on six potentially transformative medicines, Sanofi said it would improve operating efficiencies to fund growth. While discussing its capital allocation policy, Sanofi said that, apart from cash generated from its businesses, it has the wherewithal to raise capital through asset disposals and monetizing its stake in Regeneron after the lockup period expires in December 2020. See Also: 5 Stocks Moving On ASH Presentations The Sanofi-Regeneron Collaboration Sanofi and Regeneron entered a global collaboration agreement in November 2007 to develop fully human therapeutics antibodies using the latter's VelociSuite technologies.",SAN,en,Benzinga
2019-12-10 08:13:09-05:00,Sanofi : Says Sutimlimab Trial Meets Endpoints | MarketScreener,"By Michael Dabaie Sanofi SA said a Phase 3 trial of sutimlimab in people with primary cold agglutinin disease met its primary and secondary endpoints. The primary efficacy outcome was a… | December 10, 2019",SAN,en,MarketScreener
2019-12-10 07:56:02-05:00,"The Daily Biotech Pulse: ASH Meeting Wraps, Fast Track Designation For Equillium, Pfizer To Buy $3M In ContraFect Shares","The following are top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs Dec. 9.) Acceleron Pharma Inc (NASDAQ: XLRN ) Aimmune Therapeutics Inc (NASDAQ: AIMT ) Aptose Biosciences Inc (NASDAQ: APTO ) (moved on ASH presentation) argenx SE – ADR (NASDAQ: ARGX ) ArQule, Inc. (NASDAQ: ARQL ), which agreed to be bought by Merck & Co., Inc. (NYSE: MRK ) Arvinas Inc (NASDAQ: ARVN ) Avadel Pharmaceuticals PLC (NASDAQ: AVDL ) Bausch Health Companies Inc (NYSE: BHC ) BioNTech SE – ADR (NASDAQ: BNTX ) BridgeBio Pharma Inc (NASDAQ: BBIO ) (appointed oncology scientist Eli Wallace as chief scientific officer for its oncology programs) Bristol-Myers Squibb Co (NYSE: BMY ) (reacted to ASH presentation) Constellation Pharmaceuticals Inc (NASDAQ: CNST ) Deciphera Pharmaceuticals Inc (NASDAQ: DCPH ) Eidos Therapeutics Inc (NASDAQ: EIDX ) Epizyme Inc (NASDAQ: EPZM ) (reacted to ASH presentation) Flexion Therapeutics Inc (NASDAQ: FLXN ) Forty Seven Inc (NASDAQ: FTSV ) (reacted to ASH presentation) GALAPAGOS NV/S ADR (NASDAQ: GLPG ) Global Blood Therapeutics Inc (NASDAQ: GBT ) Globus Medical Inc (NYSE: GMED ) Immunomedics, Inc.",SAN,en,Benzinga
2019-12-10 07:47:00-05:00,Regeneron Stock Slides as French Drug Giant Sanofi Mulls Selling Stake,Regeneron’s stock dropped 2.6% in pre-market trading after French drug giant Sanofi said it may sell its stake in the U.S. biotech leader.,SAN,en,MarketWatch
2019-12-10 05:53:04-05:00,"Sanofi shares rally on new margin goals, narrow drug focus","Shares in Sanofi rose on Tuesday after the French drugmaker said it would focus on vaccines and treatments like its promising eczema medicine Dupixent to grow sales, in a business revamp seen as potentially leading to spin-offs.",SAN,en,Reuters
2019-12-10 05:45:03-05:00,Spanish Banks Commit to Reduce Their Carbon Footprint | MarketScreener,"By Maitane Sardon Spanish banks including Banco Santander SA, Banco Bilbao Vizcaya Argentaria SA and CaixaBank SA said Monday that they commit to reducing the carbon footprint of their… | December 10, 2019",SAN,en,MarketScreener
2019-12-10 05:05:00-05:00,"StockBeat: Sanofi Surges After Ditching Diabetes, Cardio Research",https://www.investing.com/news/stock-market-news/stockbeat-sanofi-surges-after-ditching-diabetes-cardio-research-2037619,SAN,en,Investing.com
2019-12-10 03:43:08-05:00,Sanofi : shares rally after firm narrows focus on key drugs | MarketScreener,"Shares in Sanofi rose on Monday after the French drugmaker said it was discontinuing research in diabetes and cardiovascular diseases and would focus on treatments such as its eczema medecine Dupixent… | December 10, 2019",SAN,en,MarketScreener
2019-12-10 03:36:00-05:00,Sanofi shares rally after firm narrows focus on key drugs,https://www.investing.com/news/stock-market-news/sanofi-shares-rally-after-firm-narrows-focus-on-key-drugs-2037582,SAN,en,Investing.com
2019-12-09 16:55:03-05:00,"Sanofi, Maker of World's Biggest Insulin, to Exit Diabetes Research | MarketScreener","By Denise Roland The maker of the world's biggest-selling insulin has given up on finding new diabetes drugs. Sanofi SA, which makes Lantus, said Monday it would stop investing in… | December 9, 2019",SAN,en,MarketScreener
2019-12-09 13:08:59-05:00,"PreMarket Prep Recap: Small Biotech Firms Looking Healthy, Street Fades Macy's Downgrade","When a particular sector gets hot in this momentum driven market, if often gets hotter. And that's exactly what's happening in the biotech sector. Whether it was on positive drug news from the ASH Conference or a takeover, the issues in the biotech sector dominated the largest percentage gainer list and were discussed at the top of today's PreMarket Prep Show . Merger Mania Continuing with last's week trend of consolidation in the industry, two major players Merck (NYSE: MRK ) and Sanofi (NYSE: SNY ), made acquisitions to bolster their pipeline and augment future growth. One was telegraphed by the price action at the end of last week and the other was kept under wraps. The price action last week in Arqule Inc (NASDAQ: ARQL ) gave no indication that the company was going to be taken out for $20/share as it posted a modest 9-cent gain for the week. However, the huge gain in Synthorx Inc . (NASDAQ: THOR ) last week, … Full story available on Benzinga.com",SAN,en,Benzinga Feeds
2019-12-09 08:31:00-05:00,French pharma giant Sanofi buys Synthorx for $2.5bn,Synthorx is a clinical-stage biotech company develops therapies to treat those with cancer and auto-immune disorders. Sanofi is hoping its first multi-billion dollar deal in almost two years will pay off Read More…,SAN,en,Capital.com
2019-12-09 07:09:02-05:00,Sanofi : Synthorx Shares Up 165% After Sanofi Buyout Offer | MarketScreener,"By Chris Wack Synthorx shares were up 165% to $66.28 premarket after Sanofi said it was buying the clinical-stage biotechnology for $68 a share in cash. The deal has an equity value of… | December 9, 2019",SAN,en,MarketScreener
2019-12-09 06:02:03-05:00,Sanofi to Buy Cancer Biotech Company Synthorx for $2.5 Billion | MarketScreener,"By Denise Roland Sanofi SA has agreed to buy cancer biotech company Synthorx Inc. for $2.5 billion, the first big move by new Chief Executive Paul Hudson to reinvigorate the sprawling French… | December 9, 2019",SAN,en,MarketScreener
2019-12-09 05:32:05-05:00,Sanofi Acquiring Synthorx for $2.5B to Strengthen Immuno-Oncology Portfolio,Sanofi said on Monday it had agreed to buy California-headquartered biotechnology firm Synthorx in a cash deal worth about $2.5 billion aimed at beefing up the French drugmaker’s pipeline of drugs for cancer and auto-immune disorders.,SAN,en,Coinspeaker
2019-12-09 04:31:52-05:00,Sanofi to acquire US biotech firm Sythorx $2.5bn,Mubasher: Sanofi on Monday said it will take over US biotechnology company Synthorx in a cash deal that valued the latter at $2.5 billion.,SAN,en,Mubasher Info
2019-12-09 03:13:53-05:00,France's Sanofi to buy immuno-oncology specialist Synthorx,No summary available.,SAN,en,UrduPoint
2019-12-09 02:51:48-05:00,Sanofi to buy Synthorx for $2.5B,"Bolstering its immuno-oncology pipeline, Sanofi (SNY) will acquire all of the outstanding shares of Synthorx (THOR) for $68 per share in cash, representing",SAN,en,Seeking Alpha
2019-12-09 02:08:00-05:00,Sanofi to acquire Synthorx for $2.5 billion,The French pharmaceutical company said it plans to take control of all outstanding shares of Synthorx for $68 per share in cash.,SAN,en,MarketWatch
2019-12-09 01:43:00-05:00,France's Sanofi to buy Synthorx for $2.5 billion,https://www.investing.com/news/stock-market-news/frances-sanofi-to-buy-synthorx-for-25-billion-2036615,SAN,en,Investing.com
2019-12-09 01:40:38-05:00,France's Sanofi to buy Synthorx for US$2.5 billion,France's Sanofi said on Monday it had agreed to buy Synthorx in a cash deal worth around US$2.5 billion as it seeks to beef up its immuno-oncology pipeline.,SAN,en,Channel NewsAsia
2019-12-09 01:00:39-05:00,"SANOFI VA ACQUÉRIR SYNTHORX POUR 2,5 MILLIARDS DE DOLLARS ET RENFORCER SON PORTEFEUILLE EN IMMUNO-ONCOLOGIE","SANOFI VA ACQUÉRIR SYNTHORX POUR 2,5 MILLIARDS DE DOLLARS ET RENFORCER SON PORTEFEUILLE EN IMMUNO-ONCOLOGIE …",SAN,en,Zonebourse
2019-12-05 04:30:00-05:00,Global Esophageal Cancer Drugs Market 2019-2023 | Evolving Opportunities with Eli Lilly and Company and Sanofi | Technavio,LONDON--(BUSINESS WIRE)-- #Biotechnology--Global esophageal cancer drugs market is poised to grow by USD 1.5 billion during 2019-2023 at a CAGR of over 8% during the forecast period.,SAN,en,Business Wire
2019-12-04 16:43:44-05:00,"Najarian Brothers Highlight Unusual Option Activity In Sanofi, JetBlue And More","On CNBC's ""Fast Money Halftime Report,"" Jon Najarian said traders were aggressively buying the December $15.50 calls in Teck Resources Ltd (NYSE: TECK ) on Wednesday. They picked the $15.50 strike, although the price has already jumped above that level. Najarian followed the trade and he is going to hold the position until the December expiration. Sanofi SA (NASDAQ: SNY ) was also active. Traders … Full story available on Benzinga.com",SAN,en,Benzinga Feeds
2019-12-04 10:52:00-05:00,"Global Anti-infective Drugs Market Report 2019 with Forecasts to 2024, Led by Novartis, Merck & Co, Sanofi, GSK, and Gilead Sciences - ResearchAndMarkets.com","DUBLIN--(BUSINESS WIRE)--The ""Anti-infective Drugs Market - Growth, Trends, and Forecast (2019 - 2024)"" report has been added to ResearchAndMarkets.com's offering. Anti-infectives drugs have been one of the major segments for many pharmaceutical companies for decades. Over the past two decades, the infection rate has grown significantly, particularly across low and middle-income countries. There are a large number of companies well-established in the market with their products in the form of an",SAN,en,Business Wire
2019-12-02 11:09:45-05:00,Why Lexicon Pharma Shares Are Moving Lower,"Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX ) shares were retreating sharply Monday morning on an adverse development with its Type 1 diabetes drug candidate sotagliflozin. Lexicon was co-developing the pipeline asset with Sanofi SA (NASDAQ: SNY ) but has terminated the alliance effective Sept. 9. FDA Firm On Rejection Decision The actively traded, small-cap biotech Lexicon said it has been notified by the Office of New Drugs of the FDA that the agency is standing by its prior position and denying the company's appeal of the complete response letter related to its NDA for its Type 1 diabetes drug sotagliflozin. Sotagliflozin, going by the trade name Zynquista, is an oral dual inhibitor of two proteins responsible for … Full story available on Benzinga.com",SAN,en,Benzinga
2019-12-02 08:30:00-05:00,Ligand Enters into Worldwide OmniAb® Platform License Agreement with Sanofi,"SAN DIEGO--(BUSINESS WIRE)--Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces it has entered into a worldwide OmniAb license agreement with Sanofi. Under the agreement, Sanofi will be able to use Ligand’s full OmniAb antibody discovery platform which includes OmniRat®, OmniFlic®, OmniMouse®, OmniChicken® and OmniClic™ in addition to Ligand’s patented antigen technology. OmniAb is licensed to over 40 corporate partners globally, and this deal with Sanofi adds to a growing portfolio of",SAN,en,Business Wire
2019-12-02 07:30:00-05:00,Baxter to Expand Advanced Surgery Portfolio With Acquisition of Seprafilm Adhesion Barrier,"DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX), a leading global medical products company, today entered into a definitive agreement to acquire Seprafilm Adhesion Barrier and related assets from Sanofi. The agreement is the latest example of Baxter’s continued focus on acquiring products and technologies that have a strong strategic fit with the company’s leading portfolio across the hospital, including in the operating room. The transaction contemplates a cash purchase",SAN,en,Business Wire
2019-11-28 13:00:00-05:00,"Global Diabetes Care (Insulin, OAD & GLP-1) Market 2019-2023 - Key Players are Novo Nordisk, Sanofi, and Eli Lilly","DUBLIN, Nov. 28, 2019 /PRNewswire/ -- The ""Global Diabetes Care Market (Insulin, OAD & GLP-1): Industry Analysis & Outlook (2019-2023)"" report has been added to ResearchAndMarkets.com's offering. Diabetic population is growing considerably all over the world. AAMEO region is experiencing…",SAN,en,PR Newswire
2019-11-25 12:38:38-05:00,Sanofi ex-employee can join hemophilia treatment rival BioMarin - judge,"Sanofi SA's Genzyme unit cannot block a former employee from joining BioMarin Pharmaceutical Inc, where he would help launch a gene therapy treatment for hemophilia that would compete with a drug his ex-employer markets, a Massachusetts judge has ruled.",SAN,en,Reuters
2019-11-25 05:47:40-05:00,Novartis takes on Sanofi and Amgen with a $9.7 billion takeover of heart drugmaker,Swiss drugmaker Novartis is betting on heart drug prospect inclisiran in a $9.7 billion takeover of The Medicines Co.,SAN,en,CNBC
2019-11-25 03:35:33-05:00,"Novartis takes on Sanofi, Amgen with US$9.7 billion takeover of heart drug maker","Novartis AG is buying U.S. biotechnology company The Medicines Co for about US$9.7 billion, the Swiss drugmaker said on Sunday, as it seeks to expand its portfolio of medicines against cardiovascular disease.",SAN,en,Channel NewsAsia
2019-11-22 13:14:03-05:00,Sanofi : Head of Strategy to Retire -- Reuters | MarketScreener,"--The chief strategy boss at French drugmaker Sanofi will leave the company at the end of this month, Reuters reported Friday. --Muzammil Mansuri's retirement comes as the company undergoes a… | November 22, 2019",SAN,en,MarketScreener
2019-11-22 06:42:58-05:00,Exclusive: Sanofi's strategy boss to leave as CEO readies revamp | MarketScreener,"Sanofi executive vice president in charge of strategy and business development, Muzammil Mansuri, a member of the French drugmaker's executive committee, will leave the firm by the end of the month,… | November 22, 2019",SAN,en,MarketScreener
2019-11-21 13:25:51-05:00,Drugmaker Sanofi said to weigh options for $30 bn consumer-health business,"Sanofi has been talking to financial advisers to gauge shareholder feedback.Sanofi shares rise as much as 2.9% in Paris, reversing an earlier decline, for their biggest intraday gain in four months",SAN,en,Livemint
2019-11-20 06:00:00-05:00,Sanofi and Aetion launch enterprise-wide collaboration to advance regulatory submissions using real-world evidence,"BRIDGEWATER, N.J. and NEW YORK , Nov. 20, 2019 /PRNewswire/ -- Sanofi announced today an enterprise-wide collaboration with health care technology company Aetion that will integrate Sanofi's real-world data platform, DARWIN, with the Aetion Evidence Platform ® with the objective of advancing more efficient use of real-world evidence (RWE), facilitating regulatory-grade studies with deep transparency, and unlocking access to new real-world data. Both companies have invested in RWE platforms, recognizing the pressing need for accurate, fast, and cost-effective research and the important role RWE could play in meeting this need. Sanofi's DARWIN compiles and analyzes de-identified data from hundreds of millions of patients across disease states, while Aetion's platform analyzes real-world data to produce transparent, rapid, and scientifically validated answers about the effectiveness, safety, and value of drugs. By combining these platforms, Sanofi is seeking to elevate its capabilities in conducting regulatory-grade analytics, opening new doors for the development and application of medical treatments.",SAN,en,Benzinga Feeds
2019-11-20 03:24:25-05:00,Sanofi : Below a major resistance level | MarketScreener,"The price of shares in Sanofi is close to a major medium term resistance level around 85.25 EUR. A correction phase over the short term appears to be the logical outcome. | November 20, 2019",SAN,en,MarketScreener
2019-11-18 22:34:55-05:00,"Buy Sanofi, target price Rs 7,170: Dharmesh Shah",Dharmesh Shah recommended to keep stoploss at Rs 6650.,SAN,en,The Economic Times India
2019-11-13 20:56:35-05:00,"Analyst Calls: Lupin, Info Edge, Sanofi, CIL",Prabhudas Lilladher has upgraded Lupin to hold from reduce and raised target price to Rs 760 from Rs 730 .,SAN,en,The Economic Times India
2019-11-13 17:33:26-05:00,"Seguradora Líder, administradora do DPVAT, rebate críticas de ineficiência e diz que ampliou combate a fraudes","Consórcio formado por 73 seguradoras é responsável pela gestão do seguro obrigatório que o governo decidiu extinguir a partir de 2020, alegando fraudes e altos custos. Acidente ocorrido na BR-376 Adilson Marques/RPC A Seguradora Líder, responsável pela administração do Seguro DPVAT, rebateu ao G1 as críticas feitas pela Superintendência de Seguros Privados (Susep) de ineficiência no chamado ""seguro obrigatório"". A Susep, autarquia vinculada ao Ministério da Economia que fiscaliza os seguros, disse ter sido consultada pelo governo antes de ser anunciado, na última segunda (11), o fim do DPVAT, a partir do ano que vem. E que comprovou com dados a ""baixa eficiência"" do seguro, mas não detalhou quais foram as informações apresentadas ao ministério. Afirmou apenas que a operação do DPVAT representa 1,9% do volume de receitas de seguros no país, mas consome 19% dos recursos de fiscalização da superintendência. Susep: DPVAT era ineficiente e 'havia corrupção enorme' Veja perguntas e respostas sobre o DPVAT ""Não há nada que indique ineficiência na gestão do Seguro DPVAT"", afirma a gestora do seguro obrigatório. ""Ao contrário.",SAN,pt,Globo
2019-11-12 14:13:00-05:00,Analgesics World Market Review 2015-2019 and Forecast to 2030 - ResearchAndMarkets.com,"DUBLIN--(BUSINESS WIRE)--The ""Analgesics Global Market Report 2020"" report has been added to ResearchAndMarkets.com's offering. The global analgesics market was valued at about $30.26 billion in 2018 and is expected to grow to $35.95 billion at a CAGR of 4.4% through 2022. Major players in the market are Bayer Healthcare, Pfizer, Sanofi, Johnson & Johnson and Novartis AG. The analgesics market has been geographically segmented into North America, Western Europe, APAC, Eastern Europe, South",SAN,en,Business Wire
2019-11-11 10:32:00-05:00,"The Zacks Analyst Blog Highlights: Novo Nordisk, Allergan, Sanofi, Novartis and J&J","The Zacks Analyst Blog Highlights: Novo Nordisk, Allergan, Sanofi, Novartis and J&J",SAN,en,Zacks Investment Research
2019-11-08 13:00:41-05:00,"Turbinado pelo crdito no varejo, lucro de grandes bancos cresce 19% no trimestre","Juntos, Banco do Brasil, Bradesco, Ita Unibanco e Santander Brasil apresentaram lucro lquido de R$ 21,946 bilhes no terceiro trimestre",SAN,pt,Jornal do Comercio
2019-11-08 03:26:00-05:00,"Pharma Stock Roundup: AGN, NVO Q3 Earnings, FDA Nod to SNY & NVS' Products",Novo Nordisk (NVO) and Allergan (AGN) release Q3 results. FDA approves Sanofi's quadrivalent flu vaccine for older adults and Novartis' long-acting biosimilar version of Amgen's Neulasta.,SAN,en,Zacks Investment Research
2019-11-06 02:53:56-05:00,Sanofi invests in innovation to create healthy outcomes,"Innovation has become a major calling card for the established Paris-headquartered multinational pharmaceutical Sanofi, according to the company's senior executives.",SAN,en,Chinadaily European
2019-11-06 02:53:56-05:00,Healthcare provider gives back to the community,"From cultural exchanges to healthcare promotion, Sanofi has devoted itself to living up to its corporate social responsibility initiatives in a bid to support Chinese people's health, according to the company.",SAN,en,Chinadaily European
2019-11-05 06:53:31-05:00,"The Daily Biotech Pulse: FDA Nod For Sanofi, BioCryst's Edema Drug In Japan, Myriad's Q1 Disappointment","Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Nov. 4) Agile Therapeutics Inc (NASDAQ: AGRX )(follow-on rally following positive Adcom verdict for Twirla) Amgen, Inc. (NASDAQ: AMGN ) Beigene Ltd (NASDAQ: BGNE ) Bioanalytical Systems, Inc. (NASDAQ: BASI ) Bio-Rad Laboratories, Inc. (NYSE: BIO ) Cabaletta Bio Inc (NASDAQ: CABA ) Deciphera Pharmaceuticals Inc (NASDAQ: DCPH ) Frequency Therapeutics Inc (NASDAQ: FREQ ) Horizon Therapeutics PLC (NASDAQ: HZNP ) Karyopharm Therapeutics Inc (NASDAQ: KPTI )(reacted to its third-quarter results) Oyster Point Pharma Inc (NASDAQ: OYST ) (IPOed Oct. 31) Phathom Pharmaceuticals Inc (NASDAQ: PHAT ) Recro Pharma Inc (NASDAQ: REPH ) ZEALAND PHARMA/S ADR (NASDAQ: ZEAL ) Down In The Dumps (Biotech stocks hitting 52-week lows on Nov. 4) Cleveland BioLabs, Inc. (NASDAQ: CBLI ) Helius Medical Technologies Inc (NASDAQ: HSDT ) Mersana Therapeutics Inc (NASDAQ: MRSN ) Midatech Pharma PLC-ADR (NASDAQ: MTP ) Rockwell Medical Inc (NASDAQ: RMTI ) Tetraphase Pharmaceuticals Inc (NASDAQ: TTPH ) Stocks In Focus Seattle Genetics Claims Rights To Disputed Antibody-Drug Conjugate Intellectual Property Following the filing of a declaratory judgment action by DAIICHI SANKYO/S ADR (OTC: DSNKY ), Seattle Genetics, Inc. (NASDAQ: SGEN ) said the antibody-drug conjugate tech used in Daiichi Sankyo's metastatic cancer drug candidate DS-820 , among others, rightfully belongs to it. ""The linker and other ADC technology used in these drug candidates are improvements to Seattle Genetics' pioneering ADC technology, the ownership of which are automatically assigned to Seattle Genetics under the terms of the agreement,"" the company said.",SAN,en,Benzinga
2019-11-04 00:06:23-05:00,"Regulator waives off clinical trials, clears Sanofi TB drug","NEW DELHI: India’s drug regulator has approved Sanofi (India)’s new anti-tuberculosis drug rifapentine, waiving local clinical trials in a move to bolster efforts to prevent latent infections from progressing into active TB.“We have recently received final approval for rifapentine from the Indian regulatory authorities. Rifapentine is now officially registered in India,” Thibaud Lefort, Sanofi’s global health business chief, told ET on the sidelines of the 50th Union World Conference of Lung Health in Hyderabad.While India carries the highest burden of TB with an estimated 2.69 million cases in 2018, more alarming is the possibility of a large pool of people harbouring the ‘silent infection.’ About 40% of the country’s population is estimated to have latent TB infection.The waiver granted to Sanofi’s rifapentine, which is sold under the brand Priftin, is in the public interest, with a restricted marketing licence to supply the drug only for the government-run national TB programme.Sanofi is now in talks with the government on the price of the drug, following its decision on Thursday to slash the price by 66%.",SAN,en,The Economic Times India
2019-10-31 07:06:39-05:00,Santander Totta aumenta lucro para 390 milhões até setembro,"Para o aumento dos lucros do Santander Totta contribuiu a evolução positiva das comissões, da atividade seguradora e dos resultados em operações financeiras.",SAN,pt,Jornal de Negócios
2019-10-31 05:06:42-05:00,Sanofi inks pact with Unitaid; to reduce TB drug Rifapentine price by 70%,"HYDERABAD: In a landmark development, global biopharmaceutical company Sanofi will lower the price of Rifapentine, a critically important drug used to prevent tuberculosis (TB), as part of the agreement with Unitaid, the Global Fund to Fight AIDS, Tuberculosis and Malaria, an official release said on Thursday.The announcement came at the 50 th Union World Conference on Lung Health 2019 being held here.Scale-up of affordable Rifapentine stands to benefit over a million people in India alone, where more people suffer from TB than anywhere else in the world.The Indian government has set ambitious targets to eliminate TB by 2025.Sanofi's rifapentine medicine, Priftin, is already on the list of WHO prequalified products, registered in 11 countries and is in the process of being registered in many other countries.""Sanofi is very pleased to have concluded this innovative agreement. We believe that this sustainable commercial approach will widen access to the new standard of care for latent tuberculosis infection.",SAN,en,The Economic Times India
2019-10-31 02:01:18-05:00,"Sanofi : 3Q Net Profit Tumbles, Sales Rise Ahead of Forecasts | MarketScreener","By Carlo Martuscelli Sanofi S.A. said Thursday that third quarter net profit fell on difficult comparables, while sales climbed. Net profit was 1.77 billion euros , compared with… | October 31, 2019",SAN,en,MarketScreener
2019-10-31 01:45:03-05:00,Tuberculosis drug price slashed in global push to thwart killer disease,"HYDERABAD, India: French pharmaceutical giant Sanofi slashed the price of a key anti-tuberculosis (TB) drug on Thursday (Oct 31), boosting the battle against the world's deadliest disease alongside the US launch of tests for a new treatment. The initiatives came as the United Nations seeks to …",SAN,en,Channel NewsAsia
2019-10-31 01:40:16-05:00,TB drug price slashed in global push to thwart killer disease,"French pharmaceutical giant Sanofi slashed the price of a key anti-tuberculosis drug on Thursday, boosting the battle against the world's deadliest disease alongside the US launch of tests for a new treatment.",SAN,en,Digital Journal
2019-10-30 13:52:11-05:00,Santander keeping plans in Argentina for new consumer finance division | MarketScreener,"Banco Santander SA is keeping its plans to create a consumer finance division in Argentina despite the election of Peronist president Alberto Fernandez, the bank`s regional head for South America… | October 30, 2019",SAN,en,MarketScreener
2019-10-30 08:04:27-05:00,"Santander Brasil tem lucro de R$ 3,6 bi no 3T19","O banco Santander Brasil (BOV:SANB11) registrou lucro líquido de R$ 3,608 bilhões no terceiro trimestre deste ano, uma alta de 5,8% em relação aos…",SAN,pt,ADVFN (Brazil)
2019-10-30 07:14:20-05:00,"Santander Brasil registra lucro de R$3,6 bilhões no 3T19","O Santander registrou lucro no Brasil, no entanto, registrou queda de 75% no balanço a nível mundial por causa do Brexit. Clique aqui",SAN,pt,Suno Research
2019-10-30 07:08:00-05:00,Santander Brasil tem lucro recorrente acima do esperado no 3º tri,"Por Carolina MandlSÃO PAULO (Reuters) - O banco Santander Brasil divulgou resultados do terceiro trimestre que superaram as estimativas dos analistas, impulsionados principalmente pelo segmento de varejo.O lucro líquido… Leia mais",SAN,pt,Extra
2019-10-30 06:26:06.185000-05:00,"Santander Brasil tem lucro de R$ 3,6 bilhões no terceiro trimestre","Resultado ficou 5,8% acima do obtido nos três meses anteriores.",SAN,pt,Globo
2019-10-30 01:35:00-05:00,Santander profit hit by $1.65 billion U.K. charge,Banco Santander SA said Wednesday that third-quarter net profit fell sharply as it reported a 1.49 billion-euro ($1.65 billion) charge related to its U.K….,SAN,en,MarketWatch
2019-10-29 07:58:03-05:00,Sanofi : Regeneron Gets EU OK for Expanded Dupixent Use | MarketScreener,"By Colin Kellaher Sanofi and Regeneron Pharmaceuticals on Tuesday said the European Commission approved expanded use of Dupixent for adults with chronic rhinosinusitis with nasal polyposis,… | October 29, 2019",SAN,en,MarketScreener
2019-10-28 05:33:00-05:00,Sanofi (SNY) to Report Q3 Earnings: What's in the Cards?,Sanofi's (SNY) Specialty Care and Vaccines units are likely to have driven third- quarter earnings.,SAN,en,Zacks Investment Research
2019-10-18 11:53:13-05:00,Zantac Recall Widens as Sanofi Pulls Its Drug Over Carcinogen Fears,"The company’s announcement follows decisions by Walgreens, CVS and others to remove the drug from their shelves and after other manufacturers recalled their products.",SAN,en,New York Times Digital
2019-10-18 10:57:41-05:00,Sanofi recalls popular heartburn drug Zantac as FDA investigates probable carcinogen,"Sanofi said it will voluntarily recall Zantac as the drugmaker and FDA investigate the source of NDMA, a probable carcinogen.",SAN,en,USA Today
2019-10-16 00:27:08-05:00,"Is Banco Santander, S.A.'s (BME:SAN) CEO Pay Justified?","José Antonio Álvarez Álvarez is the CEO of Banco Santander, S.A. (BME:SAN). First, this article will compare CEO…",SAN,en,ACI Information Group
2019-10-02 18:02:26-05:00,Mylan loses bid to axe Sanofi insulin patents ahead of trial,A federal judge on Wednesday dealt a setback to generic drug company Mylan NV in its bid to invalidate patents owned by Sanofi SA relating to its insulin drug Lantus.,SAN,en,Reuters
2019-09-30 17:43:00-05:00,Walgreens (WBA) Becomes Latest Retailer to Suspend Zantac Sales,Walgreens (WBA) announced today that they would be suspending the sales of Sanofi's (SNY) heartburn medication Zantac.,SAN,en,Zacks Investment Research
2019-09-30 10:54:00-05:00,"Zacks.com featured highlights include: Sanofi, KB Home and NRG Energy","Zacks.com featured highlights include: Sanofi, KB Home and NRG Energy",SAN,en,Zacks Investment Research
2019-09-27 16:14:03-05:00,Sanofi wins first bellwether trial in Taxotere litigation,"A jury in Louisiana federal court has found that Sanofi's breast cancer chemotherapy drug Taxotere did not cause a woman to develop permanent hair loss, in the first of thousands of lawsuits over the drug to go to trial.",SAN,en,Reuters
2019-09-27 06:56:12-05:00,"The Daily Biotech Pulse: ESMO Conference Gets Underway, J&J's Darzalex Snags Another Approval, Kaleido Biosciences CFO To Leave","The following is a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs Sept. 26.) AstraZeneca plc (NYSE: AZN ) GlaxoSmithKline plc (NYSE: GSK ) Sanofi SA (NASDAQ: SNY ) ZEALAND PHARMA/S ADR (NASDAQ: ZEAL ) Down In The Dumps (Biotech stocks that hit 52-week lows Sept. 26.) ABIOMED, Inc. (NASDAQ: ABMD ) Adaptive Biotechnologies Corp (NASDAQ: ADPT ) Aduro BioTech Inc (NASDAQ: ADRO ) AEterna Zentaris Inc. (NASDAQ: AEZS ) Akcea Therapeutics Inc (NASDAQ: AKCA ) Amicus Therapeutics, Inc. (NASDAQ: FOLD ) AnaptysBio Inc (NASDAQ: ANAB ) Aridis Pharmaceuticals Inc (NASDAQ: ARDS ) AzurRx BioPharma Inc (NASDAQ: AZRX ) Bellerophon Therapeutics Inc (NASDAQ: BLPH ) BioMarin Pharmaceutical Inc. (NASDAQ: BMRN ) (announced submission of clinical trial application to U.K. regulators for its investigational therapy for phenylketonuria) BioNano Genomics Inc (NASDAQ: BNGO ) BridgeBio Pharma Inc (NASDAQ: BBIO ) Calithera Biosciences Inc (NASDAQ: CALA ) Catalyst Biosciences Inc (NASDAQ: CBIO ) Cellectis SA (NASDAQ: CLLS ) China SXT Pharmaceuticals Inc (NASDAQ: SXTC ) Corvus Pharmaceuticals Inc (NASDAQ: CRVS ) CytomX Therapeutics Inc (NASDAQ: CTMX ) strong>DiaMedica Therapeutics Inc (NASDAQ: DMAC ) Eloxx Pharmaceuticals Inc (NASDAQ: ELOX ) Enanta Pharmaceuticals Inc (NASDAQ: ENTA ) ( announced mid-stage results of NASH treatment candidate) Enochian Biosciences Inc (NASDAQ: ENOB ) Erytech Pharma SA (NASDAQ: ERYP ) Five Prime Therapeutics Inc (NASDAQ: FPRX ) Gemphire Therapeutics Inc (NASDAQ: GEMP ) Gritstone Oncology Inc (NASDAQ: GRTS ) HTG Molecular Diagnostics Inc (NASDAQ: HTGM ) IGM Biosciences Inc (NASDAQ: IGMS ) (initial public offering on Sept.",SAN,en,Benzinga
2019-09-26 10:59:00-05:00,Here's Why Sanofi (SNY) is Outperforming Its Industry Of Late,Sanofi's (SNY) stock is on an upward trajectory this year. Let us have a look at the reasons for the same.,SAN,en,Zacks Investment Research
2019-09-25 08:38:00-05:00,Moving Average Crossover Alert: Sanofi,"Sanofi (SNY) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.",SAN,en,Zacks Investment Research
2019-09-25 06:13:13-05:00,"The Daily Biotech Pulse: PhaseBio Leaps On Trial Results, Pacira Set To Join SmallCap 600 Index, Positive Readout For Amgen's Blood Cancer Drug","Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Sept. 24) Bioanalytical Systems, Inc. (NASDAQ: BASI ) Celgene Corporation (NASDAQ: CELG ) Natera Inc (NASDAQ: NTRA ) Sanofi SA (NASDAQ: SNY ) ZEALAND PHARMA/S ADR (NASDAQ: ZEAL )(announced positive results for the pediatric Phase 3 trial of dasiglucagon for severe hypoglycemia in diabetes) Down In The Dumps (Biotech stocks hitting 52-week lows on Sept. 24) Aduro BioTech Inc (NASDAQ: ADRO ) Advaxis, Inc. (NASDAQ: ADXS ) AEterna Zentaris Inc. (NASDAQ: AEZS ) Akcea Therapeutics Inc (NASDAQ: AKCA ) AnaptysBio Inc (NASDAQ: ANAB ) China SXT Pharmaceuticals Inc (NASDAQ: SXTC ) Citius Pharmaceuticals Inc (NASDAQ: CTXR ) Catalyst Biosciences Inc (NASDAQ: CBIO ) Cellectis SA (NASDAQ: CLLS ) Clovis Oncology Inc (NASDAQ: CLVS ) Crinetics Pharmaceuticals Inc (NASDAQ: CRNX ) Eloxx Pharmaceuticals Inc (NASDAQ: ELOX ) Endologix, Inc. (NASDAQ: ELGX ) Erytech Pharma SA (NASDAQ: ERYP ) Five Prime Therapeutics Inc (NASDAQ: FPRX ) Fulcrum Therapeutics Inc (NASDAQ: FULC Innoviva Inc (NASDAQ: INVA ) Kalvista Pharmaceuticals Inc (NASDAQ: KALV ) Mersana Therapeutics Inc (NASDAQ: MRSN ) Myovant Sciences Ltd (NYSE: MYOV ) Neon Therapeutics Inc (NASDAQ: NTGN ) Onconova Therapeutics Inc (NASDAQ: ONTX ) ProQR Therapeutics NV (NASDAQ: PRQR ) Sarepta Therapeutics Inc (NASDAQ: SRPT ) Satsuma Pharmaceuticals Inc (NASDAQ: STSA ) (priced its IPO on Sept. 13) Seelos Therapeutics Inc (NASDAQ: …",SAN,en,Benzinga
2019-09-24 22:15:59-05:00,Popular antacid Ranitidine under cancer watch,"By Teena ThackerNew Delhi: Indian authorities are closely monitoring the sale of heartburn drug Ranitidine after the US drug regulator said it had found a cancer-causing impurity called N-nitrosodimethylanine (NDMA) in some products containing Ranitidine.Ranitidine is a commonly prescribed medicine for countering acidity and is on the World Health Organisation’s ‘Model List of Essential Medicines’. In India, a host of companies including GalxoSmithKline, JB Chemicals, Cadila Pharma, Zydus Cadila, Dr Reddy’s, Sun Pharmaceuticals sell over 180 versions of the drug. The market size for Ranitidine brand in India is Rs 688.6 crore, as per data shared by AIOCD PharmaTrac.To ensure patient safety, the Drug Controller General of India (DCGI) on Tuesday directed state drug regulators to ask pharmaceutical companies to check their products for the carcinogen. It also asked them to ensure that the drug is sold only under prescription.“The drug Ranitidine is approved for multiple indications in the country and is available in various formulations including tablets, injections, etc.",SAN,en,The Economic Times India
2019-09-24 07:12:30-05:00,"The Daily Biotech Pulse: Sandoz Recalls Ulcer Drug, Anchiano Strikes Agreement With ADT Pharma, Proteon Announces Reverse Merger","The following is a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs Sept. 23.) Applied Therapeutics Inc (NASDAQ: APLT ) Avadel Pharmaceuticals PLC (NASDAQ: AVDL ) ( announced a communication from the FDA allowing it to proceed with a reduced sample size in a Phase 3 study of its drug to treat excessive daytime sleepiness) Bioanalytical Systems, Inc. (NASDAQ: BASI ) Bio-Rad Laboratories, Inc. Class A Common Stock (NYSE: BIO ) Celgene Corporation (NASDAQ: CELG ) Cesca Therapeutics Inc (NASDAQ: KOOL ) DURECT Corporation (NASDAQ: DRRX ) Enlivex Therapeutics Ltd (NASDAQ: ENLV ) Sanofi SA (NASDAQ: SNY ) SpringWorks Therapeutics Inc (NASDAQ: SWTX ) ZEALAND PHARMA/S ADR (NASDAQ: ZEAL ) Down In The Dumps (Biotech stocks that hit 52-week lows Sept. 23) Aduro BioTech Inc (NASDAQ: ADRO ) AEterna Zentaris Inc. (NASDAQ: AEZS ) Akcea Therapeutics Inc (NASDAQ: AKCA ) (announced departures of CEO, president and COO, and the appointment of board member Damien McDevitt as interim CEO) BioNano Genomics Inc (NASDAQ: BNGO ) Catalyst Biosciences Inc (NASDAQ: CBIO ) Cellectis SA (NASDAQ: CLLS ) Clovis Oncology Inc (NASDAQ: CLVS ) (announced acquisition of rights to FAP-targeted radiopharmaceuticals from 3B Pharmaceuticals for $12 million) Erytech Pharma SA (NASDAQ: ERYP ) Invivo Therapeutics Holdings Corp (NASDAQ: NVIV ) Kalvista Pharmaceuticals Inc (NASDAQ: KALV ) KITOV PHARMA LT/S ADR (NASDAQ: KTOV ) Mersana Therapeutics Inc (NASDAQ: MRSN ) Neon …",SAN,en,Benzinga
2019-09-23 11:08:00-05:00,Regeneron/Sanofi Gets Positive CHMP Opinion for Dupixent,Regeneron (REGN) and Sanofi get positive CHMP recommendation for the label expansion of asthma drug Dupixent in an additional indication.,SAN,en,Zacks Investment Research
2019-09-23 08:15:03-05:00,"Sanofi (SNY) Soars to 52-Week High, Time to Cash Out?","Sanofi (SNY) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.",SAN,en,Zacks Investment Research
2019-09-20 05:59:00-05:00,"Regeneron, Sanofi's Dupixent gets positive opinion",Regeneron Pharmaceuticals Inc. (REGN) and Sanofi (SNY) said Friday the European Medicines Agency's Committee for Medicinal Products for Human Use has adopted…,SAN,en,MarketWatch
2019-09-18 19:00:00-05:00,Big Pharma is breaking into the $3 billion digital therapeutics market,Bayer and Sanofi are dipping their toes in the digital therapeutics (DTx) space this week through investments and strategic partnerships.,SAN,en,Business Insider
2019-09-18 15:42:00-05:00,"One chart reveals how the cost of insulin has skyrocketed in the US, even though nothing about it has changed","The skyrocketing cost of insulin has become a crisis in the US. Some people are dying because they can't afford the life-saving drug. In the last decade, the list prices of common types of insulin have roughly tripled, even though they're the exact same products offered 10 years ago. In 2009, the list price for a 10-milliliter vial of Humalog, a fast-acting insulin made by Eli Lilly, was about $93. Today it costs closer to $275. Similarly, Novo Nordisk's fast-acting insulin Novolog cost almost $93 for a 10-milliliter vial in 2009. Today, it costs about $290. The prices of Humalog and Novolog have essentially increased in lockstep . We've seen similar price hikes for Lantus, a common long-acting insulin made by Sanofi, and long-acting Levemir, also made by Novo Nordisk. Insulin manufacturers are facing mounting pressure to lower their list prices. Last year, the Minnesota attorney general filed a lawsuit against the big three insulin makers for alleged price gouging, and in February, Maryland Congressman Elijah Cummings and Vermont Sen.",SAN,en,Business Insider
2019-09-17 07:38:12-05:00,Abbott Partners With Sanofi to Upgrade Diabetes Management,Abbott (ABT) collaborates with Sanofi to revolutionize diabetes care through technological advancements.,SAN,en,Yahoo Finance
2019-09-16 03:10:36-05:00,Analysts slash Sanofi target over Ankleshwar plant sale,"The stock ended flat at ₹5,928 on Friday.",SAN,en,The Economic Times India
2019-09-12 03:41:00-05:00,J&J's Ponesimod Superior to Aubagio in Relapsing MS Patients,"J&J (JNJ) announces superiority of its multiple sclerosis candidate, ponesimod compared to Sanofi's Aubagio in patients with relapsing form of the disease.",SAN,en,Zacks Investment Research
2019-09-12 00:06:22-05:00,"Colgate, GSK Pharma, Honeywell and Sanofi continue their outperformance",MNC stocks getting a premium due to their clean balance sheet and high level of transparency.,SAN,en,The Economic Times India
2019-09-11 08:46:00-05:00,"Lexicon (LXRX) Settles With Sanofi for $260M, Shares Rally",Lexicon Pharmaceuticals (LXRX) settles with Sanofi related to termination of their alliance for development of Zynquista in type I and type II diabetes.,SAN,en,Zacks Investment Research
2019-09-09 08:10:21-05:00,Should Value Investors Buy Sanofi (SNY) Stock?,"Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.",SAN,en,Zacks Investment Research
2019-09-05 11:52:00-05:00,Podcast: Why Big Pharma Is Betting on a New Biotech Therapy,"Biotech companies like Moderna and Translate are backed by the biggest names in Big Pharma: Merck (MRK), Sanofi (SNY), AstraZeneca (AZN), and GlaxoSmithKline (GSK).",SAN,en,Barron's
2019-08-30 02:06:39-05:00,"Buy Sanofi India, target Rs 7500: ICICI Securities","Sanofi’s Q2CY19 revenues grew 9 per cent YoY to Rs 748 crore, mainly due to growth in power brands, new launches.",SAN,en,The Economic Times India
2019-08-29 03:16:00-05:00,Regeneron-Sanofi Get Favorable Ruling Against Amgen in Court,Regeneron (REGN) and partner Sanofi get a favorable ruling against Amgen in the ongoing litigation of Praluent.,SAN,en,Zacks Investment Research
2019-08-26 16:46:44-05:00,Judge rejects Sanofi bid to exclude experts in Taxotere hair loss...,A federal judge in New Orleans has rejected Sanofi SA's bid to exclude two expert witnesses retained by plaintiffs to help prove their claims in thousands of lawsuits that its cancer treatment Taxotere caused them to suffer permanent hair loss.,SAN,en,Reuters
2019-08-26 11:31:00-05:00,"Banco Santander, S.A. (NYSE:SAN), (SC) - Santander Group Expands Use Of Ripple Payments Technology",Banco Santander SA (NYSE: SAN) is building a payments network that will allow Latin American customers to freely transfer money to the U.S. via a …,SAN,en,Benzinga
2019-08-22 08:10:12-05:00,Is Sanofi (SNY) a Great Value Stock Right Now?,"Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.",SAN,en,Zacks Investment Research
2019-08-15 15:28:13-05:00,Sanofi beats bid to exclude expert ‘Trojan horse’ testimony on...,A federal judge has rejected a bid by patients who allege Sanofi SA's cancer treatment Taxotere caused their permanent hair loss to prevent the drugmaker from presenting expert testimony based on an ex-employee's new analysis that showed minimal such side effects.,SAN,en,Reuters
2019-08-12 20:44:48-05:00,Sanofi seeks billions from Mylan in EpiPen antitrust lawsuit,"Sanofi SA wants Mylan PLC to pay up to $11.7 billion in damages for engaging in a scheme to squelch competition to its EpiPen allergy treatment, which became the center of a firestorm over drug price increases.",SAN,en,Reuters
2019-08-09 08:50:00-05:00,"Pharma Stock Roundup: AGN, NVO Earnings, EU Nod to SNY & ABBV Drugs for New Patients",Allergan (AGN) and Novo Nordisk (NVO) report Q2 results. AbbVie's (ABBV) Maviret and Sanofi's (SNY) Dupixent receive approval for new patient population in Europe.,SAN,en,Zacks Investment Research
2019-08-06 06:22:08-05:00,"The Daily Biotech Pulse: Sanofi's Dupixent Found Effective For Pediatric Itchy Skin, Novavax Gets Nod For Late-Stage Study, Allakos Offering",Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks No biotech stocks hit 52-week highs Monday. Down In The Dumps (Biotech stocks hitting 52-week lows on Aug. 5) Acer Therapeutics Inc (NASDAQ: ACER ) Aclaris Therapeutics Inc (NASDAQ: ACRS ) Actinium Pharmaceuticals Inc (NYSE: ATNM ) Adaptimmune Therapeutics PLC – ADR (NASDAQ: ADAP ) Adaptive Biotechnologies Corp (NASDAQ: ADPT ) Agios Pharmaceuticals Inc (NASDAQ: AGIO ) Akcea Therapeutics Inc (NASDAQ: AKCA )(announced its subsidiary Keryx Biopharmaceuticals has reached a settlement agreement with Endo International PLC (NASDAQ: ENDP )'s Par Pharam related to Auryxia) Akebia Therapeutics Inc (NASDAQ: AKBA ) Alder Biopharmaceuticals Inc (NASDAQ: ALDR ) Amneal Pharmaceuticals Inc (NYSE: AMRX )( reported below-consensus Q2 results and cut its 2019 guidance) AnaptysBio Inc (NASDAQ: ANAB ) Arcus Biosciences Inc (NYSE: RCUS ) Assertio Therapeutics Inc (NASDAQ: ASRT ) Atara Biotherapeutics Inc (NASDAQ: ATRA ) Bellicum Pharmaceuticals Inc (NASDAQ: BLCM ) Atreca Inc (NASDAQ: BCEL ) Cellectis SA (NASDAQ: CLLS ) Champions Oncology Inc (NASDAQ: CSBR ) China SXT Pharmaceuticals Inc (NASDAQ: SXTC ) Crinetics Pharmaceuticals Inc (NASDAQ: CRNX ) Cyclerion Therapeutics Inc (NASDAQ: CYCN ) Eloxx Pharmaceuticals Inc (NASDAQ: ELOX )(commenced Phase 2 study of ELX-02 in cystinosis) Endo International Enochian Biosciences Inc (NASDAQ: ENOB ) ESSA Pharma Inc (NASDAQ: EPIX ) Galmed Pharmaceuticals Ltd (NASDAQ: GLMD )(reacted to Q2 results) GENFIT S A/ADR (NASDAQ: GNFT ) GlycoMimetics Inc (NASDAQ: GLYC )(reported that Phase 3 trial evaluating sickle cell disease drug it is co-developing with Pfizer Inc.,"SAN,RUBY",en,Benzinga
2019-08-03 09:18:19-05:00,"The Week Ahead In Biotech: Focus On Earnings Deluge, Mid-Year Clinical Trial Readouts","Biotech stocks went about in a steady manner this week amid a slew of big pharma and biotech earnings announcements, a handful of FDA approvals and a few clinical trial readouts. Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX ) was a huge casualty as the micro-cap stock fell steeply on severing of a licensing pact with Sanofi SA (NASDAQ: SNY ). Here are the key catalysts that can sway biotech stocks in the unfolding week. Conferences SVB Leerink Spotlight Series: Rare & Genetic Diseases Conference – Aug. 7, in Boston, Massachusetts Canaccord Genuity Growth Conference - Aug. 7-8, in Boston Clinical Trial Readouts Leap Therapeutics Inc (NASDAQ: LPTX ) is scheduled to provide an update on DKN-01 in combination with Merck & Co., Inc. (NYSE: MRK )'s Keytruda in ornithine transcarbamylase deficiency. Pending Mid-2019 Clinical Readouts Immunic Inc (NASDAQ: IMUX ) – interim Phase 2 dosing analysis for IMU-838 in ulcerative colitis Conatus Pharmaceuticals Inc (NASDAQ: CNAT ) – 48-week liver function data from a Phase 2 study dubbed ENCORE-PH for emricasan in non-alcoholic steatohepatitis cirrhosis Alkermes Plc (NASDAQ: ALKS ) – Phase 3 top-line data for diroximel fumarate in relapsing remitting multiple sclerosis IMMUTEP LTD/S ADR (NASDAQ: IMMP ) – initial Phase 2 data for eftilagimod alpha and Keytruda in non-small cell lung cancer and head and neck cancer Aevi Genomic Medicine Inc (NASDAQ: GNMX ) – Phase 1b data for AEVI-002 in pediatric …",SAN,en,Benzinga
2019-07-30 06:00:00-05:00,"The Daily Biotech Pulse: European Cheer For Merck, Legal Victory For Coherus, Medpace Picks Up On Earnings","Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on July 29) Acasti Pharma Inc (NASDAQ: ACST ) Array Biopharma Inc (NASDAQ: ARRY ) GENMAB A/S/S ADR (NASDAQ: GMAB ) (IPOed July 18) Grifols SA - ADR ADR Class B (NASDAQ: GRFS ) Hologic, Inc. (NASDAQ: HOLX ) Novocure Ltd (NASDAQ: NVCR ) Odonate Therapeutics Inc (NASDAQ: ODT ) Repligen Corporation (NASDAQ: RGEN ) Down In The Dumps (Biotech stocks hitting 52-week lows on July 29) Acer Therapeutics Inc (NASDAQ: ACER ) Advaxis, Inc. (NASDAQ: ADXS ) Cancer Genetics Inc (NASDAQ: CGIX ) Champions Oncology Inc (NASDAQ: CSBR ) China SXT Pharmaceuticals Inc (NASDAQ: SXTC ) Genprex Inc (NASDAQ: GNPX ) Kiniksa Pharmaceuticals Ltd (NASDAQ: KNSA ) Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX )(slumped in reaction to Sanofi SA (NASDAQ: SNY )'s decision to terminate their collaboration agreement regarding sotagliflozin that is being evaluated for Type 2 diabetes) Myovant Sciences Ltd (NYSE: MYOV ) Neovasc Inc (NASDAQ: NVCN ) Neon Therapeutics Inc (NASDAQ: NTGN ) Neuralstem, Inc. (NASDAQ: CUR ) Novavax, Inc. (NASDAQ: NVAX ) Oncolytics Biotech, Inc. (NASDAQ: ONCY ) Personalis Inc (NASDAQ: PSNL )( IPOed June 20) Cytori Therapeutics (NASDAQ: PSTV ) Proteostasis Therapeutics Inc (NASDAQ: PTI ) Tonix Pharmaceuticals Holding Corp (NASDAQ: TNXP ) TRACON Pharmaceuticals Inc (NASDAQ: TCON ) Unity Biotechnology Inc (NASDAQ: UBX ) Vistagen Therapeutics Inc (NASDAQ: VTGN ) Wave Life Sciences Ltd (NASDAQ: WVE ) (reacted …",SAN,en,Benzinga
2019-07-29 09:38:00-05:00,"Sanofi (SNY) Q2 Earnings Top, Dupixent Shines, EPS View Up",Sanofi (SNY) beats estimates for second-quarter earnings. Key immunology drug Dupixent drives sales. The company ups its earnings growth expectations for the year.,SAN,en,Zacks Investment Research
2019-07-29 07:53:00-05:00,Lexicon's stock loses more than half its value after Sanofi's notice to end alliance,"Shares of Lexicon Pharmaceuticals Inc. lost more than half their value (down 53.4%) toward a record low in active premarket trading Monday, after the drug…",SAN,en,MarketWatch
2019-07-29 04:24:13-05:00,Sanofi raises outlook after strong second quarter,"Sanofi has raised its 2019 outlook on the back of strong second-quarter results, which benefited from double-digit growth at the French drugmaker's vaccines and rare diseases businesses.",SAN,en,Reuters
2019-07-29 03:56:00-05:00,"Merger cheer, Sanofi lift European shares; Fed in focus",https://www.investing.com/news/stock-market-news/merger-cheer-sanofi-lift-european-shares-fed-in-focus-1937288,SAN,en,Investing.com
2019-07-25 07:07:00-05:00,MORGAN STANLEY: These 7 pharma companies will be critical to fighting infectious diseases brought on by climate change,"Global warming will bring an increased prevalence of several deadly tropical diseases and a need for new vaccines, according to a Morgan Stanley research note dated Tuesday. Between 383 million and 725 million more people may be exposed to Zika, dengue and other diseases by 2050, depending on the pace and severity of global warming, the analyst said. To fight those diseases, we'll need vaccines worth roughly $50 billion to as much as $170 billion. Morgan Stanley said Sanofi and GlaxoSmithKline are best positioned to help fight the diseases. Moderna, Takeda Pharmaceutical, Merck, Johnson & Johnson's Janssen Pharmaceuticals, and Pfizer could play a big role, too. Visit the Markets Insider homepage for more stories . The rise in global temperatures will bring about a growing presence of infectious disease creating a ""critical role"" for biopharmaceutical companies, according to a Morgan Stanley research note dated Tuesday. By 2050, between 383 million and 725 million more individuals may be exposed to diseases that are spread by mosquitoes, such as Zika, dengue and yellow fever, the researchers said.",SAN,en,Business Insider
2019-07-24 08:07:00-05:00,'We're light years ahead of where we were': Novartis CEO Vas Narasimhan told us how the Swiss drug giant is using AI for everything from evaluating managers to predicting its financials (NVS),"Novartis CEO Vas Narasimhan has been a prominent advocate for using tech like AI in the pharmaceutical industry. The drugmaker has made the biggest inroads with increasing the use of technology in its operations, because tech ""can really help you make better decisions,"" he said. Tech is being used at Novartis to help run research trials and in hopes of finding new drugs , but also in areas like sales, finance, and measuring its corporate culture, Narasimhan told Business Insider. Click here for more BI Prime stories. Since taking the reins at Novartis early last year, CEO Vas Narasimhan has been a prominent voice on the potential for technology in the pharmaceutical industry. At Novartis, he's walking the walk. The Swiss drug giant is using tech like AI and data science for tasks like finding new drugs as well as to help run sales and finance operations, Narasimhan told Business Insider during a phone interview last week. ""If you think back to where we were January of last year to where we are now, I think we're light years ahead of where we were,"" he said.",SAN,en,Business Insider
2019-07-22 14:00:00-05:00,"The future of HIV treatments will change dramatically in the next decade, Citi says. These 3 companies could be the biggest winners.","Since 2012, a preventive HIV medication has been available in the US, making it possible for those at risk to reduce their chances of contracting the disease. Citi analysts predict the US market for these types of drugs will nearly triple by 2030 to about $5.5 billion, thanks to factors like President Donald Trump's new plan to stop HIV . New drugs from US drug giant Merck, HIV-focused drugmaker ViiV Healthcare, and biopharma Gilead could dominate the preventive HIV market over the next decade, the Citi team says. Click here for more BI Prime stories . The market for HIV prevention drugs is set to take off. Analysts at Citigroup predict that US sales could nearly triple in the next decade, surging from $2 billion today to $5.5 billion in 2030. Even though the preventive treatments collectively known as PrEP have ""proven one of the most effective forms of HIV prevention in the US,"" use is still relatively low worldwide and in the US, the Citi analysts said, because of barriers like cost and stigma. ""Increasing PrEP use will be complex but with significant commercial and medical returns,"" they wrote.",SAN,en,Business Insider
2019-07-19 11:11:00-05:00,Swiss drug giant Novartis has done $60 billion in deals over the past 18 months. One sentence from its CEO reveals the core strategy. (NVS),"Swiss drugmaker Novartis's new CEO, Vas Narasimhan , has been adjusting the company to focus on prescription medicines. As part of that, he's led more than $60 billion in deals over about 18 months, with more to come. ""I aspire for us to target on the order of 5% of our market cap in M&A, focused in either building therapeutic area depth or building out new technology platforms,"" Narasimhan told Business Insider on Thursday. Novartis also isn't backing away from a strategy of focusing on earlier-stage biotech companies , even though they can be riskier bets. Click here for more BI Prime stories. When Vas Narasimhan started as the new CEO of Swiss drug giant Novartis, he began refocusing the company on a key business area: prescription medicines. Until recently, alongside top-selling psoriasis, multiple sclerosis, and vision-loss drugs, Novartis was also making contact lenses and skin products, and even had a hand in consumer health products like toothpaste. Narasimhan still wanted Novartis to be diversified, but across different diseases and types of technology, instead of across types of healthcare products.",SAN,en,Business Insider
2019-07-17 15:01:00-05:00,How 2 top leaders at Google's $4.5 billion venture arm prepare tech entrepreneurs to jump into the 'screwed up' US healthcare industry,"Entrepreneurs with a background in tech are now looking at healthcare as the next area to be disrupted. But GV's David Schenkein and Krishna Yeshwant have tried to avoid backing companies with founders who have a background in tech alone. Instead, the team will send the entrepreneurs out on crash courses to learn more about the industry. Yeshwant said it takes about six months to fully understand that the healthcare industry is both ""screwed up"" and has ""perverse"" incentives. Very few entrepreneurs make it to that point, he said. Click here for more BI Prime stories. For those with a tech background looking to tackle the $3.5 trillion healthcare industry, there's a lot to learn. VCs David Schenkein and Krishna Yeshwant have seen it play out before. Schenkein and Yeshwant are both physicians and venture capitalists who co-lead the life science investment team at GV , formerly Google Ventures. GV oversees more than $4.5 billion invested in 300 companies. Here's how it goes: An entrepreneur who's done a stint at a big tech company in Silicon Valley decides to take a crack at healthcare after getting a glimpse of how complicated the system can be.",SAN,en,Business Insider
2019-07-15 21:09:07-05:00,Sanofi: Bullish rounding signals reversal of corrective trend,Sanofi is a cash-rich company and has seen its core RoE improving from 15.4 per cent in CY14 .,SAN,en,The Economic Times India
2019-07-15 07:00:00-05:00,A startup using AI to find new treatments for rare diseases just raised $121 million. Here’s why its CEO still has a dire prediction for the industry.,"Recursion, a biotech company making new drugs using AI technology, just closed a $121 million Series C round with investors like the venture-capital firm Menlo Ventures. Around the pharmaceutical industry, many companies have been launching their own AI efforts. CEO Chris Gibson predicts that, with so much AI hype, the industry is poised to hit an inflection point and ""go through the valley of disillusionment."" Still, he says that companies like Recursion that are finding and developing new drugs have the best chance of success. Click here for more BI Prime stories. Talk of AI is everywhere, especially in healthcare. Companies are flooding into the space, promising to solve age-old problems by revolutionizing how prescription drugs are made and sold. A very different prediction comes by way of Chris Gibson, the CEO of AI-powered biotech Recursion Pharmaceuticals. ""We are just coming off a peak hype cycle and about to go through the valley of disillusionment,"" he told Business Insider. ",SAN,en,Business Insider
2019-07-12 08:10:15-05:00,Are Investors Undervaluing Sanofi (SNY) Right Now?,"Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.",SAN,en,Zacks Investment Research
2019-07-11 05:16:00-05:00,FDA Accepts Sanofi's BLA for Myeloma Candidate to Review,The FDA accepts for review Sanofi's (SNY) BLA for isatuximab as a potential treatment for relapsed/refractory multiple myeloma. The FDA will declare its decision by April 2020.,SAN,en,Zacks Investment Research
2019-07-01 16:33:03-05:00,Mylan seeks dismissal of Sanofi's EpiPen antitrust lawsuit,"Mylan Plc is urging a federal judge to reject rival drugmaker Sanofi SA's claims the company engaged in a scheme to squelch competition to its EpiPen allergy treatment, which became the center of a political firestorm over price increases.",SAN,en,Reuters
2019-07-01 10:00:00-05:00,Regeneron/Sanofi's Dupixent Gets Positive CHMP Recommendation,Regeneron's (REGN) Dupixent gets favorable recommendation from CHMP for moderate-to-severe atopic dermatitis in adolescents aged 12-17 years.,SAN,en,Zacks Investment Research
2019-06-28 08:22:00-05:00,Buzzy digital health startup Livongo just filed to go public at a $2.5 billion valuation,"Livongo, a company that sells diabetes monitoring technology, on Friday filed paperwork to go public with the US Securities and Exchange Commission. The company most recently had a post-money valuation of $800 million. Livongo is seeking to raise up to $200 million in its IPO and achieve a valuation of $2 billion to $2.5 billion, according to a person familiar with the matter. Click here for more BI Prime stories. Livongo, a company that sells diabetes monitoring technology, just filed to go public. The company on Friday filed paperwork with the US Securities and Exchange Commission to trade on the Nasdaq under the ticker symbol LVGO. Livongo plans to raise up to $200 million in its IPO and achieve a valuation of $2 billion to $2.5 billion, according to a person familiar with the matter. The terms of the offering are subject to change as the IPO draws near. Livongo was founded in 2014 and operates diabetes and other chronic disease management programs using a glucose meter and other devices on behalf of big companies and insurers who pay monthly fees.",SAN,en,Business Insider
2019-06-27 04:30:00-05:00,FDA Accepts Sanofi's BLA for Meningitis Vaccine to Review,"The FDA accepts for review Sanofi's (SNY) BLA for MenQuadfi, a meningococcal vaccine candidate, presently under development to prevent meningococcal meningitis.",SAN,en,Zacks Investment Research
2019-06-27 01:39:00-05:00,Regeneron & Sanofi Get FDA Nod for Dupixent Label Expansion,Regeneron (REGN) and partner Sanofi obtain FDA approval for Dupixent for the treatment of chronic rhinosinusitis with nasal polyposis in adults.,SAN,en,Zacks Investment Research
2019-06-21 04:30:00-05:00,Sanofi/Regeneron's Asthma Candidate Meets Goal in Study,Sanofi/Regeneron's IL-33 antibody REGN3500 meets primary endpoint in phase II study in asthma. It does not show increased benefit compared to Dupixent.,SAN,en,Zacks Investment Research
2019-06-20 08:47:00-05:00,"The Zacks Analyst Blog Highlights: Alphabet, Amazon, Apple, Sanofi and Walgreens","The Zacks Analyst Blog Highlights: Alphabet, Amazon, Apple, Sanofi and Walgreens",SAN,en,Zacks Investment Research
2019-06-19 08:27:00-05:00,Sanofi is leaning on Google's AI and cloud-computing tools for drug advances (GOOGL),"This is an excerpt from a story delivered exclusively to Business Insider Intelligence Digital Health Pro subscribers. To receive the full story plus other insights each morning, click here . France-based pharma giant Sanofi is teaming up with Google to use the tech giant's AI and cloud-computing tools in a new Innovation Lab, per Bio Space. The goal of the partnership is threefold: to speed up drug discovery, maximize operational flows, and improve the patient experience. Using AI to streamline complex and costly processes is a budding trend within the pharma industry. Pharma giants are rushing to get a hold of AI. Eli Lilly struck a $560 million deal with San Francisco-based AI developer Atomwise — which also holds partnerships with Merck and AbbVie — to accelerate drug discovery earlier this month, and AstraZeneca tied up with UK-based BenevolentAI in May. It makes sense for pharma companies to lean on tech that makes drug development more efficient: Drug makers shell out $2.6 billion to develop a new prescription medication and bring it to market, up from the $1 billion it cost in the early 2000s.",SAN,en,Business Insider
2019-06-18 09:54:01-05:00,"Sanofi, Google Partner On Health Care-Focused Virtual Innovation Lab","Sanofi SA (NASDAQ: SNY ) and Alphabet Inc (NASDAQ: GOOG ) (NASDAQ: GOOGL ) said Tuesday they have joined forces to launch a virtual Innovation lab with the aim of transforming how medicine and health services are delivered using emerging data technologies. The Innovation Lab will develop both scientific and commercial projects, according to the drugmaker and Full story available on Benzinga.com",SAN,en,Benzinga
2019-06-18 00:26:49.261000-05:00,"French Drugmaker Sanofi, Google to Use Data Tech for Innovations","French healthcare company Sanofi has teamed up with Google to work on innovations, aimed at using emerging data technologies to change how medicines and health services will be delivered in future.",SAN,en,The New York Times
2019-06-11 08:03:00-05:00,Lilly Announces Tradjenta Cardiovascular Outcome Study Data,Tradjenta leads to fewer events of hypoglycemia and modest weight reduction in type II diabetes patients compared to Sanofi's Amaryl.,SAN,en,Zacks Investment Research
2019-06-10 11:34:00-05:00,Sanofi (SNY) in Focus: Stock Moves 5.5% Higher,"Sanofi (SNY) shares rose nearly 6% in the last trading session, amid huge volumes.",SAN,en,Zacks Investment Research
2019-06-07 09:20:44-05:00,France's Sanofi bets on new CEO to drive sluggish drug sales,https://www.investing.com/news/stock-market-news/frances-sanofi-bets-on-new-ceo-to-drive-sluggish-drug-sales-1891692,SAN,en,Investing.com
2019-06-07 06:24:33-05:00,"The Daily Biotech Pulse: Vertex Bets Big On Gene-Editing Therapies, Sanofi Poaches Novartis For CEO Role, Relief In Europe for Endologix","Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on June 6) BIOFRONTERA AG/ADR (NASDAQ: BFRA ) BIO-TECHNE Corp (NASDAQ: TECH )(announced a deal to buy University of Minnesota startup B-MoGen technology) Blueprint Medicines Corp (NASDAQ: BPMC ) Zynex Inc. (NASDAQ: ZYXI ) Down In The Dumps (Biotech stocks hitting 52-week lows on June 6) Acorda Therapeutics Inc (NASDAQ: ACOR ) Aduro BioTech Inc (NASDAQ: ADRO ) Akebia Therapeutics Inc (NASDAQ: AKBA ) Aptinyx Inc (NASDAQ: APTX ) Axovant Gene Therapies Ltd (NASDAQ: AXGT )(reported six-month follow-up data from the first dose cohort in the Phase 2 trial of AXO-Lenti-PD for the treatment of Parkinson's disease and also issued pipeline update) Bellicum Pharmaceuticals (NASDAQ: BLCM ) Caladrius Biosciences Inc (NASDAQ: CLBS ) Cellectis SA (NASDAQ: CLLS ) Collegium Pharmaceutical Inc (NASDAQ: COLL ) Dynavax Technologies Corporation (NASDAQ: DVAX ) Evolent Health Inc (NYSE: EVH ) Fennec Pharmaceuticals Inc (NASDAQ: FENC ) Harvard Bioscience, Inc. (NASDAQ: HBIO ) Hemispherx BioPharma, Inc (NYSE: HEB ) IMMURON LTD/S ADR (NASDAQ: IMRN ) IMMUTEP LTD/S ADR (NASDAQ: IMMP ) Invivo Therapeutics Holdings Corp (NASDAQ: NVIV ) MOTIF BIO PLC/S ADR (NASDAQ: MTFB ) Navidea Biopharmaceuticals Inc (NYSE: NAVB ) Neuronetics Inc (NASDAQ: STIM ) Puma Biotechnology Inc (NASDAQ: PBYI ) Seres Therapeutics Inc (NASDAQ: …",SAN,en,Benzinga
2019-06-07 03:47:48-05:00,"European stocks head for best week in 2 months, Sanofi jumps",European stocks were on course to notch their best weekly performance in two months on Friday as a jump in shares of French pharma giant Sanofi added to the positive mood created by expectations of more moves by central banks to stir growth.,SAN,en,Reuters
2019-06-06 17:58:28-05:00,Sanofi to name Novartis exec Hudson as next CEO - Reuters,"Sanofi (SNY) is expected to name Novartis (NVS) executive Paul Hudson to become its new CEO starting Sept. 1, and current CEO Olivier Brandicourt will reti",SAN,en,Seeking Alpha
2019-06-06 17:10:24-05:00,Exclusive: French drugmaker Sanofi poised to appoint Novartis' Paul Hudson as next CEO,https://www.investing.com/news/stock-market-news/exclusive-french-drugmaker-sanofi-poised-to-appoint-novartis-paul-hudson-as-next-ceo-1891071,SAN,en,Investing.com
2019-05-31 00:00:00-05:00,Innate Pharma announces publication in Cell on innovative multifunctional NKp46 NK cell engagers (NKCEs),"The findings describe potential first-in-class NKp46 NKCEs, a new generation of multifunctional antibody-based molecules for fighting cancer The NKCE technology provides a versatile platform to generate formats that co-engage multiple receptors Ongoing R&D collaborations for NKCEs with Sanofi and AstraZeneca Marseille, France, May 31, 2019, 7:00 AM CEST Innate Pharma SA (the ""Company"" - Euronext Paris: FR0010331421 – IPH) today announces the publication of data demonstrating the potential of multifunctional NKp46 NKCEs in cancer immunotherapy. These findings, led by Professor Eric Vivier and the Innate Pharma teams in collaboration with Aix−Marseille University and the Marseille Immunopole cluster, were released in an article entitled "" Multifunctional natural killer cell engagers targeting NKp46 trigger protective tumor immunity "" in the online issue of Cell yesterday . ""Our multifunctional NKp46 NKCE technology provides a versatile platform to generate formats with the potential to co-engage up to three activating receptors on NK cells and two different tumor antigens on cancer cells,"" explains Eric Vivier, Chief Scientific Officer of Innate Pharma, Professor at Aix-Marseille University and lead author of this publication. "" These preclinical observations demonstrate the potential of NKp46 NKCEs, which were stable and had promising chemistry and manufacturing profiles compatible with industrial development.",SAN,en,Benzinga
2019-05-23 04:03:00-05:00,Alphabet to Aid Pharma Giants Enhance Clinical Trial Process,"Alphabet's (GOOGL) Verily joins hands with Novartis, Sanofi, Otsuka and Pfizer to revolutionize the clinical trial methods.",SAN,en,Zacks Investment Research
2019-05-21 07:00:00-05:00,Google sister-company Verily is teaming with big pharma on clinical trials,"Verily, Alphabet's health and life sciences division, just announced strategic alliances with Novartis, Sanofi, Otsuka and Pfizer.",SAN,en,CNBC
2019-05-20 12:01:29-05:00,Billionaire Gets Santander on Board for Spanish Grocer Rescue,"Banco Santander SA reached an agreement with Mikhail Fridman’s LetterOne investment fund to prevent Distribuidora Internacional de Alimentacion SA from having to seek creditor protection, ending months of uncertainty over the future of the troubled Spanish grocer.",SAN,en,Bloomberg
2019-05-20 03:35:00-05:00,Is Banco Santander (BSBR) a Great Pick for Value Investors?,Let's see if Banco Santander (BSBR) stock is a good choice for value-oriented investors right now from multiple angles.,SAN,en,Zacks Investment Research
2019-05-18 10:10:00-05:00,Sanofi: A Robust Pharma Giant With Strong Growth In Q1,Sanofi is a pharma company putting in very consistent performances. Pretty much the entire net income gets converted into free cash flow. This paves the way for,SAN,en,Seeking Alpha
2019-05-16 07:07:57-05:00,Regeneron and Sanofi's Libtayo shows positive effect in mid-stage skin cancer study,No summary available.,SAN,en,Seeking Alpha
2019-05-14 23:00:00-05:00,Sanofi Joins Drugmakers' Move to Treat Patients With Software,Sanofi is joining other big pharmaceutical companies in expanding beyond pills and injections into a new frontier of tech-based treatments that doctors can prescribe.,SAN,en,Bloomberg
2019-05-14 09:15:41-05:00,Santander Plans to Cut Spain Workforce by 11% in Efficiency Push,Banco Santander SA plans to cut its workforce by 11% in Spain as the lender continues the process of shuttering duplicated branches following the purchase of Banco Popular Espanol SA two years ago.,SAN,en,Bloomberg
2019-05-05 00:05:06-05:00,Banco Santander-Chile (BSAC) on Q1 2019 Results - Earnings Call Transcript,No summary available.,SAN,en,Seeking Alpha
2019-05-03 07:23:52-05:00,Alnylam down 3% premarket on Sanofi exit,No summary available.,SAN,en,Seeking Alpha
2019-05-03 00:10:00-05:00,"Pharma Stock Roundup: MRK, LLY, PFE Report Q1 Earnings, SNY, ABBV Drugs Get EU Nod","Merck (MRK), Pfizer (PFE), Lilly (LLY) announce Q1 results. European Commission grants approval to AbbVie's (ABBV) Skyrizi and Sanofi's (SNY) Zynquista.",SAN,en,Zacks Investment Research
2019-05-02 08:10:22-05:00,Should Value Investors Buy Banco Santander-Brazil (BSBR) Stock?,"Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.",SAN,en,Zacks Investment Research
2019-05-02 07:16:16-05:00,"The Daily Biotech Pulse: FDA Nod For Sanofi's Dengue Vaccine, Veracyte Offering, Biogen Reports Positive Data",Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on May 1) Alcon AG (NYSE: ALC ) (announced presentation of new clinical data and innovative technology at the Cataract Refractive Suite during the American Society of Cataract and Refractive Surgery) Down In The Dumps (Biotech stocks hitting 52-week lows on May 2) Acorda Therapeutics Inc (NASDAQ: ACOR ) Aptevo Therapeutics Inc (NASDAQ: APVO ) Athenex Inc (NASDAQ: ATNX ) Auris Medical Holding Ltd (NASDAQ: EARS )(began to trade on a reverse stock-split adjusted basis) Caladrius Biosciences Inc (NASDAQ: CLBS ) Eyegate Pharmaceuticals Inc (NASDAQ: EYEG ) Heron Therapeutics Inc (NASDAQ: HRTX )(stymied by a CRL issued for its post-operative pain medication) KemPharm Inc (NASDAQ: KMPH ) Opiant Pharmaceuticals Inc (NASDAQ: OPNT ) Psychemedics Corp. (NASDAQ: PMD ) Strongbridge Biopharma plc (NASDAQ: SBBP ) (reacted to its first quarter results) Related Link: Attention Biotech Investors: Mark Your Calendar For These May PDUFA Dates Stock In Focus FDA Okays Sanofi's Dengue Vaccine With Restrictions Sanofi SA (NASDAQ: SNY ) said the FDA approved its Dengvaxia for the prevention of dengue disease caused by serotypes 1-4 of the virus in individuals 9 through 16 years of age living in endemic areas of the U.S. with a lab-documented prior infection.,"SAN,SBBP",en,Benzinga
2019-05-01 20:46:00-05:00,Sanofi’s Dengue Vaccine Gets FDA Approval,"Sanofi dengue vaccine was approved in the U.S., the first treatment cleared by American regulators to protect against the mosquito-borne viral infection.",SAN,en,The Wall Street Journal
2019-05-01 20:07:30-05:00,Sanofi wins U.S. approval to sell dengue vaccine but with major restrictions,"The U.S. Food and Drug Administration on Wednesday gave Sanofi SA's dengue vaccine Dengvaxia a very narrow approval as the company continues to suffer from evidence that its vaccine, which took 20 years to develop, can cause severe infections in some people.",SAN,en,Reuters
2019-05-01 17:46:50-05:00,Sanofi wins FDA approval to sell dengue shot in parts of U.S.,The U.S. Food and Drug Administration on Wednesday approved Sanofi SA's dengue vaccine Dengvaxia for use in the United States among people aged 9 through 16 who have laboratory-confirmed previous dengue infection and live in endemic areas.,SAN,en,Reuters
2019-04-30 20:18:07-05:00,Banco Santander SA (SAN) CEO José Antonio Álvarez Álvarez on Q1 2019 Results - Earnings Call Transcript,No summary available.,SAN,en,Seeking Alpha
2019-04-30 12:56:07-05:00,Banco Santander's (BSBR) CEO Sergio Rial on Q1 2019 Results - Earnings Call Transcript,No summary available.,SAN,en,Seeking Alpha
2019-04-30 12:45:07-05:00,"Banco Santander, S.A. (SAN) Q1 2019 Earnings Call Transcript","SAN earnings call for the period ending March 31, 2019.",SAN,en,The Motley Fool
2019-04-30 12:34:42-05:00,Sanofi declares EUR 3.07 dividend,"Sanofi (SNY) declares EUR 3.07/share annual dividend, 1.3% increase from prior dividend of EUR 3.03. Forward yield 7.9%. Payable May 13. See SNY Dividend S",SAN,en,Seeking Alpha
2019-04-30 12:00:34-05:00,Attention Biotech Investors: Mark Your Calendar For These May PDUFA Dates,"Biotech stocks bucked the broader market uptrend in April, thanks to the volatility associated with the sector. Some of the catalysts that drove stocks include clinical trial readouts, capital raising and regulatory decisions. PDUFA dates are deadlines for the FDA to review new drugs. The FDA is normally given 10 months to review new drugs. If a drug is selected for priority review, the FDA is allotted six months to review the drug. These time frames begin on the date that an NDA is accepted by the FDA as complete. Here are the key PDUFA catalysts for the upcoming month. Can Sanofi's Controversial Dengue Vaccine Clear FDA Hurdle? Company: Sanofi SA (NASDAQ: SNY ) Type of Application: BLA Candidate: Dengvaxia dengue vaccine Indication: Dengue Date: May 1 The FDA accepted the BLA with priority review designation in October. Dengvaxia has already been approved in some countries, with the initial approval coming through in 2015. However, data released subsequently has shown the vaccine can cause serious infections if administered to people who haven't been infected previously.",SAN,en,Benzinga
2019-04-30 09:27:18-05:00,Banco Santander (Brasil) S.A. 2019 Q1 - Results - Earnings Call Slides,No summary available.,SAN,en,Seeking Alpha
2019-04-30 08:23:43-05:00,Banco Santander-Chile reports Q1 results,No summary available.,SAN,en,Seeking Alpha
2019-04-30 00:06:27-05:00,Santander Beats Profit Estimate With Latin America Leading Gains,Banco Santander SA’s first quarter profit beat analyst estimates as its Latin American units continued to compensate for a complicated business environment in Europe.,SAN,en,Bloomberg
2019-04-29 05:57:24-05:00,FDA OKs CV benefit claim for Regeneron and Sanofi's Praluent,No summary available.,SAN,en,Seeking Alpha
2019-04-27 10:44:12-05:00,"The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trial Readouts And IPOs","Biotech stocks staged a recovery this week after being in the red in the previous two weeks. AbbVie Inc (NYSE: ABBV )'s psoriasis drug Skyrizi received FDA nod. The week also saw the release of strong quarterly earnings by big European pharma giants such as Novartis AG (NYSE: NVS ), Sanofi SA (NASDAQ: SNY ) and Roche Holdings AG Basel ADR (OTC: RHHBY ). Here are a few key catalysts a biotech investor should stay focused on in the unfolding week. Conferences 2019 The Association for Research In Vision and Ophthalmology annual meeting – April 28- May 2, in Vancouver, British Columbia 17th International Conference on Pharmaceutical Microbiology and Biotechnology - April 29-30, in London 4th World Heart Congress - April 29 - May 1 in Kyoto, Japan 22nd American Society of Gene and Cell Therapy annual meeting – April 29- May 2, in Washington D.C. 3rd International Conference on Medical and Clinical Microbiology - May 1-2, in Kyoto 2019 American Academy of Neurology annual meeting – May 4-10, in Philadelphia, Pennsylvania PDUFA Dates Regeneron Pharmaceuticals Inc (NASDAQ: REGN ) and Sanofi await FDA verdict on their sBLA for Praluent injection.",SAN,en,Benzinga
2019-04-26 20:21:26-05:00,FDA approves expanded label for Regeneron/Sanofi's cholesterol drug,"The U.S. Food and Drug Administration on Friday approved Regeneron Pharmaceuticals Inc's cholesterol drug Praluent as a treatment to cut the risk of heart attacks, stroke and other major cardiovascular events.",SAN,en,Reuters
2019-04-26 18:59:14-05:00,Sanofi S.A. (SNY) CEO Olivier Brandicourt on Q1 2019 Results - Earnings Call Transcript,No summary available.,SAN,en,Seeking Alpha
2019-04-26 15:33:26-05:00,Sanofi (SNY) Q1 2019 Earnings Call Transcript -- The Motley Fool,"SNY earnings call for the period ending March 31, 2019.",SAN,en,The Motley Fool
2019-04-26 05:29:50-05:00,Sanofi top line up 6% in Q1,"Sanofi ([[SNY]]) Q1 results (€): Revenues: 8,391M (+6.2%); Pharmaceuticals: 6,262M (+5.3%); Consumer Healthcare: 1,256M (+1.5%); Vaccines: 873M (+22.8%). N",SAN,en,Seeking Alpha
2019-04-26 02:57:32-05:00,Sanofi Profit Jumps on Sales of Vaccines and a Rising New Drug,"Sanofi’s profit rose more than expected last quarter, powered by sales of vaccines and newcomer Dupixent, an eczema and asthma drug set to become a blockbuster. The stock had its biggest gain so far this year.",SAN,en,Bloomberg
2019-04-26 01:24:28-05:00,Sanofi beats by €0.10,No summary available.,SAN,en,Seeking Alpha
2019-04-22 07:51:25-05:00,Santander Investors Were Less Happy to Re-Elect Carnegie-Brown,Banco Santander SA’s shareholders backed the re-election of Vice Chairman Bruce Carnegie-Brown at their annual general meeting earlier this month with less enthusiasm than they showed for other directors.,SAN,en,Bloomberg
2019-04-11 14:49:06-05:00,Sanofi's Libtayo conditionally OK'd in Canada,No summary available.,SAN,en,Seeking Alpha
2019-04-10 19:00:00-05:00,Here's how drugmakers like Sanofi are trying to calm the outrage over the cost of the life-saving medicine insulin,"Critics call the new programs ""PR stunts,""and say drug companies should just lower their prices.",SAN,en,Business Insider
2019-04-10 08:24:19-05:00,Sanofi sets a fixed price of insulin at $99 per month for some patients,The move is a pre-emptive one as the French drugmaker is set to testify before the House Energy and Commerce Committee on the rising prices of insulin later in the day.,SAN,en,CNBC
2019-04-10 05:27:20-05:00,Sanofi provides insulins access at $99,No summary available.,SAN,en,Seeking Alpha
2019-04-10 04:00:00-05:00,Sanofi to cut U.S. insulin costs for some patients to $99 per month,"Sanofi SA said on Wednesday it will cut the cost of its insulin products to $99 per month for uninsured patients and others who pay cash for it in the United States, as the French drugmaker contends with intense criticism over the high price of the life-sustaining diabetes medication.",SAN,en,Reuters
2019-04-08 06:25:19-05:00,Sanofi concludes RNAI therapeutics alliance with Alnylam,Sanofi (SNY) and Alnylam (ALNY) have concluded the research and option phase of the companies’ 2014 RNAi therapeutics alliance in rare genetic diseases. Th,SAN,en,Seeking Alpha
2019-04-03 09:36:36-05:00,Botin Calls on Santander's Investors to Lobby ECB Over Capital,Ana Botin on Wednesday tried to enlist investors and analysts covering Banco Santander SA to lobby on behalf of the Spanish lender to persuade the European Central Bank that its capital requirements are too tough.,SAN,en,Bloomberg
2019-04-03 02:12:52-05:00,Santander Targets $1.4 Billion of Savings in New Strategic Plan,Banco Santander SA pledged to cut 1.2 billion euros ($1.4 billion) of costs and ramp up investment in digital and its prized Brazilian business as the Spanish lender seeks to revive its moribund share price.,SAN,en,Bloomberg
2019-04-02 04:51:00-05:00,Inovio Closes Enrollment in Brain Cancer Study Before Time,Inovio (INO) concludes enrollment in the phase I/II study on INO-5401+INO-9012 combined with Regeneron/Sanofi's Libtayo for the newly-diagnosed subjects with glioblastoma prior to the scheduled date.,SAN,en,Zacks Investment Research
2019-04-01 08:10:17-05:00,Is Banco Santander-Brazil (BSBR) Stock Undervalued Right Now?,"Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.",SAN,en,Zacks Investment Research
2019-03-29 07:32:43-05:00,European advisory group backs expanded use of Sanofi's Mozobil,No summary available.,SAN,en,Seeking Alpha
2019-03-27 14:17:30-05:00,Banco Santander Chile to buy 49% stake in Santander Consumer Chile,No summary available.,SAN,en,Seeking Alpha
2019-03-22 14:13:00-05:00,FDA Rejects Oral Treatment for Type 1 Diabetes,"Lexicon Pharmaceuticals is developing the treatment, which is called Zynquista, with French pharmaceutical giant Sanofi.",SAN,en,The Wall Street Journal
2019-03-22 13:39:04-05:00,UPDATE 1-FDA rejects Sanofi-Lexicon add-on pill for type 1 diabetes,"The U.S. Food and Drug Administration declined to approve a drug developed by Sanofi SA and Lexicon Pharmaceuticals Inc intended for use with insulin in patients with type 1 diabetes, the companies said on Friday.",SAN,en,Reuters
2019-03-22 13:21:34-05:00,FDA rejects Sanofi-Lexicon add-on pill for type 1 diabetes,"The U.S. Food and Drug Administration declined to approve a drug developed by Sanofi SA and Lexicon Pharmaceuticals Inc intended for use with insulin in patients with type 1 diabetes, the companies said on Friday.",SAN,en,Reuters
2019-03-21 12:02:28-05:00,eHealth and Kingsway Financial Services only financial gainers whereas; China Bat Group leads losers,No summary available.,SAN,en,Seeking Alpha
2019-03-18 17:59:00-05:00,"Regeneron, Sanofi Get EC Nod for Label Expansion of Praluent",Regeneron (REGN) and partner Sanofi receives approval in Europe for the label expansion of Praluent to reduce cardiovascular (CV) risk in adults with established atherosclerotic CV disease.,SAN,en,Zacks Investment Research
2019-03-18 11:34:20-05:00,Exclusive: Sanofi says working on CEO succession plan,"Pharmaceuticals group Sanofi is working on a plan to find a new CEO in agreement and consultation with current chief executive Olivier Brandicourt, a spokesman for the French drugmaker told Reuters on Monday.",SAN,en,Reuters
2019-03-18 11:12:54-05:00,Sanofi working on CEO succession plan,No summary available.,SAN,en,Seeking Alpha
2019-03-15 15:09:15-05:00,EC OKs CV benefit claim for Regeneron and Sanofi's Praluent,No summary available.,SAN,en,Seeking Alpha
2019-03-14 08:10:10-05:00,Are Investors Undervaluing Banco Santander-Brazil (BSBR) Right Now?,"Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.",SAN,en,Zacks Investment Research
2019-03-12 15:02:45-05:00,Banco Santander Chile closes $149M bond offering on Swiss market,No summary available.,SAN,en,Seeking Alpha
2019-03-11 14:25:21-05:00,FDA OKs Regeneron and Sanofi's Dupixent for younger patients with atopic dermatitis,No summary available.,SAN,en,Seeking Alpha
2019-03-11 14:25:21-05:00,FDA OKs Regeneron and Sanofi's Dupixent for atopic dermatitis,No summary available.,SAN,en,Seeking Alpha
2019-03-01 08:48:14-05:00,European advisory group backs Sanofi's Dupixent for asthma,No summary available.,SAN,en,Seeking Alpha
2019-03-01 08:33:02-05:00,European advisory group backs Sanofi's Zynquista in T1D,No summary available.,SAN,en,Seeking Alpha
2019-02-28 09:10:24-05:00,Sanofi: Performance Review And Way Forward,No summary available.,SAN,en,Seeking Alpha
2019-02-27 20:03:04-05:00,FDA OKs expanded label for Sanofi's Soliqua,No summary available.,SAN,en,Seeking Alpha
2019-02-25 20:09:25-05:00,Amgen prevails in PCSK9 patent dispute with Regeneron and Sanofi,No summary available.,SAN,en,Seeking Alpha
2019-02-25 12:16:25-05:00,Highlights From The Brazilian Central Bank Lecture,No summary available.,SAN,en,Seeking Alpha
2019-02-12 13:29:59-05:00,"In Unprecedented Move, Santander Declines To Redeem $1.7 Billion CoCo Bond Issue","Banco Santander SA has earned its ""special place in markets hell"" - as Bloomberg columnist Marcus Ashworth termed it. Shares of Santander erased and earlier gain and closed lower on Tuesday after the bank confirmed anxious bondholders fears by affirming that it would refuse to exercise a call option on a €1.5 billion ($1.7 billion) issue of Additional Tier 1s - better known as contingent convertible, or CoCo - bonds. Santander's decision makes it the first European bank in the still-young $340 billion market for bank AT1 notes to decline to call the bonds after the standard five-year term. A spokesman for the bank told BBG that it wouldn't redeem the bonds out of an “obligation to assess the economics and balance the interests of all investors."" The price of the bonds, which are one of the riskiest tranches of debt that can be issued by a European bank, also slid: Now that the bank has declined to redeem the bonds, defying accepted practice for what is still a relatively new asset class, holders of the euro-denominated bond will lose their 6.25% coupon, and the coupon will switch to the five-year swap rate, plus 541 basis points, which, at the prevailing rate, is about 5.55%, according to BBG .",SAN,en,Zero Hedge
2019-02-04 17:26:15-05:00,Banco Santander SA (SAN) CEO José Antonio Álvarez on Q4 2018 Results - Earnings Call Transcript,No summary available.,"SANT,SAN",en,Seeking Alpha
2019-02-04 17:26:15-05:00,Banco Santander SA (SAN) CEO José Antonio Álvarez on Q4 2018 Results - Earnings Call Transcript,No summary available.,SAN,en,Seeking Alpha
2019-02-04 11:35:34-05:00,Banco Santander-Chile 2018 Q4 - Results - Earnings Call Slides,No summary available.,"SANT,SAN",en,Seeking Alpha
2019-02-04 11:35:34-05:00,Banco Santander-Chile 2018 Q4 - Results - Earnings Call Slides,No summary available.,SAN,en,Seeking Alpha
2019-02-04 11:35:34-05:00,Banco Santander-Chile 2018 Q4 - Results - Earnings Call Slides,No summary available.,"SANT,SAN",en,Seeking Alpha
2019-02-04 11:35:34-05:00,Banco Santander-Chile 2018 Q4 - Results - Earnings Call Slides,No summary available.,SAN,en,Seeking Alpha
2019-02-04 11:35:34-05:00,Banco Santander-Chile 2018 Q4 - Results - Earnings Call Slides,No summary available.,"SANT,SAN",en,Seeking Alpha
2019-02-04 11:35:34-05:00,Banco Santander-Chile 2018 Q4 - Results - Earnings Call Slides,No summary available.,SAN,en,Seeking Alpha
2019-01-30 22:54:06-05:00,Banco Santander's (BSBR) CEO Sergio Rial on Q4 2018 Results - Earnings Call Transcript,No summary available.,"SANT,SAN",en,Seeking Alpha
2019-01-30 22:54:06-05:00,Banco Santander's (BSBR) CEO Sergio Rial on Q4 2018 Results - Earnings Call Transcript,No summary available.,SAN,en,Seeking Alpha
2019-01-30 13:05:34-05:00,Dunxin Financial Holdings leads financial gainers; Franklin Resources and Banco Santander among losers,No summary available.,SAN,en,Seeking Alpha
2019-01-30 06:41:58-05:00,Banco Santander (Brasil) S.A. reports Q4 results,No summary available.,"SANT,SAN",en,Seeking Alpha
2019-01-30 06:41:58-05:00,Banco Santander (Brasil) S.A. reports Q4 results,No summary available.,SAN,en,Seeking Alpha
2019-01-07 10:57:02-05:00,Banco Santander (Brasil) S.A. goes ex-dividend tomorrow,No summary available.,SAN,en,Seeking Alpha
2019-01-07 10:57:02-05:00,Banco Santander (Brasil) S.A. goes ex-dividend tomorrow,No summary available.,SAN,en,Seeking Alpha
2019-01-02 15:51:09-05:00,"Brazil stocks, real gain in first session after Bolsonaro takes office",No summary available.,SAN,en,Seeking Alpha
2019-01-02 15:51:09-05:00,"Brazil stocks, real gain in first session after Bolsonaro takes office",No summary available.,SAN,en,Seeking Alpha
2019-01-02 13:00:02-05:00,Farmland Partners leads financial gainers; GWG Holdings and Hexindai among losers,No summary available.,SAN,en,Seeking Alpha
2019-01-02 13:00:02-05:00,Farmland Partners leads financial gainers; GWG Holdings and Hexindai among losers,No summary available.,SAN,en,Seeking Alpha
2019-01-02 12:26:08-05:00,Brazil stocks broadly higher as new president makes moves,No summary available.,SAN,en,Seeking Alpha
